



ANNUAL REPORT 2021-22



The **IBN SINA**
Pharmaceutical Industry PLC

Quality we Assure



In the name of Allah, the most
gracious, the most merciful

CONTENTS

04

INTRODUCTION

32

MANAGEMENT REPORT

79

SUSTAINABILITY INITIATIVES

| | |
|-----|--|
| 04 | Cover Story |
| 05 | Letter of Transmittal |
| 06 | বিজ্ঞপ্তি |
| 08 | Notice |
| 10 | Vision |
| 11 | Mission |
| 12 | Forward Looking Statement |
| 13 | Strategic Objective |
| 14 | Core Values and Code of Corporate Philosophy |
| 15 | Our Guiding Principles |
| 18 | Awards and Recognitions |
| 19 | Quality Policy |
| 20 | Board of Directors |
| 21 | Corporate Management |
| 22 | Corporate Profile |
| 23 | Directors' Profile |
| 32 | চেয়ারম্যানের বিবৃতি |
| 35 | Chairman's Address |
| 37 | পরিচালনা পর্ষদের প্রতিবেদন |
| 48 | Directors' Report |
| 59 | Statement from the Managing Director |
| 63 | Financial Highlights |
| 64 | Horizontal and Vertical Analysis |
| 65 | Value Added Statement |
| 66 | Market Value Added Statement |
| 67 | Economic Value Added Statement |
| 68 | Performance Indicators |
| 76 | Shareholders' Information |
| 77 | Share Performance |
| 78 | Pattern of Shareholdings |
| 79 | Our Approach to the Sustainability |
| 80 | Integrated Report |
| 84 | Value Creating Business Model |
| 86 | Financial Capital |
| 88 | Human Capital |
| 91 | Manufactured Capital |
| 100 | Intellectual Capital |
| 109 | Social and Relationship Capital |
| 118 | Natural Capital |
| 120 | Human Resource Accounting |
| 121 | Health, Safety and Environment |

CONTENTS

122 OUR GOVERNANCE

| | |
|-----|---|
| 122 | Corporate Governance |
| 129 | Report of the Audit Committee |
| 132 | Nomination and Remuneration Committee (NRC) Report |
| 133 | Code of Conduct for the Board |
| 137 | Declaration on Financial Statements by MD and CFO |
| 138 | Statement of Directors Responsibilities for Financial Report |
| 139 | Dividend Distribution Policy |
| 141 | Unclaimed Dividend Information |
| 142 | Internal Control, Internal Audit and Compliance and Risk Management |
| 145 | Policy on Communication with Shareholders and other Stakeholders |
| 146 | Organizational Chart |
| 147 | Certificate of Compliance |
| 148 | Compliance Status on Corporate Governance Code of BSEC |

153 REPORTS AND FINANCIAL STATEMENTS

| | |
|-----|---|
| 154 | Independent Auditor's Report |
| 159 | Consolidated Statement of Financial Position |
| 160 | Consolidated Statement of Profit or Loss & Other Comprehensive Income |
| 161 | Consolidated Statement of Changes in Equity |
| 162 | Consolidated Statement of Cash Flows |
| 163 | Statement of Financial Position |
| 164 | Statement of Profit or Loss & Other Comprehensive Income |
| 165 | Statement of Changes in Equity |
| 166 | Statement of Cash Flows |
| 167 | Notes to the Consolidated Financial Statements |

201 REPORT OF THE SUBSIDIARY COMPANIES

| | |
|-----|------------------------------------|
| 201 | The IBN SINA Natural Medicine Ltd. |
| 212 | The IBN SINA API Industry Ltd. |
| 223 | The IBN SINA Polymer Industry Ltd. |

234 DISCLOSURES CHECKLIST & MISCELLANEOUS

| | |
|-----|--|
| 234 | Excerpts from 37th Annual General Meeting |
| 235 | Annual Report Review Checklist |
| 239 | Corporate Governance Disclosure Checklist |
| 241 | Virtual Annual General Meeting (AGM) Logistics |
| 242 | Notes |
| 243 | প্রস্তুতি ফরম এবং হাজিরা পত্র |



COVER STORY

The IBN SINA Pharmaceutical Industry PLC has a time-honored background in Bangladesh about four decades as medicine manufacturing company. Now, The IBN SINA Pharma has grown to be one of the leading companies in Pharma industry of Bangladesh.

The Company is committed making sustainability an integral part to continually enable the people in good health for better life, improving the environmental and social performance through mainstream of health services ensuring availability of quality medicines which we commonly refer to as our corporate foot print.

We work for the nation as a whole with pertinacious incitement and firm determination to ensure quality and ethical standing attributing the sustainable growth and development to serve the mankind.

Our belief is that the values mentioned above we carry for the sustainable development in business and services has manifested the credibility of the Company.

The Company's priority as a good corporate citizen is to earn money in ethical manner that is both socially and ecologically responsible and of obviously sustainable. "Quality we Assure" is reflecting the essence of our motto saying "Believe, It's time to reach the new heights".



LETTER OF TRANSMITTAL

To
The Respected Shareholders,
Bangladesh Securities and Exchange Commission,
Dhaka Stock Exchange Limited and
Chittagong Stock Exchange Limited

Disclosure of Annual Report for the year ended June 30, 2022

Dear Sir(s)

Enclosed please find a copy of the Annual Report together with the Audited Statement of Financial Position as at June 30, 2022 and the Statement of Profit or Loss and other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year ended June 30, 2022 along with the notes and the Directors' Report thereon and Consolidated and Subsidiary Companies Financial Statements of The IBN SINA Pharmaceutical Industry PLC for your kind information and record.

Thank you,
Yours sincerely,

Md. Kabir Hossain
Company Secretary

Dated: September 05, 2022

৩৮-তম বার্ষিক সাধারণ সভার বিজ্ঞপ্তি

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি-এর সম্মানিত শেয়ারহোল্ডারগণকে জানানো যাচ্ছে যে, আগামী ৩০ অক্টোবর ২০২২, রবিবার সকাল ৯:৩০ টায় কোম্পানীর ৩৮-তম বার্ষিক সাধারণ সভা বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের আদেশ নং বিএসইসি/সিএমআরআরসিডি/২০০৯-১৯৩/০৮, তারিখ: ১০ মার্চ ২০২১ অনুসারে ডিজিটাল (ভার্চুয়াল) প্ল্যাটফর্মের মাধ্যমে অনুষ্ঠিত হবে। সভায় নিম্ন বর্ণিত বিষয়সমূহ আলোচনা করা হবে :

ক. সাধারণ আলোচ্যসূচি:

১. ২০২১-২২ অর্থ বছরের নিরীক্ষিত হিসাব এবং তার ওপর নিরীক্ষক ও কোম্পানীর পরিচালনা পর্ষদের প্রতিবেদন গ্রহণ ও অনুমোদন;
২. ২০২১-২২ অর্থ বছরের লভ্যাংশ অনুমোদন;
৩. পরিচালক নিয়োগ/নির্বাচন;
৪. ইন্ডিপেন্ডেন্ট পরিচালক নিয়োগ/ পুনর্নিয়োগ অনুমোদন ;
৫. ২০২২-২৩ অর্থ বছরের জন্য নিরীক্ষক নিয়োগ এবং তাঁদের পারিশ্রমিক নির্ধারণ এবং
৬. ২০২২-২৩ অর্থ বছরের জন্য কমপ্লায়ান্স অডিটর নিয়োগ এবং তাঁদের পারিশ্রমিক নির্ধারণ।

খ. বিশেষ আলোচ্যসূচি:

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি থেকে ন্যাচারাল মেডিসিন ডিভিশন পৃথকীকরণ এবং এটির Net Asset দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসির সাবসিডিয়ারী কোম্পানী, দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. এ হস্তান্তর সংক্রান্ত কার্যক্রম অনুমোদন।

১. বিশেষ সিদ্ধান্ত : “দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর ন্যাচারাল মেডিসিন ডিভিশনের ৩০ জুন, ২০২২ সমাপ্ত অর্থ বছরের নিরীক্ষিত হিসাবের Net Asset যার মূল্যমান ২০,৮১,৬৯,৬৭০/- (বিশ কোটি একাশি লক্ষ ঊনসত্তর হাজার ছয়শত সত্তর) টাকা নির্বিঘ্ন উৎপাদন সহ উন্নত ব্যবসা পরিচালনার জন্য এতদ্বারা সাবসিডিয়ারী কোম্পানী, দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. এ স্থানান্তরিত হলো।”


২. বিশেষ সিদ্ধান্ত : “দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এবং দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. (সাবসিডিয়ারী কোম্পানী) এর মধ্যে সম্পাদিত “Vendors Agreement” এর আলোকে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর ন্যাচারাল মেডিসিন ডিভিশনের ৩০ জুন, ২০২২ সমাপ্ত অর্থ বছরের নিরীক্ষিত Net Asset যার মূল্যমান ২০,৮১,৬৯,৬৭০/- (বিশ কোটি একাশি লক্ষ ঊনসত্তর হাজার ছয়শত সত্তর) টাকা দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর ৯৯.৯৯% শেয়ারের মালিকানাধীন সাবসিডিয়ারী কোম্পানী, দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. (আইএনএম) এর শেয়ার গ্রহণের (Consideration other than cash) বিপরীতে উল্লিখিত Net Asset আইএনএম এ হস্তান্তর অনুমোদন করা হলো।”

কোম্পানীর সম্মানিত শেয়ারহোল্ডারগণকে উক্ত সভায় যথাসময়ে অংশগ্রহণ করার জন্য অনুরোধ করা যাচ্ছে।

তারিখ

০৫ সেপ্টেম্বর ২০২২

বোর্ডের আদেশক্রমে



(মো. কবীর হোসেন)

কোম্পানী সেক্রেটারী

টীকা:

ক. রেকর্ড ডেট (২৯ সেপ্টেম্বর ২০২২, বৃহস্পতিবার) এ কোম্পানীর শেয়ার রেজিস্টার অথবা ডিপোজিটরি রেজিস্টারে যে সকল শেয়ারহোল্ডারগণের নাম রেকর্ডভুক্ত থাকবে তাঁরাই কেবল বার্ষিক সাধারণ সভায় অংশগ্রহণ, ভোট প্রদান এবং লভ্যাংশ পাবার যোগ্য বলে বিবেচিত হবেন;

খ. সভায় অংশগ্রহণ ও ভোট প্রদানে উপযুক্ত কোন শেয়ারহোল্ডার তাঁর পক্ষে অন্য কোন ব্যক্তিকে সভায় অংশগ্রহণ ও ভোটদানের জন্য প্রক্সি নিয়োগ করতে পারবেন। সভা অনুষ্ঠানের নির্ধারিত সময়ের অন্তত পক্ষে ৭২ ঘন্টা পূর্বে প্রক্সি ফরম ২০.০০ টাকার রেভিনিউ স্ট্যাম্প সহকারে যথাযথভাবে পূরণ করে কোম্পানীর রেজিস্টার্ড অফিসে সরাসরি অথবা ই-মেইল shareipi@ibnsinapharma.com এর মাধ্যমে জমা দিতে হবে;

গ. বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের আদেশ নং বিএসইসি/সিএমআরআরসিডি/২০০৬-১৫৮/২০৮/এডমিন/৮১, তারিখ ২০ জুন ২০১৮ অনুসারে, বার্ষিক প্রতিবেদন ২০২১-২২ এর সফট কপি শেয়ারহোল্ডারগণের কোম্পানীতে সংরক্ষিত স্ব-স্ব ই-মেইলের মাধ্যমে প্রেরণ করা হবে এবং কোম্পানির ওয়েবসাইটেও (www.ibnsinapharma.com) পাওয়া যাবে;

ঘ. শেয়ারহোল্ডারগণ বার্ষিক সাধারণ সভা শুরুর ৪৮ ঘন্টা পূর্ব থেকে এবং এজিএম চলাকালীন সময়ে ভার্সুয়াল লিংক (<https://agmbd.live/ibnsinapharma2022>) অথবা ই-মেইল (shareipi@ibnsinapharma.com) এর মাধ্যমে প্রশ্ন ও মন্তব্য এবং ভোটাধিকার প্রয়োগ করতে পারবেন। শেয়ারহোল্ডারগণ ১৬ সংখ্যার বিও আইডি/৫ সংখ্যার ফলিও নাম্বার সহ সংশ্লিষ্ট পরিচয় নির্দেশক তথ্য নিশ্চিত করে উক্ত লিংক এ লগইন করতে পারবেন;

ঙ. ৩০ অক্টোবর ২০২২, রবিবার সকাল ৯:৩০ টায় মিটিং শুরুর পূর্বেই শেয়ারহোল্ডারগণকে 'সিস্টেমে লগইন' করার অনুরোধ করা যাচ্ছে। উল্লেখ্য সকাল ৯:১৫ টায় সরাসরি সম্প্রচার কার্যক্রম শুরু হবে। ভার্সুয়াল সভায় যুক্ত হতে প্রয়োজনে ০১৭০৯-৬৪৫০৮১ নাম্বারে যোগাযোগ করুন এবং

চ. বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের বিজ্ঞপ্তি নং এসইসি/সিএমআরআরসিডি/২০০৯-১৯৩/১৫৪, তারিখ ২৪ অক্টোবর ২০১৩ এবং ঢাকা স্টক এক্সচেঞ্জ লিস্টিং রেগুলেশনস, ২০১৫ ও চট্টগ্রাম স্টক এক্সচেঞ্জ লিস্টিং রেগুলেশনস, ২০১৫ মোতাবেক ৩৮তম বার্ষিক সাধারণ সভায় কোন ধরনের উপহার/উপহার কুপন/খাদ্য বক্স বিতরণ করা হবে না।

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি
এর মুদ্রিত বার্ষিক প্রতিবেদন ২০২১-২২ এর
সফট কপির জন্য দয়া করে উপরের
“কিউআর কোডটি” স্ক্যান করুন।



NOTICE OF THE 38th ANNUAL GENERAL MEETING

Notice is hereby given that the **38th ANNUAL GENERAL MEETING** of the Shareholders of **The IBN SINA Pharmaceutical Industry PLC** will be held on **Sunday, October 30, 2022** at 9:30 AM by using **Digital Platform** pursuant to the BSEC's Directive BSEC/CMRRCD/2009-193/08 dated March 10, 2021 to transact the following businesses:

A. Ordinary Businesses:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended June 30, 2022 together with the Auditors' Report and the Directors' Report thereon.
2. To approve dividend for the year 2021-22.
3. To appoint/re-elect Directors.
4. To approve the appointment/re-appointment of the Independent Directors.
5. To appoint Statutory Auditors for the financial year 2022-23 and to fixup their remuneration.
6. To appoint Compliance Auditors for the financial year 2022-23 and to fixup their remuneration.

B. Special Businesses:

To approve the demerging of Natural Medicine Division from The IBN SINA Pharmaceutical Industry PLC (IPI) and transfer its Net Assets to The IBN SINA Natural Medicine Ltd., a Subsidiary Company of IPI.

To consider and if deemed fit, to pass with or without modification(s), the following resolutions as Special Resolutions:

1. RESOLVED THAT, Net Assets at Tk. 20,81,69,670/- (Taka Twenty Crore Eighty One Lac Sixty Nine Thousand Six Hundred Seventy) as at June 30, 2022 of Natural Medicine Division of The IBN SINA Pharmaceutical Industry PLC be and is hereby transferred to the Subsidiary Company, The IBN SINA Natural Medicine Ltd. for better management and to make ease of operations of its natural medicine production and businesses.

2. RESOLVED FURTHER THAT, the 'Vendors Agreement' executed between The IBN SINA Pharmaceutical Industry PLC (IPI) and The IBN SINA Natural Medicine Ltd. (Subsidiary Company of IPI) to effect the transfer of Net Assets at Tk. 20,81,69,670/- (Taka Twenty Crore Eighty One Lac Sixty Nine Thousand Six Hundred Seventy) as at June 30, 2022 of Natural Medicine Division of The IBN SINA Pharmaceutical Industry PLC to its 99.99% owned Subsidiary Company, The IBN SINA Natural Medicine Ltd. in exchange of consideration other than cash as against acquiring of shares held by the holding Company, The IBN SINA Pharmaceutical Industry PLC be and is hereby approved.

The respected shareholders of the Company are requested to attend/participate the meeting in time.

Dated :
September 05, 2022

By Order of the Board of Directors



Md. Kabir Hossain
Company Secretary

Notes:

- a. The Shareholders whose names will appear in the Share Register of the Company or Depository Register (CDBL) on the "Record Date" i.e. Thursday, September 29, 2022 respectively are eligible to attend/participate and vote at the Annual General Meeting (AGM) and entitled to the Dividend.
- b. A Member entitled to attend and vote at the Annual General Meeting, may appoint a proxy to attend and vote in his/her stead. The Proxy Form must be affixed with the revenue stamp of Tk. 20.00 and be sent physically at the Registered Office of the Company or through email: shareipi@ibnsinapharma.com at least 72 hours before the scheduled time of the virtual meeting.
- c. Pursuant to the BSEC Notification No. BSEC/CMRRCD/2006-158/208/Admin/81 dated June 20, 2018, soft copy of the Annual Report 2021-22 will be sent to the Shareholders' respective e-mail addresses as available with us. The Annual Report 2021-22 will also be available in the Company's website at: www.ibnsinapharma.com.
- d. The Shareholders will be able to submit their questions/comments through virtual link (<https://agmbd.live/ibnsinapharma2022>) or e-mail (shareipi@ibnsinapharma.com) 24 hours before commencement of the AGM and during the AGM. For logging into the system, the Shareholders need to put their 16-digit Beneficiary Owner (BO) ID/Folio number and other credentials as proof of their identity in visiting the said link.
- e. Shareholders are requested to login to the system prior to starting of the meeting at 09:30 AM on Sunday, October 30, 2022. The webcast will start at 09:15 AM. Please contact at +8801709-645081 for any queries in accessing the virtual meeting and
- f. In compliance with the Bangladesh Securities and Exchange Commission's Circular No. SEC/CMRRCD/2009-193/154, dated October 24, 2013 and The Listing Regulations of Stock Exchanges, No Gift/Gift Coupon/Food Box shall be distributed at the ensuing 38th AGM.

**Please scan the given "QR Code"
instead of printing the report.
It contains the soft copy of the
Annual Report, 2021-22 of
The IBN SINA Pharmaceutical Industry PLC**



VISION



The IBN SINA Pharmaceutical Industry PLC's vision is to become a premier specialty pharmaceutical company, with a balanced focus in complementary therapeutic areas. Our primary responsibility lies towards the people of Bangladesh and ultimate responsibility towards humanity at large.

MISSION

A publicly listed company working for the nation as a whole with pertinacious incitement and firm determination to ensure the quality and ethical standing attributing the sustainable growth and development to serve the mankind.




Board approved vision and mission statements of the Company. The Board of Directors in its 45th meeting redefined the Company's vision and mission. We are driving towards our vision.

FORWARD LOOKING STATEMENT

This forward looking statement predicts our outlook to the future actions as expectations or possibilities. Information in the Annual Report reveals management's thinking and views based on commercial operation, business and economy during the year under review and future events and its proposition. However, these statements do not give assurance against certain risks and uncertainties. Therefore, actual future outcome and trends forecasted in the enterprising statements may differ significantly due to the following reasons:

- Changes in national economic and financial conditions;
- Changes in Government policy issues;
- Fluctuations in international prices which influence the foreign exchange market;
- Instability of capital market;
- Changes in corporate tax structure and VAT in Pharmaceutical sector;
- Changes in the competitive markets of the country;
- Unusual forex volatility;
- Sudden Ecological and Demographical changes;
- Inconsistency of the factors regarding Market Competitors, Suppliers and Pricing.





STRATEGIC OBJECTIVES

- To serve humanity by providing the highest quality of products and services;
- To maintain the ethical standard in all its functions;
- To follow WHO-cGMP requirement from procurement to finished goods;
- To March onward for sustainable growth and continuous improvements;
- To ensure consumers' satisfaction;
- To ensure welfare oriented health services;
- To establish a set of managerial succession and adopting technological changes to ensure successful development of the Company;
- To emerge as a healthier and stronger medical service at the top of the pharmaceutical sector;
- To invest in the thrust and priority sectors of the economy;
- To pay more importance in human resources as well as financial capital;
- To ensure lucrative career path, attractive facilities and excellent working environment;
- To ensure zero tolerance on negligence in compliance with the regulatory issues;
- To provide impeccable and progressively better customer services using changed technologies;
- To train and develop human resources continuously and provide adequate logistics to satisfy customers' need;
- To motivate team members taking part in the job with sense of belongingness;
- To strengthen corporate governance practice culture;
- To ensure Corporate Social Responsibilities (CSR) through all activities;
- To contribute to positive change, such as reversing climate and other environmental change and its related disclosures.

CORE VALUES AND CODE OF CORPORATE PHILOSOPHY

We carry some core values and code of corporate philosophy that are practiced

01. Trust in Almighty Allah;
02. Highest Principle of Honesty, Integrity and Conscience;
03. Equity and Justice;
04. Environmental Consciousness;
05. Adoption of Changed Technology and Advancement;
06. Proper Delegation, Transparency and Accountability;
07. Human Interest is the first priority that is attached to the country's growth and prosperity;
08. Employees are trained with the object of developing leaders to be next successors;
09. Emphasize on creativity and innovation to achieve organizational excellence;
10. Employees have an obligation to know and understand not only the guidance contained in the Code of Conduct but also the spirit on which it is built;
11. Recognize the rights of shareholders in creating wealth, jobs and the sustainability of a financially sound enterprise;
12. Ensure timely and accurate disclosure of all material information regarding the entity;
13. Ensure strategic guidance of the company, effective monitoring of management and the Board's accountability to the company and the shareholders;
14. Monitor and assess how risk is minimized and how performance is maximized;
15. Customers Satisfaction;
16. Team Work in adherence with the truth and transparency;
17. In accordance with the agreed Code of Conducts, the Company;
 - a. Acts with integrity, competence, dignity and in an ethical manner while dealing with stakeholders as a whole;
 - b. Acts and encourages others to behave in a professional and ethical manner;
 - c. Endeavors to maintain and improve the competence of all in the business;
 - d. Uses reasonable care and exercise independent professional judgment;
 - e. Not restrains others from responding their professional obligations.

ETHICAL PRINCIPLES



OUR GUIDING PRINCIPLES

The spirit of the company is derived from some of our guiding principles as follows:-

COMMITMENTS





The IBN SINA Pharmaceutical Industry PLC won ICSB Award for Corporate Governance Excellence in the category of "Pharmaceutical and Chemical Companies" at the 8th ICSB National Award 2020 held on 12.12.2021 at Radisson Blu Dhaka Water Garden. Md. Kabir Hossain Executive Director (Plants) and Company Secretary received the award from Hon'ble Commerce Minister, Government of Bangladesh, Mr. Tipu Munshi, MP.



AWARDS AND RECOGNITIONS



Bronze Award in the Pharmaceutical and Chemical Companies Category from ICSB for Corporate Governance Excellence in 2020



Gold Award in the Pharmaceutical and Chemical Companies Category from ICSB for Corporate Governance Excellence in 2019



Certificate of Appreciation 15th ICAB National Award for Best Presented Annual Report 2014



Gold Award in the Pharmaceutical and Chemical Companies Category from ICSB for Corporate Governance Excellence in 2018



ICMAB Best Corporate Award (Certificate of Merit) in 2012



QUALITY POLICY

The IBN SINA Pharmaceutical Industry PLC
is committed to

serve humanity by manufacturing and providing quality medicines and services to its customers.



maintaining ethical standards in all its functions following the requirements of cGMP and regulatory authorities.



marching onward for sustainable growth and continual improvement.



BOARD OF DIRECTORS

Kazi Harun or Rashid

Chairman

Prof. Dr. AKM Sadrul Islam

Managing Director

Prof. Dr. Choudhury Mahmood Hasan

Director Technical and Director Finance

Prof. ANMA Zaher

Director

Prof. Col. Dr. Zehad Khan (Retd.)

Director

Dr. Mohammad Ayub Miah

Director

Md. Abdus Salam FCA, FCS

Independent Director

Abdus Sadeque Bhuiyan

Independent Director

CORPORATE MANAGEMENT

Executive Committee

| | |
|-----------------------------------|-----------|
| Prof. Dr. Choudhury Mahmood Hasan | Chairman |
| Prof. Dr. AKM Sadrul Islam | Member |
| Dr. Mohammad Ayub Miah | Member |
| Md. Kabir Hossain | Secretary |

Audit Committee

| | |
|-----------------------------------|-----------|
| Md. Abdus Salam, FCA, FCS | Chairman |
| Prof. Col. Dr. Zehad Khan (Retd.) | Member |
| Abdus Sadeque Bhuiyan | Member |
| Md. Kabir Hossain | Secretary |

Nomination And Remuneration Committee

| | |
|-----------------------------------|-----------|
| Abdus Sadeque Bhuiyan | Chairman |
| Md. Abdus Salam FCA, FCS | Member |
| Prof. Col. Dr. Zehad Khan (Retd.) | Member |
| Md. Kabir Hossain | Secretary |

CSR Committee

| | |
|---------------------------------|-----------|
| Prof. Dr. Shah Md. Bulbul Islam | Chairman |
| Prof. Dr. AKM Sadrul Islam | Member |
| Kazi Harun or Rashid | Member |
| Md. Kabir Hossain | Secretary |

Chief Financial Officer

Md. Jasim Uddin, FCA

Company Secretary

Md. Kabir Hossain

Head of Internal Audit and Compliance

Abdur Rakib

Head of Share Department

Md. Aminur Rahman

Statutory Auditors

Malek Siddiqui Wali
Chartered Accountants
9-G, Motijheel C/A
Dhaka-1000

Compliance Auditors

Itrat Hussain & Associates
The Glass House (13th floor)
38, Gulshan Avenue
Gulshan-1, Dhaka-1212
Bangladesh

Bankers

Al-Arafah Islami Bank Ltd.
Islami Bank Bangladesh Ltd.
First Security Islami Bank Ltd.
Shahjalal Islami Bank Ltd.
Prime Bank Limited
Sonal Bank Limited
Shimanto Bank Limited

Registered Office

Tanin Center, 3 Asad Gate
Mirpur Road, Mohammadpur
Dhaka-1207, Bangladesh.

Corporate Website

www.ibnsinapharma.com

CORPORATE PROFILE

Nature of Business
Manufacturing and Marketing of
Pharmaceutical Products and Natural Medicine





DIRECTORS'
PROFILE



Kazi Harun or Rashid
Chairman

Kazi Harun or Rashid comes from a noble family on 1st April, 1950. He is an M. Com. in Accounting. He did his graduation from the University of Dhaka.

Kazi Harun or Rashid has been serving The IBN SINA Pharmaceutical Industry PLC in different levels as Director since 2016. He served the Company as Finance Director; Member, Executive Committee and Audit Committee with dedication and integrity. Presently he is serving as the Chairman of the Company from June 16, 2021 to till now.

Kazi Harun or Rashid is a former Chairman, Board of Directors, of Islami Bank Bangladesh Ltd. (IBBL) and Chairman, Audit Committee of IBBL.

Kazi Harun or Rashid is also Director of The IBN SINA API Industry Ltd.; Managing Director of The IBN SINA Natural Medicine Ltd.; Managing Director of The IBN SINA Polymer Industry Ltd.; Managing Director of The IBN SINA Consumer Products Ltd.; Proprietor of Kazi Trading Corporation, Harun Textile and Member Finance of Board of Trustees, The IBN SINA Trust.

Kazi Harun or Rashid has 38 years of versatile professional and business expertise.



Prof. Dr. AKM Sadrul Islam
Managing Director

Prof. AKM Sadrul Islam was born on 7th April 1955 in Jashore. He did Ph.D in Mechanical Engineering from University of London, U.K. in 1988. He served BUET and Islamic University of Technology (a subsidiary organ of OIC) for 36 years as Professor and Head of Department from 1980 to 2016. He was also a Visiting Professor of University Technology Malaysia; a Guest Professor of Institute of Ocean Energy, Saga University, Japan.

Prof. Islam is also Ex- Chairman, Mechanical Engineering Division, Institution of Engineers Bangladesh (IEB) and Secretary General, Bangladesh Society of Mechanical Engineers (BSME).

He has been serving the Company in different levels as Director, since 2003; Member, Executive Committee since 2005; and formerly Director, Finance, Chairman of the Audit Committee and Managing Director from 2014 to till now.

Prof. Islam is also a Director, The IBN SINA API Industry Ltd., The IBN SINA Natural Medicine Ltd., The IBN SINA Polymer Industry Ltd., IBN SINA Hospital Sylhet Ltd., IBN SINA Diagnostic Center, Lalbag Ltd. and Member of Board of Trustees of The IBN SINA Trust.



Prof. Dr. Choudhury Mahmood Hasan
Director, Technical and Finance

Dr. Choudhury Mahmood Hasan was born on 31st August 1953, in Chittagong District of Bangladesh. He obtained B. Pharm. (Hons) and M. Pharm. (Thesis group) degree from the Dhaka University, securing First position in First Class in both the examinations. He received his Ph.D. in 1982 from the Dept. of Pharmaceutical Chemistry at the University of Strathclyde, Glasgow, United Kingdom. He was awarded Commonwealth Scholarship for doing Ph.D. (1978-1981) in the Univ. of Strathclyde, Glasgow, Commonwealth Academic Staff Fellowship (1990-1991) to work as a visiting scientist in the same university and Japan Society for the Promotion of Science (JSPS) Senior Fellowship (Nov-Dec, 2004) for doing research in Tokushima Bunri University, Tokushima, Japan.

Dr. Hasan joined the Department of Pharmacy, DU, in 28th January, 1978 and progressed through the ranks to Professor in the same department in March, 1992 and retired on 30th June 2019. He was the Chairman of this Dept. from 1992 to 1993. He was the Director of Drug Administration, Ministry of Health and Family Welfare, from July 1993 to January 1997. He was elected as the Dean of the Faculty of Pharmacy for two terms from 1999 to 2003. He was the Chairman of BCSIR (Bangladesh Council of Scientific and Industrial Research) from 11th August 2005 to 10th August 2008. He was the Vice-Chancellor of Manarat International University for four years from 13th October, 2012 to 12th October, 2016. Emeritus Professor of Pharmacy Dept. of Manarat Int. University from 1st February, 2021 till date.

He was the member of Pharmacy Council (1993-1997, 2001-2008) and also the Chairman of Accreditation and Education Committee. Dr. Hasan, as a member of expert committee, played the pivotal role for the inclusion of "herbal drugs" in the National Drug Policy 2005 and which later on incorporated in the Drug Ordinance 2005.

His research focuses on the chemical and biological studies of local medical plants with emphasis on structure elucidation of the secondary metabolites by spectroscopic techniques (UV, IR, NMR, MS etc.). So far his supervised/co-supervised the research of at least 5 Ph.D and about 60 M.Pharm. students of Dhaka University. At present he is co-supervisor/co-supervisor of 7 Ph.D and 3 M.pharm students. He is the main/co-author of 301 peer-reviewed papers published in international and national scientific journals. He was the chairman/co-chairman/ plenary lecturer/ presenter/ participator in 66 international seminars/symposia held in 25 countries of the world (including UK, USA, Japan, Canada, Germany, Sweden, Spain, Australia etc.).

For his outstanding contribution in medicinal plant research and in biological science he was awarded Habibur Rahman Gold Medal 2003, Bangladesh Academy of Science Gold Medal 2006 (senior group), Chandrabati Gold Medal 2007 and Atish Dipankar Gold Medal 2008.

Dr. Hasan is a member of American Chemical Society (ACS), American Society of Pharmacognosy (ASP), Fellow of the Bangladesh Academy of Sciences (FBAS), Elected Vice President of FBAS, for 3 Years from 2019 and fellow of Royal Society of Chemistry (FRSC).

He was a Director of Essential Drug Company Ltd (EDCL) owned by Govt. of Bangladesh. (1993-1997). Dr. Hasan has been serving as Director of The IBN SINA Pharmaceutical Industry PLC since 2013 and currently he is serving as Director, Technical and Finance of the Company and Managing Director of The IBN SINA API Industry Ltd., He is also the Director of The IBN SINA Natural Medicine Ltd. The IBN SINA Polymer Industry Ltd., Prof. Hasan is the Chairman of the Board of Trustees of The IBN SINA Trust (IST).



Prof. ANMA Zaher
Director

Prof. Abu Nasser Muhammad Abdus Zaher was born in a respectable Muslim family of Companygonj, Noakhali in the year 1948.

Prof. Zaher has been serving as Director of The IBN SINA Pharmaceutical Industry PLC since 1983.

He achieved his Masters Degree in English Literature. He started his professional life with teaching at Khandaker Mosharraf Hossain Degree College in the early seventies. Later he joined at the Royal Embassy of Kingdom of Saudi Arabia in Dhaka, Bangladesh as the Secretary of the Embassy and Ambassador and performed duties for about 13 years. He joined The IBN SINA Pharmaceutical Industry PLC in 1989 as Managing Director of the Company.

Prof. Zaher was Chairman of Islami Bank Bangladesh Ltd., Chairman of Islami Banks Consultative Forum (IBCF), Vice Chairman of Bangladesh Association of Banks and Board Member of General Council for Islami Banks & Financial Institutions (CIBAFI). He was a member of the Advisory Committee of the Bangladesh Association of Pharmaceutical Industries (BAPI).

Prof. Zaher is also a Director of The IBN SINA Natural Medicine Ltd. and Member of Board of Trustees of The IBN SINA Trust.



Professor Col. Dr. Zehad Khan (Retd.)
Director

Professor Col. Dr. Zehad Khan (Retd.) was born in a noble family in the district of Kishoreganj in the year 1957. He secured 21st position in SSC examination from Dhaka Board in 1976. He got admitted in Dhaka Medical College in 1978. But he was awarded the scholarship of ex. Soviet Union and obtained MD degree from Abu Ali IBN SINA Medical College, Tajikistan in 1986.

Dr. Khan received MCPS in 1997 and FCPS in 1998. After working at Cardiology Department in Combined Military Hospital (CMH), Dhaka for three years, he went to Germany for one and half year. He completed advanced training in Interventional Cardiology under renowned Professor KH KUCK there. Due to his significant contribution in medical treatment, he received FRCP from Royal College of Physicians and Surgeons (Glasgow) and FACC from American College of Cardiology.

Dr. Khan joined in Bangladesh Army Medical Corps in 1988. He worked in different Combined Military Hospitals (CMH), Chittagong Hill Tracts and United Nation's Hospital in Ivory Coast. He also worked as a Professor in Armed Forces Medical College, Dhaka.

Dr. Khan retired from Bangladesh Army in 2014. Now, he is working as a Senior Consultant Cardiology in IBN SINA Cardiac Center, IBN SINA Hospital, Dhanmondi. He is also working as a visiting Professor in Abdul Hamid Medical College and as an honorary Professor in IBN SINA Medical College.

Dr. Khan introduced Transradial Intervention (Angiogram and through hand Arteries) in Combined Military Hospital (CMH), Dhaka. He also introduced Electrophysiology in that Hospital with successful treatment of arrhythmia.

Dr. Zehad Khan served as Director of The IBN SINA Pharmaceutical Industry PLC since 2016 to 2018.

He is a member of Cardiac Interventional Society, Bangladesh, Chairman of various Social Welfare Associations like AN Foundation, PRAC. He is member of governing body of Tamirul Millat Kamil Madrasah, Tongi.

He is also a Director of The IBN SINA API Industry Ltd. and Member of Board of Trustees of The IBN SINA Trust.



Dr. Mohammad Ayub Miah
Director

Dr. Mohammad Ayub Miah is a specialist in Institutionalization of Zakat Management, Policy and Administrative Reforms, Agriculture, Food and Industrial Policy Reforms, SME Development, Islamic Micro-finance Operations, Corporate Governance, Poverty Alleviation Strategies etc.

Dr. Mohammad Ayub Miah has got a brilliant and ornamental career in the Bangladesh civil service for long 30 years. He served in as many as 15 Ministries and attached Departments of the Government of Bangladesh in different capacities. Before retirement he worked as Secretary in the Ministry of Food & Disaster Management and Ministry of Water Resources. He was the founder Managing Director of Small & Medium Enterprise Foundation under Ministry of Industries.

He represented the Government of Bangladesh in the Board of Directors of different public and private sector enterprises including Unilever Bangladesh, Reckit & Bankiser, Shilpa Bank, Atlas Bangladesh, Bangladesh Sugar & Food Industries Corporation, Bangladesh Steel Mills Corporation, Bangladesh Small & Cottage Industries Corporation, and Triple Super Phosphate Company.

After his retirement from the civil service he has been working as Chief Executive Officer (CEO) of Center for Zakat Management (CZM) for last twelve years. CZM is a non-profit charity organization promoting Zakat and advocating for institutionalizing zakat for poverty alleviation

Dr. Miah is also a Director of The IBN SINA Polymer Industry Ltd., Subsidiary Company of The IBN SINA Pharmaceutical Industry PLC and Member of Board of Trustees of The IBN SINA Trust.

Dr. Mohammad Ayub Miah obtained his Bachelor and Master's degree in Political Science and Ph.D. in Public Administration from the University of Dhaka. He was awarded Post Graduate Diploma for Advanced Studies in Economic and Social Studies from Victoria University of Manchester, U.K. He completed a senior management training course from Birmingham University and Civil Service College, London. He obtained various trainings in foreign countries including USA, UK, Japan, Switzerland, China, Singapore etc. He attended conferences of International Labour Organization (ILO) and World Intellectual Property Organization. He was born in 02 December 1954 at Patuakhali.



Md Abdus Salam FCA, FCS
Independent Director and Chairman, Audit Committee

Md Abdus Salam FCA, FCS is a former President of the Institute of Chartered Accountants of Bangladesh (ICAB) and Vice President of the Institute of Chartered Secretaries of Bangladesh (ICSB). He also served both ICAB and ICSB Institutes as the Council Member. He obtained his Bachelor of Honours and Master Degree in Accounting from the University of Dhaka in 1975 and 1976 respectively and qualified as Chartered Accountant from the Institute of Chartered Accountants of Bangladesh in 1989 and became Fellow of the Institute in 1994. He was awarded Burmah Eastern and the BCIC scholarships to pursue his CA degree.

He has been rendering services to the Institute in various capacities and as a member of different standing and non-standing Committees, including Board of Studies, the Technical & Research Committee, Editorial Board and Review Committee for published Accounts & Reports. He was elected to Dhaka Regional Committee of the Institute and served as the Secretary in 2000 and in one of regular Faculty Members of the Institute. He was also the Technical Adviser of the IDA Technical Assistance project for Chartered Accountants titled "Development of Accounting and Auditing Standard in Bangladesh" financed by the World Bank. He is a Fellow Member of the Institute of Chartered Secretaries of Bangladesh. He was Vice president for the term 2005-2006 and the Treasurer for the term 2004-2005 of the Institute of Chartered Secretaries of Bangladesh. He has been serving as elected Councilor of the said Institute since its establishment in 1997. He is a Charter Member and Best Past President of the Lions Club of Dhaka Meghna for the term 1993-94. He is a Life Member of Dhaka University Accounting Alumni Association, Bangladesh Economic Association and Bangladesh Computer Society. He attended various national and international seminars/conferences in United Kingdom, Australia, Canada, Saudi Arabia, UAE, Italy, Thailand, India, Pakistan, Sri Lanka and Nepal.

Salam in his career served in a number of Government autonomous bodies and multilateral international development organizations including Bangladesh Power Development Board as Additional Director of Accounts, General Manager Finance in National Tea Company and as Mission Team Leader and Consultant/Expert for UNDP, ADB, World Bank, CIDA, DFID, NORAD, SIDA, EC, DANIDA in a number of projects in the fields of financial management, auditing and governance. He has completed an assignment as the National Finance Expert with the PEDPII of Asian Development Bank.

He was the Member of the Board of Directors of Islami Bank Bangladesh Ltd., Director of Coal Power Generation Company Ltd., Electricity Generation Company Ltd. (Govt. Body), Dhaka Stock Exchange and Chittagong Stock Exchange and Member of South Asian Federation of Accountants (a SAARC body).

He is also Independent Director of Matin Spinning Mills Ltd. and Union Capital Ltd.



Abdus Sadeque Bhuiyan
Independent Director and
Chairman, Nomination and Remuneration Committee (NRC)

Abdus Sadeque Bhuiyan was born in a noble Muslim family in the district of Dhaka in 1959. He obtained his Bachelor and Master's Degree in Social Welfare from the University of Dhaka. He has completed the Diploma Associate of the Institute of Bankers, Bangladesh (DAIBB). Mr. Bhuiyan, former Deputy Managing Director of Islami Bank Bangladesh Limited commenced his career by joining IBBL on February 07, 1984.


He has 34 years of versatile professional experience and expert in Banking, Finance, Human Resource and Administration etc. Now he is serving as Independent Director and Chairman of the Nomination and Remuneration Committee (NRC) of The IBN SINA Pharmaceutical Industry PLC from 16th January 2022 to till now.

During his long professional career, he attended various national and international training and participated in seminars, workshops & symposiums on Banking and Finance in USA, UK, Canada, Singapore, China, Australia, Malaysia, Hong Kong, UAE, Thailand and Nigeria.

He also acted as the Treasurer of Association of Anti Money Laundering Compliance Officer's of Banks in Bangladesh (AACOBB).

Abdus Sadeque Bhuiyan has attachment with different associations like Member of the Association of Bankers Bangladesh (ABB) and also life Member of Registered Graduate of Dhaka University.

Abdus Sadeque Bhuiyan is also Independent Director of The IBN SINA API Industry Ltd. and The IBN SINA Natural Medicine Ltd. Subsidiary Companies of The IBN SINA Pharmaceutical Industry PLC.



স্ৰোম্যানের
বিবৃতি

বিসমিল্লাহির রাহমানির রাহীম

সম্মানিত শেয়ারহোল্ডারগণ,

আসসালামু আলাইকুম ওয়া রাহ্মাতুল্লাহ।


দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর ৩৮ তম বার্ষিক সাধারণ সভায় আপনাদের সবাইকে জানাই আন্তরিক শুভেচ্ছা ও মোবারকবাদ। আজকের এ মহতী অনুষ্ঠানে ২০২১-২২ অর্থ বছরে কোম্পানীর আর্থিক অবস্থা, অর্জন সমূহ এবং উল্লেখযোগ্য তৎপরতার বিবরণ আপনাদের সামনে পেশ করা হলো।

সংক্ষিপ্ত ব্যবসায়িক বিবরণ

আপনারা সবাই অবগত আছেন যে, কোম্পানীর বেশীর ভাগ ব্যবসায়িক সাফল্য নির্ভর করে বিদ্যমান জাতীয় ও আন্তর্জাতিক আর্থ-সামাজিক এবং পারিপার্শ্বিক অবস্থা সমূহের ওপর। আলোচ্য অর্থ বছরে আমাদের জন্য কোভিড-১৯ করোনা ভাইরাসের ৩য় ও ৪র্থ ঢেউ মোকাবিলা করে কোম্পানীকে এগিয়ে নিয়ে যাওয়া যথার্থই একটি চ্যালেঞ্জ ছিল।

কোম্পানী কাজক্ষিত অর্জনের মধ্য দিয়ে আরও একটি বছর অতিবাহিত করেছে। আমাদের গৃহীত বস্তুনিষ্ঠ কর্ম-কৌশল বিক্রয় ও মুনাফার লক্ষ্যমাত্রা অর্জনে ধারাবাহিক সাফল্য অব্যাহত রাখতে সক্ষম হয়েছে।

আমি আনন্দের সাথে আলোচ্য অর্থ বছরে কোম্পানীর উল্লেখযোগ্য অগ্রগতি ও অর্জন সমূহের বিবরণ নিম্নে উপস্থাপন করছি :



ওপরের সূচক সমূহ কোম্পানীর ক্রমবর্ধমান উন্নয়নের চিত্র প্রকাশ করেছে। আগামীতে অধিকতর সাফল্য অর্জনের ব্যাপারে আমরা দৃঢ় প্রতিজ্ঞ ও আশাবাদী।

বাংলাদেশের অর্থনৈতিক প্রবৃদ্ধির চালিকা শক্তি হিসেবে ওষুধ শিল্প মৌলিক ভূমিকা পালন করেছে। ২০২১-২২ অর্থ বছরে বাংলাদেশ মজবুত অর্থনৈতিক প্রবৃদ্ধি ধরে রাখতে সক্ষম হয়েছে। পূর্ববর্তী বছরের তুলনায় ওষুধ শিল্পের প্রবৃদ্ধি না হলেও আমাদের কোম্পানীর প্রবৃদ্ধি ছিল ১৪.৯৬%। ২০২১-২২ অর্থ বছরে দেশের অর্থনৈতিক প্রবৃদ্ধির হার ছিল ৬.৯৪%।

চলমান অনেক অভ্যন্তরীণ ও বহিঃ চ্যালেঞ্জ থাকা সত্ত্বেও উন্নত প্রযুক্তি ব্যবহারের মাধ্যমে দক্ষতার সাথে নিরবিচ্ছিন্নভাবে কারখানা চালু রেখে উৎপাদন সক্ষমতা উল্লেখযোগ্য হারে বৃদ্ধি করা হয়েছে। প্রতিযোগিতামূলক বাজারে আমরা আমাদের অবস্থান ধরে রেখেছি। স্থানীয় বাজার বিস্তৃতির লক্ষ্যে বিক্রয় ও বিতরণ পদ্ধতির আধুনিকায়ন, পণ্যের বহুমুখীকরণ এবং উৎপাদন সক্ষমতা শক্তিশালী করা হয়েছে।

ভবিষ্যৎ পরিকল্পনা

আমি বিশেষভাবে উল্লেখ করতে চাই, সাম্প্রতিক সময়ে ডলার বাজারে অস্থিরতা ও চলমান রাশিয়া-ইউক্রেন যুদ্ধের প্রভাবের ফলে বিশ্বব্যাপী জ্বালানী তেল সহ নিত্য প্রয়োজনীয় পণ্যের মূল্য আন্তর্জাতিক বাজারে নতুন করে বৃদ্ধি পাওয়ায় বাংলাদেশের আমদানী ব্যয় বহুগুণ বেড়ে গেছে। বাংলাদেশ সরকার এবং সংশ্লিষ্ট কর্তৃপক্ষ তথা বাংলাদেশ ব্যাংক বাজারে বৈদেশিক মুদ্রার তারল্যের সংকট দূরীকরণের জন্য বেশ কিছু পদক্ষেপ গ্রহণ করেছেন। কোম্পানী এসব সমস্যা থেকে মুক্ত নয়। আমরা আশা করছি, শীঘ্রই এসব সমস্যা দূরীভূত হবে।

আগামী দিনের সকল সুযোগ কাজে লাগিয়ে কোম্পানীকে এগিয়ে নেয়ার ব্যাপারে আমরা দৃঢ় প্রত্যয়ী। পরিচালনা পর্ষদ কোম্পানীর উজ্জ্বল ভবিষ্যৎ বিনির্মাণে বহুমুখী কৌশল অবলম্বনের মাধ্যমে টেকসই উন্নয়নের ধারাবাহিকতা রক্ষায় বদ্ধপরিকর।

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি থেকে ন্যাচারাল মেডিসিন ডিভিশন পৃথকীকরণ

আপনারা জেনে আনন্দিত হবেন যে, কোম্পানীর টেকসই উন্নয়ন অব্যাহত রেখে পরিচালনা পর্ষদ নিয়ন্ত্রক সংস্থার এতদসংক্রান্ত নির্দেশনা প্রতিপালন এবং বার্ষিক সাধারণ সভায় শেয়ারহোল্ডারগণের অনুমোদনক্রমে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি থেকে ন্যাচারাল মেডিসিন ডিভিশনকে পৃথক করার লক্ষ্যে ন্যাচারাল মেডিসিন ডিভিশন এর ৩০ জুন, ২০২২ সমাপ্ত অর্থ বছরের নিরীক্ষিত হিসাবের নেট সম্পদ কোম্পানীর ৯৯.৯৯% মালিকানাধীন সাবসিডিয়ারী, 'দি ইবনে সিনা ন্যাচারাল মেডিসিন লি.' এর শেয়ার গ্রহণের বিপরীতে (Consideration other than cash) হস্তান্তর করার সিদ্ধান্ত গ্রহণ করেছে।

এ্যাকটিভ ফার্মাসিউটিক্যাল ইনগ্রুইয়েন্টস (এপিআই)

ফার্মাসিউটিক্যাল পণ্যের চাহিদা বৃদ্ধির সাথে সাথে এপিআই পণ্যের চাহিদাও বৃদ্ধি পেয়েছে। দেশীয় বাজারের পাশাপাশি এর রপ্তানির নতুন দ্বার উন্মোচিত হচ্ছে। এপিআই পণ্যের চাহিদা বৃদ্ধি বিবেচনায় এনে আমদানী নির্ভরতা কমিয়ে আনার লক্ষ্যে নিরবিচ্ছিন্ন ওষুধের কাঁচামাল সরবরাহের সুবিধার্থে বাংলাদেশ সরকার মুন্সিগঞ্জ জেলার গজারিয়ায় এ্যাকটিভ ফার্মাসিউটিক্যাল ইনগ্রুইয়েন্টস (এপিআই) শিল্প পার্ক স্থাপন করেছে।

আমরা এ প্রকল্পের সাথে যুক্ত রয়েছি। আমাদের এপিআই প্রকল্পের নির্মাণ কাজ চূড়ান্ত পর্যায়ে রয়েছে। আশা করছি, আগামী বছর উক্ত প্লান্টে বাণিজ্যিক উৎপাদনের কাজ শুরু করা যাবে। কমপ্লায়ন্ট উৎপাদন সুবিধা অবশ্যই কোম্পানীর বাজার ব্যবস্থা বিস্তৃতির নতুন ক্ষেত্র তৈরী করবে।

ইবনে সিনা পলিমার প্রকল্প

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর একটি নতুন উদ্যোগ 'ইবনে সিনা পলিমার প্রকল্প'। প্লাস্টিক ও পলিমার জাতীয় পণ্য এবং পেট বোতল উৎপাদন ও বাজারজাত করণের জন্য গাজীপুর জেলার মাওনায় এটি স্থাপিত হবে। ইতোমধ্যে প্রকল্পের মূল পরিকল্পনা এবং কারখানার লে-আউট প্লান সম্পূর্ণ হয়েছে। এ প্রকল্পের উৎপাদিত পণ্য ইবনে সিনার অন্যান্য চালু প্রকল্পগুলোতে ব্যবহৃত হবে।

পদক প্রাপ্তি ও স্বীকৃতি

আপনারা জেনে খুশী হবেন যে, দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি ইনস্টিটিউট অফ চার্টার্ড সেক্রেটারীজ অফ বাংলাদেশ (আইসিএসবি) থেকে ফার্মাসিউটিক্যাল এবং কেমিক্যাল কোম্পানী সেক্টরে অন্যান্য বিষয়ের সাথে মজবুত আর্থিক অবস্থা, অভিজ্ঞ ব্যবস্থাপনা, বিশ্বস্ততা এবং পণ্য মানের ব্যাপারে আপোষহীনতার ওপর কার্পোরেট গভর্নেন্স এক্সিলেন্স-২০২০ জাতীয় পদক লাভ করেছে।

প্রিয় ভাই ও বোনরা,

আমরা আশাবাদী, ২০২২-২৩ অর্থ বছর কোম্পানীর জন্য আরও সুসংবাদ বয়ে আনবে। আমি দৃঢ়তার সাথে বলতে চাই ব্যবসায়িক প্রবৃদ্ধি অর্জন ও শেয়ারহোল্ডারগণের স্বার্থ সংরক্ষণের লক্ষ্যে আমরা উপযুক্ত পদক্ষেপ গ্রহণ করেছি। আমাদের প্রতি আপনাদের গভীর আস্থা ও বিশ্বাসের জন্য আন্তরিক ধন্যবাদ জ্ঞাপন করছি।

শেয়ারহোল্ডারগণের মতামত, গঠনমূলক সমালোচনা ও পরামর্শকে পরিচালনা পর্ষদ গুরুত্ব সহকারে মূল্যায়ন করেন এবং এটিকে অগ্রগতি ও সাফল্য অর্জনের মূল চালিকাশক্তি হিসেবে গণ্য করেন।

আমি সাফল্য অর্জনে অবদান রাখার জন্য কোম্পানীর ব্যবস্থাপনা কর্তৃপক্ষ ও সর্বস্তরের দক্ষ কর্মকর্তা-কর্মচারীগণের অর্থবহ সহযোগিতার জন্য আন্তরিক ধন্যবাদ ও কৃতজ্ঞতা জানাচ্ছি। সকলের আন্তরিক প্রচেষ্টা ব্যবসায়িক প্রবৃদ্ধি অর্জনকে শক্তিশালী করেছে। আমরা যে সাফল্য অর্জন করেছি তা মহান আল্লাহর রহমতে সকলের সম্মিলিত প্রচেষ্টার কারণেই সম্ভব হয়েছে। আমি সংশ্লিষ্ট সবার অবদানের কথা কৃতজ্ঞতার সাথে স্বীকার করছি।


আমি আরও কৃতজ্ঞতা জ্ঞাপন করছি যে, আমাদের সম্মানিত ক্রেতাসাধারণ, শুভাকাঙ্ক্ষী, চিকিৎসক, ব্যাংকার, সরবরাহকারী, বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন, ঢাকা স্টক এক্সচেঞ্জ লি., চট্টগ্রাম স্টক এক্সচেঞ্জ লি., সেন্ট্রাল ডিপোজিটরি বাংলাদেশ লিমিটেড, বাংলাদেশ এসোসিয়েশন অব পাবলিকলী লিস্টেড কোম্পানিজ, রেজিস্ট্রার অব জয়েন্ট স্টক কোম্পানিজ এন্ড ফার্মস, জাতীয় রাজস্ব বোর্ড, শ্রম অধিদপ্তর, কলকারখানা ও প্রতিষ্ঠান পরিদর্শন অধিদপ্তর, সরকারি বিভিন্ন সংস্থাসমূহ এবং কোম্পানীর ব্যবসার সাথে সংশ্লিষ্ট সবাইকে তাঁদের অব্যাহত সহযোগিতার জন্য।

আমি কোম্পানীর ভবিষ্যৎ অগ্রগতি ও উন্নতির জন্য এবং সর্বোপরি দেশ ও জাতির কল্যাণের জন্য মহান আল্লাহ পাকের দরবারে দোয়া করছি।

পরিশেষে আমি গভীর শ্রদ্ধার সাথে স্মরণ করছি কোম্পানীর প্রতিষ্ঠাকালীন পরিচালকগণকে যারা আমৃত্যু স্বাস্থ্যখাতে অসামান্য অবদান রেখে গেছেন। মহান আল্লাহ পাক তাঁদেরকে জান্নাতুল ফেরদাউস নসীব করুন, আমিন।

কারী হারুন অর রশিদ

চেয়ারম্যান



Bismillahir Rahmanir Rahim

The Esteemed Shareholders

Assalamu Alaikum Wa Rahmatullah


We are delighted to welcome you all at the 38th Annual General Meeting of The IBN SINA Pharmaceutical Industry PLC. In this auspicious occasion we would like to present to you the Annual Report for the year 2021-22 showing the financial position, achievement and the notable performance of the Company.

Business Overview

You are all aware that, the Company's operational success mostly depends on the factors of socio-economic situation exists nationally and globally where we had to face the intensity of third and fourth wave of pandemic COVID-19 and as such the year 2021-22 was challenging for us.

However, the IBN SINA Pharma conducted another year of appreciating performance. We continued our growth momentum, meeting sales and profit targets and achieving the success in consistent pursuit of our strategic objectives.

I am pleased to place the following key performances achieved in the year under review:



All the indicators mentioned above show that the Company is progressing and doing well. We hope it will perform even better in the years to come.

The Pharma Industry plays a fundamental role as driving force for economic growth of Bangladesh. The economic growth of Bangladesh remains strong during FY 2021-22. Bangladesh economy grew 6.94% in the outgoing fiscal year 2021 with pharma industry did not accrue growth while our Company's growth was attained at 14.96%.

Despite of many ongoing internal and external challenges, we have significantly increased our productivity by upgrading technology and constantly adhering to ensuring efficient factory management in all aspects. To ensure this competitiveness in the market, we were in track. We expanded our domestic market through reforming the distribution system, enriching and diversifying our product portfolio, enhancing the manufacturing capacities in different technical aspects.

Looking ahead

I should mention that amid of growing concerns over the forex volatility and consequent problem worldwide due to ongoing Russia-Ukraine war amidst pandemic worldwide, Bangladesh's import expenses have ballooned on account of fresh hike in prices of essential commodities including fuel on the global market in the recent months mainly for the mentioned reasons. Government and the related regulatory authorities, like Central Bank took some stringent policies aiming to improve the foreign currency liquidity situation on the money market. The Company is not also out of such consequential effect, we expect overcoming the acute economic austerity soon will result stability of the forex.

The future is of great opportunities, the Company is confident to harness this opportunities. The Board is vigilant to look ahead with a sense of direction and concern for better future of the Company. As a matter of strategic diversification, the initiatives taken by the Board expect to reach the destination planned for sustainable growth of the Company.

Demerging of Natural Medicine Division from The IBN SINA Pharmaceutical Industry PLC (IPI) and transfer of its Net Assets to The IBN SINA Natural Medicine Ltd., Subsidiary Company of IPI.

You will be happy to know that keeping in view of ensuring more sustainable growth of the Company, for better management and to make ease of operation of its natural medicine production and

businesses, the Board of Directors of The IBN SINA Pharmaceutical Industry PLC decided to demerge the Natural Medicine Division of the Company through transferring its "Assets and Liabilities duly audited" as at year ended June 30, 2022 in the form of "Net Assets" to its 99.99% owned Subsidiary Company- The IBN SINA Natural Medicine Ltd.- in exchange of consideration other than cash as against acquiring of the shares held by the holding Company, The IBN SINA Pharmaceutical Industry PLC, subject to approval by the Shareholders at this Annual General Meeting of the Company as "Special Business" and compliance with the necessary regulatory requirements in this regard.

Active Pharmaceutical Ingredients (API)

The demand of API products is eventually expanding in the domestic market as well as new export frontiers. To facilitate supply of raw materials of drugs and to reduce the dependency on importing API, timely action has been taken to keep pace with global shifting of the sector and implementing the Government's Active Pharmaceutical Ingredients (API) Park considering the impact of ensuing LDC graduation in the Pharmaceutical Sector.

And we are not also outside of this view. The construction works of API Project, The IBN SINA API Industry Ltd. have been advanced towards the final stage. Hopefully, production in the API plant will be started by the next year. This compliant state-of-the-art production facility will certainly uplift the market exposure of the Company to a phenomenal status.

IBN SINA Polymer Project

Another initiative taken by The IBN SINA Pharmaceutical Industry PLC is IBN SINA Polymer Project to produce and market PET Bottles, ED Vials and related Polymer products, etc. To establish this project an area has been cited in Mawna of Gazipur district. Meanwhile Master Plan of the project site and the factory layout plan is completed. Certainly it will be a profitable project in comparison to investment. The Polymer Product to be produced will be used in the IPI and its Subsidiaries.

Awards and Recognition

The IBN SINA Pharmaceutical Industry PLC is awarded National Award for Corporate Governance Excellence 2020 from the Institute of Chartered Secretaries of Bangladesh (ICSB) under the Pharmaceutical Chemical Companies Sector, among others, key strengths the of Company's strong financial position, experienced management, trusted brand and committed quality, we assure.

Dear Brother and Sister (s),

We hope the year 2022-23 will continue to be another successful year for The IBN SINA Pharmaceutical Industry PLC. We remain confident that we are taking the right actions to continue to grow the businesses and deliver value-for-money to our shareholders. Thank you very much for your continued trust on us.

The Board of Directors accepts with gratitude the reviews, criticism and suggestions of our valued shareholders and consider them as a catalytic factor in attainment of the success and continued progress of the Company.

I sincerely show my immense impression for the dedication, commitment and skills of the employees of all levels and acknowledge for the contributions made by the management to bring this success. It is their efforts that drive the business forward, delivering excellent performance and strong growth across our businesses. The success we have achieved is only possible because of the collective efforts of all concerned. I thankfully acknowledge their contributions to the Company.

We are grateful to our valued customers, well-wishers, healthcare professionals, bankers, suppliers, Bangladesh Securities and Exchanges Commission, Dhaka Stock Exchange Limited, Chittagong Stock Exchange Limited, Central Depository Bangladesh Ltd., Bangladesh Association of Publicly Listed Companies (BAPLC), Registrar of Joint Stock Companies and Firms, National Board of Revenue (NBR), Government Agencies and all other concerned.

Lastly, I pray to the Almighty Allah (swt) to bless us with success and help us in our endeavor marching towards a bright future and benevolence to our people as a whole, and also show our profound gratitude recalling the memories of the founding directors, promoters of the Company for their significant contributions in the health sector until their death. Let us all please join praying to the Almighty Allah (swt) for their eternal peace and place in the Jannatul Ferdous, Ameen.



Kazi Harun or Rashid
Chairman

পরিচালনা পর্ষদের
প্রতিবেদন

বিসমিল্লাহির রাহমানির রাহীম

সম্মানিত শেয়ারহোল্ডারগণ,

আসসালামু আলাইকুম ওয়া রাহমাতুল্লাহ।

কোম্পানীর পরিচালনা পর্ষদের পক্ষ থেকে আপনাদের সবাইকে ৩৮তম বার্ষিক সাধারণ সভায় আন্তরিক শুভেচ্ছা ও স্বাগত জানাচ্ছি। ০১ জুলাই ২০২১ থেকে ৩০ জুন ২০২২ সমাপ্ত অর্থ বছরের কার্যক্রমের ওপর পরিচালনা পর্ষদের প্রতিবেদন এবং নিরীক্ষক কর্তৃক নিরীক্ষিত আর্থিক বিবরণী সমূহ আপনাদের মূল্যবান দিক নির্দেশনা, মতামত ও সদয় বিবেচনার জন্য পেশ করা হল। আলোচ্য অর্থ বছরে কোম্পানীর ব্যবসায়িক সাফল্যের জন্য মহান রাব্বুল আলামীনের দরবারে শুকরিয়া আদায় করছি।

এ প্রতিবেদনটি কোম্পানী আইন, ১৯৯৪ (সংশোধিত-২০২০) এর ধারা ১৮৪ এবং বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন বিধি ১৯৮৭, বিএসইসি কর্পোরেট গভর্নেন্স কোড ২০১৮, ফাইন্যান্সিয়াল রিপোর্টিং কাউন্সিল, বাংলাদেশ কর্তৃক গৃহিত ইন্টারন্যাশনাল একাউন্টিং স্ট্যান্ডার্ড, ইন্টারন্যাশনাল ফাইন্যান্সিয়াল রিপোর্টিং স্ট্যান্ডার্ড এবং ঢাকা স্টক এক্সচেঞ্জ লিষ্টিং রেগুলেশন ২০১৫ ও চট্টগ্রাম স্টক এক্সচেঞ্জ লিষ্টিং রেগুলেশন ২০১৫ মোতাবেক প্রস্তুত করা হয়েছে।

মূল কার্যক্রম

কোম্পানীর মূল কার্যক্রম হচ্ছে সর্বোচ্চ মান সম্পন্ন এ্যালোপ্যাথিক, ইউনানী ও হারবাল ওষুধ উৎপাদন ও বাজারজাতকরণের মাধ্যমে বাংলাদেশ ও বহির্বিদেশে আন্তর্জাতিক মান সম্পন্ন স্বাস্থ্যসেবা প্রদানের লক্ষ্যে অগ্রণী ভূমিকা পালন করা।

দৃষ্টিভঙ্গি

আলোচ্য অর্থ বছরে সামাজিক ও পরিবেশগত অবস্থার প্রতিকূলতা সত্ত্বেও দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি সর্বক্ষেত্রে তথা উৎপাদনশীলতা ও ব্যবসা পরিচালনায় উত্তম নীতিবোধ সংরক্ষণ ও উন্নয়নকে অগ্রাধিকার দেয়ার নীতিতে অবিচল থাকার চেষ্টা অব্যাহত রেখেছে।

ব্যবস্থাপনা ও ব্যবসায়িক পর্যালোচনা

আলোচ্য অর্থ বছরে কোম্পানীকে জাতীয় ও আন্তর্জাতিক বাজারে বেশ চ্যালেঞ্জের সম্মুখীন হতে হয়েছে। পরিচালকমন্ডলী প্রতিযোগিতামূলক পরিস্থিতি মোকাবেলা ও সর্বোচ্চ মুনাফা অর্জনের লক্ষ্যে মানসম্পন্ন নতুন নতুন ওষুধ উৎপাদনের ব্যবস্থা গ্রহণ করেছেন। কোম্পানী বস্তুগত উন্নয়ন, আর্থিক ব্যবস্থাপনা নিয়ন্ত্রণে সাফল্যের স্বাক্ষর রেখেছে। ফলে মানসম্মত ওষুধ উৎপাদন, মান নিয়ন্ত্রণ, যুগোপযোগী বিতরণ প্রক্রিয়া, সময়োপযোগী কর্মকৌশল প্রয়োগ করে রোগী ও ভোক্তাগণের কাছে ওষুধ পৌঁছানো অবধি অর্থবহ ভূমিকা রাখা সম্ভব হয়েছে।

বাংলাদেশের ওষুধ শিল্প খাত দেশের মোট চাহিদার ৯৮% স্থানীয়ভাবে পূরণ পূর্বক দ্রুততার সাথে এগিয়ে চলছে। ওষুধ কোম্পানী সমূহ অভ্যন্তরীণ চাহিদা পূরণের পাশাপাশি বিশ্বের বিভিন্ন দেশে ওষুধ রপ্তানী করছে। এ ক্ষেত্রে বৈশ্বিক শ্রেণীপটে ১৭৮টি দেশের মধ্যে বাংলাদেশের অবস্থান ৭১তম। দেশের জিডিপিতে ওষুধ শিল্প খাতের অবদান ১.৮৩%।

বাংলাদেশের ওষুধ শিল্প খাত সবকিছুর পরও দেশে এটির উন্নতির অসংখ্য দ্বার উন্মোচন এবং বৃহৎ পরিসরে উচ্চ মানসম্পন্ন জীবন রক্ষাকারী ওষুধের ব্যাপারে বৈদেশিক দৃষ্টি আকর্ষণ করতে সমর্থ হয়েছে। এ খাত উন্নয়নের মাত্রা বৃদ্ধির জন্য ওষুধ নীতির আলোকে প্রয়োজনীয় গবেষণার দাবী রাখে।

২০২১-২২ অর্থ বছরে শেয়ার প্রতি আয় (EPS) দাঁড়িয়েছে ১৯.৩৯ টাকা যা ২০২০-২১ অর্থ বছরে ছিল ১৫.৬৬ টাকা এবং আলোচ্য অর্থ বছরে শেয়ার প্রতি নিট সম্পদ মূল্য (NAVPS) ৮৩.৩৬ টাকা, যা পূর্ববর্তী অর্থ বছরে ছিল ৬৮.৬৯ টাকা। নিট সম্পদ মূল্য (NAV) ২,৬০৪,৩৯০,৭৬৫ টাকা, যা পূর্ববর্তী অর্থ বছরে ছিল ২,১৪৬,১৯৯,৪৭৩ টাকা। শেয়ার প্রতি নিট চলতি নগদ প্রবাহ (NOCFPS) ১৩.৪০ টাকা, যা পূর্ববর্তী অর্থ বছরে ছিল ১৭.৬৭ টাকা।

বিক্রয় প্রবৃদ্ধি অর্জন

আলোচ্য অর্থ বছরে কোম্পানী বিতরণ, বিপণন ও উৎপাদনশীলতা বৃদ্ধির ধারাবাহিকতাকে অব্যাহত রাখতে সক্ষম হয়েছে। আলোচ্য অর্থ বছরে ১৪.৯৬% বিক্রয় প্রবৃদ্ধি অর্জিত হয়েছে। সর্বমোট বিক্রয় অর্জিত হয়েছে ৮,৪৭৯,৮১৯,৫৬৯ টাকা, বিগত বছরে বিক্রয় হয়েছিল ৭,৩৭৬,০৪২,০৯৪ টাকা। মার্কেটিং, বিক্রয় ও বিতরণ বিভাগ এবং কারখানার সকল পর্যায়ের জনশক্তির সমন্বিত আন্তরিক প্রচেষ্টার ফলে এ অর্জনের ধারাবাহিকতা অব্যাহত রাখা সম্ভব হয়েছে।

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি থেকে ন্যাচারাল মেডিসিন ডিভিশন পৃথকীকরণ এবং এটির নেট সম্পদ দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর সাবসিডিয়ারী কোম্পানী, দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. এ হস্তান্তর সংক্রান্ত

কোম্পানীর টেকসই উন্নয়ন অব্যাহত রেখে পরিচালনা পর্ষদ ৯৯.৯৯% শেয়ারের মালিকানা নিয়ে ৩০ জুন, ২০২২ সমাপ্ত অর্থবছরের নিরীক্ষিত হিসাবের নেট সম্পদ যার মূল্যমান ২০,৮১,৬৯,৬৭০ (বিশ কোটি একাশি লক্ষ উনসত্তর হাজার ছয়শত সত্তর) টাকা সহ ন্যাচারাল মেডিসিন ডিভিশনকে কোম্পানী থেকে পৃথক করে “দি ইবনে সিনা ন্যাচারাল মেডিসিন লি.” এ স্থানান্তর করার সিদ্ধান্ত গ্রহণ করেছে। দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি নিয়ন্ত্রক সংস্থার প্রয়োজনীয় নির্দেশনা প্রতিপালন পূর্বক বার্ষিক সাধারণ সভায় শেয়ারহোল্ডারগণের অনুমোদন সাপেক্ষে এটি কার্যকর করবে।

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এবং দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. (সাবসিডিয়ারী কোম্পানী) এর মধ্যে সম্পাদিত “Vendors Agreement” এর আলোকে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসির ন্যাচারাল মেডিসিন ডিভিশনের জুন ৩০, ২০২২ সমাপ্ত অর্থবছরের নিরীক্ষিত Net Asset যার মূল্যমান ২০,৮১,৬৯,৬৭০/- (বিশ কোটি একাশি লক্ষ উনসত্তর হাজার ছয়শত সত্তর) টাকা দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর ৯৯.৯৯% শেয়ারের মালিকানাধীন সাবসিডিয়ারী কোম্পানী, দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. (আইএনএম) এর শেয়ার গ্রহণের (Consideration other than cash) বিপরীতে উল্লিখিত Net Asset আইএনএম এ স্থানান্তর অনুমোদনের জন্য অদ্যকার বার্ষিক সাধারণ সভায় বিষয়টি বিশেষ রেজুলেশন হিসেবে গ্রহণ করা হবে।

কোম্পানীর নাম সংশোধন

কোম্পানী আইন, ১৯৯৪ (সংশোধিত-২০২০) এর ধারা ১১(ক) এর উপধারা-ক অনুসারে কোম্পানীর নাম সংশোধন পূর্বক “দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি” করা হয়েছে।

শিল্প সম্ভাবনা ও সম্ভাব্য ভবিষ্যৎ উন্নয়ন

আলোচ্য অর্থ বছরে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি সর্বক্ষেত্রে তথা উৎপাদনশীলতা ও ব্যবসা পরিচালনায় উত্তম নীতি সংরক্ষণ ও উন্নয়নকে অগ্রাধিকার দেয়ার প্রত্যয়ে অবিচল থাকার চেষ্টা অব্যাহত রেখেছে।

উন্নয়নের শীর্ষে পৌঁছার ব্যাপারে আমরা আপোষহীন। শুধুমাত্র স্থানীয় বাজার থেকে নয় রপ্তানী বাজার থেকেও আয় বর্ধনের লক্ষ্যে উৎপাদনশীলতা বৃদ্ধির জন্য বহুমুখী পদক্ষেপ গ্রহণ করা হয়েছে। ভবিষ্যৎ উন্নয়ন ও টেকসই প্রবৃদ্ধি এবং অভ্যন্তরীণ ও আন্তর্জাতিক পরিসরে স্বাস্থ্য সেবা প্রদান অব্যাহত রাখার লক্ষ্যে জন্য বহুমুখী প্রকল্প গ্রহণের নতুন কৌশল গ্রহণ করা হয়েছে।

একটি প্রতিযোগিতামূলক ব্যবসায়িক পরিবেশে কোম্পানী প্রতিযোগিতামূলক দরে সর্বোচ্চ গুণগত মানসম্পন্ন পণ্য দিয়ে ভোক্তা সাধারণের পাশে থাকতে সক্ষম হয়েছে। কোম্পানী উন্নত প্রযুক্তির সর্বোচ্চ ব্যবহার এবং ভবিষ্যৎ চ্যালেঞ্জ মোকাবিলা করে চাহিদামাফিক পণ্য পরিবেশনের মাধ্যমে ব্যবসা সম্প্রসারণের ওপর গুরুত্ব আরোপ করে থাকে। সম্ভাব্য ভবিষ্যৎ উন্নয়নে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর দৃষ্টিভঙ্গি প্রতিবেদনের ৬২ পৃষ্ঠায় উল্লেখ করা হয়েছে।

বাংলাদেশ ফার্মাসিউটিক্যাল মার্কেট


ফার্মাসিউটিক্যাল শিল্প বাংলাদেশের একটি গুরুত্বপূর্ণ খাত। যা বর্তমানে দেশের অর্থনীতিতে উল্লেখযোগ্য অবদান রাখছে। ২০২১-২২ অর্থ বছরে বাংলাদেশ ফার্মাসিউটিক্যাল মার্কেট এর প্রবৃদ্ধি না হওয়া সত্ত্বেও দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি ১৪.৯৬% প্রবৃদ্ধি অর্জন করতে সক্ষম হয়েছে।

আর্থিক ফলাফল

০১ জুলাই ২০২১ থেকে ৩০ জুন ২০২২ অর্থ বছরের আর্থিক ফলাফলের সার সংক্ষেপ নিম্নরূপ:


| বিবরণ | পরিমাণ টাকায় | |
|----------------------------------|---------------|---------------|
| | ২০২১-২২ | ২০২০-২১ |
| করপূর্ব মুনাফা | ৭৯৯,৮৬২,৪৮৫ | ৭০৪,৪৪৮,০৫০ |
| আয়কর | ১৯৪,১৮৭,৮৬১ | ২১৫,৪৭৬,২৭৯ |
| কর পরবর্তী মুনাফা | ৬০৫,৬৭৪,৬২৪ | ৪৮৮,৯৭১,৭৭১ |
| রিটেইন্ড আর্নিংস | ২,২৮৮,২৪৭,৯৭২ | ১,৮২৯,২২৬,০০৬ |
| নীট সম্পদ মূল্য | ২,৬০৪,৩৯০,৭৬৫ | ২,১৪৬,১৯৯,৪৭৩ |
| শেয়ার প্রতি নীট সম্পদ মূল্য | ৮৩.৩৬ | ৬৮.৬৯ |
| শেয়ার প্রতি আয় | ১৯.৩৯ | ১৫.৬৬ |
| শেয়ার প্রতি নীট চলতি নগদ প্রবাহ | ১৩.৪০ | ১৭.৬৭ |

শেয়ার প্রতি নীট সম্পদ মূল্য




■ ২০২০-২১ ■ ২০২১-২২

শেয়ার প্রতি আয়



■ ২০২০-২১ ■ ২০২১-২২

শেয়ার প্রতি নীট চলতি নগদ প্রবাহ



■ ২০২০-২১ ■ ২০২১-২২

স্থায়ী সম্পদ

ধারাবাহিক উন্নয়নের অংশ হিসাবে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি'র নিম্নোক্ত অগ্রগতি সাধিত হয়েছে।

- ভূমি ক্রয় ও ভূমি উন্নয়ন।
- নতুন প্রকল্প সমূহের জন্য প্রয়োজনীয় ইমারত নির্মাণ।
- উৎপাদন, মান নিয়ন্ত্রণ ও ইউটিলিটির জন্য নতুন মূলধনী মেশিনারিজ ক্রয়।

চলমান নতুন প্রকল্পের মধ্যে সরকারী এপিআই শিল্প পার্কে দি ইবনে সিনা এপিআই ইন্ডাস্ট্রি লি. এর কার্যক্রম চূড়ান্ত পর্যায়ে রয়েছে। মার্চ, ২০২৩ এর মধ্যে এটির পরীক্ষামূলক উৎপাদন শুরু হবে-ইনশাআল্লাহ। মহামারী কোভিড-১৯ কারণে প্রকল্পের কাজ যথাসময়ে শেষ করতে বিলম্ব হয়েছে।

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি ইউনিট-২, গোপালীয়া প্রকল্পের কাজ চলছে। ভূমি উন্নয়নের কাজ সমাপ্তির পর ভবন নির্মাণের কাজ শুরু করা হবে। চক পাড়া, মাওনা, গাজীপুরে দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি. এর নির্মাণ পূর্ব কাজ চলছে। নভেম্বর, ২০২২ এ পূর্ণাঙ্গ কাজ শুরু করা হবে। এ সকল নতুন প্রকল্পের কার্যক্রম এবং নতুন মূলধনী মেশিনপত্র হোল্ডিং কোম্পানীর স্থায়ী সম্পদে যুক্ত হয়েছে। এ সময়ে যুক্ত হওয়া স্থায়ী সম্পদের বিবরণ প্রতিবেদনের ১৯৯ নং পৃষ্ঠায় বিবৃত করা হয়েছে।

উৎপাদন কার্যক্রম ও প্রযুক্তির ব্যবহার

কোম্পানীর প্লান্টের উৎপাদন ক্ষমতা, কর্মদক্ষতা, উৎপাদনশীলতা ও গুণগত মান বৃদ্ধির লক্ষ্যে উন্নত প্রযুক্তি সংযোজন, গবেষণা পরিচালনা ও প্রশিক্ষণ কার্যক্রম অব্যাহত রেখেছে। আলোচ্য বছরে ফার্মা, সেফা ও ন্যাচারাল মেডিসিন প্লান্টে সর্বাধুনিক ও উন্নত মানের মেশিনারিজ ও যন্ত্রপাতি ক্রয় ও স্থাপন এবং বেশ কিছু নতুন প্রোডাক্ট বাজারজাতকরণের মাধ্যমে সার্বিক বিনিয়োগ বৃদ্ধি পেয়েছে যা কোম্পানীর অভ্যন্তরীণ উৎস ও ব্যাংক বিনিয়োগের মাধ্যমে নির্বাহ করা হয়েছে।

উন্নত কাঁচামাল ও ওষুধের গুণগত মান

মানব কল্যাণের লক্ষ্যে কোম্পানী তার উৎপাদিত ওষুধের গুণগত

মান রক্ষায় প্রতিশ্রুতিবদ্ধ। এ লক্ষ্যে মূল উপাদানের সঠিক মান ও উৎসের সন্ধান এবং উন্নত কাঁচামাল সংগ্রহ, সংরক্ষণ ও সঠিক মাত্রার ওষুধ প্রস্তুত করার লক্ষ্যে আইপিআই টোটাল কোয়ালিটি ম্যানেজমেন্ট (TQM) সিস্টেম কার্যকর রয়েছে। বিশ্বমানের যন্ত্রপাতির মাধ্যমে উৎপাদন ও কঠোর মান নিয়ন্ত্রণের মধ্য দিয়ে উৎপাদিত ওষুধ গ্রাহকের দোরগোড়ায় শাস্ত্রীয় মূল্যে পৌঁছানোর জন্যে কোম্পানী নিরলস চেষ্টা চালিয়ে যাচ্ছে।

নতুন ওষুধ বাজারজাতকরণ

ফার্মা মেডিসিন

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি প্রচলিত ওষুধের পাশাপাশি নিয়মিত নতুন ওষুধ বাজারজাতকরণ করছে যা কোম্পানীর প্রবৃদ্ধি অর্জনে যথেষ্ট ভূমিকা রেখে যাচ্ছে। ২০২১-২২ অর্থবছরে কোম্পানী ১৫ টি জেনেরিকের মোট ২১ টি প্রোডাক্ট বাজারজাত করেছে যার মধ্যে আছে গ্লিপাট্যাব ১০ ট্যাবলেট, গ্লিপাট্যাব ২৫ ট্যাবলেট, রিভাক্যাপ ৩ ক্যাপসুল, লোটেরেক্স জি ৫ মিলি আই সাসপেনশন, ওলমিট্যাব প্লাস ২০/১২.৫ ট্যাবলেট, ওলমিট্যাব প্লাস ৪০/১২.৫ ট্যাবলেট, সিলমেডিপ ৫ ট্যাবলেট, সিলমেডিপ ১০ ট্যাবলেট, এজোপ্রেস বিআর ৫ মিলি আই ড্রপস, করডেফ ৬ ট্যাবলেট, করডেফ ২৪ ট্যাবলেট, জোরেল ১০ ট্যাবলেট, অক্সিফার ৫০০ মিলি আইভি ইনফিউশন, টারবিনক্স ট্যাবলেট, টারবিনক্স ১০ গ্রাম ক্রীম, স্পোরাজিন ১০০ মিগ্রা ক্যাপসুল, স্পোরাজিন ১০০ মিলি ওরাল সলিউশন, অপসেট ৫ মিলি আই ড্রপস, কনোফ্রেশ আই ড্রপস, বেস্টার ২৫০ মিলি মাউথ ওয়াশ, ডার্মাকম ১৫ গ্রাম ক্রীম। তন্মধ্যে স্পোরাজিন ১০০ মিলি ওরাল সলিউশন প্রোডাক্টটি ওরাল সলিউশন হিসেবে বাংলাদেশে সর্বপ্রথম বাজারজাত করা হয়েছে, যা শিশুদের বিভিন্ন ফাঙ্গাল ইনফেকশন চিকিৎসায় খুবই কার্যকর। এছাড়াও অক্সিফার ৫০০ মিলি আইভি ইনফিউশন, টারবিনক্স ট্যাবলেট, টারবিনক্স ১০ গ্রাম ক্রীম, স্পোরাজিন ১০০ মিগ্রা ক্যাপসুল, স্পোরাজিন ১০০ মিলি ওরাল সলিউশন, লোটেরেক্স জি ৫ মিলি আই সাসপেনশন, কনোফ্রেশ আই ড্রপস, বেস্টার ২৫০ মিলি মাউথ ওয়াশ, ডার্মাকম ১৫ গ্রাম ক্রীম চিকিৎসক মহলে বিশেষভাবে সমাদৃত হয়েছে।

ন্যাচারাল মেডিসিন

আধুনিক বিশ্বে বিশেষ করে উন্নত ও উন্নয়নশীল দেশগুলোতে হলিস্টিক চিকিৎসার ক্ষেত্রে পার্শ্ব প্রতিক্রিয়ামুক্ত ন্যাচারাল তথা

হারবাল, ইউনানী ও আয়ুর্বেদিক মেডিসিনের গুরুত্ব ও চাহিদা উত্তরোত্তর বৃদ্ধি পাচ্ছে। প্রতিষ্ঠাকাল থেকেই দি ইবনে সিনা ন্যাচারাল মেডিসিন উন্নতমানের ভেষজ উপাদান ব্যবহার করে গুণগত মান সম্পন্ন ইউনানী ও হারবাল প্রোডাক্ট উৎপাদন এবং বাজারজাতকরণ করে আসছে যা চিকিৎসক ও ভোক্তাগণের আস্থা অর্জনে সক্ষম হয়েছে। সময়ের অগ্রগতির সাথে সাথে ইবনে সিনা ন্যাচারাল মেডিসিন নিত্য নতুন ওষুধ বাজারজাত করছে।

বিক্রয় ও বিতরণ

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর বিক্রয় ও বিতরণ বিভাগটি সুসজ্জিত ও সমন্বিত। এ বিভাগে নিয়োজিত দক্ষ, পরিশ্রমী ও মেধা সম্পন্ন জনশক্তি নিয়ে প্রতিযোগিতা ও যুগোপযোগী বিতরণ কার্যক্রম সম্পাদন করছে। কোম্পানীর উৎপাদিত ওষুধ সরবরাহের লক্ষ্যে বিতরণ বহরে নিজস্ব প্রায় ৯০টি পরিবহন রয়েছে। তাছাড়া ২০টি সেল্‌স ডিপোর মাধ্যমে ভোক্তা সাধারণের দোরগোড়ায় জরুরী জীবন রক্ষাকারী ওষুধ যথাসময়ে সরবরাহ নিশ্চিত করছে। আধুনিক প্রযুক্তি যথা কম্পিউটার নেটওয়ার্ক Automation System ব্যবহার করে সুফল ভোগের পাশাপাশি কাস্টমার সার্ভিস ত্বরান্বিত করা হচ্ছে। আগামীতে “মডেল ডিপো” ধারণার আলোকে ডিপো ব্যবস্থাপনা পদ্ধতিকে উন্নত করার মাধ্যমে কাজক্ষত বিক্রয় লক্ষ্যমাত্রা অর্জনে এ বিভাগ সর্বদা প্রস্তুত ও প্রতিশ্রুতিবদ্ধ।

রপ্তানি কার্যক্রম

কোম্পানী রপ্তানি বাজারে নিজস্ব একটি মজবুত অবস্থান সৃষ্টি ও সম্প্রসারণ করার নিরন্তর প্রচেষ্টা অব্যাহত রেখেছে। দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি সাম্প্রতিক সময়ে এশিয়া, আফ্রিকা ও আমেরিকা এবং মধ্য ও দক্ষিণ আমেরিকার কয়েকটি দেশে কিছু পণ্য রপ্তানী করছে। এ ছাড়া আরও বেশ কিছু দেশে ব্যবসা উন্নয়নের জন্য যোগাযোগ চলছে। আইপিআই ISO 9001 : 2015 এবং ISO 22000 : 2018 সনদ লাভ করেছে যা বিভিন্ন দেশে ব্যবসার ক্ষেত্রে বিশ্বস্ত সহায়ক হবে।

মানব সম্পদ উন্নয়ন

কোম্পানী তার সুদূরপ্রসারী লক্ষ্য ও উদ্দেশ্যকে বাস্তবায়ন করার জন্য জনশক্তি পরিকল্পনা প্রণয়ন, জনবল নিয়োগ, কর্মী মূল্যায়ন, পদোন্নতি ইত্যাদি কর্মকাণ্ডের মাধ্যমে হেড অফিস, ফিল্ড ও ফ্যাক্টরির সকল পর্যায়ে একটি সুসমন্বিত অনুকূল কার্যকর কর্মপরিবেশ তৈরীর ইতিবাচক প্রয়াস অব্যাহত রেখে চলেছে।

লিগ্যাল অ্যাফেয়ার্স, ট্রেনিং এন্ড ডেভেলপমেন্ট

কোম্পানী পরিচালনা, কোম্পানীর সম্পদ এবং জমি-জমা ইত্যাদি প্রতিনিয়ত একটি আইনী সুরক্ষার মাধ্যমে আহরণ ও রক্ষণাবেক্ষণ, কোম্পানীর মানব সম্পদ সহ সার্বিক ব্যবস্থাপনার ক্ষেত্রসমূহকে যথাসম্ভব আইনানুগ রাখা, শ্রমিক ও শ্রমিক সংগঠন সহ শ্রম বিরোধসমূহের আইনী নিষ্পত্তি সাধন, মামলা-মোকদ্দমাসমূহ সুষ্ঠুভাবে পরিচালনার জন্য কার্যকর পদক্ষেপ নেয়া হয়েছে।

কোম্পানীর বিপুল সংখ্যক জনশক্তির দক্ষতা উত্তরোত্তর বৃদ্ধি সহ তাঁদের মেধা ও যোগ্যতার যুগোপযোগী উৎকর্ষ সাধনে নানামুখী প্রশিক্ষণের ব্যবস্থা গ্রহণ করা হয়েছে। উল্লেখ্য, আলোচ্য অর্থ বছরে কোম্পানীর বিভিন্ন স্তর ও বিভাগে কর্মরত প্রায় ৩,০০০ জনকে নিজস্ব ব্যবস্থাপনায় প্রশিক্ষণ দেয়া হয়েছে এবং ক্ষেত্র বিশেষে বিভিন্ন পেশাদার দেশী-বিদেশী প্রতিষ্ঠানে প্রশিক্ষণের জন্য প্রেরণ করা হয়েছে। প্রশিক্ষণোত্তর কর্মক্ষেত্রে এর প্রভাব ও কার্যকারিতা মূল্যায়ন (Effective Evaluation) করা হয়। একটি যুঁতসই প্রশিক্ষণ নীতিমালার আলোকে আগামীতে পুরো জনবলকে পর্যায়ক্রমে Need-Based Training কর্মসূচির আওতায় আনার পরিকল্পনা নেয়া হয়েছে, যা আগামীতে কোম্পানী তথা রাষ্ট্রীয় উন্নয়নে ইতিবাচক ভূমিকা রাখতে সক্ষম হবে বলে আশা করা যায়।

তথ্য প্রযুক্তি

একটি গতিশীল ফার্মাসিউটিক্যাল কোম্পানী হিসেবে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি মান সম্পন্ন পণ্য উৎপাদন ও বাজারজাত করণের প্রতিটি ধাপে সর্বশেষ তথ্য প্রযুক্তির ব্যবহার নিশ্চিত করেছে।

প্রকিউরমেন্ট, ইনভেন্টরী, উৎপাদন, কস্টিং, মানব সম্পদ, প্রশাসন, হিসাব, বিপন্ন, বিক্রয়, মার্কেট সার্ভে এবং বিতরণ মড্যুলসে ইআরপি পদ্ধতি উন্নয়ন কার্যক্রম চলছে। এ পদ্ধতি চাহিদা মোতাবেক সময়োচিত সিদ্ধান্ত ও পদক্ষেপ গ্রহণে খুবই সহায়ক।

প্রতিদৃষ্টিতা ও প্রতিযোগিতামূলক বাজারের সফলতা বয়ে আনার জন্য কোম্পানী আধুনিকায়ন ও সময়ের সদ্ব্যবহারের লক্ষ্যে সর্বশেষ তথ্য প্রযুক্তির সর্বোচ্চ ব্যবহার করতে বদ্ধপরিকর।

কর্পোরেট গভর্নেন্স কমপ্রায়াস রিপোর্ট

কর্পোরেট গভর্নেন্স কমপ্রায়াস অডিটর কোম্পানীর কমপ্রায়াস স্ট্যাটাস মূল্যায়ন করে সন্তোষজনক প্রতিবেদন পেশ করেছেন। বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন ইস্যুকৃত ‘কর্পোরেট গভর্নেন্স কোড’ (নোটিফিকেশন নং বিএসইসি/সিএমআরআরসিডি/২০০৬-১৫৮/২০১৮/এডমিন/৮০, তারিখ ০৩ জুন, ২০১৮) প্রতিপালনের মাধ্যমে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর কার্যক্রম পরিচালনায় কোম্পানী অঙ্গীকারাবদ্ধ। আলোচ্য অর্থ বছরে কোম্পানীর জন্য প্রযোজ্য “কর্পোরেট গভর্নেন্স কোড” যথাযথভাবে অনুসরণ করা হয়েছে। কমপ্রায়াস অডিটর কর্তৃক নিরীক্ষিত রিপোর্ট বার্ষিক প্রতিবেদনের ১৪৭ ও ১৪৮ পৃষ্ঠায় Annexure-B এবং Annexure-C তে সন্নিবেশিত হয়েছে।

ব্যবস্থাপনা সংক্রান্ত বিবৃতি ও পর্যালোচনা

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এর কর্পোরেট গভর্নেন্স কোড বিধি নং বিএসইসি/সিএমআরআরসিডি/২০০৬-১৫৮/২০১৮/এডমিন/৮০,

তারিখ ০৩ জুন, ২০১৮ অনুসারে কোম্পানীর চলমান সক্ষমতা, আর্থিক অবস্থা ও অন্যান্য প্রকাশিত বিবৃতিগুলো সম্পর্কে পৃথকভাবে বার্ষিক প্রতিবেদনের ব্যবস্থাপনা পরিচালকের প্রতিবেদনে ৫৯ পৃষ্ঠায় বিস্তারিত আলোচনা করা হয়েছে।

অতিরিক্ত বিধিবদ্ধ তথ্য

সম্মানিত শেয়ারহোল্ডারগণ ও স্টেকহোল্ডারগণের প্রতি জবাবদিহির দৃষ্টিভঙ্গি নিয়ে সুচারুরূপে কোম্পানী পরিচালনা করা হচ্ছে "কর্পোরেট গুড গভর্নেন্স" এর মূল উদ্দেশ্য। পরিচালকগণ বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এর Corporate Governance Code অনুসারে নিম্নে উল্লিখিত বিষয়সমূহের মান নিশ্চিত করেনঃ-

১. কোম্পানীর শিল্প দৃষ্টিভঙ্গি এবং সম্ভাব্য ভবিষ্যৎ উন্নয়ন সম্পর্কিত বিষয় বার্ষিক প্রতিবেদনের ৬২ পৃষ্ঠায় বর্ণিত হয়েছে;
২. সেগমেন্ট বা পণ্য ভিত্তিক Performance সম্পর্কিত তথ্য বার্ষিক প্রতিবেদনের ৭১ ও ৭২ পৃষ্ঠায় বর্ণিত হয়েছে;
৩. অভ্যন্তরীণ ও বহিরাগত ঝুঁকির কারণসহ ঝুঁকি ও অনিশ্চয়তা সম্পর্কিত প্রতিবেদন, স্থায়ীভেদ প্রতি হুমকি ও পরিবেশের ওপর নেতিবাচক প্রভাব সম্পর্কে প্রতিবেদনের ১৪২ পৃষ্ঠায় বর্ণিত হয়েছে;
৪. Cost of Goods Sold, Gross Profit Margin এবং Net Profit Margin সম্পর্কিত তথ্য বার্ষিক প্রতিবেদনের ৬৩ পৃষ্ঠায় বর্ণিত হয়েছে;
৫. অস্বাভাবিক কর্মকান্ড (লাভ ক্ষতি) ও তাঁর প্রভাব সম্পর্কে প্রতিবেদনে আলোচনা করা হয়েছে;
৬. কোম্পানীর ব্যবসা সংশ্লিষ্ট পক্ষের লেনদেন সম্পর্কিত তথ্য প্রতিবেদনের ১৯৪ পৃষ্ঠায় বর্ণিত হয়েছে;
৭. প্রান্তিক হিসাব ও বার্ষিক হিসাবের সাথে উল্লেখযোগ্য পার্থক্য নেই;
৮. ইন্ডিপেনডেন্ট পরিচালকসহ পরিচালকমন্ডলীর ভাতা (Remuneration) সম্পর্কিত তথ্য প্রতিবেদনের ১৮৯ পৃষ্ঠায় বর্ণিত হয়েছে;
৯. কোম্পানীর ব্যবস্থাপনা কর্তৃপক্ষ কর্তৃক প্রস্তুতকৃত আর্থিক বিবরণী সম্পর্কিত বিভিন্ন কার্যক্রমের চিত্র, ফলাফল, পরিচালনা নীতিমালা, নগদ অর্থ প্রবাহ এবং তারল্যের পরিবর্তন যুক্তিযুক্ত ও দূরদর্শী বিবেচনার ভিত্তিতে উপস্থাপিত হয়েছে;
১০. কোম্পানীর হিসাব বহি সমূহ যথাযথভাবে সংরক্ষিত হয়েছে;
১১. হিসাব নীতিমালা অনুসরণ পূর্বক আর্থিক বিবৃতি সমূহ প্রস্তুত করা হয়েছে এবং হিসাব সম্পর্কিত অনুমানগুলো বিচক্ষণতার সাথে যুক্তিসঙ্গতভাবে তৈরী করা হয়েছে;
১২. আর্থিক বিবরণী সমূহ প্রস্তুতকালে বাংলাদেশে প্রযোজ্য আন্তর্জাতিক হিসাব মান (IAS ও IFRS) অনুসরণ করা হয়েছে এবং যথাযথভাবে উপস্থাপন করা হয়েছে;

১৩. অভ্যন্তরীণ নিয়ন্ত্রণ ব্যবস্থার কার্যকর প্রয়োগ ও তত্ত্বাবধান নিশ্চিত করা হয়েছে;

১৪. ক্ষুদ্র বিনিয়োগকারীদের স্বার্থ সুরক্ষা সম্পর্কিত তথ্য প্রতিবেদনে উল্লেখ করা হয়েছে;

১৫. চলমান প্রতিষ্ঠান হিসেবে কোম্পানীর সক্ষমতা প্রমাণিত;

১৬. কোম্পানীর পরিচালনাগত ব্যাপারে পূর্ববর্তী বছরের তুলনায় কোন বিচ্যুতি নেই;

১৭. পাঁচ বছরের পরিচালনা ও আর্থিক ফলাফল সমূহ ৬৩ পৃষ্ঠায় বর্ণিত হয়েছে;

১৮. পরিচালনা পর্ষদের সভায় উপস্থিতির বিবরণ ১২৬ পৃষ্ঠায় বর্ণিত হয়েছে;

১৯. কোম্পানীর শেয়ারহোল্ডিং প্যাটার্ন ৭৮ ও ১৮১ পৃষ্ঠায় বর্ণিত হয়েছে;

২০. পরিচালনা পর্ষদের নিয়োগ অথবা পুনর্নিয়োগ সম্পর্কিত তথ্য প্রতিবেদনের ৫৬ পৃষ্ঠায় বর্ণিত হয়েছে;

২১. কোম্পানীর ব্যবস্থাপনা পরিচালক প্রদত্ত পরিচালনা (Management) সংশ্লিষ্ট পর্যালোচনা ও বিশ্লেষণ সম্পর্কিত তথ্য প্রতিবেদনের ৫৯ পৃষ্ঠায় বর্ণিত হয়েছে;

২২. বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এর নোটিফিকেশন অনুসারে ব্যবস্থাপনা পরিচালক এবং চিফ ফাইন্যান্সিয়াল অফিসার কর্তৃক আলোচ্য বছরে তাঁদের দায়িত্ব ও কর্তব্য সম্পর্কিত ঘোষণা প্রতিবেদনের ১৩৭ পৃষ্ঠায় বর্ণিত হয়েছে;

২৩. বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের প্রোফরমা অনুযায়ী কর্পোরেট গভর্নেন্স কমপ্লায়ান্স রিপোর্ট প্রতিবেদনের ১৪৭ এবং ১৪৮ পৃষ্ঠায় উপস্থাপিত হয়েছে;

IAS, IFRS সহ অন্যান্য আরোপযোগ্য আইন ও নীতি সমূহের যথাযথ বাস্তবায়ন

কোম্পানী আইন, ১৯৯৪ এবং বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন বিধি, ১৯৮৭ এবং বাংলাদেশ ফিন্যান্সিয়াল রিপোর্টিং এ্যাক্ট (FRA-2015) অনুসরণ পূর্বক কোম্পানী যাতে তার যাবতীয় আর্থিক লেনদেনের হিসাব সংরক্ষণ করা সহ সঠিক আর্থিক অবস্থা প্রকাশ করে, তা নিশ্চিত করার দায়িত্ব কোম্পানীর পরিচালনা পর্ষদের। সকল আর্থিক হিসাব প্রণয়নে International Accounting Standard (IAS) এবং International Financial Reporting Standard (IFRS) সহ অন্যান্য আরোপযোগ্য নীতি সমূহের পূর্ণ অনুসরণ পূর্বক প্রস্তুত করার প্রক্রিয়া নিশ্চিত করা হয়। আর্থিক হিসাব প্রস্তুত প্রক্রিয়ায় পরিচালকগণের করণীয় সম্পর্কিত পৃথক একটি রিপোর্ট ১৩৮ পৃষ্ঠায় দেয়া হয়েছে।

আর্থিক প্রতিবেদন : স্বচ্ছতা ও জবাবদিহিতা

আলোচ্য অর্থ বছরের প্রথম প্রান্তিক, অর্ধ-বার্ষিক ও তৃতীয় প্রান্তিকের আর্থিক হিসাব প্রস্তুত, আর্থিক বছর শেষে বার্ষিক

হিসাব এবং কার্যক্রমের যথাযথ মূল্যায়ন ও প্রকাশের দায়িত্ব পরিচালনা পর্ষদ পালন করে যাচ্ছেন। পরিচালনা পর্ষদ কর্তৃক গঠিত অডিট কমিটি এসব প্রতিবেদনের তথ্যবলীর সঠিকতা, যথার্থতা, স্বচ্ছতা ও পূর্ণাঙ্গতা নিয়মিত নিরীক্ষা করে থাকেন।

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের নোটিফিকেশন নং এসইসি/সিএমআরআরসিডি/২০০৮-১৮৩/এডমিন/০৩-৩৪, তারিখ ২৭ সেপ্টেম্বর, ২০০৯ এবং ঢাকা স্টক এক্সচেঞ্জ লিমিটেড ও চট্টগ্রাম স্টক এক্সচেঞ্জ লিমিটেড এর লিপিং রুলস ২০১৫ অনুযায়ী ২০২১-২২ অর্থ বছরের প্রথম প্রান্তিক, অর্ধবার্ষিক ও তৃতীয় প্রান্তিক এর অনির্ধারিত হিসাব কোম্পানীর ওয়েব সাইট, খবরের কাগজ ও অনলাইন নিউজ পোর্টালের মাধ্যমে প্রকাশ করা হয়েছে এবং কোম্পানী যথারীতি ও নিয়মিতভাবে BSEC, DSE, CSE সহ অন্যান্য নিয়ন্ত্রণকারী প্রতিষ্ঠান সমূহে প্রেরণ করেছে।

ব্যবসা সংশ্লিষ্ট পক্ষগণের সাথে লেনদেন

ব্যবসায় সংশ্লিষ্ট পক্ষসমূহের সাথে লেন-দেন International Accounting Standard IAS-২৪ ও ব্যবসায়িক নীতিমালা অনুসরণ করে বাণিজ্যিক ভিত্তিতে করা হয়েছে। আলোচ্য অর্থ বছরের সংশ্লিষ্ট পক্ষসমূহের সাথে লেন-দেনের প্রকৃতি, ধরণ, মান ইত্যাদি বিস্তারিতভাবে আর্থিক প্রতিবেদনের ১৯৪ পৃষ্ঠায় উপস্থাপন করা হয়েছে।

ক্ষুদ্র বিনিয়োগকারীগণের স্বার্থ সংরক্ষণ

২০২১-২২ অর্থ বছরে ক্ষুদ্র বিনিয়োগকারী শেয়ারহোল্ডারগণের স্বার্থ সুরক্ষিত। এতদ বিষয়ে বার্ষিক প্রতিবেদনের ১৮২ পৃষ্ঠায় বর্ণিত হয়েছে।

অস্বাভাবিক লাভ-ক্ষতি

২০২১-২২ অর্থ বছরে অস্বাভাবিক লাভ-ক্ষতি পরিলক্ষিত হয়নি।

পরিচালনা পর্ষদের ধারণকৃত শেয়ার

কোম্পানীর পরিচালনা পর্ষদের নাম ও তাঁদের নামের বিপরীতে ধারণকৃত শেয়ার সংক্রান্ত বিবরণী প্রতিবেদনের ৭৮ পৃষ্ঠায় বর্ণিত হয়েছে।

সুবিধাভোগী ব্যবসা নিষিদ্ধ করণ বিধিমালা প্রতিপালন

কোম্পানী তার সকল পরিচালক, সকল কর্মকর্তা-কর্মচারী এবং এর সাথে সংশ্লিষ্ট সবার জন্য শেয়ার লেনদেন এর ক্ষেত্রে বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এর বিধি অনুসারে সুবিধাভোগী ব্যবসা নিষিদ্ধকরণ বিধিমালা যথাযথভাবে প্রতিপালিত হচ্ছে।

আইনের প্রতি শ্রদ্ধা

রাষ্ট্রীয় আইন ও অন্যান্য প্রযোজ্য বিধি বিধানের যথাযথ অনুসরণ ও প্রতিপালনে সর্বোচ্চ অগ্রাধিকার প্রদান করা হচ্ছে এবং করণীয় বিষয়সমূহ যথাসময়ে ও যথাযথভাবে নিশ্চিত করা হচ্ছে। কোম্পানী আইন প্রয়োগকারী ও নিয়ন্ত্রণকারী সংস্থা এবং অন্যান্য আইন প্রণয়নকারী কর্তৃপক্ষের বিধি বিধান মেনে চলতে বদ্ধপরিকর।

শ্রম আইনের প্রতিপালন

শ্রমবান্ধব পরিবেশ বজায় রাখার লক্ষ্যে কোম্পানী বাংলাদেশ শ্রম আইন, ২০০৬ (সংশোধিত ২০১৮) ও শ্রম বিধি, ২০১৫ (সংশোধিত ২০২২) যথাযথভাবে প্রতিপালন করেছে।

দূষণমুক্ত পরিবেশ

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি পরিবেশ আইনের প্রতি শ্রদ্ধাশীল এবং এ লক্ষ্যে সংশ্লিষ্ট সকল কার্যক্রম গ্রহণ করেছে। ক্রমবর্ধমান মানবসৃষ্ট দূষণ ও বিপর্যয়ের কারণে সৃষ্ট পরিবেশ ও জনস্বাস্থ্য ঝুঁকিমুক্ত রাখা এবং উৎপাদনকালীন অভ্যন্তরীণ দূষণ ও বর্জ্য নিঃসরণে রাষ্ট্রীয় সংস্থা পরিবেশ অধিদপ্তর ও গুম্বুধ প্রশাসন অধিদপ্তরের বিধিমালা অনুসরণ করে ETP ও অন্যান্য দূষণমুক্ত কার্যক্রম পরিচালনা করে যাচ্ছে।

বিধিবদ্ধ পরিশোধ সমূহ

কোম্পানীতে কর্মরত কর্মকর্তা-কর্মচারীগণের এবং রাষ্ট্রীয় সকল বিধিবদ্ধ দেনা সমূহ যথাযথভাবে হালনাগাদ পরিশোধিত হয়েছে।

পুঁজি বাজারের বিধি সমূহ প্রতিপালন

কোম্পানী ঢাকা ও চট্টগ্রাম স্টক এক্সচেঞ্জ লি. এ তালিকাভুক্ত হওয়ার পর থেকে বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন, ঢাকা স্টক এক্সচেঞ্জ লি. ও চট্টগ্রাম স্টক এক্সচেঞ্জ লি. সহ এতদসংশ্লিষ্ট অন্যান্য কর্তৃপক্ষের সময়ে সময়ে ইস্যুকৃত আইন, বিধি ও নির্দেশনা সমূহ যথাযথভাবে প্রতিপালন করে যাচ্ছে।

উল্লেখযোগ্য আর্থিক বিবরণীর তথ্যাদি

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এর নির্দেশনা অনুযায়ী আলোচ্য বছর সহ গত ৫ বছরের উল্লেখযোগ্য আর্থিক কার্যক্রম ও ফলাফলের সংক্ষিপ্ত বিবরণী প্রতিবেদনের ৬৩ পৃষ্ঠায় বর্ণিত হয়েছে।

কোম্পানীর কর্মকর্তা, কর্মচারী ও শ্রমিকগণের জন্য কল্যাণমূলক কার্যক্রম

আলোচ্য অর্থ বছরে কোম্পানীর কর্মকর্তা ও কর্মচারীগণের জন্য কল্যাণমূলক কার্যক্রমের বিবরণী প্রতিবেদনের ১১০ পৃষ্ঠায় সন্নিবেশিত হয়েছে।

শ্রমিক মুনাফা অংশীদারিত্ব কল্যাণ তহবিল (WPPF)

শ্রম আইন, ২০০৬ (সংশোধিত ২০১৮) অনুযায়ী, কোম্পানীর চলতি বছরের মুনাফার ৫% অর্থাৎ ৪০,৩৪১,৬০৫ টাকা যথাসময়ে শ্রমিক অংশীদারিত্ব ও শ্রমিক কল্যাণ তহবিলে প্রদান করা হবে।

চলমান প্রতিষ্ঠান

পরিচালনা পর্ষদ কোম্পানীর ব্যবসায়িক গতি প্রকৃতি বিশ্লেষণের মাধ্যমে মহান আল্লাহর রহমতে নিশ্চিত হয়েছেন যে, আগামী দিনগুলোতে ব্যবসায়িক কার্যক্রম চালিয়ে নেয়ার মত যথেষ্ট সম্ভবিত্য কোম্পানীর রয়েছে। চলমান নীতিমালার আলোকেই কোম্পানীর

আর্থিক বিবরণীসমূহ প্রস্তুত করা হয়েছে। কোম্পানীর ব্যবস্থাপনা কর্তৃপক্ষের বিবেচনায় এরূপ কোন ঘটনা বা পরিস্থিতি সম্পর্কিত বৈষয়িক উদ্বেগ বা অনিশ্চয়তা সৃষ্টি হয়নি, যার দ্বারা কোম্পানী চলমান প্রতিষ্ঠান হিসেবে এর ভবিষ্যৎ কার্যক্রম চালিয়ে যাওয়ার ক্ষেত্রে সক্ষমতার বিষয়ে কোনরূপ সন্দেহ সৃষ্টি করতে পারে।

জাতীয় কোষাগারে অবদান

সামাজিক অঙ্গীকারের অংশ হিসেবে কোম্পানী নিয়মিতভাবে জাতীয় কোষাগারে অবদান রাখছে। কোম্পানী জাতীয় রাজস্ব কোষাগারে কর ও ভ্যাট বাবদ ০১ জুলাই ২০২১ থেকে ৩০ জুন ২০২২ পর্যন্ত ১,৭৮৯,৫৮৪,৮২৬ টাকা প্রদান করে জাতীয় অর্থনীতি বিকাশে উল্লেখযোগ্য অবদান রেখেছে।

ঝুঁকি ব্যবস্থাপনা

কোম্পানীর অভ্যন্তরীণ ও বহিঃস্থ ঝুঁকি সম্পর্কিত সম্ভাব্য সবক্ষেত্রে শক্তিশালী ঝুঁকি ব্যবস্থাপনা নীতি বিদ্যমান রয়েছে। এর বিবরণী প্রতিবেদনের ১৪২ পৃষ্ঠায় দেয়া আছে।

পরিচালনা পর্ষদের কোড অব কন্ডাক্ট প্রতিপালন

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এর বিধি প্রতিপালনার্থে কোম্পানীর পরিচালনা পর্ষদ পরিচালকগণের জন্য পৃথক একটি কোড অফ কন্ডাক্ট অনুমোদন করেছে। বার্ষিক প্রতিবেদনের ১৩৩ পৃষ্ঠায় সেটি বর্ণিত হয়েছে। কোড অফ কন্ডাক্টটি কোম্পানীর অফিসিয়াল ওয়েবসাইটে (www.ibnsinapharma.com) যথারীতি আপলোড করা হয়েছে।

নৈতিকতা পরিপালন

কোম্পানী নৈতিকতার ওপর সর্বোচ্চ গুরুত্ব দিয়ে থাকে। যাতে আইন কানুন ও পেশাদারিত্ব বজায় রেখে সংশ্লিষ্ট কর্মকর্তা, কর্মচারী এবং শ্রমিকবৃন্দের সঠিক ও সুচারুভাবে স্ব স্ব দায়িত্ব পালন করতে সক্ষম হন।

পরিচালনা পর্ষদের ভাতা

ইনডিপেন্ডেন্ট পরিচালক সহ পরিচালনা পর্ষদের সম্মানী ও ভাতা বাবদ ব্যয়ের পরিমাণ আর্থিক প্রতিবেদনের ২৭ নং নোটে উল্লেখ করা হয়েছে, যা বার্ষিক প্রতিবেদনের ১৮৮ পৃষ্ঠায় বর্ণিত হয়েছে।

পারিশ্রমিক নীতি

সম্মানী বিষয়ে সিদ্ধান্ত নেয়ার ক্ষেত্রে মুদ্রাস্ফীতি, প্রাইস ইনডেক্স এবং অপরাপর প্রতিযোগী কোম্পানী সমূহের সাথে সামঞ্জস্য রেখে কর্মকর্তা, কর্মচারী ও শ্রমিকগণের বেতন-ভাতা-মজুরী ইত্যাদি নির্ধারণ করা হয়। বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের জারিকৃত কর্পোরেট গভর্নেন্স কোড অনুসারে NRC কমিটির সুপারিশ মোতাবেক কার্যনির্বাহী পরিচালকগণের মূল্যায়ন ও সম্মানী বোর্ডের অনুমোদন সাপেক্ষে প্রদানের পদ্ধতি অনুসরণ করা হয়।

আর্থিক বিবরণী প্রস্তুত পরবর্তী ঘটনাবলী

আর্থিক বিবরণীর নোট নং-৩.১৮ এবং একই বিষয়ে বার্ষিক প্রতিবেদনের ১৯৮ পৃষ্ঠায় বর্ণিত বিষয় ব্যতিত ০১ জুলাই ২০২১ থেকে ৩০ জুন ২০২২ পর্যন্ত সময়ের আর্থিক বিবরণী প্রস্তুত পরবর্তী সময়ের প্রয়োজনীয়তা অথবা আর্থিক বিবরণীতে প্রকাশযোগ্য কোন ঘটনা ঘটেনি।

লভ্যাংশ প্রদানের নীতি

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের বিধি নং-বিএসইসি/সিএমআরআরসিডি/২০২১-৩৮৬/০৩ তারিখ জানুয়ারি ১৪, ২০২১ প্রতিপালনার্থে কোম্পানীর পরিচালনা পর্ষদ লভ্যাংশ ঘোষণা, লভ্যাংশ পরিশোধ, লভ্যাংশ বিতরণ এবং এ সম্পর্কিত বিবরণী শেয়ারহোল্ডারগণের জন্য নির্দেশক কাঠামো হিসেবে বার্ষিক প্রতিবেদনে প্রকাশ ও কোম্পানীর অফিসিয়াল ওয়েবসাইটে (www.ibnsinapharma.com) আপলোড করা একটি “লভ্যাংশ প্রদান নীতি” প্রণয়ন করেছে। কোম্পানীর “লভ্যাংশ প্রদান নীতি” বার্ষিক প্রতিবেদনের ১৩৯ পৃষ্ঠায় বিবৃত হয়েছে।

রিজার্ভ এন্ড সারপ্লাস

২০২১-২২ অর্থ বছরে কোম্পানীর রিজার্ভ এন্ড সারপ্লাস ২,২৯২,৬৪০,০৮২ টাকায় উন্নীত হয়েছে যা পূর্ববর্তী ২০২০-২১ অর্থ বছরে ছিল ১,৮৩৩,৬১৮,১১৬ টাকা।

অভ্যন্তরীণ নিয়ন্ত্রণ

কোম্পানীর অভ্যন্তরীণ নিয়ন্ত্রণ ব্যবস্থা সুষ্ঠু ভিত্তির ওপর প্রতিষ্ঠিত আছে এবং গৃহীত ব্যবস্থা যথাযথভাবে কাজ করছে। পরিচালনা পর্ষদ সময়ে সময়ে অভ্যন্তরীণ নিয়ন্ত্রণ পদ্ধতি মূল্যায়ন ও উন্নয়নের জন্য প্রয়োজনীয় পরিবর্তন আনয়ন করে থাকেন। পুঁজির সর্বোত্তম ব্যবহার, সর্বোচ্চ উৎপাদনশীলতা এবং স্বচ্ছতা নিশ্চিত করার জন্য একটি সুদৃঢ় অর্থনৈতিক ও অভ্যন্তরীণ নিয়ন্ত্রণ ব্যবস্থা কার্যকর রয়েছে।

পুঁজি বাজারে কোম্পানীর অবস্থান

আলোচ্য সময়ে কোম্পানীর শেয়ার ঢাকা স্টক এক্সচেঞ্জ লি. ও চট্টগ্রাম স্টক এক্সচেঞ্জ লি. এ অতিমাত্রায় বৃদ্ধি বা অবমূল্যায়িত হয়নি। শেয়ারহোল্ডারগণ সর্বদা আইপিআই এর শেয়ারের ওপর আস্থাশীল। উভয় স্টক এক্সচেঞ্জে প্রতি ১০ টাকার অভিহিত মূল্যের শেয়ার সর্বনিম্ন ২৩৫.০০ টাকা থেকে সর্বোচ্চ ৩০৭.০০ টাকায় ট্রেডিং হয়েছে।

হুইসেল ব্লোইং পলিসি

হুইসেল ব্লোইং পলিসির মাধ্যমে কোম্পানী সকল পর্যায়ের স্বচ্ছতা নিশ্চিত করা সহ যেকোন ধরনের জালিয়াতি ও ঝুঁকি ব্যবস্থাপনায় সাহায্য করে থাকে। এ নীতি অনুসরণে কোম্পানীর যেকোন কর্মকর্তা বা কর্মচারী/শ্রমিক অন্য কর্মকর্তা বা কর্মচারী/ শ্রমিকের অস্বাভাবিক ও অসঙ্গতিপূর্ণ কার্যকলাপ সম্পর্কে কর্তৃপক্ষকে কোম্পানীর স্বার্থে অবহিত করে থাকেন।

ইন্ডিপেনডেন্ট স্ক্রুটিনাইজার

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের বিধি নং-বিএসইসি/সিএমআরআরসিডি/২০০৯-১৯৩/০৮ মার্চ ১০, ২০২১ প্রতিপালনার্থে ০৫ সেপ্টেম্বর, ২০২২ তারিখে অনুষ্ঠিত পরিচালনা পর্ষদের ৩০০তম সভায় ৩০ অক্টোবর, ২০২২ তারিখে অনুষ্ঠিতব্য ৩৮তম বার্ষিক সাধারণ সভার রেজুলেশন, শেয়ারহোল্ডারগণের ভোটাধিকার প্রয়োগের সুবিধাদি পর্যবেক্ষণের জন্য এম. মোহসিন এন্ড কোং চার্টার্ড সেক্রেটারীজকে ইন্ডিপেনডেন্ট স্ক্রুটিনাইজার হিসেবে নিয়োগ দান করা হয়।

বার্ষিক সাধারণ সভা সমাপ্তির নির্দিষ্ট সময়সীমার মধ্যে নির্বাচন এবং ভোটের ফলাফলের সঠিকতা বিষয়ে বিস্তারিত তথ্যাদি ইন্ডিপেনডেন্ট স্ক্রুটিনাইজার বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এ জমা দেবেন।

কর্মকর্তা-কর্মচারী-শ্রমিক সু-সম্পর্ক

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এ কর্মরত সর্বস্তরের কর্মকর্তা-কর্মচারী-শ্রমিকগণের মাঝে কাজের প্রতি একাত্মতা, নিষ্ঠা, গভীর আন্তরিকতা, অর্থবহ সহযোগিতা ও মর্যাদাপূর্ণ ভ্রাতৃত্বপূর্ণ সুসম্পর্ক বিরাজ করছে যা কোম্পানীর উন্নয়ন ও উৎপাদনের গতিশীলতা বৃদ্ধিতে প্রতিনিয়ত শক্তি যোগাচ্ছে।

অ-দাবীকৃত লভ্যাংশ পুঁজিবাজার স্থিতিশীল করণ তহবিলে স্থানান্তর নগদ লভ্যাংশ :

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের বিধি নং-বিএসইসি / সিএমআরআরসিডি / ২০২১-৩৮৬ / ০৩ তারিখ জানুয়ারি ১৪, ২০২১ এবং ক্যাপিটাল মার্কেট স্ট্যাবিলাইজেশন ফান্ড রুলস ২০২১ প্রতিপালনার্থে কোম্পানী ১৯৯৩ থেকে ২০১৮ সাল পর্যন্ত সময়ের অ-দাবীকৃত/ অ-বিতরণকৃত/ অ-মিমাংশীত লভ্যাংশ বাবদ ২,৯২,৮১,৯৭৭.৭৮/- (দুই কোটি বিরানব্বই লক্ষ একাশি হাজার নয়শত সাতাত্তর টাকা আটাত্তর পয়সা) টাকা মাত্র ইনভেস্টমেন্ট কর্পোরেশন অব বাংলাদেশ (আইসিবি) এর অধীন “পুঁজি বাজার স্থিতিশীল করণ তহবিল” কমিউনিটি ব্যাংক বাংলাদেশ লি., গুলশান কর্পোরেট শাখায়, হিসাব নং-০০১০৩১১৫২১৩০১ এ জমা দেয়া হয়েছে। বছর ভিত্তিক অ-দাবীকৃত/অ-বিতরণকৃত/অ-মীমাংশিত লভ্যাংশের পরিমাণ বার্ষিক প্রতিবেদনের ১৪১ পৃষ্ঠায় বর্ণিত হয়েছে।

স্টক ডিভিডেন্ড (বোনাস শেয়ার)

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের বিধি নং-বিএসইসি/সিএমআরআরসিডি/২০২১-৩৮৬/০৩ তারিখ জানুয়ারি ১৪, ২০২১ এবং ক্যাপিটাল মার্কেট স্ট্যাবিলাইজেশন ফান্ড রুলস ২০২১ প্রতিপালনার্থে কোম্পানী ১৫ মার্চ, ২০২২ তারিখে ২০০৯-২০১৮ পর্যন্ত সর্বমোট ২০৩০৬৬১ (বিশ লক্ষ ত্রিশ হাজার ছয়শত একষট্টি) টি স্টক ডিভিডেন্ড (বোনাস শেয়ার) আইসিবি সিকিউরিটিজ ট্রেডিং কোম্পানী লি. এ

পরিচালিত “পুঁজিবাজার স্থিতিশীলকরণ তহবিল” এর বিও হিসাব নং-১২০১৫৩০০৭৪৫৭১২৩০ এ যথারীতি স্থানান্তর করা হয়েছে।

লভ্যাংশ

পরিচালনা পর্ষদ ২০২১-২২ অর্থবছরে ১০ টাকা অভিহিত মূল্যের প্রতিটি শেয়ারের জন্য ৬০% নগদ লভ্যাংশ প্রদানের সুপারিশ করেছে।

অডিট কমিটি

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের নোটিফিকেশন নং বিএসইসি / সিএমআরআরসিডি / ২০০৬-১৫৮ / ২০৭ / এডমিন / ৮০ তারিখ ৩ জুন ২০১৮ এর নির্দেশনা মোতাবেক পরিচালনা পর্ষদ কর্তৃক গঠিত ২ জন ইন্ডিপেনডেন্ট পরিচালকসহ বহুমুখী অভিজ্ঞতা সম্পন্ন ৩ (তিন) সদস্য বিশিষ্ট অডিট কমিটি কাজ করছে। কমিটি তার রিপোর্টে বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন ও বোর্ড কর্তৃক প্রদত্ত দায়িত্ব সম্পাদন, অভ্যন্তরীণ নিরীক্ষা পদ্ধতি, অনিরাঙ্কিত প্রান্তিক আর্থিক বিবরণী, বার্ষিক আর্থিক প্রতিবেদন প্রস্তুত এবং বহিঃ নিরীক্ষকগণের পর্যবেক্ষণগুলোর বিশদ আলোচনা ও পর্যালোচনা করেছেন। রিপোর্টিং এর কোন পর্যায়ে ন্যূনতম ত্রুটি, অমিল অথবা সত্য পরিপন্থী তথ্য না থাকায় আর্থিক অবস্থার প্রতিবেদন বাস্তব ও স্বচ্ছ হিসেবে গণ্য হয়েছে। অডিট কমিটির একটি রিপোর্ট ১২৯ পৃষ্ঠায় সন্নিবেশিত হয়েছে।

নিম্নেশন ও রেম্যুনেরেশন (NRC) কমিটি

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের কর্পোরেট গভর্নেন্স কোড (বিএসইসি / সিএমআরআরসিডি / ২০০৬-১৫৮ / ২০৭ / এডমিন / ৮০ তারিখ ৩ জুন, ২০১৮) এর ৬নং শর্ত অনুসারে ৩ (তিন) সদস্য বিশিষ্ট একটি Nomination and Remuneration (NRC) কমিটি গঠন করা হয়। আলোচ্য অর্থ বছরে NRC কমিটির কার্যক্রমের বিস্তারিত বিবরণ প্রতিবেদনের ১৩২ পৃষ্ঠায় সন্নিবেশিত হয়েছে।

কর্পোরেট সামাজিক দায়বদ্ধতা (CSR) নীতি

কর্পোরেট সামাজিক দায়বদ্ধতাকে সামনে রেখে কোম্পানীর Good Governance Practice নিয়মিত ও ধারাবাহিক প্রতিপালনের লক্ষ্যে পরিচালনা পর্ষদ অনুমোদিত কর্পোরেট সামাজিক দায়বদ্ধতা (CSR) নীতি অনুযায়ী কাজ করে যাচ্ছে। এ নীতি সৃষ্টভাবে কার্যকর করার জন্য বোর্ড তিন সদস্য বিশিষ্ট একটি উপ-কমিটি গঠন করেছে। বোর্ড গঠিত CSR উপ-কমিটি আলোচ্য অর্থ বছরে কোম্পানী কর্তৃক গৃহীত CSR নীতিমালা অনুসারে কর্পোরেট সামাজিক দায়বদ্ধতা কার্যক্রম পর্যবেক্ষণ ও পর্যালোচনা করেছে, যা প্রতিবেদনের ১০৯ পৃষ্ঠায় সন্নিবেশিত হয়েছে।

ইন্ডিপেনডেন্ট পরিচালক

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের বিধি নং বিএসইসি / সিএমআরআরসিডি / ২০০৬-১৫৮ / ২০৭ / এডমিন / ৮০ তারিখ ৩ জুন, ২০১৮ অনুযায়ী দু’জন

ইন্ডিপেনডেন্ট পরিচালক যথাক্রমে মো. আব্দুস সালাম, এফসিএ, এফসিএস, প্রাক্তন প্রেসিডেন্ট দি ইনস্টিটিউট অফ চার্টার্ড একাউন্ট্যান্টস অফ বাংলাদেশ ও আব্দুস সাদেক ভূঁইয়া, দায়িত্ব পালন করছেন। BSEC's Code of Corporate Governance, ২০১৮ অনুসারে মো. আব্দুস সালাম, এফসিএ, এফসিএস কে বার্ষিক সাধারণ সভার অনুমোদন সাপেক্ষে ০১.০১.২০২২ থেকে ৩১.১২.২০২৪ পর্যন্ত দ্বিতীয় মেয়াদের জন্য পুনর্নিয়োগ দেয়া হয়েছে।

অন্যদিকে ইন্ডিপেনডেন্ট পরিচালক মো. রফিকুল ইসলাম খান, এফসিএ এর মেয়াদকাল ৩১ ডিসেম্বর ২০২১ এ সমাপ্ত হওয়ায় BSEC's Notification, dated 03 June, 2018 অনুযায়ী আব্দুস সাদেক ভূঁইয়া বিএসএস (অনার্স), এমএসএস, ঢাকা বিশ্ববিদ্যালয়, সাবেক উপ-ব্যবস্থাপনা পরিচালক, ইসলামী ব্যাংক বাংলাদেশ লি. কে বার্ষিক সাধারণ সভার অনুমোদন সাপেক্ষে ইন্ডিপেনডেন্ট পরিচালক হিসেবে ১৬.০১.২০২২ থেকে ১৫.০১.২০২৫ পর্যন্ত প্রথম মেয়াদের জন্য নিয়োগ দেয়া হয়েছে।

কোম্পানীর এ দু'জন অভিজ্ঞ ইন্ডিপেনডেন্ট পরিচালকের সংক্ষিপ্ত জীবন বৃত্তান্ত বার্ষিক প্রতিবেদন বিবৃত হয়েছে।

পরিচালক নির্বাচন

কাজী হারুন অর রশিদ ও প্রফেসর ড. একেএম সদরুল ইসলাম কোম্পানী আইন, ১৯৯৪ এর ধারা ৯১(২) এবং কোম্পানীর সংঘ বিধির ২৮ ধারা অনুসারে ৩৮তম বার্ষিক সাধারণ সভায় অবসর গ্রহণ করবেন। অবসর গ্রহণকারী পরিচালকদ্বয় পুনর্নির্বাচনের যোগ্য। বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন প্রদত্ত নির্ধারিত পদ্ধতিতে পরিচালকদ্বয়ের সংক্ষিপ্ত জীবন বৃত্তান্ত প্রতিবেদনের ২৪-২৫ পৃষ্ঠায় সন্নিবেশিত হয়েছে।

নিরীক্ষক নিয়োগ

কোম্পানীর নিরীক্ষক মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্ট্যান্টস ২০২১-২২ অর্থ বছরের নিরীক্ষা কার্য সম্পাদন করেছেন। মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্ট্যান্টস ৩৮তম বার্ষিক সাধারণ সভায় অবসর গ্রহণ করেছেন। বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের নোটিফিকেশন নং- বিএসইসি/সিএমআরআরসিডি/২০০৯-১৯৩/১০৪ এডমিন তারিখ ২৭ জুলাই, ২০১১ অনুসারে বর্তমান নিরীক্ষক নিরীক্ষা কার্যক্রম করার যোগ্য নন।

বিধিবদ্ধ নিরীক্ষক হিসাবে নিয়োগ দেয়ার জন্য কোম্পানী দুইটি স্বীকৃত চার্টার্ড একাউন্ট্যান্টস ফার্ম থেকে 'আগ্রহ প্রকাশ' Expression of Interest (EOI) পেয়েছে। অডিট কমিটি নিরীক্ষা ফার্ম দুটির বৃত্তান্ত ও বিবরণ পর্যালোচনা করে এস এফ আহমদ এন্ড কোং চার্টার্ড একাউন্ট্যান্টস কে ২০২২-২৩ অর্থ বছরের জন্য নিরীক্ষক হিসাবে নিয়োগ দানের সুপারিশ করেছে।

বৃত্তান্ত ও বিবরণী পর্যালোচনার পর বিধি মোতাবেক উপযুক্ত বিবেচিত হওয়ায় পরিচালনা পর্ষদ অডিট কমিটির সুপারিশ মোতাবেক ২,৫০,০০০/- (দুই লক্ষ পঞ্চাশ হাজার) টাকা

সম্মানী ধার্য করে ২০২২-২৩ অর্থ বছরের জন্য এস এফ আহমদ এন্ড কোং চার্টার্ড একাউন্ট্যান্টসকে নিরীক্ষক হিসাবে ৩৮তম বার্ষিক সাধারণ সভায় শেয়ারহোল্ডারগণের অনুমোদন সাপেক্ষে নিয়োগ দানের সিদ্ধান্ত গ্রহণ করেছে।

কমপ্রায়াল অডিটর নিয়োগ

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের ইস্যুকৃত কর্পোরেট গভর্নেন্স কোড অনুযায়ী মেসার্স ইতরাত হোসেন এন্ড এসোসিয়েটস কোম্পানীর ২০২১-২২ অর্থ বছরের কমপ্রায়াল অডিট সম্পন্ন করেছেন। মেসার্স ইতরাত হোসেন এন্ড এসোসিয়েটস ৩৮তম বার্ষিক সাধারণ সভায় অবসর গ্রহণ করেন।

কোম্পানী কর্তৃক কমপ্রায়াল অডিটর হিসাবে কাজ করার জন্য স্বীকৃত দুইটি চার্টার্ড একাউন্ট্যান্টস/ সেক্রেটারীজ ফার্ম এর নিকট থেকে Expression of Interest (EOI) গ্রহণ করা হয়েছে। কমপ্রায়াল অডিট ফার্ম দুইটির বৃত্তান্ত ও বিবরণ পর্যালোচনার পর কোম্পানীর অডিট কমিটি এম. মোহসিন এন্ড কোং চার্টার্ড সেক্রেটারীজকে কমপ্রায়াল অডিটর হিসাবে ২০২২-২৩ অর্থ বছরের জন্য নিয়োগ দানের সুপারিশ করেছে।

সংশ্লিষ্ট ফার্মের বৃত্তান্ত ও বিবরণ পর্যালোচনা এবং বিধি মোতাবেক উপযুক্ত বিবেচিত হওয়ায় পরিচালনা পর্ষদ অডিট কমিটির সুপারিশ গ্রহণ করে ৭৫,০০০/- (পঁচাত্তর হাজার) টাকা সম্মানী ধার্য করতঃ ৩৮তম বার্ষিক সাধারণ সভার অনুমোদন সাপেক্ষে ২০২২-২৩ অর্থ বছরের জন্য কমপ্রায়াল অডিটর হিসেবে এম. মোহসিন এন্ড কোং চার্টার্ড সেক্রেটারীজকে নিয়োগ দানের সিদ্ধান্ত গ্রহণ করেছে।

সাবসিডিয়ারি কোম্পানির পরিচালনা পর্ষদ

কর্পোরেট গভর্নেন্স কোড এর সাথে সঙ্গতি রেখে সাবসিডিয়ারি কোম্পানীর পরিচালনা পর্ষদে কোম্পানীর প্রতিনিধিত্ব রয়েছে। সে হিসেবে প্রত্যেক সাবসিডিয়ারি কোম্পানীর পরিচালনা পর্ষদে একজন করে ইন্ডিপেনডেন্ট পরিচালক প্রতিনিধিত্ব করছেন। সাবসিডিয়ারি কোম্পানী দি ইবনে সিনা এপিআই ইন্ডাস্ট্রি লি., দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. এবং দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি. এর পরিচালনা পর্ষদের সভার কার্যবিবরণী দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর পরিচালনা পর্ষদের সভায় উপস্থাপন করা হয়েছে এবং যথাযথভাবে তা পর্যালোচনা ও নথিভুক্ত করা হয়েছে। কোম্পানীর পরিচালনা পর্ষদ সাবসিডিয়ারি কোম্পানীর সাময়িক ও বার্ষিক আর্থিক বিবরণী পর্যালোচনা করেছেন। নিম্নে ধারাবাহিকভাবে সাবসিডিয়ারি কোম্পানী গুলোর প্রকৃত চিত্র তুলে ধরা হল:-

দি ইবনে সিনা এপিআই ইন্ডাস্ট্রি লি.

এপিআই কোম্পানীর একটি অগ্রাধিকার মূলক প্রকল্প। এখানে উৎপাদিত মৌলিক কাঁচামাল নিজস্ব ব্যবহারের পাশাপাশি জাতীয় স্বার্থে দেশে এবং বিদেশে এটির ব্যবসা সম্প্রসারিত হবে। প্রত্যাশিত সময়ের মধ্যে লক্ষ্যে পৌঁছার জন্য এটির নির্মাণ ও

এতদসংশ্লিষ্ট কার্যক্রম ২০২৩ এর মধ্যে সমাপ্ত করার পদক্ষেপ গ্রহণ করা হয়েছে। দি ইবনে সিনা এপিআই ইন্ডাস্ট্রি লি. এর পরিচালনা পর্ষদের এতদসংক্রান্ত একটি বিবরণী বার্ষিক প্রতিবেদনের ২১২ পৃষ্ঠায় বর্ণিত হয়েছে।

দি ইবনে সিনা ন্যাচারাল মেডিসিন লি.

পৃথক ব্যবস্থাপনা, উন্নত পরিচালনা, নির্বিঘ্ন উৎপাদন এবং ব্যবসায়িক অগ্রগতির লক্ষ্যে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর ন্যাচারাল মেডিসিন ডিভিশন এর নেট সম্পত্তি দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. (দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর ৯৯.৯৯% সাবসিডিয়ারী কোম্পানী) এ স্থানান্তরের সিদ্ধান্ত গৃহীত হয়। যা অদ্যকার সভায় বিশেষ সিদ্ধান্ত হিসেবে গ্রহণের জন্য পেশ করা হলো।

দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. এর পরিচালনা পর্ষদের একটি বিবরণী অত্র প্রতিবেদনে ২০১ পৃষ্ঠায় সন্নিবেশিত করা হয়েছে।

দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি.

দি ইবনে সিনা পলিমার প্রজেক্ট দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর আর একটি সাবসিডিয়ারী কোম্পানী। মাওনা, গাজীপুরে অবস্থিত কারখানায় প্লাস্টিক ও পলিমার জাতীয় পণ্য এবং পেট বোতল উৎপাদন ও বাজারজাত করা হবে। স্বল্প সময়ের মধ্যে প্রকল্পের কাজ সমাপ্ত হবে বলে আশা বাদ ব্যক্ত করা হচ্ছে।

দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি. এর পরিচালনা পর্ষদের একটি বিবরণী অত্র প্রতিবেদনের ২২৩ পৃষ্ঠায় দেয়া হয়েছে।

শেয়ারহোল্ডারগণের সাথে যোগাযোগ ও সম্পর্ক

কোম্পানী আইন মোতাবেক কোম্পানী যথারীতি নিয়মিত বার্ষিক সাধারণ সভা আয়োজন করে আসছে, যার মাধ্যমে শেয়ারহোল্ডারগণকে আর্থিক ফলাফল, অগ্রগতি, গৃহীত গুরুত্বপূর্ণ কার্যক্রম ও উন্নয়ন সম্পর্কে অবহিত করা হয়। ফলে

শেয়ারহোল্ডারগণ ও সংশ্লিষ্ট প্রতিষ্ঠান কোম্পানী সম্পর্কে বিভিন্ন প্রয়োজনীয় তথ্য যথাসময়ে অবহিত হচ্ছেন। শেয়ারহোল্ডারগণ শেয়ার বিভাগ থেকে টেলিফোন, মোবাইল ফোন, ই-মেইল ও ওয়েব সাইটের (www.ibnsinapharma.com) মাধ্যমে প্রতিনিয়ত প্রয়োজনীয় তথ্যাদি সংগ্রহ ও সেবা নিতে পারছেন।

কৃতজ্ঞতা ও ধন্যবাদ জ্ঞাপন

পরিচালনা পর্ষদ ওষুধ শিল্পের সাথে সংশ্লিষ্ট স্বাস্থ্য মন্ত্রণালয়, ওষুধ প্রশাসন অধিদপ্তর, ওষুধ শিল্প সমিতি, সম্মানিত চিকিৎসক, কেমিস্টসহ জাতীয় রাজস্ব বোর্ড ও শ্রম প্রশাসনের অকুণ্ঠ সমর্থনের জন্য আন্তরিক ধন্যবাদ জানাচ্ছে।

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন, ঢাকা স্টক এক্সচেঞ্জ লি. ও চট্টগ্রাম স্টক এক্সচেঞ্জ লি. সহ সরকারের বিভিন্ন সংস্থা সমূহের সার্বিক সহযোগিতার কথা পরিচালকমণ্ডলী কৃতজ্ঞচিত্তে স্মরণ করছে।

পরিচালনা পর্ষদ ব্যবসায়িক সফলতায় আন্তরিক অবদান রাখা সহ সব পর্যায়ের ক্রেতা-ভোক্তা, পৃষ্ঠপোষক ও শুভানুধ্যায়ীকে সার্বিক সহযোগিতার জন্য আন্তরিক মোবারকবাদ জানাচ্ছে। পাশাপাশি কর্মকর্তা, কর্মচারী ও শ্রমিকবৃন্দের গভীর আন্তরিকতা, অর্থবহ সহযোগিতা, আনুগত্য ও কর্তব্য নিষ্ঠার জন্য ধন্যবাদ জ্ঞাপন করছে।

সম্মানিত শেয়ারহোল্ডারগণ পরিচালনা পর্ষদের ওপর যে আস্থা ও বিশ্বাস রেখেছেন তা তাঁদেরকে গভীরভাবে উৎসাহিত ও অনুপ্রাণিত করেছে। এটি বজায় রাখতে ব্যবস্থাপনা কর্তৃপক্ষ, কর্মকর্তা, কর্মচারী ও শ্রমিকবৃন্দ দৃঢ় প্রতিজ্ঞ।

দেশ ও জাতির অব্যাহত উন্নয়নে আমাদের সব অকৃত্রিম ও নিরলস প্রয়াস আল্লাহপাক কবুল করুন।

পরিশেষে আমাদের প্রিয় জন্মভূমি গণপ্রজাতন্ত্রী বাংলাদেশ, এ দেশের আপামর জনসাধারণ এবং কোম্পানির উত্তরোত্তর উন্নতি, সমৃদ্ধি ও সার্বিক অগ্রগতির জন্য মহান আল্লাহ রাবুল আলামীনের দরবারে রহমত কামনা করছি।

আল্লাহ হাফিজ।

পরিচালনা পর্ষদের অনুমোদনক্রমে ও পক্ষে,

প্রফেসর ড. একেএম সদরুল ইসলাম

ব্যবস্থাপনা পরিচালক

DIRECTORS' REPORT

Bismillahir Rahmanir Rahim

Distinguished Shareholders,

Assalamu Alaikum Wa

Rahmatullah

We have the pleasure to welcome you on behalf of the Board of Directors at the 38th Annual General Meeting of The IBN SINA Pharmaceutical Industry PLC (IPI) and present before you to receive, consider and adopt the Audited Financial Statements of the Company for the year ended on June 30, 2022 together with the Auditors' Report and Directors' Report thereon, for your valuable guidance, opinion and consideration. We express our gratitude to the Almighty Allah (swt) for the Company's business achievement in 2021-22.

This report has been prepared in compliance with Section 184 of the Companies Act, 1994, Rule 12 (and the schedule thereunder) of Bangladesh Securities and Exchange Rules 1987, Corporate Governance Code 2018 of Bangladesh Securities and Exchange Commission, International Accounting Standards and International Financial Reporting Standards as adopted by Financial Reporting Council, Bangladesh and The Dhaka and Chittagong Stock Exchange (Listing) Regulations, 2015.

Main Objective of the Company

The Company's main objective is to play the role usually offering to the healthcare services of highest standard through production and marketing of quality Allopathic, Unani and Herbal medicines in Bangladesh and abroad.

Outlook

IBN SINA Pharma tried to maintain the continuity of its productivity and best ethical standard of business affairs preferring the principles of sustainable development despite the adverse situation in social and environmental aspects in the year under review. The activities initiated for sustainable development of the Company viewing its future outlook may be seen in the page no. 62 of the Annual Report.

Management's Discussion and Business Analysis

The year under review, despite the unprecedented challenges, in the national and international business arena, the Company had made all-out efforts to maintain an overall progressive growth trend by virtue of timely actions taken by the Board of Directors, managing the finance efficiently through visionary steps and ensuring proper investment procedures.

As a result, continuously growing performance in the operational, financial and profitability, enabling IPI expected to hold in the leading position of Country's Pharma sector.

Mentionable that Bangladesh's pharmaceutical sector is growing rapidly, with local institutions meeting 98 percent of the Country's demand and also export pharmaceuticals to several countries across the world. In the global context, Bangladesh ranks 71st out of 178 countries in the world. Pharmaceutical industry accounts for 1.83% of the Country's GDP.

However, Bangladesh's pharmaceutical industry, nevertheless still has a lot of room for growth at home and largely in abroad especially if it focuses on high quality/life savings medicine and the country's pharmaceutical policy needs to be upgraded regularly through research and development.

In the year 2021-22, EPS stood Tk. 19.39 which was Tk. 15.66 in 2020-21. In the year under review, Net Asset Value per share is Tk. 83.36 which was Tk. 68.69 in 2020-21 and in the year 2021-22, Net Asset Value stood Tk. 2,604,390,765 which was Tk. 2,146,199,473 over the last corresponding year. NOCFPS stood Tk. 13.40 in the year under review which was previously Tk. 17.67.

Achievement in Revenue Growth

The Company registered a significant growth increasing overall productivity. In the year 2021-22 revenue growth of 14.96% was achieved compared to the preceding year. In the year 2021-22 overall sales achievement stood at Tk. 8,479,819,569 which was Tk.7,376,042,094 in the last year. This was accomplished with the coordinated efforts of all levels of employees engaged in sales, marketing and the factory.

Demerging of NMD from The IBN SINA Pharmaceutical Industry PLC (IPI) and transfer of its Net Assets to The IBN SINA Natural Medicine Ltd. (INM), a Subsidiary Company of IPI

For better management and to make ease of operation of natural medicine production and businesses, the Board of Directors of the Company has decided to demerge the Natural Medicine Division (NMD) of the Company by transferring its "Assets and Liabilities duly audited" as at year ended June 30, 2022 in the form of "Total Assets" valuing at Tk. 20,81,69,670 (Taka Twenty Crore Eighty One Lac Sixty Nine Thousand Six Hundred Seventy) as at June 30, 2022 to its 99.99% owned Subsidiary Company- The IBN SINA Natural Medicine Ltd.- in exchange of consideration other than cash as against acquiring of the shares held by the holding Company, The IBN SINA Pharmaceutical Industry PLC subject to approval at this Annual General Meeting of the Company and in compliance with the necessary regulatory requirements in this regard.

In this respect, a 'Vendors Agreement' executed between The IBN SINA Pharmaceutical Industry PLC (Vendor) and The IBN SINA Natural Medicine Ltd. (Vendee) to effect the transfer of the said Net Assets as against the acquisition of shares.

A 'Special Resolution' on the subject as specified in the "AGM Notice 2021-22" has to be adopted by the Shareholders in today's AGM of the Company.

Amendment of Company Name

As per sub-section (ka) of Section 11ka of the Companies Act, 1994 (Amendment 2020), regarding "Indication of Public Limited Company" the name of the Company has been amended as The IBN SINA Pharmaceutical Industry PLC.

In line with the same law, all necessary amendment with regard to company's registered documents like Memorandum and Articles of Association, etc. have duly been completed and approved by the relevant authorities.

Industrial Prospects and Future Sustainable Development

We are optimistic about the future outlook. Keeping such in view multi-dimensional actions have been taken to enhance productivity and revenue not only from local sales but also from the export.

In order to achieve future sustainable growth and to provide the healthcare facility locally and globally, new strategies have been formulated to explore the project diversifications.

The Company gives the utmost importance in extending businesses activities through supply of products as per demand keeping in view of future challenges depending on the advanced technologies. The Company's outlook in terms of "a general review of the future prospects" has been mentioned in the page no. 62 of the Annual Report.

Bangladesh Pharma Market


The year under review, the growth of pharmaceutical market of Bangladesh was not attained yet, The IBN SINA Pharmaceutical Industry PLC achieved 14.96% growth which is compatible with respect to the overall growth of pharma market of the Country.

Financial Results

The financial results of 2021-22 are summarized below:


| Particulars | Amount in Taka | |
|--|----------------|---------------|
| | 2021-22 | 2020-21 |
| Profit Before Tax | 799,862,485 | 704,448,050 |
| Income Tax | 194,187,861 | 215,476,279 |
| Profit After Tax | 605,674,624 | 488,971,771 |
| Retained Earnings | 2,288,247,972 | 1,829,226,006 |
| Net Asset Value | 2,604,390,765 | 2,146,199,473 |
| Net Asset Value (NAV) Per Share | 83.36 | 68.69 |
| Earnings Per Share (EPS) | 19.39 | 15.66 |
| Net Operating Cash Flow Per Share (NOCFPS) | 13.40 | 17.67 |

Net Asset Value (NAV) Per Share




■ 2020-21 ■ 2021-22

Earnings Per Share (EPS)



■ 2020-21 ■ 2021-22

NOCFPS



■ 2020-21 ■ 2021-22

Fixed Assets

As part of continual development program, The IBN SINA Pharmaceutical Industry PLC has achieved overall progress in:

1. Acquisition of Land and Land Development;
2. Building Construction Works of new projects and
3. Procurement and Commissioning of new capital machineries for production, QC and utility purpose.

Among the ongoing new projects, The IBN SINA API Industry Ltd. located at Govt. API Industrial Park is at the final stage, expecting to start pilot production in March 2023. The project works have been delayed due to doldrums of economic condition caused by pandemic prevailing worldwide.

At the Godhulia Project, Unit-2 of The IBN SINA Pharmaceutical Industry PLC are ongoing, where another project, The IBN SINA Polymer Industry Ltd. located at Muwna, Gazipur will be commissioned soon.

All these new project works and the new capital machineries are in fact adding value to fixed asset groups of the Company. Detail particulars of the fixed assets added during the year under review is stated in the page no. 199 of the Annual Report.

Technology Integration with Production Capacity

Procurement of modern technology, research and training are being continued to enrich the production capacity of the factory by increasing efficiency and skills in terms of quality and quantity as well. The investments for capital machineries, etc., for Pharm, Cepha and Natural medicine factories made during the year under review were funded from own sources and Banking institution to yield the benefits balanced financial leverage.

The Qualitative Standard of Medicine and Raw Materials

The IBN SINA Pharmaceutical Industry PLC is committed to maintain the qualitative standard of medicine. Highest efforts are given to identify genuine sources, collecting of best quality raw materials and their proper storing and also producing prescribed standard medicine for which there is an effective Total Quality Management (TQM) system in the Company. Relentless endeavor is being given to deliver the quality medicine with competitive price at the door steps of the customers.

Marketing of New Medicines

Pharma Medicine

The IBN SINA Pharmaceutical Industry PLC is regularly introducing new products along with existing products which contributed remarkably in the achievement of Company's sales growth. The IBN SINA Pharmaceutical Industry PLC has launched 21 products of 15 generics during 2021-22 fiscal year including Glipatab 10 Tablet, Glipatab 25 Tablet, Rivacap 3 Capsule, Loterex-G 5ml Eye Suspension, Olmetab Plus 20/12.5 Tablet, Olmetab Plus 40/12.5 Tablet, Cilmedip-5 Tablet, Cilmedip-10 Tablet, Azopres BR 5 ml Eye Drops, Cordef 6 Tablet, Cordef 24 Tablet, Xorel-10 Tablet, Oxyfer-500 ml IV Infusion, Terbinox 10 gm Cream, Terbinox Tablet, Sporagin 100 mg Capsule, Sporagin 100 ml Oral Solution, Opacet 5 ml Eye Drops, Combofresh 5 ml Eye Drops, Bester 250 ml Mouthwash, Dermacom 15 gm Cream. Among them Sporagin 100 ml Oral Solution was launched for the first time in Bangladesh and it is effective in the treatment of fungal infections of children. Products like Oxyfer-500 ml IV Infusion, Terbinox 10 gm Cream, Terbinox Tablet, Sporagin 100 mg Capsule, Sporagin 100 ml Oral Solution, Opacet 5 ml Eye Drops, Loterex-G 5 ml Eye Suspension, Combofresh 5 ml Eye Drops, Bester 250 ml Mouthwash, Dermacom 15 gm Cream were well accepted by the physicians.

Natural Medicine

The general acceptability and consumption of natural medicine of the people is being increased remarkably in the Country and globally in comparison with synthetic (Allopathic) medicine. The IBN SINA Natural Medicine Ltd. has achieved the trustworthiness and credibility from the physicians as well as consumers. Since its establishment it is dedicated to produce and marketing qualitative standard natural medicine (unani and herbal medicine) and medicated consumer products assuring quality raw materials.

Sales and Distribution

Sales and Distribution Department of the Company is very time befitting and well equipped and futuristic. The manpower employed in this department are experienced, skilled having knowledge of modern distribution channel management technology serving diligently. There are 90 vehicles of various types to distribute the medicine countrywide. Besides, timely distribution of the life-saving medicines at the doorsteps of the consumers is being ensured through 20 Sales Depots. Smooth communication and customer service has been accelerated adding modern technology like software, automation and networking facilities. This department is ready and

committed as always to achieve the desired sales goals using the upgraded depots management system titled 'Model Depot Concept' in the coming days as well.

Export Activities

The Company is very much hopeful to expand the export market more and to create this expected space, the utmost effort is being continual. At present, IPI is exporting a number of products to several countries in Asia, Africa, USA, Central America and South America. Many more countries of several regions are under communication for future business development. IPI's entitlement to ISO 9001:2015 & ISO 22000:2018 Certifications also contribute to expanding its access to different countries.

Human Resources Development

The HR Department is endeavoring to create an emphatic balanced complimentary working environment having the belief in equal and meritocratic employment towards attracting, retaining, developing and promoting the most qualified and competent employees regardless of their race, ethnicity, religion, gender or any other such characteristics. This policy is applicable to our recruitment, placement, promotion, training and retention strategy resulting of which ensuring the development of diverse workforce with skills and integrity giving their diligent efforts to run the total activities of the Company effectively and efficiently.

Legal Affairs, Training and Development

Legal Affairs is vigilant all the time to properly maintain land properties of the Company and also face the litigations sued against the Company, legally mitigation of industrial disputes, keeping the Company compliant of overall legal management activities. In order to develop skill as well as efficiency of all level of employees increasingly, Training and Development Department initiated the various professional training programmes. Last year, around 3,000 employees in different levels were taken under training programme of in-house and in different local & foreign professional training organizations. A plan was taken to bring the total manpower of the company in the same platform gradually of "Need-based Training" Manual adopting an appropriate training policy.

Information Technology

Being an ever expanding pharmaceutical company, The IBN SINA Pharmaceutical Industry PLC is producing quality products maintaining accuracy in every step applying the updated Information Technology and know-how. ERP System development is in progress where Procurement,

Inventory, Production, Costing, HR, Admin, Accounts, Marketing, Sales, Survey and Distribution modules are being incorporated. This system accelerates to take real time decision and action as required. Company is vigilant for more modernization and time benefiting IT system to cope up with the growing demand of the competitive challenging markets.

Corporate Governance Compliance Report

The Corporate Governance Compliance Auditors has issued a "Satisfactory" Report on the overall level of compliance by the Company. The Company is committed to run the organization in adherence to the Code of Corporate Governance (Notification No. BSEC / CMRRCD / 2006 -158 / 207 / Admin / 80, dated: 3 June 2018) issued by the Bangladesh Securities and Exchange Commission (BSEC). During the year under review the code applicable for the Company was duly followed. The compliance of the Corporate Governance Code certified by the Compliance Auditors and status of compliance of the Company are reflected respectively in "Annexure- B" and "Annexure- C" of the Annual Report page no. 147-148

Management Discussion and Analysis

Detailed discussion on the operating and financial performance of the Company along with other disclosures as required under Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC) through Notification No. BSEC / CMRRCD / 2006-158 / 207 / Admin / 80, dated June 3, 2018 has been separately reported by the Managing Director in page no. 59 of the Annual Report.

Additional Disclosures and Information

The objective of Corporate Good Governance is to run the Company effectively and legitimately with a sense of accountability and transparency to the shareholders and the society as a whole. The Company is complying with the "Corporate Governance Code" of Bangladesh Securities and Exchange Commission since it's promulgation.

The Board of Directors has confirmed the standard of corporate good governance incorporating the following additional statements in the Annual Report:

- (i) Industry outlook and possible future development of the Company is stated in the page no. 62 of the Annual Report.
- (ii) The information about the segment-wise or product-wise performance is stated in the page no.

71 and 72 of the Annual Report.

(iii) The report regarding the risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment is stated in the page no. 142 of the Annual Report.

(iv) A discussion on the cost of goods sold, gross profit margin and net profit margin is stated in the page no. 63 of the Annual Report.

(v) The detail discussion on continuity of any extraordinary activities and their implications (gain or loss) was duly been stated.

(vi) The detail discussion on the business related party transaction of the Company is stated in the page no. 194 of the Annual Report.

(ix) Explanation on any significant variance that occurs between Quarterly Financial performances and Annual Financial Statement has been stated in page no. 53.

(x) A statement of remuneration paid to the Directors including Independent Directors is stated in the page no. 189 of the Annual Report.

(xi) The financial statements prepared by the management present fairly the state of affairs of the Company, results of its operations, cash flow and changes of equity.

(xii) The Books of Accounts of the Company have been properly maintained.

(xiii) Principles of accounting have been followed in preparing the statement of accounts and estimates related to accounting have been made reasonably and with prudence.

(xiv) IAS and IFRS applicable in Bangladesh have been followed in preparing the financial statements.

(xv) The internal control system was proper and effective application and monitoring was confirmed.

(xvi) Statement of Minority Shareholders' Interest Protection has duly been stated in the Directors' Report.

(xvii) The ability of the Company as a going concern has been proved.

(xviii) There have been no remarkable deviations in the operational affairs as compared to the previous year.

(xix) Preceding five years' the key operational and financial data have been summarized in page 63.

(xxii) The attendance in Board of Directors meetings has been described in page 126.

(xxiii) The shareholding pattern of the Company has been presented in page 78 and 181.

(xxiv) Regarding the disclosures on the appointment or reappointment of Directors', the prescribed

information of the Directors' have been given in the page no. 56.

(xxv) The management discussion and analysis given by the Managing Director of the Company is stated in the page no. 59 of the Annual Report.

(xxvi) Declaration or Certification by the Managing Director and Chief Financial Officer to the Board of Directors as per "Annexure-A" of BSEC'S Corporate Governance Code is disclosed in the page no. 137 of the Annual Report.

(xxvii) The report of compliance on the Corporate Governance Code audited by Compliance Auditors has been incorporated as per Proforma prescribed by BSEC which is shown in "Annexure-B" and "Annexure-C" in the page 147 and 148 of Annual Report.

Implementation of IAS, IFRS and Other Applicable Laws and Regulations

The Board of Directors of the Company is entrusted to ensure the disclosure of actual financial position and preparation and maintenance of all types of Statutory Statements as per The Rules of Bangladesh Securities and Exchange Commission, 1987, Companies Act, 1994 and Bangladesh Financial Reporting Act, 2015. The Board of Directors is absolutely responsible to prepare all types of financial reports in line with International Accounting Standard (IAS), International Financial Reporting Standard (IFRS) and other applicable rules and regulations. The roles and responsibilities of the Directors in presentation of the financial report has been stated in page 138 of the Annual Report.

Financial Report, Accountability and Transparency

The Board of Directors discharged their due responsibilities through timely preparation and publication of 1st quarter, half yearly, 3rd quarter and Annual Financial Report at the end of each financial period and the affairs of the Company performed in the year under review. Audit Committee, a sub-committee of the Board examined the true and accountability, fairness, transparency and completeness of these reports before placement of the same to the Board for their approval.

The Company published the report (un-audited accounts) of 1st quarter, half yearly and 3rd quarter accounts as per notification of Bangladesh Securities and Exchange Commission (BSEC) and the Listing Regulations, 2015 of Dhaka Stock Exchange Ltd. (DSE) and Chittagong Stock Exchange Ltd. (CSE) through Company's Website, Newspapers and Online News Portal and submitted

the same timely to BSEC, DSE, CSE and other regulatory authorities.

Related Party Transactions

The business related party transaction of the Company is being made based on the business principle and as per International Accounting Standard IAS: 24. During the year under review, the standard, nature and the manner of related party transactions in the ordinary course of business carried out arm's length basis at commercial rates with its related parties were reflected transparently in the financial statements which is given in the page no. 194 of the Annual Report.

Minority Shareholders' Interest Protection

During the year under review, the minority shareholders' interest has duly been protected with effective means of redress. No abusive actions either directly or indirectly with regard to the interest of minority Shareholders was observed. The disclosure in this respect is stated in the page No. 182 of the Annual Report.

Unusual Profit or Loss

In the year 2021-22, there is no unusual profit or loss was observed.

Directors' Shareholding Position

Particulars of shares as against the name of the Directors of the Company have been stated in the page no.78 of the Annual Report.

Beneficiary Insider Trading Prohibition

The Company has outlined the beneficiary insider trading prohibition policy regarding the trading of Company's share for its directors, employees and concerned persons. The policy is being followed accordingly.

Adherence to the Laws

The laws of the state and other applicable rules and regulations of the Company and the affairs thereon have duly been complied with the highest preference and timely actions on the same have been ensured. The Company is committed to abide by the rules of regulatory bodies and other legislative authorities as always.

Compliance to the Labour Laws

In order to maintain labour friendly atmosphere in all aspects, the Company duly comply with Bangladesh Labour Act, 2006 (As amended 2018) and other relevant laws and regulations applicable to the Company.

Pollution Free Environment

In order to protect from risk of human health and environment, caused by increasing man-made

pollution; The IBN SINA Pharmaceutical Industry PLC is trying its best to keep pollution free environment through Effluent Treatment Plant (ETP) and follow the required laws and rules of The Directorate General of Drug Administration and Department of Environment of the Government in the factory and its surrounding as well.

Statutory Payments

All statutory payments in relation to the employees and the government have duly been made up-to-date.

Compliance to the Laws of the Capital Market

Since listing in both the Stock Exchanges of the Country, the Company strictly abides by all the laws, regulations and directions circulated from time to time by Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange Ltd. (DSE) and Chittagong Stock Exchange Ltd. (CSE) and other related authorities.

Key Information of the Financial Statements

As per direction of the Bangladesh Securities and Exchange Commission (BSEC), the key information of the financial statements of preceding five years' including current year has been summarized in the page no. 63 of the Annual Report.

Welfare Activities for the Company's Officers and Workers

The welfare activities for the Company's officers and workers taken during the year under review are briefly presented in the page no. 110 of the Annual Report.

Workers' Profit Participation Fund and Welfare Fund

The year under review 5% of the Company's profit i.e. Tk. 40,341,605 will be transferred to the workers' profit participation fund and welfare fund as per Labour Laws 2006 (As amended in 2018).

A Going Concern

By the grace of the Almighty Allah, the Board of Directors after analysis of the business trend of the Company has confirmed that the Company has enough ability to carry on business activities in the coming days as a Going Concern and the financial statements have been prepared on the basis of going concern assumption basis. As per management assessment there is no material uncertainty related to events or conditions which may cast significant doubt upon the Company's ability to continue as a going concern.

Contribution to the National Exchequer

The Company had made a significant contribution in the year 2021-22 towards the National Exchequer by

paying Tk. 1,789,584,826 as Income Tax and VAT.

Risk Management

In order to control all matters involving risks and uncertainties, the Company has a strong risk mitigation process. This has been described in details in page 142 of this Annual Report.

Directors' Code of Conduct

The Board of the Company has approved a separate Code of Conduct for its Directors in compliance with the requirement of Bangladesh Securities and Exchange Commission (BSEC) Corporate Governance Code, June 03, 2018 which is stated in the page no. 133 of the Annual Report. This Code of Conduct was duly been uploaded in the Company's official website (www.ibnsinapharma.com)

Code of Ethics and its Implementation

Highest emphasis is given on the implementation of code of ethics and principles so that the concerned officials and personnel can take appropriate decision complying the required laws and professional manner.

Directors' Remuneration

This information is incorporated in the Note no. 27 of the Notes to the Financial Statements in the page no. 188 of Annual Report with reference to the "Directors Fees and Remuneration" figures relating to the Board of Directors including Independent Directors.

Wage and Remuneration Policy

The salary and wages of the employees are usually determined considering the prevailing inflation, price index and in commensuration with the existing salary structure with other competitor companies. The procedure of evaluation and determining the honorarium of the Executive Directors are being followed within the criteria recommended by the Nomination and Remuneration Committee (NRC) duly approved by the Board as per Corporate Governance Code of BSEC.

Events after the Reporting Period

Events after the reporting period for the year 2021-22, no necessity arose for subsequent adjustment or no pecuniary issues thereto happened which is mentionable in the financial statements excepting as provided in the note no 3.18 of the Notes to the Financial Statements and disclosure of the same in the page no. 198 of the Annual Report.

Dividend Distribution Policy

In compliance with the Directive No. BSEC / CMRRCD / 2021-386 / 03, dated 14 January, 2021 of the Bangladesh Securities and Exchange

Commission (BSEC), the Board of Directors of The IBN SINA Pharmaceutical Industry PLC has formulated "The Dividend Distribution Policy" about dividend declaration, pay off, disbursement and compliance and disclosed the same publishing in the Company's annual report and official website at www.ibnsinapharma.com as a guiding framework for the shareholders to allow the Shareholders to make informed investment decisions. Company's Dividend Distribution Policy is stated in the page no. 139 of the Annual Report.

Reserves and Surplus

In the year 2021-22, Company's reserves and surplus rose to Tk. 2,292,640,082 which was Tk. 1,833,618,116 in the previous year.

Internal Control

Internal control system of The IBN SINA Pharmaceutical Industry PLC is founded on specified set code approved by the Board. The Board of Directors incorporates necessary norms and practices of internal control system for development of control management. An effective internal control system is in action to ensure the transparency, highest productivity and maximum utilization of resources.

Company's Position in the Share Market

In the year under review, the market share of the Company did not face ups and downs significantly in either Dhaka Stock Exchange Ltd. (DSE) or Chittagong Stock Exchange Ltd. (CSE). The shareholders had always been confident on The IBN SINA Pharmaceutical Industry PLC shares. In the year from July 01, 2021 to June 30, 2022, the Company's shares were traded in both stock exchanges at minimum of Tk. 235.00 to maximum of Tk. 307.00 as against the face value of Tk.10.

Whistle Blowing Policy

Company's Whistle Blowing Policy ensures to establish transparency in all aspects and also in terms of minimizing the risk management and detecting any forgery or embezzlement.

Independent Scrutinizer

As per BSEC's Directive No. BSEC/CMRRCD/2009-193/08 Dated-March 10, 2021, the Board of Directors in its 300th meeting held on 05.09.2022, appointed M. Mohashin & Co, Chartered Secretaries as an Independent Scrutinizer to observe the 38th AGM of the Company to be held on October 30, 2022 ensuring the facility to exercise the shareholder (holders of paper shares or dematerialized shares) voting rights on the resolution proposed to be considered at the general meeting.

The due process of election and detailed information of voting results shall be authenticated by Independent Scrutinizer, M. Mohashin & Co, Chartered Secretaries and be reported of the same to the BSEC within the stipulated time of conclusion of AGM.

Employee Relationships

There exists devotion to work and respectful and harmonious relationships among all levels of officers and employees in The IBN SINA Pharmaceutical Industry PLC which has accelerated the Company's progress and productivity.

Transferring the Unclaimed Dividend to Capital Market Stabilization Fund (CMSF)

Cash Dividend

Pursuant to the Bangladesh Securities and Exchange Commission's (BSEC) Directive No. BSEC / CMRRCD / 2021-386 / 03 Dated, January 14, 2021 and Bangladesh Securities and Exchange Commission Capital Market Stabilization Fund Rules, 2021, the Company transferred the amount of Tk. 2,92,81,978 (Two Crore Ninety Two Lakh Eighty One Thousand Nine Hundred Seventy Eight) only held against unclaimed or undistributed or unsettled dividend from the year 1993 to 2018 as on March 28, 2022 to the Bank Account No. SND A/C 0010311521301 titled "Capital Market Stabilization Fund (CMSF)" maintained with, Community Bank Bangladesh Ltd., Gulshan Corporate Branch, Dhaka.

Year wise unclaimed / undistributed / unsettled dividend amount is stated in the page no.141 of the Annual Report and Company's website link at <http://www.ibnsinapharma.com/investors/corporate-governance/unclaimed-dividend-information/>

Stock Dividend

Pursuant to the Bangladesh Securities and Exchange Commission's (BSEC) Directive No. BSEC / CMRRCD / 2021-386 / 03 Dated, January 14, 2021 and Bangladesh Securities and Exchange Commission Capital Market Stabilization Fund Rules, 2021, the Company transferred 20,30,661 (Twenty Lac Thirty Thousand Six Hundred Sixty One) number of Bonus Shares held against unclaimed or undistributed or unsettled stock dividend from the year 2009 to 2018 as on March 15, 2022 to the Beneficiary Account (BO) No. 1201530074571230 titled "Capital Market Stabilization Fund (CMSF)" maintained with, ICB Securities Trading Company Ltd., Dhaka.

Dividend

Based on the overall performance as reflected in the Financial Statements for the year 2021-22 of the

Company, the Board of Directors proposed cash dividend at 60% as against per share of Tk.10.

Audit Committee

As per condition no. 5 of BSEC's notification no. BSEC / CMRRCD / 2006-158 /207 / Admin /80 dated 3 June, 2018, the Audit Committee consisting of three members including two Independent Directors having prominent reputation and versatile knowledge and experience have been working prudently.

The Audit Committee had detailed discussion and analysis on its report as directed by BSEC and the Board with regards to internal audit system, preparation of unaudited periodical accounts, annual financial report and the observations of external auditors. As there was no evidence of slightest mistakes, dissemblance or information contrary to the truth, the financial report was considered as realistic and transparent. Report of the Audit Committee is presented in the page no. 129 of the Annual Report.

Nomination and Remuneration Committee

In accordance with the condition 6 of Bangladesh Securities and Exchange Commission's Code of Corporate Governance, BSEC / CMRRCD / 2006 -158 / 207 / Admin / 80 dated 3 June 2018, the Board constituted the Nomination and Remuneration Committee (NRC). The report from the Nomination and Remuneration Committee (NRC) about their activities performed during the year under review is mentioned in the page no. 132 of the Annual Report.

Corporate Social Responsibility (CSR)

In view of the corporate social responsibility of the Company, the Board of Directors has approved corporate social responsibility policy as part of accountability to the society. A three members committee; sub-committee of the Board has been formed to implement this policy. The CSR activities taken by the Company in the year under review has been stated in the page no. 109 of the Annual Report.

Independent Directors

As per notification no. BSEC / CMRRCD / 2006 -158 / 207 / Admin / 80 dated 3 June, 2018 of Bangladesh Securities and Exchange Commission (BSEC), two learned and veteran professionals respectively Md. Abdus Salam FCA, FCS, a past president of The Institute of Chartered Accountants of Bangladesh and Abdus Sadeque Bhuiyan have been performing the duties as Independent Directors of the Company.

It may be informed that as per BSEC's Code of Corporate Governance, 2018 Md. Abdus Salam FCA, FCS has been reappointed as Independent Director for the second term from 01.01.2022 to 31.12.2024 subject to approval in this AGM of the Company.

On the other hand, being the tenure of office of Independent Directorship of Md. Rafiqul Islam Khan, FCA ended on 31 December 2021, as per BSEC's Notification, Dated- 03 June 2018 on Corporate Governance Code, Abdus Sadeque Bhuiyan BSS (Hon's) MSS, DU Ex-Deputy Managing Director of Islami Bank Bangladesh Ltd. (IBBL) has been appointed as Independent Director of the Company for the first term from 16.01.2022 to 15.01.2025 subject to approval in this AGM of the Company.

The brief profile of two learned professional Independent Directors of the Company has been stated in the Directors' profile of the Annual Report.

Election of Directors

Kazi Harun or Rashid and Prof. Dr. AKM Sadrul Islam retire from the office in this Annual General Meeting as per Article 28 of Articles of Association of the Company and Section 91 (2) of the Companies Act, 1994. As per law, the retired directors are eligible to be re-elected to act as Director. The brief resume along with the required information of the directors is given under the Directors' Profile of this Annual Report.

Appointment of Statutory Auditors

Malek Siddiqui Wali, Chartered Accountants, Statutory Auditors of the Company, audited the Accounts for the year 2021-22. Malek Siddiqui Wali, Chartered Accountants retire at this meeting. As per BSEC/CMRRCD/2009-193/104/Admn, Date- 27 July, 2011 the existing auditors are not eligible for reappointment as Statutory Auditors.

The Company has received Expression of Interest (EOI) to be appointed as Statutory Auditors from two (2) recognized Chartered Accountants firms. The profile of these two audit firms was reviewed by the Audit Committee and suggested to appoint S F Ahmed & Co., Chartered Accountants as Statutory Auditors of the Company for the financial year, 2022-23.

After review and discussion over the profile and particulars of the said Firms and being eligible as per Law, the Board of Directors has concurred with the recommendation of the Audit Committee to appoint S

F Ahmed & Co., Chartered Accountants as Statutory Auditors of the Company for the financial year, 2022-23 with a remuneration of Tk. 2,50,000/- (Two Lac Fifty Thousand Taka) only subject to approval by the Shareholders in the AGM of the Company.

Appointment of Compliance Auditors

As per Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC), Itrat Hussain & Associates, Chartered Secretaries in Practice, Compliance Auditors of the Company audited the compliance status of the Company for the year 2021-22. Itrat Hussain & Associates, Chartered Secretaries in Practice retire at this AGM.

The Company has received Expression of Interest (EOI) to be appointed as Compliance Auditors from two (2) recognized Chartered Accountants / Secretaries firms. The profile of these two audit firms was reviewed by the Audit Committee and recommended to appoint M. Mohashin & Co. Chartered Secretaries as Compliance Auditors of the Company for the financial year, 2022-23.

After review and discussion over the profile and particulars of the said Firms and being eligible as per law, the Board of Directors has concurred with the recommendation of the Audit Committee to appoint M. Mohashin & Co. Chartered Secretaries as Compliance Auditors of the Company for the financial year 2022-23 with a remuneration of Tk. 75,000/- (Taka Seventy Five Thousand) only subject to approval at this AGM of the Company.

Governance of Board of Directors of Subsidiary Companies

The Company's representation in the Subsidiary Company's Board was in line with the Corporate Governance Code and accordingly, one Independent Director of The IBN SINA Pharmaceutical Industry PLC has been nominated in the Board of every Subsidiary Company The IBN SINA API Industry Ltd., The IBN SINA Natural Medicine Ltd. and The IBN SINA Polymar Industry Ltd. Minutes of the Board meetings of the Subsidiary Companies were placed before the Board of The IBN SINA Pharmaceutical Industry PLC and then duly reviewed and recorded. Board of Directors of the holding Company also reviewed the periodical and annual financial statements of the subsidiaries.

Company wise disclosures are as follows: -

The IBN SINA API Industry Ltd.

API as one of the priority projects of the Company

established to achieve basic raw materials support locally for Company's own use and for extending API business at home and abroad for the national interest. Implementation of the project is going on in full swing and expected to complete the project by the end of 2023. Mentionable that project completion has been delayed for about two years due to COVID 19 Pandemic.

The disclosures in this respect, in the form of Directors Report of The IBN SINA API Industry Ltd. may be seen in the page no. 212 of the Annual Report.

The IBN SINA Natural Medicine Ltd.

The IBN SINA Natural Medicine Ltd., Subsidiary Company of IPI formed keeping in view of ensuring more sustainable growth of Natural Medicine in a broader way having production capacity of medicated health products, food supplements, nutraceuticals and other medicated cosmetics, etc. and to establish the same as distinct entity at Shafipur, Gazipur, Bangladesh. As per of such motto, it was decided to merge the Natural Medicine Division of The IBN SINA Pharmaceutical Industry PLC (IPI) with The IBN SINA Natural Medicine Ltd. for better management and ease of operation of natural medicine production and businesses.

The disclosures for the year under review of The IBN SINA Natural Medicine Ltd. in the form of Directors' Report are stated in the page no. 201 of the Annual Report.

The IBN SINA Polymer Industry Ltd.

Another Subsidiary Company, The IBN SINA Polymer Project was formed in order to produce and market plastic/polymer related products and/or pet-bottles, etc. The development is in progress to establish the same in Chalkpara, Mawna, Gazipur, Bangladesh expected to complete within the projected time. The necessary disclosures in this respect, in the form of Directors' Report of The IBN SINA Polymer Industry Ltd. are stated in the page no. 223 of the Annual Report.

Relation and Communication with the Shareholders

The Company has been arranging regular Annual General Meetings (AGM) as per Companies Act,

1994 through which shareholders are informed about the Company's progress, important activities and the development activities undertaken during the year under review. As a result, the shareholders, concerned organizations and the people get various information about the Company in due time. The shareholders of the Company are able to collect all required information from our Share Department through landphone, mobile phone, e-mail service and website (www.ibnsinapharma.com) as well.

Recognition and Compliments

The Board of Directors extends its' heart felt gratitude to the Ministry of Health, The Directorate General of Drug Administration, National Board of Revenue (NBR), respected Doctors, Chemists, Patrons and all concerned with the pharmaceutical industry for their all-out support to us. The Board of Directors remembers gratefully the co-operation of Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange Ltd. (DSE), Chittagong Stock Exchange Ltd. (CSE) and other regulatory agencies of the Government. The Board thanks the Banks and the Financial Institutions for their support.

The Board of Directors wishes all levels of officers, employees, buyers, consumers, patrons, well-wishers and all concerned for their sincere contributions towards our business success. We are also grateful to our respected shareholders for their relentless support to the Company.

The shareholders' trustworthiness to the Board of Directors makes them confident and deeply inspired. The management and employees of all levels are committed to uphold this as we march ahead to take The IBN SINA Pharmaceutical Industry PLC forward as a leading partner in Bangladesh's business community.

May Allah Subhanahu Wa Taa'la accept all our efforts for the development of our Company, Nation and the Country at large. We pray to the Almighty Allah for His blessings for inspiring the overall progress and prosperity of our beloved Country, The People's Republic of Bangladesh.

Allah Hafiz

Approved by the Board of Directors and signed on its behalf,



Prof. Dr. AKM Sadrul Islam
Managing Director



**STATEMENT FROM THE
MANAGING DIRECTOR**

**MANAGEMENT'S
Discussion and Analysis**

Bismillahir Rahmanir Rahim

Dear Honourable
Shareholders

Assalamu Alaikum
Wa Rahmatullah

By the grace of Almighty Allah (swt), The IBN SINA Pharmaceutical Industry PLC has completed its journey of 38 years with a good track of achievement growth records in the Pharmaceutical business (Pharma and Natural Medicine). In spite of the various operational perils being prevailed, the Company has achieved a remarkable growth.

You are all aware that the world is now menaced "by war, famine and pestilence", as we see the Covid-19 is still prevailed, then Russia-Ukraine war, resulting the total supply chain of international trade is being disrupted and also, inflation has been unleashed in a way not seen for last few decades.

In this respect, the authority has already designed a plethora of dos and don'ts for such contingency situation aiming to keep the things of strategic development of the Company in order and continuous.

However, the empathetic working friendly environments in the Company inspired our dedicated workforce down to up to be completely cohesive towards the Company's growth and the mission, at large. Our efforts generated from wisdom, dedication, hard work and strong determination to play the expected role at the individual's level powered by the ethical and moral obligations led us to attain the expected results this year also similar to the past successful track records. This in turn has enabled us to maintain progressive revenue at a reasonable level in the financial year 2021-22. We acknowledge with gratitude for continual trust and support of our valued shareholders, patrons, physicians, regulatory authorities, and the end users of Company's products.

I wish to take the opportunity to share with you some facts and figures of our company as follows:

As per condition no. 1 (5) (xxv) of the Corporate Governance Code 2018 issued by Bangladesh Securities and Exchange Commission, the management's discussion and analysis representing detailed analysis of the Company's position and operations along with a brief discussion of changes in the financial statements for the year 2021-22, among others, focusing on:-

- Revenue amounting to Tk. 8,479,819,569 increased by 14.96% over the year 2020-21;
- Earnings per share (EPS) stood Tk. 19.39 which was Tk. 15.66 in the year 2020-21;
- Enriching product portfolio by introducing 21 new products with 15 generics in Pharma;
- Contribution to the National Exchequer in the form of VAT, AIT and Corporate Tax of Tk. 1,789,584,826.

Accounting Policies and Estimation for Preparation of Financial Statements

The IBN SINA Pharma follows International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS) along with the Laws of Bangladesh applicable for preparation of Financial Statements.

The accounting policies and estimation used for the preparation of financial statements of the Company has been mentioned in details in the page no. 167 of the Annual Report.

Changes in Accounting Policies and Estimation

No changes in accounting policies and estimation which have the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes was observed in the year under review and the description on the issue is stated in the page no. 173 of the Annual Report.

Comparative Analysis of Financial Performance and Operational Performance

Company performance

Below is a comparative analysis of the financial performance and financial position of our Company over the last 5 (five) years including the current year:

| Particulars | 2021-22 | 2020-21 | 2019-20 | 2018-19 | 2017-18 | 2016-17 |
|-------------------------|---------------|---------------|---------------|---------------|---------------|---------------|
| Revenue | 8,479,819,569 | 7,376,042,094 | 6,191,628,639 | 5,263,963,344 | 4,657,350,011 | 4,009,153,501 |
| Gross Profit | 3,566,070,119 | 3,100,717,195 | 2,596,563,310 | 2,161,812,203 | 1,892,629,975 | 1,623,525,321 |
| Net Profit After Tax | 605,674,624 | 488,971,771 | 392,527,310 | 336,266,870 | 452,296,714 | 233,829,346 |
| EPS | 19.39 | 15.66 | 12.56 | 10.76 | 14.48 | 8.23 |
| Dividend Payout Ratio % | 30.94 | 30.02 | 30.64 | 27.87 | 25.12 | 38.65 |
| Gross Profit Ratio % | 42.05 | 42.04 | 41.94 | 41.07 | 40.64 | 40.50 |
| Current Ratio (Time) | 1.50 | 1.26 | 0.83 | 0.84 | 0.81 | 0.89 |
| Debt Equity Ratio | 0.38 | 0.40 | 0.40 | 0.53 | 0.50 | 0.37 |
| Return on Equity % | 25.50 | 24.93 | 24.12 | 24.86 | 38.79 | 23.69 |

Detail of comparative analysis of financial performance and operational performance for current financial year with immediate preceding five years has been explained with reasons thereof in the page no. 63 of the Annual Report

Comparison of Financial Performances and Financial Position as well as Cash Flows with Peer Industry Scenario:

Peer Industry Analysis

The Company is diversified business conglomerate having several production plants. On the other hand, top leading Pharmaceutical companies are mostly

private or proprietorship Company, therefore, despite difficulties of making defined segment based comparison of financial performance or results and financial position as well as cash flows with some peer industries we have made the followings for ease of understanding.

We have selected three of the listed companies for comparison and have used ratio analysis as it is one of the best tools for assessing and comparing the financial performance of the Company based on the published Annual Report 2019-20 and 2020-21.

| Particulars | 2020-21 | | | | 2019-20 | | | |
|--|----------|-----------|--------|--------|----------|-----------|--------|--------|
| | IBN SINA | Orion Ph. | Square | Renata | IBN SINA | Orion Ph. | Square | Renata |
| Current ratio (Times) | 1.26 | 2.70 | 17.67 | 2.29 | 0.83 | 3.99 | 14.52 | 2.53 |
| Return on Equity (%) | 24.93 | 4.68 | 19.38 | 19.78 | 24.12 | 3.47 | 19.82 | 19.17 |
| Net Asset Value per Share (Tk) | 68.69 | 79.76 | 92.75 | 261.16 | 56.88 | 76.77 | 78.86 | 221.03 |
| Net operating Cash flow per share (Tk) | 17.67 | 11.04 | 12.32 | 43.40 | 15.92 | 8.04 | 12.29 | 45.70 |
| Earnings per Share (Tk) | 15.66 | 4.01 | 17.99 | 51.67 | 12.56 | 2.84 | 15.06 | 42.38 |

Financial and Economic Scenario of Bangladesh and Global Position as well briefly placed as under:

Bangladesh Perspective

As we know the Country's pharmaceutical sector is meeting 98% of its domestic demand, has the potential to become the next RMG in terms of export. Country's achievement in the Pharmaceutical sector is phenomenal and the secret of this success is the skilled human resource and matured related supply chain resources.

Besides to meeting the domestic demand, as exporter of medicines to several countries of the world, Bangladesh ranks 71st out of 134 countries in the world in terms of global pharmaceutical exports. As per market analysis by the Bangladesh

Investment Development Authority (BIDA), the demand for healthcare services is growing at about 21% annually. The Dublin-based Market insight and analysis firm, "Research and Markets" reported that the pharmaceutical market of Bangladesh is expected to surpass \$6 billion by 2025.

According to the Bangladesh Bureau of Statistics (BBS) report, the per capita income increased to US \$2,824 in the fiscal year 2021-22. It was reported that the size of the GDP stood at \$416 billion in year, 2021.

In post pandemic era, 2022's focus and priorities are move on reviving economy, restoration of supply chain and as such irrespective of being taken various recovery steps, our recommendation to the Government is to give emphasis on faster

implementation of API Park, long-term policy, value addition, more facilities like RMG sector, negotiation with WTO for extension of TRIPS agreement, updating the laws and looking into ASEAN market.

Global Perspective

According to the World Bank's released study titled "Global Economic Prospect, June 2021", economic growth in 2021 is predicted to be 5.6 percent, up from 3.5 percent in 2020. The Global growth will be 4.3 percent in 2022 and 3.1 percent in 2023, according to the study.

On the other hand, the International Monetary Fund (IMF) forecast global economic growth of 6.0 percent in 2021 in the World Economic Outlook (WEO) for April 2021, which is 0.8 percent higher than the projection in October 2020 WEO. Bangladesh keeps its growing economics with a steady growth performance where GDP growth was 5.2% in 2020 and remained positive growth trend at 6.94% in 2021 despite the grim affect of the COVID-19 pandemic prevailed last year worldwide.

The global health crisis caused by Covid-19 has hit Bangladesh's economy hard and decelerated economic growth in 2021. Nevertheless, strong remittance inflows and a rebound in export market helped recovering the economy gradually. Apart from addressing the post pandemic situation, it is required to face the challenges derived from crisis of recent Russia-Ukraine war, creating more employment, human capital and skilled labour force, efficient infrastructure and time-befitting policy enabling to attract private and foreign direct investment.

Risk and Concerns Issues Related to the Financial Statements

Efficient and Effective Risk Management is the integral part of today's business. As such, The IBN SINA Pharmaceutical Industry PLC is always subject to systematic risks of the industry and market as well.

The risks and concerned issues related to the financial statements, explaining such risk and mitigation plan thereof is described in the page no. 142 of the Annual Report.

Justification of Future Outlook and Forecast for Company's Operations, Performances and Financial Position

Pharmaceutical Industry in Bangladesh is one of the most developed Technology Sectors within the Country. In addition to substantial local growth, the pharmaceutical industries are expanding their export business with the aim to expand their business to the overseas countries. Regulatory requirement for export has invoked a compliance challenge to the exporters and this in turn generated a competition in the development of compliant cGMP production facility.

In order to cope up with the prevailing trends of expanding business locally and internationally, our

Company has earmarked its plans for a faster growth with the latest products as well as with new technological dosage forms, and at the same time, undertaken a number of ambitious new projects and development activities.

After successful completion of Cephalosporin and OSD Extension Project, the Company is going to commence works for establishing compliant manufacturing facilities in its Mawna Project Site, Gazipur. It is IBN SINA's first Industrial Park aiming to establish the new projects like Biotech, Sterile, LVP, MDI, Oncology and specialized OSD manufacturing facilities. Conceptual designs of layout plans for these facilities are completed.

Meanwhile, the construction works of API Project have been advanced towards the final stage. Production in both the plants will be started in 2023. These compliant production facilities will certainly uplift the market exposure of the Company into the zenith status.

IBN SINA Pharma management also thriving for business diversification, including pharma backward linkage and export oriented factories. In this respect, a Company named "The IBN SINA Polymer Industry Ltd." has already been formed. Necessary steps have been initiated to move the plan into materiality within the befitting time.

The Management considers new project planning and development works with a forecast of minimum 5 year with the aim to meet judicious financial assessment and impacts. Management is conscious about financial investment in each project and has set up project implementation strategies enabling to come into operation within 3 years.

While, concluding, I appreciate for the leadership offered by the Board of Directors and the Management and also I would like to express my sincere appreciation to our valued customers, shareholders, suppliers, bankers, business partners, the healthcare professionals, Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange Ltd. (DSE), Chittagong Stock Exchange Ltd. (CSE), other regulatory authorities and all other stakeholders for their trust and continued support to the Company and to all the employees of the Company for their hard endeavor.

We pray to the Almighty Allah (swt) for His gracious blessings for the Company's bright success in future.



Prof. Dr. AKM Sadrul Islam
Managing Director

FINANCIAL HIGHLIGHTS

AMOUNT IN TAKA

| PARTICULARS | 2021-22 | 2020-21 | 2019-20 | 2018-19 | 2017-18 | 2016-17 |
|---------------------------------------|---------------|---------------|---------------|---------------|----------------------|----------------------|
| Revenue | 8,479,819,569 | 7,376,042,094 | 6,191,628,639 | 5,263,963,344 | 4,657,350,011 | 4,009,153,501 |
| Revenue Growth (%) | 14.96% | 19.13% | 17.62% | 13.02% | 16.17% | 14.85% |
| Cost of Goods Sold (COGS) | 4,913,749,450 | 4,275,324,899 | 3,595,065,328 | 3,102,151,141 | 2,764,720,036 | 2,385,628,180 |
| COGS Growth (%) | 14.93% | 18.92% | 15.89% | 12.20% | 15.89% | 14.58% |
| Gross Profit | 3,566,070,119 | 3,100,717,195 | 2,596,563,310 | 2,161,812,203 | 1,892,629,975 | 1,623,525,321 |
| Gross Profit Ratio (%) | 42.05% | 42.04% | 41.94% | 41.07% | 40.64% | 40.50% |
| Net Profit before Tax | 799,862,485 | 704,448,050 | 565,083,268 | 452,141,557 | 561,423,618 | 306,468,807 |
| Net Profit after Tax | 605,674,624 | 488,971,771 | 392,527,310 | 336,266,870 | 452,296,714 | 233,829,346 |
| Net Profit Ratio | 7.14% | 6.63% | 6.34% | 6.39% | 9.71% | 5.83% |
| Workers P.P. Fund & Welfare Fund | 40,341,605 | 35,733,665 | 28,607,860 | 22,692,136 | 28,184,657 | 15,354,783 |
| No. of Shareholders | 12,085 | 11,841 | 11,264 | 11,748 | 10,969 | 11,249 |
| Return on Equity | 25.50% | 24.93% | 24.12% | 24.86% | 38.79% | 23.69% |
| Current Ratio | 1.50 | 1.26 | 0.83 | 0.84 | 0.81 | 0.89 |
| NAV per Share | 83.36 | 68.69 | 56.88 | 47.32 | 39.28 | 38.90 |
| Earning per Share (Restated) | - | - | - | - | 14.48 | 8.23 |
| Earning per Share (Original) | 19.39 | 15.66 | 12.56 | 10.76 | 15.92 | 9.06 |
| Price Earning Ratio (Time) | 15.30 | 15.76 | 17.84 | 24.54 | 16.17 | 27.36 |
| Quoted Price per Share-DSE (Year End) | 296.70 | 246.70 | 224.10 | 264.10 | 257.40 | 247.90 |
| Dividend per Share | 60% Cash | 47% Cash | 38.50% Cash | 30% Cash | 30% Cash & 10% Stock | 25% Cash & 10% Stock |
| Reserve & Surplus (Year End) | 2,292,640,082 | 1,833,618,116 | 1,464,782,691 | 1,165,986,262 | 943,332,576 | 557,265,854 |
| Dividend Yield | 2.02% | 1.91% | 1.72% | 1.14% | 1.55% | 1.41% |
| Dividend Payout Ratio | 30.94% | 30.02% | 30.64% | 27.87% | 25.12% | 38.65% |
| Retained Earning | 2,288,247,972 | 1,829,226,006 | 1,460,390,581 | 1,161,594,152 | 938,940,466 | 552,873,744 |
| Retained Earning (Yearly) | 418,212,862 | 342,126,724 | 272,239,346 | 242,535,989 | 338,683,522 | 143,455,216 |
| Current Assets | 1,683,200,873 | 1,457,828,253 | 1,073,716,818 | 964,225,217 | 859,761,961 | 643,644,663 |
| Current Liabilities | 1,124,020,711 | 1,155,278,552 | 1,298,015,548 | 1,144,311,664 | 1,062,536,232 | 726,608,044 |
| Fixed Assets (Net) | 2,342,489,248 | 2,209,734,247 | 2,038,773,015 | 1,684,778,351 | 1,409,800,123 | 1,116,332,498 |
| Net Assets Value (NAV) | 2,604,390,765 | 2,146,199,473 | 1,777,006,599 | 1,478,296,395 | 1,227,208,578 | 1,104,963,231 |
| NOCFPS | 13.40 | 17.67 | 15.92 | 13.87 | 6.16 | 4.38 |
| Debt Equity Ratio | 0.38 | 0.40 | 0.47 | 0.53 | 0.50 | 0.37 |

CONSOLIDATED HORIZONTAL AND VERTICAL ANALYSIS

| Horizontal Analysis | 2021-22 | 2020-21 | 2019-20 | 2018-19 | 2017-18 |
|---|---------------|---------------|---------------|---------------|---------------|
| Consolidated Statement of Profit or Loss And Other Comprehensive Income Data | | | | | |
| Net revenue | 14.96% | 19.13% | 17.62% | 13.02% | 16.17% |
| Gross profit | 14.93% | 18.92% | 15.89% | 12.20% | 15.89% |
| Operating profit | 12.08% | 22.41% | 28.43% | 20.47% | 21.64% |
| Profit before tax | 13.54% | 24.66% | 24.98% | -19.47% | 83.19% |
| Profit for the year | 23.87% | 24.57% | 16.73% | -25.65% | 93.43% |
| EPS | 23.87% | 24.64% | 16.73% | -32.41% | 75.72% |
| Consolidated Statement of Financial Position Data | | | | | |
| Total non-current assets | 10.03% | 1.05% | 26.74% | 17.84% | 4.68% |
| Total current assets | 15.46% | 35.77% | 11.36% | 12.15% | 33.58% |
| Total Assets | 12.09% | 11.90% | 21.49% | 15.84% | 13.32% |
| Share capital | 0.00% | 0.00% | 0.00% | 0.00% | 10.00% |
| Retained earnings | 25.09% | 25.26% | 25.72% | 23.71% | 69.83% |
| Total equity attributable to owners of the Company | 22.12% | 20.96% | 20.21% | 20.46% | 11.06% |
| Total non-current liabilities | 3.82% | 49.60% | 75.53% | 35.44% | -52.98% |
| Total current liabilities | -2.71% | -11.00% | 13.43% | 7.70% | 46.23% |
| Total liabilities | -0.63% | 2.20% | 22.90% | 11.17% | 15.68% |
| Total equity and liabilities | 12.09% | 11.90% | 21.49% | 15.84% | 13.32% |



| Vertical Analysis | 2021-22 | 2020-21 | 2019-20 | 2018-19 | 2017-18 |
|---|----------------|----------------|----------------|----------------|----------------|
| Consolidated Statement of Profit or Loss And Other Comprehensive Income Data | | | | | |
| Net revenue | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Gross profit | 42.05% | 42.04% | 41.94% | 41.07% | 40.64% |
| Operating profit | 10.16% | 10.42% | 10.14% | 9.29% | 8.71% |
| Profit before tax | 9.43% | 9.55% | 9.13% | 8.59% | 12.05% |
| Profit for the year | 7.14% | 6.63% | 6.34% | 6.39% | 9.71% |
| Consolidated Statement of Financial Position Data | | | | | |
| Total non-current assets | 60.95% | 62.09% | 68.75% | 65.91% | 64.79% |
| Total current assets | 39.05% | 37.91% | 31.25% | 34.09% | 35.21% |
| Total assets | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Share capital | 7.81% | 8.33% | 9.21% | 11.20% | 11.81% |
| Retained earnings | 53.09% | 47.57% | 42.50% | 41.07% | 38.45% |
| Total equity attributable to owners of the Company | 60.90% | 55.90% | 51.71% | 52.26% | 50.26% |
| Total non-current liabilities | 13.02% | 14.06% | 10.52% | 7.28% | 6.22% |
| Total current liabilities | 26.08% | 30.04% | 37.77% | 40.46% | 43.52% |
| Total liabilities | 39.10% | 44.10% | 48.29% | 47.74% | 49.74% |
| Total equity and liabilities | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |

VALUE ADDED STATEMENT

For the year ended 30 June, 2022

Amount in Taka

| PARTICULARS | 2021-22 | Percentage (%) | 2020-21 | Percentage (%) |
|---|----------------------|----------------|----------------------|----------------|
| VALUE ADDED | | | | |
| Turnover & other income | 8,507,141,470 | | 7,389,505,458 | |
| Less: Material costs & services | 3,623,693,998 | | 3,395,761,244 | |
| | 4,883,447,472 | 100.00 | 3,993,744,214 | 100.00 |
| APPLICATIONS | | | | |
| To Employees as salaries, wages & allowances | 2,211,227,119 | 45.28 | 1,896,077,859 | 47.48 |
| To Providers of finance as financial charges | 47,329,924 | 0.97 | 39,998,318 | 1.00 |
| To National exchequer | 1,789,584,826 | 36.65 | 1,352,951,124 | 33.88 |
| For replacement of fixed assets as depreciation | 223,660,922 | 4.58 | 215,593,525 | 5.40 |
| Dividend to Shareholders | 187,461,762 | 3.84 | 146,845,047 | 3.68 |
| For future growth as retained earnings | 424,182,920 | 8.69 | 342,278,342 | 8.57 |
| | 4,883,447,472 | 100.00 | 3,993,744,214 | 100.00 |



- To Employees as salaries, wages & allowances
- To Providers of finance as financial charges
- To National exchequer
- For replacement of fixed assets as depreciation
- Dividend to Shareholders
- For future growth as retained earnings

- To Employees as salaries, wages & allowances
- To Providers of finance as financial charges
- To National exchequer
- For replacement of fixed assets as depreciation
- Dividend to Shareholders
- For future growth as retained earnings


MARKET VALUE ADDED (MVA) STATEMENT

Market value added statement reflects the Company's performance evaluated by the market through the share price of the Company. This statement shows the difference between market capitalization and book value of the shares outstanding. In other words, it is the sum of all capital claims held against the Company plus the market value of debt and equity.


The higher MVA is the better indication. A high MVA indicates the Company has created substantial wealth for the shareholders. A negative market value added means the value of management's actions and investments are less than the value of the capital contributed to the Company by the capital market.

The following statement shows how the MVA has been calculated for the year 2021-22 and 2020-21 :-

| Particulars | Amount in Million Taka | |
|------------------------------------|------------------------|-----------------|
| | 2021-22 | 2020-21 |
| Market Value of Shares Outstanding | 9269.98 | 7707.81 |
| Book Value of Shares Outstanding | 312.44 | 312.44 |
| Market Value Added | 9582.42 | 7,395.37 |



Market Value of Shares Outstanding



Market Value Added

ECONOMIC VALUE ADDED STATEMENT

For the year ended 30 June, 2022









Economic value added (EVA) is a measure of a company's financial performance based on the residual wealth calculated by deducting its cost of capital from its operating profit, adjusted for taxes on a cash basis. EVA can also be referred to as economic profit, and it attempts to capture the true economic profit of a company.

(Amount in Taka)


| Particulars | 2021-22 | 2020-21 |
|---|----------------------|----------------------|
| Operating Profit | 861,499,089 | 768,643,598 |
| Provision for Income Tax | (194,187,861) | (215,476,279) |
| Net Operating Profit After Tax (NOPAT) | 667,311,228 | 553,167,319 |
| Charges for Capital | | |
| Capital Employed | 3,186,266,079 | 2,690,128,975 |
| WACC | 11.87% | 12.14% |
| Capital Charges | 378,158,041 | 326,643,747 |
| Economic Value Added | 289,153,187 | 226,523,571 |
| Capital Employed | | |
| Total Assets | 4,310,286,790 | 3,845,407,527 |
| Less: Current Liabilities | 1,124,020,711 | 1,155,278,552 |
| Capital Employed | 3,186,266,079 | 2,690,128,975 |




PERFORMANCE INDICATORS




OPERATING PERFORMANCE



FINANCIAL POSITION ANALYSIS




FINANCIAL POSITION ANALYSIS




SEGMENT WISE REPORTS


Year Wise Total Sales Contribution 2021-22




Year Wise Unit Sales Contribution 2021-22




Division Wise Performances : 2021-22



Therapeutic Class wise Sales Contribution: 2021-22




Top 10 Brand's Contribution: 2021-22




SEGMENT WISE REPORTS


Division Wise Sales Contribution %




Therapeutic Class Share % : 2021-22




NET ASSETS VALUE




SHARE PERFORMANCE




RETURN ON SHAREHOLDERS' FUND (%)




CURRENT RATIO




NAV PER SHARE (RESTATED)




ROCE (%)




MARKET CAPITALIZATION (BDT MIL.)




DIVIDEND YIELD




PRICE EARNING RATIO (TIMES)




DEBT EQUITY RATIO



NOCFPS



EBITDA (%)



SHAREHOLDERS' INFORMATION

For the year ended 30 June 2022

STATUS OF SHAREHOLDINGS-2022 (JUNE)

| | | |
|-------------------------|--------------|----------|
| Directors' and Sponsors | : 13,957,918 | (44.67%) |
| Public | : 9,765,603 | (31.26%) |
| Institutions | : 7,520,106 | (24.07%) |



As per BSEC Notification no.-SEC/CMRRCD/2008-183/Admin/03-34 dated 27.09.2009
The Quarterly Reports are given below :-

QUARTERLY RESULTS

During the year 2021-22 operational results of the Company were announced on-

| | |
|----------------------|------------------|
| First Quarter Report | 10 November 2021 |
| Half Yearly Report | 24 January 2022 |
| Third Quarter Report | 24 April 2022 |



DIVIDEND : FINANCIAL YEAR 2020-21

| | |
|---|-------------------|
| Board Meeting for the Year 2020-21 | 21 September 2021 |
| Record Date for the Year 2020-21 | 18 October 2021 |
| 37th Annual General Meeting for the Year 2020-21 | 18 November 2021 |
| Commencement of Cash Dividend Warrant Distribution for the Year 2020-21 | 9 December 2021 |
| Completion of Cash Dividend Warrant Distribution for the Year 2020-21 | 13 December 2021 |
| Submission of Dividend Distribution Report | 23 December 2021 |

SHARE PERFORMANCE

| PARTICULARS | DSE | CSE |
|-----------------------------|-------------------------------|-------------------------------|
| Stock Symbol | IBNSINA | IBNSINA |
| Business Segment | Pharmaceuticals and Chemicals | Pharmaceuticals and Chemicals |
| Company ID | 18464 | 13013 |
| Listing Year | 1989 | 1996 |
| Market Category | A | A |
| Electronic Share | Y | Y |
| Total Number of Outstanding | 31,243,627 | 31,243,627 |

| PARTICULARS | JUNE 2022 | JUNE 2021 |
|--|------------|------------|
| Market Capitalization- DSE (BDT million) | 9269.98 | 7707.81 |
| Market Capitalization- CSE (BDT million) | 9045.03 | 7520.35 |
| EPS (BDT) | 19.39 | 15.66 |
| DPS (BDT) | 6.00 | 4.70 |
| Payout ratio (%) | 30.94% | 30.02% |
| Share Price- DSE (BDT) | 306.00 | 240.70 |
| Share Price- CSE (BDT) | 31,243,627 | 240.70 |
| Weighted average number of share outstanding | | 31,243,627 |



Source: DSE and CSE website

PATTERN OF SHAREHOLDINGS

AS AT JUNE 30, 2022

| Particulars | No. of shares held | % of holding |
|---|---------------------------|-------------------|
| Shares held by : | | |
| (a) Parents or Subsidiary or Associated Companies and other related parties : | N/A | - |
| (b) i) Shares held by Directors | | |
| Representative | | |
| IBN SINA Trust | 13,843,312 | 44.308 |
| Kazi Harun or Rashid | Rep. IBN SINA Trust | |
| Prof. Dr. AKM Sadrul Islam | Rep. IBN SINA Trust | |
| Prof. ANMA Zaher | Rep. IBN SINA Trust | |
| Prof. Dr. Choudhury Mahmood Hasan | Rep. IBN SINA Trust | |
| Dr. Mohammad Ayub Miah | Rep. IBN SINA Trust | |
| Prof. Col. Dr. Zehad Khan (Retd.) | Rep. IBN SINA Trust | |
| Prof. Dr. Shamsuddin Ahmed | Rep. IBN SINA Trust | |
| Md. Abdus Salam, FCA, FCS (Independent Director) | self | Nil |
| Abdus Sadeque Bhuiyan (Independent Director) | self | Nil |
| (b) ii) Shares held by Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit & Compliance and their spouses | | |
| | No. of shares held | Percentage |
| Kazi Harun or Rashid Chairman | self | 103,692 |
| Prof. Dr. AKM Sadrul Islam Managing Director | self | 2,765 |
| Prof. Dr. Choudhury Mahmood Hasan Director | self | 6,939 |
| Prof. Col. Dr. Zehad Khan (Retd.) Director | self | 1210 |
| Company Secretary, his Spouse and minor children | self | 342 |
| Chief Financial Officer, his Spouse and minor children | self | Nil |
| Head of Internal Audit and Compliance, his spouse and minor children | self | Nil |
| (c) Shares held by top five salaried employees other than the Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and their spouses | | |
| Md. Nurullah | self | Nil |
| Md. Abdul Khaleque | self | 335 |
| Md. Parvez Kabir | self | Nil |
| Md. Ilyus | self | Nil |
| Md. Shah Alam | self | Nil |
| (d) Shareholders holding 10% or more voting right : | | |
| | N/A | - |

Note : Total 13,843,312 no. of shares are registered against the name of Seven Trustees nominated by The IBN SINA Trust. None of the individual Director/Shareholder holds more than 10% share.

OUR APPROACH TO THE SUSTAINABILITY

Our approach to sustainability focuses on creating and protecting value, driving growth and innovation, and providing societal value through our core business activities, to make a meaningful contribution to the Country. The significant social benefits delivered through our products and services are supported by our CSR activities.

In our sustainability strategy we have prioritized following four key areas:-



INTEGRATED REPORT

This Integrated Report provides a multidimensional view of The IBN SINA Pharmaceutical Industry PLC's performance over the year 2021-22.

It has been prepared in accordance with the guiding principles and content elements outlined by the International Integrated Reporting Council (IIRC).

ABOUT THIS REPORT

The IBN SINA Pharmaceutical Industry PLC's integrated report aims to provide a balanced and accurate reflection of our strategy, performance, opportunities and outlook in relation to material financial, economic, social and governance issues. The intent of the report is primarily to address value-creation considerations of long-term investors but also provides appropriate information to all our key stakeholders. Our target is to preserve, create and deliver sustainable value for all of our stakeholders by using an integrated approach through the six capitals.

REGULATIONS WE FOLLOW

- Companies Act 1994;
- Financial Institutions Act 1993;
- Securities and Exchange Rules 1987;
- Corporate Governance Code issued by BSEC in 2018;
- Relevant Rules and Regulations of Bangladesh Bank and
- And other applicable laws and regulations of the land.

REPORTING FRAMEWORKS AND GUIDELINES

- International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS);
- Global Reporting Initiative (GRI)-GR4 Framework;
- International Integrated Reporting Framework by International Reporting Council;
- SAFA Integrated Reporting Checklist;
- ICAB Corporate Governance Checklist and
- ICSB Secretarial Standards.

SCOPE AND BOUNDARIES OF THIS REPORT

The report covers the period from July 01, 2021 to June 30, 2022, which encompasses the activities that have been carried out within the geographical boundary of Bangladesh and global operation of IBN SINA and its subsidiary.

We have referred to the guidelines of Integrated Report, issued by the Institute of Chartered Accountants of Bangladesh (ICAB) in the form of 'Integrated Reporting Checklist', which is in congruence with the integrated reporting framework prototype issued by the International Integrated Reporting Council (IIRC).

In clarifying the Company's operations and financial performance, we have extracted the financial information from the Audited Financial Statements for the financial year ended June 30, 2022 with relevant comparative information. The financial statements consistently comply with the mandated requirements of the laws of the land and of the industry that includes Companies Act 1994, Securities and Exchange Rules 1987, BSEC's Corporate Governance Code, 2018, International Financial Reporting Standards and other relevant acts and rules applicable for the Company.

Capitals of Value Creation

The IBN SINA Pharmaceutical Industry PLC aims to preserve, create and deliver sustainable value for all of our stakeholders through the six capitals model, a more balanced approach to generating holistic and actionable reports.

There are challenges in targeting and prioritizing best methods to be considered for sustainable development of the Company. To meet the challenges, framework of 6 Capitals has been developed. Integrated reporting using these 6 Capitals as synthesis of both qualitative and quantitative data to demonstrate tangibly, how the IBN SINA Pharma creates value over time.



Financial Capital

Financial Capital is obtained through financing either equity or grants, or generated through operations or investments. Financial Capital of the Company is utilized effectively and efficiently under the guidelines developed by the Board of Directors.

Human Capital

Human capital also termed as 'Human Resource' is very important in many areas ranging from strategic planning to company image, customer satisfaction to legal compliance and so on. Hence, the importance of Human Capital for achieving Company's strategic objectives cannot be over emphasized. The Company has a team of around 4000 employees with adequate experience, skills,

qualifications and competencies to manage the day-to-day operations. Various trainings are conducted from time to time to enhance skills of the staff.

Manufactured Capital

Manufactured capital refers to manufactured physical objects that are available to an organization for use in the provision of services. The physical assets of the Company are broadly classified into: Land, Buildings, Furniture & fixtures, Motor Vehicles, Machinery & equipment and Computer equipment, etc.

All of the physical assets of the Company are efficiently utilized for the purpose of business and adequately covered against potential threats through insurance coverage and manage the same accessing

different technologies applicable for the purpose.

Intellectual Capital

Intellectual Capital refers to organizational knowledge based intangibles, including 'Intellectual Property' such as patents, copyrights, software, rights and licenses and 'Organizational Capital' such as knowledge, systems, procedures and protocols.

The Company through its experience of operations spread over 38 years has refined standardized and documented its operating procedures. The procedures are flexible and adaptive to absorb innovations necessary to respond to the changes. The library of the said procedures is effectively and efficiently utilized to introduce new and alternate products, expand customer base, and resultantly increase profits.

Social and Relationship Capital

Social and Relationship Capital includes shared norms, common values and behavior, key stakeholder relationships, intangible association with organization's brand and reputation and organization's social license to operate.

Social and relationship capital is one of the key assets that an organization has. It is the image and reputation of the company that all stakeholders

carry with them and plays an important role in achievement of strategic objectives and future growth. The Company realizes the due importance of social and relationship capital and assigns customer satisfaction as top priority in all customer dealings. The Company has maintained healthy relationship with customers, agents, surveyors, reinsurers, reinsurer brokers, vendors, banks and all other shareholders.

Natural Capital

Natural Capital refers to all renewable and non-renewable environmental resources and processes that provide services that support the past, current or future prosperity of an organization and includes air, water, land, minerals, forests etc. Natural capital creates the ecosystems for human beings to survive. The utmost importance is that an organization efficiently manages natural capital to avoid any harm to the ecosystems in the long term. The Company continues to contribute to the sustainable environment by gradually moving towards the paperless operations, installing energy conservative technologies, encourage plantation across all its premises, and encourage efficient use of water to reduce water wastage. Continuation to work towards promoting green office environment is our passion.

Key elements of our Integrated Report



Strategic Focus and Future Outlook

Our business strategy and future outlook defines our short, medium and long-term strategic objectives and the resource allocation mechanism in place to implement those strategic objectives. Referring page no 13 for details on corporate strategy where the strategic objectives have also been defined in respective capitals. Our forward looking statement (Page no. 12) addresses our expected condition and performance, status of projects disclosed last year also explaining about the sources of information and assumptions used for projections.

Risk and Opportunities

Principles of materiality are applied in assessing the information required to be included in our report and the materiality assessment is also discussed in our Report. This report focuses on risks, opportunities and challenges that have a material impact on our capitals. Company's risk management and internal control processes are discussed in detail on page 142 Directors' report, financial statements and sustainability report represents our integrated thinking and the way we make decisions.

| Assurance On | Assurance Providers |
|--------------------------------------|---|
| Financial Statement and Audit Report | Malek Siddiqui Wali Chartered Accountants |
| Corporate Governance Certification | Itrat Hussain and Associates Chartered Secretaries-in-Practice |
| Provident Fund Financial Audit | Masih Muhith Haque & Co. Chartered Accountants |
| Gratuity Fund Financial Audit | HM Enam & Co. Chartered Accountants |
| Superannuation Fund Financial Audit | Masih Muhith Haque & Co. Chartered Accountants |
| Entity Credit Rating | Alpha Credit Rating Limited |

Management Responsibility

All material and significant disclosures reported are aligned with the applicable disclosure requirements as per Companies Act 1994, Bangladesh Securities and Exchange Commission guidelines and notification issued time to time and other applicable rules and regulations. To enhance governance inaccuracy, risk management and controls, the contents of this Report have been reviewed by a team of directors headed by the Managing Director of the Company.

Disclaimer

It is noted that the integrated annual report includes forward-looking statements which relates to the possible future financial position and results of the

company's operations. These are not statements of fact but rather statements by the management based on current estimates and expectations of future performance. No assurance can be provided on these forward-looking statements, and shareholders are advised to exercise caution in this regard.

Availability of the Annual Report

The Annual Report of the Company is sent to all shareholders through email in due course of time whose email address is available with us as per CDBL record on record date and copy of the same is also made available on the website of the Company: www.ibnsinapharma.com. In case of non-receipt of the Annual Report sent through email, shareholders are welcome to collect the same from the Registered Office of the Company.

VALUE CREATING BUSINESS MODEL

Our value creation business model is the hub of everything we do. It defines risk and opportunities in our external environment, inputs we consume, activities we carry on, the relationships we depend on and the outputs and outcomes we desire to achieve while creating sustainable value for our shareholders, in the short, medium, and long term.

INPUTS

Financial Capital

- Strong balance sheet;
- A disciplined capital expenditure investment approach;
- Planned prioritization of capital allocation and
- Strong operating cash flow generation.

Human Capital

- Experienced leadership team;
- High performance and innovative culture;
- Empowered local management and
- Industry-specific specialist skills.

Manufactured Capital

- Complex manufacturing expertise;
- A production system specialized in ophthalmology that manufactures high-quality products;
- Stable supply through a global product supply network;
- Expanding production capacity through construction of new plants and conversion of plants to smart factories and
- Globally competitive, scalable and widely accredited manufacturing facilities.

Intellectual Capital

- Trusted IBN SINA brand;
- Excellent technologies and knowledge ;
- Data utilization;
- Targeted and efficient product portfolio renewal and
- Strong presence in emerging markets.

Social and Relationship Capital

- Insights from patients and medical professionals;
- Partnerships with medical professionals and suppliers;
- Strong stakeholder relationships and corporate reputation;
- Robust corporate governance framework and
- Support of local communities.

Natural Capital

- Focus on environmental protection;
- Use of environmentally friendly water resources and
- Initiatives to reduce consumption of scarce natural resources.

SPECIFIC ACTIVITIES/OUTPUTS

OUTCOMES

Develop and provide products and services that utilize digital and other technologies to meet the needs of people

"Quality we assure"
for patients and people

Provide solutions to medical issues such as early detection of conditions and provide training for medical professionals problems

Development and improvement of qualitative medicine

Develop, popularize and conduct an overseas rollout of products and services that leverage the strengths of IBN SINA and its partner companies and organizations

Increased corporate value for IBN SINA and its partners

Provide employees with career realization opportunities, growth opportunities and a digital workplace provide training for medical professionals

Improvement in employee skills and fulfillment in work

Use sustainable technologies and efficiently utilize water resources

Realization of a carbon-free and recycling-oriented society

Engaging the shareholders and investors towards the realization of a sustainable society and corporate growth

Stable shareholders' returns

FINANCIAL CAPITAL

Our aim to create value for all of our shareholders by managing our financial capital in a commercially astute and diligent manner, thereby harnessing opportunities for long-term sustainable economic growth.

FINANCIAL CAPITAL

Our capital allocation decisions are integrated into our strategy and budget planning processes, driven by our overall objective of growing shareholder value sustainably. Key considerations driving our capital allocation include achieving an effective allocation between maintaining our intellectual and manufacturing assets to secure operational returns, protecting the strength of our balance sheet to give us stability and flexibility through business cycles, investing in value-based organic and inorganic growth opportunities and rewarding our shareholders

through dividends and/or share buy-back programmes. The Board provides oversight of capital and budget allocations, ensuring the most effective deployment of available capital resources.

FINANCIAL PERFORMANCE:

The financial performance of the Company is measured in terms of various key financial metrics, which includes operating profit, return on capital employed, cash flow generation, gearing and liquidity. Key operating and financial information for the year 2021-22, along with the preceding four years' information is presented below:

(Amount in Crore)



| Particulars | 2021-22 | 2020-21 | 2019-20 | 2018-19 | 2017-18 |
|-------------------|---------|---------|---------|---------|---------|
| Revenue | 847.98 | 737.60 | 619.16 | 526.40 | 465.73 |
| Gross Profit | 356.61 | 310.07 | 259.66 | 216.18 | 189.26 |
| Profit before tax | 80.00 | 70.44 | 56.51 | 45.21 | 56.14 |
| Profit after tax | 60.57 | 48.90 | 39.25 | 33.63 | 45.23 |

Revenue increased by 110.38 in 2021-22, driven by volume growth and portfolio initiatives to upgrade packing. Even though there has been a major growth in volume & turnover, the Company has effectively managed to ensure significant control over operating expense over the year resulting in an achievement of 23.87% higher profit after tax compared to previous year. Despite the increase in cost of goods sold by 14.93%, the gross profit margin increased by 14.96% because of various

efficiency measures and productivity initiatives taken across a wide array of spectrums.

Year on year net finance expenses increased due to short term borrowings availed for working capital, capital expenditure management both machineries and plant to support volume growth.


Current tax expense is in line with profit growth & EPS for the full year stands at BDT 19.39.




FINANCIAL POSITION

| Particulars | 2021-22 | 2020-21 | 2019-20 | 2018-19 | 2017-18 |
|-------------------------|---------|---------|---------|---------|---------|
| Current Assets | 168.32 | 145.78 | 107.37 | 96.42 | 85.98 |
| Current Liabilities | 112.40 | 115.53 | 129.81 | 114.43 | 106.25 |
| Non-Current Assets | 262.71 | 238.76 | 236.27 | 186.42 | 158.20 |
| Non-Current Liabilities | 56.12 | 54.06 | 36.14 | 20.59 | 15.20 |
| Paid Up Capital | 31.24 | 31.24 | 31.24 | 31.24 | 28.40 |


CURRENT RATIO




DEBT EQUITY RATIO



ROCE (%)



RETURN ON ASSET (%)



CASH POSITION

| Particulars | 2021-22 | 2020-21 | 2019-20 | 2018-19 | 2017-18 |
|--------------------------|---------|---------|---------|---------|---------|
| Cash flow from operating | 41.86 | 55.22 | 49.75 | 43.34 | 19.20 |
| Cash flow from investing | (30.23) | (24.20) | (63.09) | (40.82) | (25.05) |
| Cash flow from financing | (5.21) | (22.86) | 16.34 | (2.30) | 17.00 |

DIVIDEND

The Board of Directors has recommended a cumulative dividend for the year ended June 30, 2022, i.e., 60% per share as cash. The dividend is subject to final approval by shareholders at the Company's 38th Annual General Meeting (AGM) to be held on October 30, 2022.

TAXATION

The effective tax rate decreased from 24.95% in 2020-21 to 24.07% in 2021-22. The current tax increase is in line with the decrease in profit before tax. Deferred tax has decreased from last year due to higher deferred tax asset base in 2021-22.


HUMAN CAPITAL

Human Resource Department of the Company is performing human capital management from talent acquisition to employee job separation. HR is overseeing various aspects of employment such as compliance with labor law and employment standards, interviewing, administering the employee benefits, management of employee personal files and software records with the required documents/information for

future reference. It's serving as the link between the organization's management and its employees.

With the outbreak of the covid-19 epidemic in recent years, the world has been started to a new normal life. Hence, The IBN SINA Pharma's team has reached out to the remote areas of Bangladesh to serve humanity by manufacturing and providing quality medicines and services to its customers.

OUR HUMAN CAPITAL VALUE CREATION MODEL



Human Capital

The HR department is observing and maintaining all employees' education, technical or on-job training, mental and emotional health, punctuality, loyalty, moral wellbeing, problem solving, people management and communication skills. These knowledge and skills are used to increase productivity and value for the Company. We manage Human Capital to see our employee's abilities as resources to be utilized for value creation in organizations by getting people to change their behavior to more economically viable behaviors. HR department focuses on the intellectual skills and procedural knowledge that creates our employees' into human capital.

Recent Activities

Our recent achievements are modernization of the Company's KPI policy, HR manual, restructuring Company's organogram, strong monitoring of all employees, employee relation buildup, skill development program and new increment policy etc. The positive changes in HR manual are playing a big role for the Company. HR department is focusing more on employee development. Internal and external training programs are going on with a new pace to ensure better productivity.

Authority gives the opportunity for the best performer to perform Umrah from different departments every year. All the expenses of Umrah of those employees are borne by the Company. This is very encouraging among all those employees.

HUMAN RESOURCE POLICIES AND PRACTICES



Succession Planning

The IBN SINA Pharmaceutical Industry PLC is leading the way in expanding its business through new plan, new products & technologies. The Human Resources Department is one step ahead in implementing a long term and sustainable succession plan by recruiting skilled & qualified personnel to fill the vacancies and meet the business needs & technological advancement. The HR department is always ready to take measures for sustainable development of the Company by replacing talent & qualified leaders. The successors are also developed through the Standard Operating Procedure (SOP) and by gathering sufficient experience in the job place.

Human Resource Accounting

Human resource accounting (HRA) is recording and identification of human cost & judges their economic value to the organization. We calculate and record the cost of recruitment, selection, training and development of our employees. Human resource department observes to all employees recruitment cost, training and development cost, welfare cost, health benefit cost etc. For the purpose of increased productivity and profit to the organization, to improve management by analyzing the investment of HR, to determine the impact of people on the business and their contribution, to attract and retain qualified people, to facilitate the efficiency of human resource, to monitor the effectiveness of human resource utilization, to increase employees life time value.

Employee Relations

There is a very fraternal and cordial relationship between the officers and workers within the Company. We sincerely extend our hand of cooperation to each other in any situation. Here all workers and officers carries different status. Even then there is no distance or misunderstanding between the employees. All are working like a team to achieve organizational goal.

Culture & Leadership Behavior

IPI administrators usually adjust their leadership behavior to accomplish the mission of the organization, and this could influence the employees' job satisfaction. It is therefore essential to understand the relationship between organizational cultures, leadership behavior and job satisfaction of employees. Our culture within our organization is

playing an important role to ensure a happy and healthy environment. In communicating and promoting the organizational ethics to employees, their acknowledgement and acceptance of it can influence their working behavior and attitudes. Our interaction between the leadership and employees is good. The latter will make a greater contribution to team communication and collaboration. It will also be encouraged to accomplish the mission and objectives assigned by the organization, thereby enhancing job satisfaction.

Donation for deceased coworkers

We have supported our 11 (eleven) deceased coworker's family through our superannuation fund in the last year. HR department is working closely with the families to rehabilitate them properly.

Career Development

The IBN SINA Pharma builds up employee's career by organizing various domestic and foreign trainings. These efforts are made to increase work efficiency and overall quality. The IBN SINA Pharma provides quality medicine from the realm of ethics, so we have the opportunity to develop a career through moral education. There is an opportunity to start a career as an officer and go up to Executive Director. Organization does not create any barrier to develop employees' career. The organization does everything necessary for the development of the individual.

Team Spirit

The HR family is formed with a wonderful conference of sincerity, dynamism based on ethical standard. The HR department is moving forward with excellent team spirit and dedication. Our HR team is a unique combination of manpower that has the skills, professionalism, sophistication, and ethics to run the organization. This department is strongly committed to be a strategic business partner of the Company.

There is a pink tinge of fidelity in every aspect of the Company's policy making. We will bring our Company to a higher stage by delivering continuous effort. Finally, Human Resource Department is on its way to the dream of green in the midst of severe drought as the vigilant in all the activities of the Company by ensuring highest level of professionalism and efficiency by the grace of almighty Allah.



Training & Development Department

Training allows employees to acquire new skills, sharpen existing ones, perform better, increase productivity and be better leaders in any organization. Since a company is the aggregate of what employees achieve individually, IPI has done everything in its power to ensure that employees perform at their peak. IPI has focused in strengthening the training and development activities for this goal.

In a rapidly evolving landscape, productivity is not only dependent on employees, but also on the technology they use. Training and development goes a long way in getting employees up to date with new

technology, use existing ones better and then discard the outdated ones. This goes a long way in getting things done efficiently and in the most productive way IPI aims to adopt new technologies and skills efficiently in order to boost the productivity through making special impetus on different types of trainings of its employees.

To transform IPI into a learning organization and encourage a culture of continual learning among employees we have launched several training and development initiatives.

We value our knowledgeable, hardworking, honest and innovative human resources as one of the most vital capital in our investment strategy.




MANUFACTURED CAPITAL

Manufactured Capital is the collection of physical, material and technological objects that are available to an organization for use in the provision of services and therefore in fulfilling its purpose. Investment in manufactured capital is vital in order to produce high quality medicines that would contribute to sustainable advantage. Significant investment in our manufactured capital is an ongoing phenomenon that aims to safeguard our ability to deliver the quality products for sustainable growth and continual improvement.

Our Sources of Manufactured Capital

| |
|--|
| Current Good Manufacturing Practices (cGMP) |
| ISO 9001:2015 |
| Plant Infrastructure |
| Manufacturing Facilities, Technology and Equipment |
| Manufacturing Process |
| Environment, Health and Safety Provision |
| Distribution Network |



Our Pharma Plant

The IBN SINA Pharmaceutical Industry PLC (IPI) was founded in the year 1983 on a campus of about 14 acres of land, about 56 km away from Dhaka city. Its commercial production was started in May 1986 since its journey with a few products. Now the Manufacturing Plant has been established with modern state of the art technology and equipped with, high standard machineries and for the production and quality checking of various dosage forms of several therapeutic classes by the 'Current Good Manufacturing Practices' standards of various international regulatory authorities like WHO cGMP, ISO etc.

This Plant contains General Production Building, Injection Building and Cephalosporin Building. The site houses other supplementary infrastructures including Admin Building, Warehouse, Engineering Building, Officers Quarter etc. Our Utility Infrastructure has been designed including Water Treatment Facility (DM, RO & WFI Plant), Boiler, Compressor, Generator etc. to ensure adequate supply of water, electricity, steam and gas. Besides, we have a central ETP for waste management. A Specialized Compliance Formulation Plant at Mawna (Sreepur, Gazipur), API project at Munshiganj and Central warehouse at Kaliakoir are under construction.

IPI is now producing more than 400 pharmaceutical products with various types of dosage forms

including solid dosage forms (tablets and capsules), parenteral products (ampoules, vials), liquid dosage forms including syrup, solutions, suspensions & powder for suspension (dry syrups); sterile ophthalmic products, cream, ointments, gel, eye drops and sachet etc. covering almost all therapeutic classes where a lot of products are in the launching pipeline.

The production site follows the best practices for fire, water and air management system, employee health and safety issues. In totality, this plant does not only result in increased production capacity, but also has resulted compliance with more regulatory requirements, safeguarding the environment, safety and health protection of employees in the workplace and environment.

IPI Plant at a glance

Location

Shafipur, Kaliakoir
Gazipur, Bangladesh

Area

14 acres

Production Facilities

General Pharma Plant
Natural Medicine Division
Cephalosporin Division

Production lines

- Solid dosage forms (tablets capsules and Sachet)
- Liquid dosage forms including syrup, solutions, suspensions
- Powder for suspension (dry syrups)
- Sterile and non-sterile ophthalmic and tropical products (cream, ointments, gel eye & nasal drops)
- Parenteral products (ampoules, vials)
- Prefilled Syringes, Lyophilized Vials
Small Volume Parenteral (SVP), Biotech
Metered Dose Inhaler (MDI) and Dry Power Inhaler (DPI) (Pipeline).

Manufacturing Facilities, Technologies and Equipments

Tablets

Tablets are the major product ranges in OSD (Oral Solid Dosage) production facilities comprising about 45% of the total pharma production. To fulfill the market demand a new compliance area has been developed where many sophisticated machines like Auto-granulation line, Fette Tablet Compression machine from Germany, Sejong Tablet Compression machine from South Korea, Romaco Compactor for potent and sensitive drug have been incorporated in this area.

Moreover, we have another two dedicated granulation unit (one is Auto-granulation), six sophisticated tablet compression machine, six tablet coating machine including IMA tablet coating (from Italy) which is highly sophisticated and faster, eight blister machine including Heino-Ilsemann blister machine (from Germany) with auto-cartoning, Romaco blister machine (from Germany) with auto-cartoning and 21CFR part11. Besides we have two Auto tablet counting machines.

Capsule

Two sophisticated automatic capsule filling machines Pam from India and NJP from China are now in operation. These machines have versatile capacity of filling pellets and liquid in hard gelatin shell. Two existing automatic Zanasi Capsule filling Machines are used for non-antibiotic & miscellaneous antibiotic production. In view of the increased demand of existing powder fill capsule products & considering the upcoming new products to our product range, the IPI management has installed a high capacity powder capsule filling machine recently. This machine can also be used for pellet filling. Now we are fulfilling present demand by blistering with Hoonga blister machine from Korea and newly installed high capacity Tien Tuan blister machine from Vietnam.

Injectable (Parenteral) Products and Inhaler

The injection production facilities comprise Class A (ISO Class 5) production area and the adjacent areas are of different classification and there is a change room facilities as per compliance. The sterile products are manufactured in high tech machine like Rota (Germany) and Flexicon (Denmark).

IPI is launching Prefilled Syringes, Lyophilized Vials, Small Volume Parenteral (SVP), Biotech, Metered Dose Inhaler (MDI) and Dry Power Inhaler (DPI) preparations to its product portfolio by dedicated sophisticated machines like Lyophilizer (Freeze Dryer) (Tofflon, China), Solution Preparation Vessel and CIP & SIP Skid (Tofflon, China), Automatic Prefilled Syringe Filling & Sealing Machine (iDOSETECHNO, Spain), Flexicon Dry Powder Filling Machine (Denmark), Freeze Drying Microscope (FDM) (McCRONE, USA), Fedegari Autoclave (Italy) and Vaporized Hydrogen Peroxide (VHP) Sterilizer (China). Some Injectable productions including Esolok 40mg Injection, Prolok 40mg Injection, Pantolok 40mg Injection and Oxyfer 500mg Injection already in the market.



Ophthalmic (Sinavision)

Ophthalmic Products are marketed under the division named "Sinavision". These include ophthalmic drops, ointment and gels. All the ophthalmic products are manufactured in class A under HVAC system in a background class B. We have installed a fully automatic ophthalmic eye drops production line including automatic washing, drying, autoclaving, filling and sealing. A fully automatic eye drops filling machine Idositechno from Spain (under installation) and an automatic lamitube filling machine from China has been installed.



Semisolid Products

Some popular brands of topical ointments, creams and gels are produced in IBN SINA Pharma factory. These products are manufactured with automatic Italian Axomatic Lamitube Filling Machine that's on line with emulsifier. Products are Fungicort cream, Fungin cream, Fungin-B cream & Neocort ointment etc. In every year new products are adding with existing products.

Liquid Products

IBN SINA Pharma is one of the leading manufacturers of liquid pharma products in Bangladesh. It has five production lines including (1) Auto- Glass Bottle Line for Syrups, (2) Auto-Antanil Production Line, (3) High Capacity PET Line for Syrup and Suspension Products, (4) the Pediatric Drops & Suspension Line, and (5) High Capacity PET Bottle (Vitalgin) filling line.

Auto PET Bottle and other Liquid Production Line are most sophisticated liquid production lines. There have bottle feeding unit, rotary bottle washing unit, light checking unit, multi head linear liquid filling unit, capping & sealing unit, auto sticker labeling unit and

packing line with auto carton strapping unit. It has a production capacity of 120-150 bottles per minute.

A dedicated & compliance online Gavisol Suspension process & filling line is under construction.


Powder for Oral Suspension Products

Powder for suspensions are mainly antibiotic products intended for children and young patients. We have two separate areas for production of powder for suspensions. The major powder for suspension brands are Bactin, Nitasol, Erymex, Romycin, Buticef, Iluca etc.

Sachet

Unisaline is a popular brand of IBN SINA for ORS. We have a self-contained separate production facility for sachets, lined with three-sophisticated sachet filling machines. IBN SINA Pharma has already started marketing of Unisaline with different flavor like Fruity Lemon, Fruity Orange & Fruity Mango. Many new products including Tasty & Rise ORS are in pipeline. Other non ORS sachet brand is Sinalax, which was introduced in Bangladesh by IBN SINA Pharma for the first time.

Manufacturing Process



Fire, Water & Air Management System

Fire Management System

IPI uses intelligent addressable fire detection system. Fire drills are done at least two in every year and training is provided to the personal who are the member of the fire team.

Our actions in this context are:

- We have adequate training facilities against fire, earthquake and other disasters. Almost all employees were trained against fire defense by Bangladesh Fire Service and Civil Defense.
- All the areas including Production, QA, QC, PD, Microbiology, Warehouse and other utility areas are covered by smoke detectors and modern fire alarm system.
- The whole facility is equipped with adequate number of fire extinguishers and fire hoses with fire hydrant. We also have proper evacuation system, assembly point with dedicated rescue and first aid team.
- High pressure fire pumps along with standby pump and jokey pumps are installed to fight against fire.



Water management system

Pure water is very essential and inevitable element for every Pharmaceutical Industry. IPI is committed and constantly working on improving the water management of the company and plant as conserving water will contribute to more sustainable water availability.

Our actions in this context are:

- We have the most modern RO (Reverse Osmosis) Plant with 3000 Ltr/hr capacity for fulfilling our present water demand.
- We have another most modern DM (Demineralization) Plant with 3000 Ltr/hr capacity for fulfilling our present water demand.

Air management system

IPI has the right air management technology installed in all buildings as pharmaceutical manufacturing facilities require high quality of air because the products are ingested of placed in humans and animals.

Our actions in this context are:

- We have individual Air Handling Unit (AHU) with HEPA filter.

- We have precise temperature control system.
- We have precise humidity control system.
- We have precise pressure difference control system by software.

Environment, Health and Safety Consideration

The inherent safety risks relating to the pharmaceutical and chemical industry is always be a key focus as standardized health, safety and environment (HSE) process that are embedded across all of our operations. The IBN SINA Pharmaceutical Industry PLC is committed to pursue excellence in Health, Safety and Environment conducts its activities safety and in an environmentally responsible manner. Safety is our first priority. It is integral to our culture.

In order to ensure reliable and safe operations, we continue to focus on day to day management of operational risks, including risks related to Health, Safety and Environment. To promote safety throughout the business operations, execute management meets regularly to review environment and safety performance.

It is the nature of our industry that our people face many stressful situations in the workplace. We continue to offer comprehensive health and wellness service to our employees. Our employee's Physical and emotional wellbeing appears to be in line with the industry norms related to Health, Safety and Environment.

Environment Consideration

IPI gives utmost importance to environment protection and strictly avoid the activities which may have any adverse impact on the environment. We believe that environment protection should be implemented due to climate changes and natural calamities which affect our country every year. We have therefore designed the production process in the most resource and energy -efficient way as possible.

Our actions in this contexts are:

- We have established an Effluent Treatment Plant (ETP) of capacity 500 liters/hr. to treat effluent from plant.
- We are conducting incineration by Prism Bangladesh Foundation.

Health & Safety Consideration

Our Plant has been designed following the modern concept of safety guidelines. We make regular safety assessments and ensure compliance with all existing laws in the field of environmental protection, hygiene and safety at work. A special care and training is planned for the safe handling of Hazardous chemical. A Standard Operating Procedure (SOP) on safety guidelines is followed by each and every person in our Plant.



Our Steps to Health, Safety and Environment

- We have a specialized medical team in our plant premises for employee's health related issues.
- For COVID-19 and others related issues we always concern about our employee's health and safety. We arrange COVID-19 vaccines for our employees and strictly follow the safety rules.
- Our all areas are well furnished by modern fire alarm system, adequate number of fire extinguishers, fire hoses with fire hydrant and others fire safety equipments.
- We have well trained fire fighter team and adequate training system.
- We have a central Effluent Treatment Plant (ETP) of capacity 500 liters/hr. to treat effluent from plant.
- We send all of our hazardous pharmaceutical products to Prism Bangladesh Foundation for incineration by double chamber incinerator maintaining 1100 temperature at Medical Waste Management Plant.

NATURAL MEDICINE

Nature is divine; the motto of the 21st century is "Back to the Nature"

The IBN SINA Natural Medicine Ltd., a Subsidiary of The IBN SINA Pharmaceutical Industry PLC is dedicated to serve humanity by manufacturing and providing quality medicines and services to its customers with marching onward for sustainable growth and continual improvement.

Back to Nature

Our approach is to using natural resources in a conservative way and taking initiative to reduce any adverse impact not only on human being but also on nature to make a greener environment.

About natural Medicine

IBN SINA Natural Medicine plant is equipped with the latest technological support in 2008 with a view to facilitate the best natural therapeutic service to the people .within a very short time our natural medicine has achieved a goodwill and credibility of medical professionals and consumers for its efficacy and quality .Following this trend most of the leading pharmaceutical companies have also started marketing of the natural medicine production. The growth is increasing day by day after starting its

journey .it has undergone potential expansion in multiple sectors due to its responsible business practices. The ranking of the natural medicine division is among the most important multidisciplinary groups and advocates for the principle of the care for the future, high professionalism, employee friendly approach, financial stability transparency, safety and leadership. It is striving to strengthen its market access in locally and globally. Formulating its competitive strategies and putting emphasis on productivity enhancement, thus playing a pivotal role in the country's commerce and trade sectors.

Manufactured Capital

Investment in manufactured capital is vital in order to produce high-quality medicines that contribute to sustainable competitive advantage .Significant investment in our finished products, manufacturing facilities, operations, technologies, capacities and distribution is an ongoing phenomenon that aims to safeguard our resources,satisfy the customer needs and achieve the strategic intent of the business.

Sources of Manufactured Capital



Manufacturing Process

Production is ongoing with separate manufacturing division, these are Unani division and Herbal division very soon we are going to open Auyabadic medicine division .

Unani Division

Facilities are decorated with sophisticated production machnaries for tablet, capsule, powder (Sufoof) and syrup products with enlarged area. Here is top selling products like Vinsina Herbalisyrup, Hazmi syrup, Alkof, Basok syrup, sinar syrup and Myrosin etc syrup. Among the topical products Vigogel and demaris.

This area is furnished with art of state machinaries for tablet, capsule, powder, sachet products. There is a new sensitive product probiotic manufacturing area has built and production ongoing. Lyophilized papaya products is first time in Bangladesh for the treatment of the dingo fever has launched. The major products in the herbal division are Rebio capsule, Isbulgul plus sachet, Ginsin capsule, Dirolina capsule , silicap capsule etc.

| Input | Process | Output |
|--|---|--|
| <ol style="list-style-type: none"> 1. API, excipient, various types herbs and packing materials are received and inspected as per standard operating procedure SOP and kept in quarantine area. 2. Sample analysis is done by Quality Control whereby QC performs identification, potency determination and necessary test of materials. 3. Following QC approval, pass levels are fixed on container and materials are shifted from quarantine to a specific approved area for preservation . 4. Material requisition is placed by production department along with batch manufacturing procedure of the product. 5. Materials are collected as for bill of materials and sent to Production for dispensing. 6. Purity, temperature, humidity and other condition of the materials are checked by the production and quality assurance and 7. Materials are weighted and dispensed to production as per requisition. | <ol style="list-style-type: none"> 1. The IBN SINA natural medicine have several dosage forms like capsule, tablet, oral liquid, ointment-cream, probiotic, Halawa, sachet and powder dosage form. Manufacturing procedure of these dosage forms are different and has separate SOP. 2. Rooms and machines are fully cleaned and prepared for production having HVAC system. 3. Medicine and product is processed according to validated SOP. The production operator and officer follow the written SOP and keep record of all the activities along with sufficient retention sample. 4. The in process quality is checked by QA at every step of manufacturing and quality is ensured in every steps. 5. After completion of every sub process, sample analysis is performed by the QA and sent to QC for evaluation. 6. Upon approval by QC, QA fix the label on the container and gives approval for next step and 7. The prerequisites environment and the regulatory condition of the products are maintained and ensured by the QA and Production at every level. | <ol style="list-style-type: none"> a) After packaging of products, all documents are reviewed by the QA and approved for distribution and sales. b) Representative sample form every batch is kept by the QA up to the shelf life of the product for monitoring real life. c) Real time instability study up to the shelf life is performed by the QA for further development and d) When launching new products, product development and accelerated and real-time stability is performed by R&D. |

Ensuring Quality

Our journey for maintaining better quality begins from Raw Material selection process. We have the standard vendor selection procedure to select the right party for our intended quality products. Quality control and quality assurance department are full furnished and equipped with art of state equipment and machineries in the light of the latest technology such as AASP,HPLC, FTIR, TLC, UV visible spectrophotometer, digital polarimeter, pH meter, moisture balance etc. We assure the quality of raw materials and finished product equally. The quality assurance department ensures and monitors quality of the product in every step of manufacturing operation critically. As a result, it becomes possible to deliver quality products to the customer.

Product Development

The PD department is playing vital and the pioneer role in healthcare of Bangladesh, maintaining the ethical standard regarding safety of human health issue. The PD is developing various new products to fulfill the new market demands depending on the latest innovation and customer's requirement. Moreover they are continuously searching cost effective quality products. Experts on relevant field including Ph.D professionals and other experienced Pharmacist and trained personnel and reputed natural medicine advisors are also involved in continuously improvement of the product development.

Herbarium and Standard Sample

There is a standard and well furnished herbarium and plant profiles in the natural medicine factory. Here, a team of efficient manpower including qualified taxonomist for identification of different Raw Materials and also preserved them accordingly.

Engineering Department

This department is equipped with all essential machineries tools and utensils to run the factories smoothly. A balanced technical team with electrical, mechanical, HVAC, utilites expert in this line in sufficient quantities for routine and preventive maintenance. The utilities sector is well furnished with own power generating generator, boiler, oil free air compressor and HVAC system. We have canteen and prayer facilities in self contained facilities.

Technical Team

This natural medicine ltd. is enriched with technically qualified both in academically and professionally. These are pharmacist, chemist, and botanist, BUMS, taxonomist, microbiologist and supply chain specialist. They all are under schedule training with evaluation programs. The training is conducted with items expert both from local and aboard. These programs assist us to keep up- to- date both in technically and professionally.





INTELLECTUAL CAPITAL

Our intellectual capital supports our commitment to increase the number of lives that benefit our focused therapeutic class of high quality, affordable medicines.



Our Products Portfolio

We strongly focus on to develop topper product portfolio in Bangladesh. As a consequence, we analyze the customer demand, competitor activity, international market and so on to strengthen the existing portfolio by launching new and innovative product and technology as well as introducing new molecule in Bangladesh. Our product portfolio is:

| Therapeutic Class | Description | IPI's Strength |
|-------------------|--|---|
| Antibiotic | "Antibiotics, also known as antibacterials, are medications that destroy or slow down the growth of bacteria. They include a range of powerful drugs and are used to treat diseases caused by bacteria. When used properly, Antibiotics fight against infections and can save lives. The first antibiotic was Penicillin. Penicillin-based antibiotics, such as Ampicillin, Amoxicillin, and Penicillin G, are still available to treat a variety of infections and have been around for a long time. There are different types of antibiotics, but most of them can be classified into 6 groups: 1. Penicillins (such as Penicillin, Amoxicillin etc), 2. Cephalosporins (such as Cephadrine, Cefixime etc), 3. Aminoglycosides (such as Gentamicin, Tobramycin etc), 4. Tetracycline (such as Tetracycline, Doxycycline etc), 5. Macrolides (such as Azithromycin, Erythromycin etc), 6. Fluoroquinolones (such as Ciprofloxacin, Levofloxacin etc). Other antibiotics include Chloramphenicol, Fusidic acid, Nitrofurantoin etc." | We are enriched in Penicillins with brands Sinamox, Sinaclox, Sinaflox etc, Oral Cephalosporins with brands like Cefixim, Merocef, Meroclav etc, Macrolides with brands like Romycin, Clarith etc, Fluoroquinolones with Bactin, Floromox, Gemitab etc. We strongly cover institutions and hospitals by Cephalosporin and Carbapenem injectables like Axosin, Gen4, Taxceph, Merotrax etc. We produce antibiotics by maintaining all the cGMP guidelines, with world class raw materials from different renowned sources and are committed to serve the people with highest quality products. |

| Therapeutic Class | Description | IPI's Strength |
|------------------------|--|--|
| Anti-ulcerant | "This class of drugs is used to treat ulcers in the stomach and the upper part of the small intestine. There are several types of anti-ulcerant drugs like the proton pump inhibitors which work by blocking the secretion of gastric acid of parietal cells of stomach; H2 receptor blockers stop the action of histamine on the gastric parietal cells which ultimately inhibits the secretion of gastric acid; non systemic antacids provide local acid neutralizing effect and anti-foaming agents are used to reduce bloating, discomfort or pain caused by formation of excessive gas in stomach." | We are very strong in anti-ulcerant portfolio having pioneer brands like Dexlan and Gavisol. We have introduced Dexlan First time in Bangladesh. We also have introduced Gavisol first time in Bangladesh among the local manufacturer. Dexlan and Esolok are the first bioequivalent Dexlansoprazole and Esomeprazole Capsule respectively in Bangladesh. We also have some potential brands in this portfolio including Xorel, Pantolok etc. |
| Antiasthmatic | Antiasthmatic drugs are used to treat asthma, bronchitis, emphysema or bronchiectasis. Asthma is a major non-communicable disease (NCD), affecting both children and adults, and is the most common chronic disease among children. Inflammation and narrowing of the small airways in the lungs cause asthma symptoms, which can be any combination of cough, wheeze, shortness of breath and chest tightness. | We are enriched with different classes of antiasthmatic drugs including Ventisal, Ventisal-L, Xofyl, Montex etc. |
| Antihistamine | Antihistamines are drugs that can relieve allergy symptoms such as runny nose, sneezing, and congestion. These drugs help treat conditions caused by too much histamine, a chemical created by body's immune system. Antihistamines are most commonly used by people who have allergic reactions to pollen and other allergens. They are also used to treat a variety of other conditions such as stomach colds, anxiety and more. | We have a number of potential antihistamine brands including Bilamin, Fexomin, Rupamin, Ebamin, Sinamin, Nosemin, Silora etc. Among them Bilamin is completely non-sedative. So, Bilamin is very much suitable for active people involved in driving, learning etc. |
| Cough Medicines | Cough medicines are used to relieve from cough. There are 2 types of OTC cough medicines: Cough expectorants and antitussives. Expectorants are a type of cough medicine that thins mucus in the respiratory tract, making it easier to expel. Antitussives are cough suppressants. | Our cough medicines are enriched with a number of popular brands like Lytex, Bromotex and Sinakof. |
| Antidiabetic | "Antidiabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetes is a disease in which the blood glucose, blood sugar, levels are too high. Diabetes can lead to several life-threatening complications, including stroke, heart attack, chronic kidney diseases, neuropathy, visual impairment etc. Diabetes patients are tremendously increasing in Bangladesh." | "We have different class of antidiabetic drugs including Linax, Linax plus, Taglimet, Glipatab etc. that are confidently prescribed by renowned diabetologists and other doctors. As these products are needed to take for long time, we are giving special price offer for most of the CVS products as a patient benefit." |

| Therapeutic Class | Description | IPI's Strength |
|-------------------------------|--|---|
| Antispasmodic | Antispasmodic drugs reduce muscle spasms of the intestine, biliary system, urinary bladder & uterus. These drugs are used for the treatment of pain in gastrointestinal, biliary, urinary and gynecological diseases such as gastroenteritis, diarrhoea, dysentery, biliary colic, enterocolitis, cholecystitis, colonopathies, mild cystitis & spasmodic dysmenorrhoea. | We have potential brands in this portfolio like Visceral, Alverate, Buscon etc. |
| Antineuropathic | Antineuropathic drugs are used to treat neuropathic pain. Neuropathic pain can be defined as a process occurring after a primary lesion or disease of the somatosensory nervous system. The pathophysiological states that determine the onset of neuropathic pain mostly involved are metabolic disorders (e.g. peripheral diabetic neuropathy (PDN), neuropathies associated with viral infections (e.g. post-herpetic neuralgia, HIV, leprosy), autoimmune disorders affecting the central nervous system (e.g. multiple sclerosis and Guillain-Barre syndrome), chemotherapy-induced peripheral neuropathies, damage to the nervous system of traumatic origin (e.g. spinal cord injury (SCI) and amputation), inflammatory disorders, hereditary neuropathies, and channelopathies. | We have potential antineuropathic brands like Neurega, Neuralgin, Remylin etc. |
| CVS drugs | Cardiovascular drugs are used to treat high blood pressure, heart failure, angina and heart attacks etc. Cardiovascular diseases (CVDs) are the leading cause of death globally. Cardiovascular disease occur as a result of heredity or behavioral risk factors like unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. Cardiovascular diseases are considered as life threatening as it may lead to stroke, myocardial infarction and ischemia, if not appropriately treated. | Our CVS portfolio includes a number of products like Olmedip, Orabis, Cilmedip, Colostat, Restat, Diplor, Diplor Plus etc. As these products are needed to take for long time, we are giving special price offer for most of the CVS products as a patient benefit. |
| CNS drugs | The central nervous system consists of the brain and spinal cord. It is referred to as "central" because it combines information from the entire body and coordinates activity across the whole organism. Different classes of drugs are used to treat CNS diseases. | We have different types of CNS related drugs imparting strong image among Neurologists, Psychiatrists and other doctors community. The brands include Moodnor, Myotril, Remood, Rivacap etc. |
| Gastroprokinetic agent | Gastroprokinetic agent is a type of drug which enhances gastrointestinal motility by increasing the frequency or strength of contractions, but without disrupting their rhythm. They are used to treat certain gastrointestinal symptoms, including abdominal discomfort, bloating, constipation, heart burn, nausea, and vomiting; and certain gastrointestinal disorders, including irritable bowel syndrome, gastritis, gastroparesis, and functional dyspepsia. | Our gastroprokinetic drug includes Dopadon. |

| Therapeutic Class | Description | IPI's Strength |
|--|--|--|
| NSAIDs | NSAIDs (nonsteroidal anti-inflammatory drugs) are some of the most commonly used pain medicines in adults. They are also a common treatment for chronic (long-term) health problems, such as arthritis (rheumatoid arthritis, osteoarthritis, and others). NSAIDs also can decrease inflammation, such as fever, swelling and redness. | We are enriched with wide ranges of NSAIDs brands including Nupralgin, Nupralgin Plus, Etolac, Preservin, Preservin SR, Anodyne, Anodyne SR, Longpara, Sinapol, PAC, Oxiflam, Algirex etc. |
| Laxative | Laxatives, purgatives or aperients are substances that loosen stools and increase bowel movements. They are used to treat and prevent constipation. Constipation is a condition which occurs when the movements of bowel become less frequent and stools become difficult to pass. It happens most often due to changes in diet or routine, or due to inadequate intake of fiber. | We have laxative drugs to treat and prevent constipation like Sinalac. |
| "Vitamin Minerals and Hematinics" | Vitamins and minerals are used as a supplement to relieve from the symptoms of Vitamins and mineral deficiency in the body. Vitamins and minerals are organic compounds that our bodies use in very small amounts for a variety of metabolic processes. Basically, they keep us healthy and help our bodies to function. They support healthy development of body, strong immune function and emotional and mental vitality. Also, they convert food into energy and repairs cellular damage. We get vitamins and minerals from the foods we eat especially from fruits and vegetables. But daily food habit of many people fails to maintain the daily requirement of Vitamin-Minerals for the body and is causing an ultimate need of Vitamin-Mineral supplemental medicines. Haematinics are substances required in the formation of blood & are used for treatment of anaemia. | Our Vitamins-Minerals and Hematinics portfolio is enriched with a number of popular brands. These brands are used to relieve from deficiency of vitamins and minerals of children and adults. The brands include Vitalgin, Sinagold, Sinasilver, Lyovit, Coraltab, Coraltab DX, D, Junivit, Biozinc, Biozinc-B, Ipical, Ipical-D, Zepiron, Zepiron Plus, Oxyfer etc. |
| Topical Dermatological agents | Topical Dermatological agents are the medicines used to treat skin conditions include topical and oral drugs for the treatment of a wide variety of diseases of the skin, hair and nails. These agents are applied directly on the skin to treat skin conditions. Topical dermatological agents include anti-inflammatory agents, anti-infective agents, antifungal, antiviral, agents for psoriasis such as topical corticosteroids, emollients, astringents, agents to treat acne, local anesthetics, cleansing agents and so on. | We have renowned topical dermatological brands including Terbinolx, Dermacom, Dermacort, Dermastin, Sinacort, Fungin, Fungin-B, Neocort, Fungicort etc. |
| ORS | Oral rehydration solutions (ORS) are used to treat dehydration caused by diarrhea, a common illness for all age groups. Unlike other fluids, the ratio of the ingredients in an ORS matches what the body needs to recover from a diarrheal illness. This simple mixture saves millions of lives with very low cost. | We have very popular ORS brands like Unisalene, Unisalene Fruity (Mango), Unisalene Fruity (Orange), Unisalene Fruity (Lemon). |

| Therapeutic Class | Description | IPI's Strength |
|----------------------|--|---|
| Antiviral | Antiviral drugs are one class of antimicrobials used for treating viral infections. The general idea behind modern antiviral drug design is to identify viral proteins, or parts of proteins, that can be disabled. Most of the antiviral drugs now available are designed to help deal with COVID-19, SARS, Influenza, Dengue fever, Zika, HIV, Hepatitis, Polio, Ebola, Influenza, etc. | We have potential antiviral products like Favitab. It is a tablet preparation of Favipiravir 200 mg. Favipiravir was approved in 2014, in Japan to treat influenza that were unresponsive to conventional treatment. Favipiravir shows its efficacy at targeting several strains of influenza. It is indicated for the treatment of novel viruses including Ebola and most recently, Covid-19. We also have Clovir exerts its antiviral effect on herpes simplex virus (HSV) and varicella-zoster virus by interfering with DNA synthesis and inhibiting viral replication. |
| Antiprotozoal | Antiprotozoal agents are a class of drugs used to treat infections caused by protozoa, which are single-cell organisms, belonging to a group of parasites. Protozoan typically are microscopic and similar to plants and animals as they are eukaryotes, thus having a clearly defined cell nucleus. Many of the most prevalent and deadly human diseases are caused by a protozoan infection, including African sleeping sickness, amoebic dysentery, and malaria. Diarrhea continues to be a major cause of childhood mortality and morbidity in developing countries. Southeast Asian region including Bangladesh, experienced the highest mortality rate among children with diarrhea. | "We are enriched with drugs to fight against protozoan infections. Our antiprotozoal portfolio includes several brands like Metsina, Nitasol. Metsina, a popular brand is available as suspension, tablet and IV dosage form. Metsina is very much effective in amoebic dysentery and some other protozoal infection." |
| Antiemetic | An antiemetic is a drug that is effective against vomiting and nausea. Antiemetic are typically used to treat motion sickness, pregnancy and the side effects of opioid analgesics, general anaesthetics, and chemotherapy directed against cancer. | We are enriched in antiemetics with brands like Emiston & Palostat. They are effectively used to treat nausea and vomiting due to motion sickness, pregnancy and the side effects of opioid analgesics, general anaesthetics, and chemotherapy directed against cancer. |
| Antifungal | "Antifungal medicines treat fungal infections. Fungus in the soil, air and on your skin can cause yeast infections, ringworm, and nail and skin infections. Breathing in fungal spores can lead to respiratory illnesses. People who have weak immune systems are more prone to fungal infections that require antifungal medicine. Over one billion people in Bangladesh are believed to suffer from a fungal infection annually. These increasing number of fungal infected patients contributing a distinguishable progression on antifungal drug market in Bangladesh." | We have wide range of both topical and oral products like Terbinox, Sporagin, Ketotab, Fungin, Fungin-B, Illuca etc. We have introduced Sporagin oral solution first time in Bangladesh. |

| Therapeutic Class | Description | IPI's Strength |
|--------------------------|--|---|
| Anti-fibrinolytic | "Fibrinolysis is a process that prevents blood clots from growing and becoming problematic. Antifibrinolytics are medicines that promote blood clotting by preventing or slowing down a process called fibrinolysis, which is the breakdown of blood clots. Antifibrinolytic agents may be used to help prevent or treat serious bleeding in patients who have certain conditions, such as hemophilia, very heavy menstrual bleeding, or some types of vascular tumors." | We have potential drug Nexyl to treat haemorrhage or risk of haemorrhage in increased fibrinolysis that may occur in conditions like Prostatectomy and bladder surgery, Menorrhagia, Epistaxis, Conization of the cervix, Management of dental extraction in patients with coagulopathies, Ulcerative colitis, Haematuria, Gastrointestinal haemorrhage. |
| Ophthalmic drugs | Ophthalmic drugs are used to treat a large number of diseased states of the eye. These states may include bacterial infections, viral infections, Fungal infections, eye inflammation, eye allergy, eye injury, glaucoma, cataract and dry eye. | We have very strong image in ophthalmic market. We are producing a variety of popular ophthalmic products from different therapeutic classes including Antibiotic (Floromox, Levosina, Bactin, Cloram, Romycin, Tomycin etc), Steroid (Loterex, Isolon, Eylon, Dexon etc), Antibiotic plus Steroid combination (Loterex-G, Loterex-T, Dexon-G, Bactin-D etc), NSAIDs (Bromofen, Nep-TS, Etolac etc), Antiallergic (Patalon, Patalon-DS, Ketof etc), Antifungal (Fungin, Natoph), Drugs for Dry Eye Syndrome (Sinafresh, Glamor, Polygel, Optear etc), Anti glaucoma (Avost, Avost Plus, Azopress etc), Ophthalmic Vitamin and Mineral (Optagold), Anticataract (Ractovit). |
| Other | There are many other classes of drugs IPI owns. | We have many other brands from different therapeutic classes like Glucocorticoids (Cordef), Muscle relaxant (Bacofen, Myoson), Drugs for BPH (Urocap, Urocap-D), Antiarthritis supplement (Articulex, Ostorin), Drugs for vertigo (Cinarzin, Cinarzin Plus). We have also many other drugs from different classes. |

Management Approach

IPI PLC's Intellectual Capital consisting of tacit knowledge, trusted brand, systems and processes, and innovative products as the building blocks of new growth line.



INPUTS

- Tacit Knowledge
- Reputed Brand
- Organizational Capital
- Relational Capital
- Technology

MANAGEMENT FOCUS

- Develop skills and expertise of employees
- Staff retention
- Continuous investment in IT infrastructure
- Technology innovations
- Investment in brand building initiatives
- Utilize our relationships for sustainable value creation

OUTPUTS

- Brand equity growth
- Market share increase
- Improved skills of employees
- Most innovative pharmaceutical Company

New Launched Products

The IBN SINA Pharmaceutical Industry PLC has launched 21 products of 15 generics during 2021-22 fiscal year including Glipatab 10 Tablet, Glipatab 25 Tablet, Rivacap 3 Capsule, Loterex-G 5ml Eye Suspension, Olmetab Plus 20/12.5 Tablet, Olmetab Plus 40/12.5 Tablet, Cilmedip-5 Tablet, Cilmedip-10 Tablet, Azopres BR 5 ml Eye Drop, Cordef 6 Tablet, Cordef 24 Tablet, Xorel-10 Tablet, Oxyfer-500 ml IV Injection, Terbinox 10 gm Cream, Terbinox Tablet, Sporagin 100 mg Capsule, Sporagin 100 ml Oral Solution, Opcet 5ml Eye Drops, Combofresh 5 ml Eye Drops, Bester 250 ml Mouthwash, Dermacom 15 gm Cream. Among them Sporagin 100 ml Oral Solution was launched for the first time in Bangladesh and it is effective in the treatment of fungal infections of children. Products like Oxyfer-500 ml IV Injection, Terbinox 10 gm Cream, Terbinox Tablet, Sporagin 100 mg Capsule, Sporagin 100 ml Oral Solution, Opcet 5ml Eye Drops, Loterex-G 5ml Eye Suspension, Combofresh 5 ml Eye Drops, Bester 250 ml Mouthwash, Dermacom 15 gm Cream were well accepted by the physicians.

FIRST TIME IN BANGLADESH



Quality Control (Q.C)

It has separate Quality Control Department for each Manufacturing division. Each Quality Control Laboratory has the following wings-



For Conforming to the Quality of-

- Raw Materials ● Packaging Materials
- Intermediate Products ● Bulk and Finished Products

All laboratories are equipped with modern facilities and sufficient sophisticated equipment.

The IBN SINA Pharmaceutical Industry PLC has dedicated international regulatory affairs section under Quality Control Department to register the products in overseas market such as United States of America, Venezuela, Guatemala, Myanmar, Sri-Lanka, Cambodia, Vietnam, Laos, Kenya, Somalia, Afghanistan, Yemen, Mali, Bhutan, Georgia, Ghana, Mauritius, Senegal, Uganda and Zimbabwe.

Quality Assurance

Another important department is Quality Assurance (QA) whose prime responsibilities are to ensure the quality of products at every step of production operation and release/rejection of finished products. To carry out the QA activities effectively, it has the following sections:

- Separate in process QA Laboratory for each section of production department for proper monitoring of production operation, supervision of production environments, recording and documentation.
- Compliance
- Validation and Calibration
- Documents preparation, distribution and archiving
- Training

To supervise the effectiveness and applicability of the quality assurance system, QA perform the following activities:

- Implementation of cGMP and training;
- Change control management;
- Deviation management;
- Risk assessment & management;
- CAPA management;
- Conduct Internal audit;
- Annual product quality review;
- Market complain handling;

- Process validation IPQA instrument calibration;
- Documents like SOP, BMR, BPR, master list etc preparation, distribution and archiving;
- Packing materials checking, approval and controlling and
- Retention sample management.

For proper co-ordination among the different departments, we developed Quality Operation Management System. Quality is our commitment and we are marching on ward to achieve this goal. Quality management System (QMS) and international standard cGMP are in practice now. We are trying to achieve the recognition of TGA, Australia first and then we shall proceed for other international compliance certification one by one.

Product Development (PD)

Product Development is an important wing of The IBN SINA Pharmaceutical Industry PLC We have two separate PD Departments for Pharma and Natural Medicine. Both are enriched with a number of highly qualified and experienced personnel.

The goal of PD Department is to develop innovative, high quality pharmaceutical products in a cost-effective way maintaining its highly ethical issues regarding human health.

Our experienced PD team is dedicated to develop & introduce quality products according to ICH guidelines and continuous improvement of new and existing product for customer satisfaction, environmental change, technology change and other competitors. The inter department liaison of PD with Strategic Marketing Department, QA, QC, Purchase & Production helps a successful introduction of a new product to the valued customers.

PD Department is equipped with highly sophisticated machineries and equipments of cGMP standard for development of new products in an efficient manner.

PD team ensures following activity

- Preformulation Study
- Pharmaceutical Formulation
- Stability Study
- Process Development and Validation
- Pharmaceutical Analysis
- Reformulation
- Preparation of Samples for DGDA and Documents
- Comparative Dissolution Study with Innovator Products
- Technology Transfer to Production, QC & QA

We have developed central PD laboratory and Scale-up area for Process Validation for The IBN SINA Pharmaceutical Industry PLC having required space with all modern equipments facility.

PD yields around 20-25 new products in health sector every year. This active participation of The IBN SINA Pharmaceutical Industry PLC in pharmaceutical sector stands as one of the leading pharmaceutical industries in Bangladesh.



SOCIAL AND RELATIONSHIP CAPITAL

Engagement with the corporate responsibility and sustainability initiatives supports with our key stakeholders and sharing values with them as fundamental to sustainable growth. We, as a responsible corporate citizen, carry out business activities with transparency, integrity that enables us to invest in various socio-economic development activities for the well-being of our country.

Social and Relationship Capital (SRC) includes shared norms, common values and behavior, key stakeholder relationships, intangible association with organization's brand and reputation and organization's social license for business operation.

We think social and relationship capital as one of the key assets of the Company. It acts as the image and reputation of the organization. Viewing this perspective, due importance of social and relationship capital is given maintaining healthy relationship to the stakeholders, the beneficiary concerned like customers, suppliers, surveyors, reinsurers, vendors, banks and all other stakeholders.



CSR in Operational Activities

To cultivate good governance practice in the Company, there is a policy on the Corporate Social Responsibility (CSR). CSR Committee formed by the Board conducts the CSR activities of the Company as per "Corporate Social Responsibility Policy of the Company":-

- Conducting business in a socially responsible and ethical manner;
- Protecting the environment and the safety of people;
- Supporting human rights maintaining relationship with the stakeholders and employees; and
- Engaging, learning, respecting and supporting the communities and cultures with which we work.

These can be achieved through our products and spirits which enrich the quality of human life enabling people's feelings happy in the application of CSR strategy, an effective tool for business success. The core components of CSR practiced in the company are described below:-

CSR for the Employees

Considering the overall welfare, safety and security for the officers and workers, Company has formed a Provident Fund (PF), Gratuity and Superannuation Fund. Separate Trustee Board is entrusted to govern these funds. Besides of these, group insurance for workers of factory and full time health services for the workers employed in the factory are also available. Expenditure of the treatment for partial or total physical damage for accidental causes during and out of normal course of service is being endeavored from the Company and also a special amount as donation is given to the successor of deceased personnel causing accidental death during and out of normal course of action.

Group Insurance

As per Section- 99 of Bangladesh Labour Laws 2006 (as amended in 2018), the Company has established

Group Insurance for its employees with the recognized Insurance Company.

Officer Workers Benevolent Fund

Employees are being facilitated from Officers-Workers Benevolent Fund where financial assistance is required. It recognizes our employees with respect, dignity, caring each other that ensure good atmosphere of the employment.

Superannuation Fund

This is a structural pension program approved by the Board for the wellbeing of its employees in order to mitigate the various specified problems like accidental death, disablement, serious chronic illness, etc. during the period under job. During the year under review, total 11 officers and workers were facilitated paying 7,350,000/- (Taka Seventy Three Lac Fifty Thousand) to the successors of the deceased members of this Fund



Donation on Death

When a regular employee of IPI dies during working hours or later, the family members of deceased employee are provided some financial assistance as instant support. In many cases, the Company also takes up the responsibility of education of the children of the deceased employee as an acknowledgement of their contribution and dedication to the Company.

Medical Expense Provided to Insolvent Employees

The employees who are not capable of paying the expenditure incurred for their medical treatment for various diseases/accidental causes happened either during in course of service or in any other way are being taken under special consideration for payment of such medical expense. In the year 2021-22 total medical expense supported by the Company is about more than Tk. 20 (Twenty) Lac.

Community Improvement

The IBN SINA Pharmaceutical Industry PLC believes that this program can be developed through a combination of cares to individual employee like matching support arrangements between the company and the employees which build team spirit particularly among the employees by participatory activities for community development.



Sponsoring Holy Umrah

Sponsoring to perform holy Umrah is another CSR scheme for the employees of IPI. Every year certain number of good performers from respective departments of the Company are selected. Employees are very enthusiastic and refreshed having such opportunity from the Company.

Work with Recreation

The IBN SINA Pharmaceutical Industry PLC arranges Annual Picnic, Cultural Programs, Sports and Visits for its employees for congenial environment among the workers and better outcome.





Gift for New Born Baby

Children are the special gift of the Creator and the beauty of the world. About 5,000 (five thousand) officers and employees are working in this organization. The Company presents gift box to the employees to share the joy of a newborn baby and parental feelings.

Setting up Medicine & Doctor's Corner

A medicine corner has been established so that employees can purchase medicine instantly from medicine corner for themselves and their family members at considerate price.



Human Rights

We are committed to upholding the Universal Declaration of Human Rights by the UN and the labor standards set out by the International Labour Organization and Bangladesh Labour Laws 2006 (As amended 2018).



Employee Training and Education Program

The IBN SINA Pharmaceutical Industry PLC considers the education and training as the core theme to promote employees' interest in attracting future potentiality, focuses on the "Right-to-Know" and "Partners-in-leadership" that aim to bring sustainable improvement of the personnel in the Company and for the nation as well.

The training given to the employees in the year 2021-22 in-house and abroad is shown in the page no. 90 of the Annual Report.

CSR for Society

Workers' Profit Participation Fund


Being handed over the Cheque of WPPF amounting to 33,94,698 (Taka Thirty Three Lac Ninety Four Thousand Six Hundred Ninety Eight) to the Director General, Bangladesh Sromik Kallyan Foundation, Labour and Employment Ministry, Government of Bangladesh.



Free Health Care Complex

A free medical center is running 5 days a week at Shafipur, Gazipur for the underprivileged people especially for Mother and Child those who are inhabitants of factory area. Factory workers are being taken under free medical treatment by the qualified Doctors and Hakims (Natural Medicine Practitioner) in the campus.





Medicine Donation

As part of the CSR activities, Company had donated good volume of medicine to different recognized charity events/organizations.



Emergency Food Support

The Company provides emergency food assistance to thousands of vulnerable flood affected people of the Country.

Scholarship for Medical Students

One of the CSRs that IPI undertakes focus on the education of the medical students. Always tries to help the future medical service providers through financial and other motivational means. Till the reporting date, a total of 45 students are receiving scholarship.

Warm Cloth Distribution

The IBN SINA Pharmaceutical Industry PLC during the session of winter provided warm clothes to the underprivileged standing beside them in the society located in Rangpur, Kurigram, Dinajpur, Rajshahi and Thakurgaon.



Environmental Initiatives



Forestation

As part of ongoing commitment to the Social and Environmental Responsibilities and policy to protect and improve the environment we have embarked on a program of tree plantation yearly to extend the greenery and landscape of the country. The afforestation program was taken in the territory of factory, projects and countrywide through Depots' surrounding area.



Paperless-Operations

The corporate world is turning to paperless environment. It has learnt that minimizing the use of paper can help conserve the environment, prevent deforestation and maintain the supply of fresh oxygen. IPI PLC drives to transform its paper work into a high-tech and innovative digital operation and communication with customers and employees.

Virtual Office Activity

IPI PLC operates a digital working environment that offers employees the opportunity to access virtual office activities like meeting, training and online books, etc.

Use Natural Lights

The IBN SINA Pharmaceutical Industry PLC promotes an energy-saving behavior at work. Artificial lights have been reduced while the use of sunlight is maximized in the day time. Lights during the lunch & prayer break are switched off.

Reduction in Business Travel

To reduce its carbon footprint and energy conservation initiatives, the company has minimized its travelling. Most operations requiring in-person interaction have been digitalized using online communication mediums.

Waste Minimization

Economizing on the use of water is also a part of our environmental conservation initiatives. We are encouraging team members to take special care in saving water and prevent its wastage. To prevent the build-up of waste, cleanliness is regularly checked up and paper, plastic, metal and wet garbage are segregated from trash to ease disposal and recycling.

Relationship Capital: Connecting Our Stakeholders

We focus to create value over different time horizons, stakeholders are prioritized for consultation based on the factors of influence, responsibility, proximity, dependency, willingness to engage, and representation. Stakeholders are consulted on regular basis through relevant departments.

Stakeholder Engagement Policy

The Company believes in maintaining effective, transparent and frequent interaction with the Stakeholder through sharing/dissemination of financial performance of the Company including significant various changes issues. The Company's aims to achieve the following objectives:


- * Identification, prioritization and understanding of all stakeholders;
- * Maintain healthy and sustained relationship with the stakeholders;
- * Provide access of the relevant information to enhance public image of the Company;
- * Provision of sharing feedback and resolving the complaints as early as possible.

Response to Shareholders Queries

The Company has implemented multiple channels of communication like platform of AGM/GM, shareholders' corner of share department, office of public relation, company website, Annual Report, requisite disclosures pattern, etc. to maintain an effective relationship with the shareholders of the Company.

Company's Secretariat Department handles the inquiries from shareholders and investors, as well as other interested parties. Quarterly performance result is being published duly in the company's website. Share Department keeps them very vigilant to provide the requisite services to the shareholders at their due expectation.

STAKEHOLDER ENGAGEMENT



Customer Complaint Form

Customers' complaints are being dealt with as per SOP. Our customers can provide their feedback or complaints, if any, by filling up a "Customer Complaint Form" available to each depot. In response to their complaint, feedback is given ensuring necessary corrective measures as required so that repetition of such problem could be avoided in future.

Management Coordination and Business Review Meeting

IPI PLC conducts management coordination meeting on a monthly basis and business review meeting on a quarterly basis comprising of Mid-Level and Top-Level Management with a view to developing future leaders of the company where change management, team building, HR development, overall business performance and topics on current socio-economic condition is highly emphasized upon and discussed extensively.



Activities for Medical Professionals

IPI PLC's aims at sharing with medical professionals useful information on various subjects of medical interest, organizing and sponsoring clinical meeting from time to

time, arranging video shows on acute medical emergencies and so forth. The Strategic Marketing Department carries out programs like scientific seminars, round table meetings, rural promotional campaigns, intern doctor's reception programs and many more.

Scientific seminar is a continuous medical education program, where individual departments or host institutions present a particular research based case study with medical professionals and learners of medical college. Rural promotional campaigns are conducted among Diploma in medical faculty doctors, who work as a community based health service provider. Such campaigns help to increase the involvement of rural level medical professionals with the company.



Publication of IBN SINA Health Magazine

A monthly IBN SINA Health Magazine sponsored by The IBN SINA Pharmaceutical Industry PLC is being delivered to our doctors, patrons and to the people to extend awareness about the various health related matters, It may be noted here that the Magazine contains contemporary important health topics contributed by reputed specialized doctors.



NATURAL CAPITAL

According to the International Institute for Sustainable Development, "Natural capital is the land, air, water, living organisms and all formations of the Earth's biosphere that provide us with ecosystem goods and services imperative for survival and well-being. Furthermore, it is the basis for all human economic activity."

Natural capital is continually providing us with something of value, whether it is the air that we breathe, the water that we drink, or the raw materials that we use in our products.

The problem is that we have not traditionally placed a financial value on these natural resources. By not placing a financial value on them, it became easy to destroy forests, pollute rivers, endanger species and habitats, and otherwise plunder our natural resources.

Now, however, we are starting to recognize the value of natural capital.

Ways to Manage our Natural Capital

The calculations for placing a financial value on natural capital in a business are still being developed, but here are a few ways that we can begin to consider natural capital in our business, from easiest to most challenging:

1. In general, any steps that we take to reduce waste, conserve water, and improve energy efficiency will move ours in the right direction. We can begin with easier steps, such as switching to recycled paper, setting up double-sided printing, and eliminating the use of all disposable items such as paper plates in the office kitchen.
2. From there, we can move on to areas of bigger impact. For example, removing waste from our production process will conserve natural resources - while also possibly providing cost savings to ours as well.
3. We may eventually want to begin accounting for natural capital in our business by using the Natural Capital Protocol, a framework designed to help businesses better manage natural capital.

One of the best parts about considering natural capital in our business is that it makes good business sense. When we conserve resources and eliminate waste, we save money, which directly benefits our bottom line.

Waste Management

Our key Initiatives towards waste management is Reduce, Reuse and Recycle.

Reduction of Paper Use

As paper is our main form material use in day today operation, we have taken initiatives to reduce paper usage. Setting up double-sided printing, reminder for necessity of printing, draft printing etc. Create paperless work environment by implementing e-QMS, e-logbook, e-learning system, steps ERP, leave management & KPI system.

Use Reusable Items

Eliminating the use of all disposable items such as paper plates, paper napkins, paper mug or cup in the office kitchen. In that place we use, reusable ceramic plates, glass mug/ cap & reusable towel. Continued to outsource all the photocopy machines to a third party and get refill the print cartridge and use to maximum possible duration indirectly.

Recycling of Waste

We continue to validate partner for paper, polybag, plastic, and glass bottle, foils collection to shred our waste in an environmental friendly manner and achieve reduction of our total waste.

Our Priorities



Waste Management



Water Consumption



Energy Consumption



Conserve eco-system

Water Consumption

We focus our efforts on reducing our water consumption for the long term; working on recycling and reuse of effluents. As a result we installed sensor taps, created awareness on water conservation aiming water management.

Ground Water
No use

Potable water/PW/WFI
71600 m3

Underground water
89500 m3

Mineral Water (Packed)
5 m3

Energy Consumption

Our key energy consumptions are electricity used for office premises and fuel used for business travelling. We continue to focus on enhancing energy efficiency in all aspects of our operations.

| | 2021-22 | 2020-21 |
|---|--------------|-------------|
| Non Renewable Fuel Consumption (KJ) | 10107000 kWh | 9150000 kWh |
| Non Renewable Electricity Consumption (Kilo joules Mn) | 23500 kWh | Nil |

Our Key Initiatives to Reduce Energy Consumption

- Timer switches to Air-Conditioners (A/Cs) to our office which operates in working hours.
- Conducting staff trainings online to reduce commuting energy use and cost.
- Encouraged employees to use electricity and fuel in a responsible manner in their day to day activities.
- Master key switches on all Office floors have enabled us to bring about greater energy efficiency.

Utilization of natural daylight

With the aim of ensuring sustainability benefits in terms of energy savings, we have adopted a building design emphasizing access to daylight and enjoy benefit from bringing natural light into the building. Maximizing the usage of daylight is one of the cost-effective means of reducing the consumption of energy.

● **Solar PV Panels:** We have installed solar PV panels to provide electricity support from renewable energy. The main objective of setting up solar panels is to reduce pressure on natural grid/generator for power supply. Our company is looking forward to strive towards a pollution free environment with a better future for our country and this is a step in that direction.

Conserve Eco-System

Ecological Plan

Appropriate landscaping is done so that no water can accumulate in case of heavy rain. Also many plants and grass are grown in the open space so that no dust can be generated from the bare land. The drainage system is designed in such a way that generation of dust is controlled. An appropriate ecological balance is done by implementing planned greeneries.

Effluent Treatment Plant (ETP)

We have an ETP with neutralizing capacity of total waste generated from manufacturing site. Liquid waste or effluent is collected through industrial drainage system

network spread below each production floor. Production rooms and central washing area have industrial hygiene type floor trap installed and through UPVC piping network all the waste are collected to underground PIT outside of production building which is directly connected to ETP through pipeline and wastage will be passed through Effluent Treatment Plant (ETP) for treatment and making it safe for the environment. After final treatment of effluent with the help of ETP, the water is used for gardening purpose of the factory premises or it is discharged to the local central drainage network. Everyday routine test is carried out in the laboratory to ensure the compliance with the regulations.

Incinerator

An incinerator is generally defined as any furnace used in the process of burning solid waste for the purpose of reducing the volume of the waste by removing combustible materials. The incinerator is used for disposal of waste materials of rejected tablets, capsules, powders, blisters, ampoules, vials etc. from daily manufacturing. During formulation of medicine, wastage or process loss is 2-3% which is not recoverable. This type of wastage is also incinerated by passing through incinerator. We have annual contact with PRISM Bangladesh Foundation for incineration of solid waste by monthly.

Upgraded Lighting System

In order to improve energy efficiency and lower carbon emissions, LED lighting fixtures has been installed in our office as well as in manufacturing plant. By investing in the installation of LED lighting, we have adopted one of the energy efficient substitutes and assure the savings of energy consumed in lighting the facility.

Looking Ahead

The way forward we continue to focus on adopting best practices in Energy Management, Water Management, Emission Control and Effluent and Waste Management across our value chain. Whist being a responsible corporate citizen to support more greenery projects towards environmental protection.



Human Resource Accounting (HRA) is the process of identifying and measuring data about human resources and communicating this information to the interested parties. In the HRA approach, costs related to human resources are treated as assets on the balance sheet as opposed to the in traditional accounting approach which treats them as expenses on the income statement. It is an attempt to identify and report the investment made in human resources of the Company that are currently not accounted for in the conventional accounting practices.

We are working towards establishing a Human Resource Accounting system to ensure clarity and focus on the investments made in the Human Resources. We are also finalizing an HR Dashboard in ERP system which will provide important intelligence about the total HR system regularly.

In order to develop skill as well as efficiency of all level of employees increasingly, Training and Development department initiated the various professional training programmes as per according to training calendar. A Plan was taken to bring the manpower of the company in the same platform gradually of "Need-based Training" Manual.

Training cost comprises of formal training cost, on job training cost, special training cost and development programs in the year 2021-22, Company incurred for its employee training as under:

| Types of Training | Description | Amount |
|---------------------------------|---|--------------|
| Training, Workshop & Conference | Training organized by the Company and different organizations | Tk. 398,2118 |

Expenses of Different Welfare Issues:

| Types of Training | Description | Amount |
|-------------------|--|----------------|
| Welfare Issues | Sickness/Treatment/Family Problem/fooding/superannuation facilities/Gift for New Born Baby / donation on family crisis moment etc. | Tk. 49,997,067 |

HEALTH, SAFETY AND ENVIRONMENT

The inherent safety risks relating to the pharmaceutical and chemical industry is always be a key focus as standardized health, safety and environment (HSE) processes that are embedded across all of our operations. The IBN SINA Pharmaceutical Industry PLC is committed to pursue excellence in Health Safety and Environment and conducts its activities safely and in an environmentally responsible manner.

Safety is our top priority. It is integral to our culture. We believe zero harm is possible, through a singular focus and disciplined teamwork.

In order to ensure reliable and safe operations, we continue to focus on day-to-day management of operational risks, including risks related to Health, Safety and Environment. To promote safety throughout the business operations, executive management meets regularly to review environment and safety performance.

It is in the nature of our industry that our people face many stressful situations in the workplace. We continue to offer comprehensive health and wellness services to our employees. Our employees' physical and emotional wellbeing appears to be in line with the industry norms related to Healthy, Safety and Environment.




CORPORATE GOVERNANCE

The objective of corporate governance of The IBN SINA Pharmaceutical Industry PLC is to run the company with the sense of four pillars of governance- fairness, transparency, accountability and independence to the shareholders and the society as a whole. The company is directed and managed under the Code of Conducts approved by the Board in light of the directives given by the concerned regulatory bodies to establish the good governance in the company and to fulfill the stakeholders' rightful expectations.

The stakeholders associated with the company are responsive to follow the general principles built on companies' values and the ethical standards, we are proud of it. Corporate good governance structures encourage creating of values and ensuring of accountability.




OUR CORPORATE GOVERNANCE FRAMEWORK



The Board of Directors

The Board consists of a Chairman, two Functional Directors, three Non-Executive Directors and two Independent Directors having versatile and adequate professional acquaintance of knowledge, skills and proficiency. The Board is the supreme authority while the Executive Committee, the Audit Committee, Nomination and Remuneration Committee (NRC) and Corporate Social Responsibility (CSR) Committee are four wings of the Board working in unison for smooth operation and development of the company.



- Non-executive Director
- Independent Non-executive Director
- Executive Director

Policy on Appointment of Directors

BSEC notifications and Companies Act are strictly followed regarding appointment of directors. As per the Companies Act, 1994, Directors are subject to retirement by rotation in every AGM. The term of an Independent Director is three years and may be lengthened by another three years. With regards to nomination, removal and casual vacancy of the Directors, Company follows all relevant laws, rules and regulations applicable for the company.

The Directors of the company are:

Nominated Directors

Nominated by the Sponsor Shareholders

Non-Executive Independent Directors

Being appointed/recommended to be appointed as per the prescribed qualifications of Independent Directors pursuant to the Corporate Governance Code of BSEC.



New Director Recommendation

Nominated Director
Nominated by Sponsor/Director Shareholder
Independent Director
Recommended from various sources



Appointment by the Board

Newly appointed Director,
Casual vacancy are filled by the Board
Existing Director- subject to retirement by rotation
at the AGM but eligible for re-appointment



Approval by the Shareholders at the AGM


Approval of appointment of
New Directors and Re-appointment
of existing Directors by rotation

Practice of the Board

The Board is responsible for formulation of overall planning, policies and strategies and guidelines of the activities and implementation thereof to achieve the goals and objectives of the Company and ultimately remains accountable to the Shareholders.

The Board of Directors of the Company has laid down a Code of Conduct for the Chairperson, Other Board Members and Chief Executive and annual compliance of the code based on the recommendation of the Nomination and Remuneration Committee (NRC) which are duly recorded and posted in the Website of the Company.

In accomplishment the affairs of the Company, the Board is guided by Corporate Governance Code of BSEC and in compliance with the Companies Act 1994, Labour Act 2006, (Amended in 2018) Memorandum and Articles of Association of the Company and the Service Rules of the Company and other relevant applicable laws and regulations. The Board also remains them responsible for efficient and effective implementation of the policies and strategies adopted time to time.



As recommended by the NRC, the Board approved the roles and responsibility of the Chairman. The principal features of the role of the Chairman comprise the following:

- Providing leadership to the Board;
- Taking responsibility for the Board's composition and development;
- Ensuring proper information for the Board;
- Planning and conducting Board meetings effectively;
- Getting all Directors involved in the Board's work;
- Ensuring the Board's focus on key tasks;
- Engaging the Board in assessing and improving its performance;
- Overseeing the induction and development of Directors; and
- Supporting the Managing Director.

Adequate Number of Non-Executive Directors

In line with Corporate Governance best practice, the company maintains 6 (Six) non-executive directors including 2 (Two) Independent Directors out of total 8 (Eight) Directors.

Independent Directors in the Board and their Independence

As per the Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC), one-fifth of the total Directors of the Board is Independent Directors, thus out of the total eight (8) Directors 2 (two) Directors are Independent, having no interest in the Company. Independence of the respective Independent Directors is confirmed during their selection and appointment and remains them committed to continue with such principle of independence throughout their tenure.

Chairman of the Board

The Chairman of the Company is elected by the Board of Directors and the Board considers the Chairman being independent and Non-Executive Director.

Role of the Chairman

The Chairman's primary role is to ensure that the Board is effective in its task of setting and implementing the Company's direction and strategy.


Annual Appraisal of the Board's Performance and Disclosure

Appraising a board's performance can clarify the individual and collective roles and responsibilities of its Directors, and provide better knowledge expecting from them which can help boards become more effective. Board appraisals may also improve the working relationship between a company's Board and its management.

The Board formulates the policy, guide the implementation process, review the performance of the implemented policies and give suggestion for correction of withers deem necessary. In this way Board assesses whether the desired outcome have been achieved by utilizing its resources within the expected timeframe. The Board members have always taken bonafide decisions that have benefitted the Company as a whole and the disclosures of their performance in this respect have duly been appraised.

Annual Evaluation of the Managing Director by the Board

Process for Evaluating the Effectiveness of the Board of Directors



The Board of Directors evaluates the activities of Managing Director based on performance evaluation criteria duly recommended by the Nomination and Remuneration Committee and approved by the Board along with the goals set forth for him considering the Company's vision and mission at the beginning of each year. The Board considers both financial and non-financial goals during the appraisal.

Training and Development of the Board

The Board recognizes the importance of ensuring that Directors are continuously being developed to acquire or enhance the requisite knowledge and skills to discharge their duties effectively.

All new Directors appointed to the Board attend a formal induction programme to familiarize themselves with the company's strategy and aspiration, understanding of the line of businesses and corporate functions, key financial highlights, audit, compliance and risk management.

Financial and Accounting Knowledge and Expertise of the Directors

Our Board of Directors consists of members who possess a wide variety of knowledge and experience in finance, economy, management, business administration, marketing, law and related key business matters. This ensures that together, they

formulate the right policy for the development of the business while having specialized skills and ability to foresee developments across a larger perspective and with enough independence to audit the management in a balanced manner.

Bangladesh Secretarial Standard (BSS)

The company has conducted its Board meetings and records the minutes of the meeting as well as maintaining required books and records in line with the provisions of the Bangladesh Secretarial Standard (BSS) as notified by Bangladesh Securities and Exchange Commission (BSEC).

Whistle Blowing Policy

The Whistle Blowing Policy ensures to establish transparency in all aspects and also in terms of minimizing the risk management and detecting any forgery or embezzlement.

Board and Committee Meetings

The composition of the Board and its sub-committees as of 30 June 2022 and the attendance of Directors at the Board and its sub-committees meetings held during 2021-22 have been disclosed detail are given below.

The Requisite Committees

Audit Committee

Attendance At Board Meeting

| Name of Directors | Position | Number of Meeting | |
|-----------------------------------|---------------------------------------|----------------------|----------|
| | | Eligible to Attended | Attended |
| Kazi Harun or Rashid | Chairman | 11 | 11 |
| Prof. Dr. AKM Sadrul Islam | Managing Director | 11 | 11 |
| Prof. ANMA Zaher | Director | 11 | 0 |
| Prof. Dr. Choudhury Mahmood Hasan | Director Technical & Director Finance | 11 | 10 |
| Dr. Mohammad Ayub Miah | Director | 11 | 09 |
| Prof.Col. Dr. Zehad Khan (Retd.) | Director | 11 | 10 |
| Md. Abdus Salam, FCA, FCS | Independent Director | 11 | 09 |
| Abdus Sadeque Bhuiyan | Independent Director | 07 | 07 |
| Md. Rafiqul Islam Khan, FCA | Independent Director | 04 | 04 |

Leave of absence was duly granted.


In Attendance

| | | | |
|-------------------------|---------------------------------------|----|----|
| Md. Kabir Hossain | Company Secretary | 11 | 11 |
| Md. Jasim Uddin, FCA | Chief Financial Officer | 11 | 11 |
| Sayed Amimul Ihsan, FCS | Sr. Manager Corporate Affairs | 11 | 11 |
| Md. Abdur Rakib | Head of Internal Audit and Compliance | 11 | 11 |

The Board has formed an Audit Committee comprising of 3 (three) members having adequate versatile and financial competence as prescribed by the BSEC duly approved by the Board. The Committee is empowered, among other things, to examine any matter relating to the financial affairs of the company and to review all audits, internal control and inspection programs, internal policies and adherence to the compliance requirements. The number of the meetings held during the year 2021-22 was 8 (Eight).

The details about the Audit Committee including background, composition, responsibilities, meetings, reporting and activities carried out by the Audit Committee is disclosed in the title of "Report of the Audit Committee" in the page no. 129 of the Annual Report.

Key Functions of Audit Committee



Nomination and Remuneration Committee

To cultivate a good governance practice in the Company, the Nomination and Remuneration Committee (NRC) was formed as a sub-committee of the Board in compliance with the corporate governance code of Bangladesh Securities and Exchange Commission (BSEC). The Committee comprises of three Directors including two Independent Directors. The number of the meetings held during the year 2021-22 was 04 (Four).

NRC assists the Board in formulating the nomination criteria or policy for determining qualifications, positive attributes, experiences related to Company. The NRC also assists the Board to formulate policy for formal and continued process of considering remuneration/ honorarium of Directors/Executive Directors and above hierarchy.


Report of the Nomination and Remuneration Committee is stated in the page no. 132 of the Annual Report.

Remuneration of Chairman and the Directors

The Chairman of the company is a non-executive and hence does not receive any remuneration from the Company. Executive Directors including Managing

Director is remunerated as recommended by the NRC and approved by the Board of the Company. A description of remuneration paid to the Directors is given in the page no. 132 of the Annual Report.

REMUNERATION



Executive Committee

The Executive Committee (EC) is a committee consisting of 3 (Three) Directors duly nominated by the Board to execute the discretions and functions as accorded by the Board and as per Service Rules of the Company. Company Secretary is the Secretary of the Executive Committee. The number of the meetings of EC held during the year 2021-22 was 9 (Nine).

Other Operational Committees

The Managing Director discharges the roles and responsibilities with the help of the following operational committees formed with the skills and experienced senior officials. These committees are being directly monitored and guided by the Managing Director. The performance evaluation of the company critically adopts strategic action plan to achieve the yearly targets set by the Board of Directors.

The various committees are as follows:-

01. Development Plan and Monitoring Committee;
02. Quality Assurance Committee;
03. Marketing Coordination Committee;
04. Construction Committee;
05. Budget Monitoring Committee;
06. New Product Monitoring Committee;
07. Disciplinary Committee;
08. Factory Technical Committee;
09. Extended Purchase Committee;
10. Factory Tender/Quality Evaluation Committee
11. Inventory Management Committee;
12. Risk Management and Control Committee;
13. CBA Dealing Committee.

Company Secretary

Md. Kabir Hossain acts as Company Secretary who has diversified experience in various professional fields for last 36 years. He completed

BSc (Hons) MSc in Chemistry from University of Dhaka. The Board of Directors clearly defined the roles, responsibilities and duties of Company Secretary.

Chief Financial Officer

Md. Jasim Uddin FCA, Chief Financial Officer (CFO) of The IBN SINA Pharmaceutical Industry PLC is a fellow member of the Institute of Chartered Accountants of Bangladesh (ICAB). He is responsible to supervise the Accounts and Financial activities of the Company. The Board of Directors clearly specified the roles, responsibilities and duties of CFO.

Head of Internal Audit and Compliance

Md. Abdur Rakib acts as the Head of Internal Audit and Compliance (HIAC) has completed Professional Level from the Institute of Chartered Accountants of Bangladesh (ICAB). The Board of Directors clearly set out the roles and responsibilities of the Head of Internal Audit and Compliance as recommended by the Audit Committee.

Internal Audit and Compliance


The Company considers that internal audit and compliance is one of the important regular functions of the Company. The Company has an independent internal audit and compliance department which is run under the supervision of Managing Director of the Company where Audit Committee oversees the activities of the Internal Audit and Compliance Department.

Maintaining a Website

The Company has an official website linked with the website of the exchanges (www.ibnsinapharma.com). The company made available the detailed disclosures on its website as required under the Listing Regulations, 2015 of Dhaka Stock Exchange Ltd. (DSE).

Corporate Social Responsibility (CSR) Policy

To cultivate good governance practice in the Company, the approved a policy on the Corporate Social Responsibility (CSR) keeping the corporate best practice of the world in view. To conduct the Corporate Social Responsibility of the Company, a CSR Committee is formed by the Board. Accordingly the CSR committee is working as per the terms of "Corporate Social Responsibility Policy":-



These can be achieved through our products and spirits which enrich the quality of human life enabling people's feelings happy in the application of CSR strategy, an effective tool for business success. The core components of CSR practiced in the company are described in the page no. 110 of the Annual Report.

REPORT OF THE AUDIT COMMITTEE

Dear Esteemed Shareholder(s)

Assalamu Alaikum Wa-Rahmatullah,

The Audit Committee is a sub-committee of the Board of Directors of The IBN SINA Pharmaceutical Industry PLC (IPI) and responsible to oversee the financial reporting process. The committee assists the Board for ensuring that the financial statements reflect a true and fair view of the state of affairs of the Company and good governance system within the business. The duties of the Audit Committee are clearly set forth in writing. The Committee is considered as the overseer of the companies for protecting interest of the stakeholders, in particular, shareholders.

Constitution of the Audit Committee

The Committee consists of three Directors including two Independent Directors. Md. Abdus Salam FCA, FCS, Chairman of the Committee and Abdus Sadeque Bhuiyan are two Independent Directors. Prof.Col.Dr. Zehad Khan (Retd.) , a non-executive Director is another Member of the Committee. Md. Kabir Hossain, the Company Secretary acts as the Secretary of the Committee, who is responsible for effective implementation of action plans approved in the meeting. All the members of the Committee have businesses acumen and are knowledgeable individuals with integrity who are able to ensure compliance with financial, regulatory and corporate laws with the meaningful contributions to the business as well.

Meeting and Attendance of the Audit Committee

During the year 2021-22, eight (8) meetings of the Audit Committee were held. Chief Financial Officer (CFO) and the Head of Internal Audit and Compliance (HIAC) always attended the meeting on invitation to meet instant queries of the Audit Committee. In addition, Heads of different Departments whose audit reports were placed to the Audit Committee were also present in the meetings to respond to the issues derived from the reports of Internal Audit and Compliance Department. The number of Audit Committee meetings held and the attendance by each member during the year 2021-22 are given as follows:

| Name of Members | Designation | Position | Number of meetings held while a member | Number of meetings attended | Remarks |
|----------------------------------|------------------------|--------------|--|-----------------------------|---------------------------|
| Md. Abdus Salam FCA, FCS | Independent Director | Chairman | 8 | 8 | - |
| Md. Rafiqul Islam Khan FCA | Independent Director | Ex. Chairman | 2 | 2 | Retired on 31.12.2021 |
| Prof.Col. Dr. Zehad Khan (Retd.) | Non-Executive Director | Member | 7 | 7 | - |
| Abdus Sadeque Bhuiyan | Independent Director | Member | 6 | 6 | Inducted as on 16.01.2022 |
| Md. Kabir Hossain | ED & Company Secretary | Secretary | 8 | 8 | - |

Role of the Audit Committee

The Audit Committee shall:

- Oversee the financial reporting process;
- Monitor choice of accounting policies and principles;
- Monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report;
- Oversee appointment and performance of external auditors for the holding company and its subsidiaries;
- Hold meeting with the external or statutory

auditors for review of the annual financial statements before submission to the Board for approval or adoption;

- Review along with the management, the annual financial statements before submission to the Board for approval;
- Review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;
- Review the adequacy of internal audit and compliance function;
- Review the Management's Discussion and

- Analysis before disclosing in the Annual Report;
- (j) Review statement of all related party transactions submitted by the management;
- (k) Review Management Letters or Letter of Internal Control weakness issued by statutory auditors;
- (l) Oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external Auditors; and
- (m) Oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by the Commission.

Coordination with the External Auditors

- a) Audit Committee also reviewed the external auditors' audit plan, including its nature and scope, audit report, evaluation of internal controls and coordination between the internal and external auditors;
- b) The Committee also arranged a meeting with the representatives of the External Auditors on September 03, 2022 for review of the Annual Financial Statement 2021-22 before submission to the Board for perusal and recommendation; and
- c) Review the findings and recommendations made by the external auditors for removal of recurrence of irregularities.

Internal Audit and Compliances

- a) The annual and quarterly audit plans including the audit methodology in assessing and rating risks of auditable areas reviewed to ensure adequate scope and comprehensive coverage on the audit activities of the Company.

- b) The Internal Audit reports encompassing the audit issues, audit recommendations and the Management's responses reviewed. Improvement actions suggested by the internal auditors in the areas of internal controls, systems and efficiency enhancements discussed with Management.

- c) The implementation of these recommendations through follow-up audit reports reviewed to ensure all key areas duly addressed.

- d) Audit Committee reviewed annual audit calendar and approved Internal Audit and Compliance review plan 2022-23. The Committee also reviewed individual review report including findings, cause and impact. They also reviewed and monitored action plan arising from the findings of the reviews.


Financial Reporting

- a) The quarterly, half-yearly and annual financial results of The IBN SINA Pharmaceutical Industry PLC reviewed and the relevant announcements made to the regulatory authorities, like BSEC and Stock Exchanges by the Board of Directors.

- b) The quarterly, half-yearly and annual financial statements of the subsidiary Company's- The IBN SINA API Industry Ltd ,The IBN SINA Natural Medicine Ltd. and The IBN SINA Polymer Industry Ltd. duly reviewed by the Committee prior to submission to the Board of Directors for approval.

- c) The quarterly, half-yearly and annual financial statements of the Company reviewed prior to submission to the Board of Directors for approval to ensure the financial reporting and disclosures made in compliance with the relevant laws.

- d) Audit Committee reviewed the quarterly and annual financial statements of the Company with



the Finance Director and Managing Director before recommending them to the Board of Directors for approval. The Committee also concluded that the financial statements presented a true and fair view of the Company's financial performance.

Reporting to Shareholders and other interested parties

It reports to shareholders and other interested parties on annual basis by means of presenting a summary of its activities in the form of 'Audit Committee Report'. During the year under review, the committee met Eight (8) times to discharge its duties and responsibilities and accordingly forwarded their reports to the Board. The Board is of the view that there was no other issues having significant material impact on the company's Financial Statements which needed to be disclosed to the Board or the regulatory authorities.

Deliberations of the Audit Committee in 2021-22

During the year 2021-22, the Audit Committee carried out its regular functions on the areas pertaining to its responsibilities. Some of the issues that are performed during the year under review for improvement of operational performance of the Company are listed below:

- a) The Audit Committee reviewed the Consolidated Financial Statements of The IBN SINA Pharmaceutical Industry PLC for the year 2021-22, which include Statement of Financial Position, Statement of Profit or Loss and other Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows and Notes to the Financial Statements;
- b) The Audit Committee also reviewed the Financial Statements of the subsidiaries (The IBN SINA API Industry Ltd. The IBN SINA Natural Medicine Ltd. and The IBN SINA Polymar Industry Ltd.) for the year 2021-22, which include Statement of Financial Position, Statement of Profit or Loss and other Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows and Notes to the Financial Statements;
- c) The Committee recommended for approval of the Annual Financial Statements of the Company to the Board;
- d) The Committee recommended for appointment as External Auditors, S.F. Ahmed & Co, Chartered Accountants for the Audit of the The IBN SINA Pharmaceutical Industry PLC and its subsidiaries- The IBN SINA API Industry Ltd., The IBN SINA Natural Medicine Ltd. and The IBN SINA Polimar Industry Ltd. for 2022-23 and fixing up their remuneration;
- e) The Committee recommended for appointment of Company's Compliance Auditors M. Mohashin & Co, Chartered Secretaries for the year 2022-23 and fixing up their remuneration;
- f) The activities were persuaded as approved Annual Audit Plan of the Company for the year 2021-22;
- g) Reviewed the un-audited quarterly and half-yearly financial statements before their submission to the

Board for final review and approval;

- h) Reviewed the Company's yearly budget before submission to the Board for final review and approval;
 - i) Reviewed the yearly internal audit calendar, audit process and effectiveness of internal audit;
 - j) Reviewed the Auditor's Certification on Corporate Governance Compliance for the year ended 30 June 2022;
 - k) Reviewed and ascertained that the internal control system including financial and operational controls, accounting system, and reporting structure are adequate and effective;
 - l) Reviewed the periodical reports submitted by the internal auditors and recommended to the management regarding proper and prompt resolution of the irregularities/issues stated therein;
 - m) Reviewed the actions taken by the management for implementation of Audit Committee observations on the issues deliberated in the Audit Committee reports;
 - n) The Committee placed its reports regularly to the Board for review and monitoring the activities recommended on internal control system, compliance with rules and regulations of the regulatory bodies;
 - o) Based on the above review and discussion, the Audit Committee is of the view that the internal control and compliance procedures are adequate to present a true and fair view of the activities and financial status of the Company;
 - p) Discussing and giving an opinion on the status of the Risk Management Process (RMP) and the Company's business continuation as a going concern;
 - q) Audit Committee reviewed the Company's Risk Management including a deep dive into the key functional risks and mitigation plans;
 - r) Audit Committee reviewed reports of related party transactions and possible conflicts of interest;
 - s) Reviewed the findings of internal audit team and its corrective actions;
 - t) Assessed the findings of external auditors and compliance of IAS and IFRS for preparation of Financial Statements;
 - u) Reviewed the adequate internal control system of the company are in place; and
 - v) Reviewed the compliance requirements of Bangladesh Securities and Exchange Commission (BSEC) guidelines, RJSC, DSE, CSE notifications and other regulatory laws applicable for the Company;
- Audit Committee expressed their sincere thanks to all members of the Board, team of Internal Audit, team of Accounts & Finance and the Management of the Company for their active support.

On behalf of the Audit Committee

Md. Abdus Salam FCA, FCS
Chairman, Audit Committee
September 05, 2022

NOMINATION AND REMUNERATION COMMITTEE (NRC) REPORT

Nomination and Remuneration Committee (NRC) is working as per the requirements of the Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC) issued on 03 June 2018. In compliance with the Corporate Governance Code, 2018, the Board reconstituted the Nomination and Remuneration Committee (NRC). NRC is a sub-committee of the Board formed to assist the Board in formulating the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of Directors/Executive Directors and above hierarchy. The NRC also assists the Board to formulate policy for formal and continued process of considering remuneration of Executive Directors, Directors and above.

Overview of the Nomination and Remuneration Policies

Composition of the Committee

Nomination and Remuneration Committee is constituted comprising of the following members:

Abdus Sadeque Bhuiyan Chairman
Independent Director

Md. Abdus Salam FCA, FCS Member
Independent Director

Prof. Col. Dr. Zehad Khan (Retd.) Member
Non-Executive Director

Company Secretary, Md. Kabir Hossain acts as the Secretary of NRC. The Nomination and Remuneration Committees' jurisdiction, responsibilities and the duties are guided by the Terms of References (ToR) as defined by the Board of Directors as per Corporate Governance Code of BSEC.

Meeting and Attendance

Number of NRC meeting held during the year under review is four. The attendance of the meeting has duly been recorded and the members who could not attend the meeting were granted leave of absence.

Overview of the Nomination and Remuneration Policies

Nomination and Remuneration Committee recommended in formulation of Nomination and Remuneration Policy which was duly been approved by the Board. The Company follow the nomination and remuneration policies and the benchmark of which pursuing the business code of conduct and

standards perceptible in the market context and appropriate to meet the present and future needs of the Company. This Policy also covers the Nomination Criteria, Recruitment and Selection Standards, Remuneration Criteria and Evaluation Criteria.

Key Responsibilities of NRC

- Nomination and Remuneration Committee is an independent sub-committee of the Board and hence responsible and accountable to the Board and to the Shareholders;
- NRC discharges its responsibilities and oversees the functions specified in the Terms of Reference approved by the Board in line with the BSEC's Code of Governance, 2018.

Activities of the NRC performed during the year, 2021-22

The NRC carried out the following activities during the reporting period:

- Consider the Terms of Reference (ToR) of NRC, approved by the Board of Directors;
- Reviewed the induction of new Independent Director of the Company and nomination to its subsidiaries;
- Reviewed the tenure performed and recommended the compensation package of the Top Level Executives and Executive Directors of the Company;
- Reviewed the matter of renewal of contractual job of the Company Secretary; and
- Consider the BSECs' prescribed checklist for appointment of Non-Executive Directors / Independent Directors and also reviewed and recommended the appointment of Top Level Executives.



Abdus Sadeque Bhuiyan

Chairman, NRC

Monday, September 05, 2022



CODE OF CONDUCT FOR THE BOARD

Code of Conduct for Board Members (Chairman, other Board Members and Managing Director) of The IBN SINA Pharmaceutical Industry PLC on the Duties and Responsibilities, Conflict of Interest and Confidentiality, Compliance with the Laws, Rules and Regulations.

As per Condition no. 1(7)(b) of BSEC Notification no-BSEC/CMRRCD/2006-158/207/Admin/80 dated June 03, 2018 on Corporate Governance Code, based on the recommendation of the Nomination and Remuneration Committee (NRC), the Board of Directors of the Company has laid down a code of conduct for the Chairman, Board Members and Managing Director of the Company including among others, prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.

I. INTRODUCTION

The Board of Directors hereby establishes its Code of Conduct to provide guidance to its members regarding prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.

Compliance with the provisions of this Code will allow the Board to fully implement its Governance Manual; to enhance relationships and foster teamwork among the Board members and also with staff; and to build respect, confidence, and credibility with the stakeholders and shareholders at large.

II. STANDARDS OF CONDUCT AND CODE OF ETHICS

Each Board Member shall adhere to the following Code of Conduct and Ethics:

1. The Directors shall maintain high ethical and moral character, both professionally and personally, so that their behavior will reflect positively upon the Board of The IBN SINA Pharmaceutical Industry PLC.
2. Members of the Board shall use proper care and exercise independent professional judgment and competence in the performance of their duties.
3. The Board shall maintain confidentiality about all matters that are considered in the meetings.

4. It is required to be familiar and comply with the provisions of the Companies Act., 1994. In addition to such compliance, Board members to be aware of the "conflict of interest" contained in the Companies Act, 1994.

5. None of the Directors will have private contracts or business dealings with any Department of the Company.

6. The Board shall exercise due diligence to avoid breaches of duty and/or obligations.

7. Board decisions and actions are to be based on integrity, competence, and independent judgment on the merits and benefits to the stakeholders/shareholders of the Company.

8. Board Member will play full and active role in the work of the Company to fulfill their duties and responsibilities responsibly and at all times, act in good faith and in the best interests of the Company.

9. The dealings of the Board with the public and their affairs should be to the best of their ability.


10. Board Members will strive to cultivate and maintain good relations with the Shareholders, Customers and Employees as set forth in the Code.

11. It has the duty to ensure the safeguarding of funds and the assets of the Company.

12. The Directors must carry out their fiduciary obligations responsibly that is, take appropriate measures to ensure that the Company uses resources efficiently, economically and effectively, avoiding waste and extravagance.

13. Board Member who misuse information gained by virtue of their position may be liable for breach of contract under the Companies Act, 1994 (Amendment 2020) and/or insider dealing legislation.

14. The Directors must comply with the Service Rules of the Company and relevant rules and regulations applicable for the Company.



III. DUTIES AND RESPONSIBILITIES OF DIRECTORS

A Director is responsible to:

1. Carry out his/her fiduciary duties with a sense of objective judgment and independence in the best interests of the Company and Stakeholders as a whole.
2. Perform his duties in an independent and objective manner and avoid activities that may impair, or may appear to impair, their independence or objectivity or official responsibilities.
3. Be informed of the Memorandum and Articles of Association of the Company, its mission, vision, values, policies and codes of conduct as they pertain to the duties of a Director;
4. Attend Board meetings regularly, serve on committees of the Board as appointed and contribute from personal, professional and life experience to the deliberations of the Board;
5. Exercise due care and diligence in the performance of his / her duty and employ his/her skills pursuant to applicable laws and objectives of the Company;
6. Be independent and impartial in giving advice and in expressing views on any issue which comes up for consideration and/or decision of the Board.
7. Not be influenced by self-interest, outside pressure, expectation of reward or fear of criticism;
8. Act with honesty and integrity and conduct himself / herself in a manner consistent with the nature of the responsibilities and the maintenance of public confidence in the conduct of the Board's business;
9. Voice clearly and explicitly, at the time taking a decision any contrary view to a decision being considered by the Board;
10. Maintain solidarity with fellow Directors in support of a decision that has been made in good faith in a legally constituted meeting, by Directors in reasonably full possession of the facts;
11. Request review of a decision, if she/he has reasonable grounds to believe that the Board has acted without full information or in a manner inconsistent with its fiduciary obligations;
12. Allow the executives of the Company to independently discharge their functions in conformity with the underlying governance practices;
13. Comply with all other codes and policies approved by the Board from time to time.
14. The Directors shall unless otherwise required by law, maintain confidentiality and shall not divulge/disclose any information obtained in

discharging their duties.

15. For not to use any confidential information for his/her personal gain, directly or indirectly, received or obtained by him in his/her capacity as a member of the Board.

IV. CONFLICT OF INTEREST

The fundamental relationship between each director and the Company is absolutely based on fiduciary. Essential to trust is a commitment to honesty and integrity. These narrations are intended to ensure the maintenance of the highest standard and integrity of the Board.

The Directors shall put the interests of the Company ahead of any personal interest or the interest of any other person, group or entity. It also means performing his / her duties and transacting the affairs of the Company in such a manner that promotes public confidence and trust in the integrity, objectivity, impartiality and high standard of ethics of the Board.

(1) Definition

(a) A conflict of interest refers to situations in which personal, occupational or financial considerations may affect, or appear to affect, a Director's objectivity, judgment or ability to act in the best interest of the Company.

(b) A conflict of interest may be real, potential or perceived in nature.

(c) A real conflict of interest arises where a Director has a private or personal interest.

(d) A potential conflict of interest may arise when a Director has a private or personal interest such as an identified future commitment.

(e) A perceived or apparent conflict of interest situation in one where a person of ordinary prudence has reason to doubt or believe that a Director has a conflict of interest.

(f) Full disclosure, in itself, does not remove a conflict of interest unless the Board, having analyzed the disclosed facts, considers the conflict neither material nor of any significance.

(2) Pecuniary Advantage

(a) No Director shall directly or indirectly receive any profit from his / her position as such, provided that the Directors may receive reasonable payments for their services and reimbursement for reasonable expenses incurred by them in the performance of their duties.

(b) The pecuniary interests of immediate family

members (including the immediate family members of a Director's spouse) or close personal or business associates of a Director are also considered to be the pecuniary interests of the Director.

(3) Principles for Dealing with Conflict of Interest

(a) Both prior to serving on the Board and during the term of office, each Director must openly disclose a potential, real or perceived conflict of interest sooner the any matter of conflict arises and/or come into the knowledge.

(b) If a Director is not assured whether she/he is in a conflict of interest situation, the matter may be brought to the attention of the Chairman of the Board for advice and guidance empathetically.

(c) If there is any question or doubt about the existence of a real or perceived conflict, the Board will determine by majority vote if a conflict exists. The concerned Director potentially in conflict of interest shall withdraw from the meeting when the Board discusses the issue.

(d) The disclosure and decision as to whether a conflict exists shall be duly recorded in the minutes of the meeting.

V. CONFIDENTIALITY

It is the responsibility of Directors to know what information is confidential and to obtain clarification when in doubt. Except as s/he may be compelled by applicable legal process, a Director must, both while having and after ceasing to have that status, treat as confidential all information regarding the policies, internal operations, systems, business or affairs of the Company obtained by reason of his / her status

as a Director and not generally disclosed to the public. A Director shall not use information obtained in his/her capacity as a Director for personal benefit. Each Director shall avoid activities which may create appearances that he has benefited from confidential information received as a Director

VI. GENERAL PROVISIONS

1. Board of Directors shall govern the Company within the purview of the Memorandum of Association (MOA) and Article of Association (AOA) of the Company.

2. The Board must operate the Company in accordance with the rules set forth in the Service Rules of the Company and the decision taken by the Board and the Shareholders in General Meeting time to time.

3. The Board must comply with the Companies Act, Corporate Governance Code of BSEC, the Rules and regulations, Directives and Notifications given / issued / promulgated by the concerned regulatory bodies of the Country.

4. The provisions of this policy/code do not excuse any Board member from other restrictions of state or company law regarding conflicts of interest.

5. Any breach of this Code of Conduct and Ethics shall be reported to the Audit Committee. The Committee will investigate as appropriate and report its findings and recommendations to the Board and if feels expedient may place the same to the Shareholders in General Meeting.

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

DECLARATION BY MANAGING DIRECTOR AND CHIEF FINANCIAL OFFICER

September 05, 2022

The Board of Directors
The IBN SINA Pharmaceutical Industry PLC
Tanin Center, 3 Asad Gate, Mirpur Road
Mohammadpur, Dhaka-1207.

Subject: Declaration on Financial Statements for the year ended on 30 June 2022.

Dear Sirs,

Pursuant to the condition No. 1(5)(xxvi) imposed vide the Commission's Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 Dated 3 June 2018 under section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

- (1) The Financial Statements of The IBN SINA Pharmaceutical Industry PLC for the year ended on 30 June 2022 have been prepared in compliance with International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in the Bangladesh and any departure there from has been adequately disclosed;
- (2) The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;
- (3) The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;
- (4) To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
- (5) Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and
- (6) The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

In this regard, we also certify that:

- (i) We have reviewed the financial statements for the year ended on 30 June 2022 and that to the best of our knowledge and belief:
 - (a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - (b) These statements collectively present true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.
- (ii) There are, to the best of knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,



Prof. Dr. AKM Sadrul Islam
Managing Director



Md. Jasim Uddin FCA
Chief Financial Officer

STATEMENT OF DIRECTORS' RESPONSIBILITIES FOR FINANCIAL REPORT

The Directors are responsible for ensuring that the Company keeps proper books of accounts of all the transactions and the financial statements for the period from 01 July 2021 to 30 June 2022 and gives a true and fair view of the state of affairs and profit for the year.

The Directors also ensure that the financial statements have been prepared and presented in accordance with the International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS) as adopted by Financial Reporting Council, Bangladesh and provide the information as required by the Companies Act 1994 (Amended in 2020), Bangladesh Securities and Exchange Ordinance 1969, Bangladesh Securities and Exchange Commission Rules 1987 and The Regulations, 2015 of the Dhaka Stock Exchange Ltd. and Chittagong Stock Exchange Ltd.

It ensures that the estimates and judgments relating to the financial statements were made on a prudent and reasonable basis, so that they reflect in a true and fair manner and reasonably present the Company's true state of affairs.

The Company has taken proper and sufficient care in installing a system of internal control, which is reviewed, evaluated and updated on regular basis. To augment those objectives, the Board of Directors has formed an Audit Committee as per code of Governance of Bangladesh Securities and Exchange Commission (BSEC). They have performed their responsibilities without any undue interference

from any of the Directors.

Internal Audit and Compliance Department of the Company conducts periodic audits to provide reasonable assurance that the established policies and procedures of the Company are consistently followed.

The Company has adequate resources to continue operational existence for the foreseeable future and therefore, has continued to adopt the going concern basis in preparing the Accounts.


The Board of Directors confirms that International Accounting Standards, as adopted in Bangladesh by the Institute of Chartered Accountants of Bangladesh, have been adhered to, subject to any material departure being disclosed and explained in the notes to the accounts.

The Directors also confirm that the annual reports together with the Directors' Report and the Financial Statements Consolidated and solo have been prepared in compliance with the law, rules and regulatory guidance.

The Auditors of the Company, Malek Siddiqui Wali, Chartered Accountants, had carried out the Annual Audit to review on the system of internal controls, as they consider appropriate and necessary, for expressing their opinion on the financial statements. They have also examined the financial statements made available by the management together with all the financial records, related data and Minutes of the Board, relevant policies and expressed opinion thereon.



Prof. Dr. AKM Sadrul Islam
Managing Director



Md. Kabir Hossain
Company Secretary

DIVIDEND DISTRIBUTION POLICY

Introduction

In compliance with the Directive No. BSEC / CMRRCD / 2021-386 / 03 dated 14 January, 2021 of the Bangladesh Securities and Exchange Commission (BSEC), the Board of Directors of The IBN SINA Pharmaceutical Industry PLC ("IBN SINA Pharma" or the "Company") has formulated The Dividend Distribution Policy about dividend declaration, pay off, disbursement and compliance and disclosed the same publishing this statement as a guiding framework for the shareholders in the company's annual report and official website.

This statement provides a brief outline of the legal and regulatory provisions relating to dividend, key issues in dividend considerations and the procedure for the declaration, approval and payment of dividend.

Definitions

- The Act" means The Companies Act, 1994.
- The Company" means The IBN SINA Pharmaceutical Industry PLC.
- AGM" means Annual General Meeting.
- Board" means Board of Directors of The IBN SINA Pharmaceutical Industry PLC.
- Shareholders" means Members whose name is registered in the Member Register of the Company.
- Shares" means Ordinary Equity Shares.

Concept of Dividend

Dividend is the share of the profit payable to the Shareholders of a Company as recommended by the Board of Directors and subsequently approved by the Company in General Meeting to distribute the same among its Shareholders in proportion to the amount paid up on shares held by the respective Shareholders in the form of Cash and/or Stock (Bonus). No dividend shall be paid otherwise than out of profit of the Company.

Kinds of Dividend

The Act deals with two types of dividend - Interim and Final.

Interim dividend is the dividend declared by the Board being authorized by the Act between two AGMs during any financial year out of the profits/the surplus shown in the Financial Statements.

Final dividend is the dividend derived out of the profits/the surplus shown in the particular year's Financial Statements of the Company which is recommended by the Board and thereafter be approved by the Shareholders at the AGM of the Company. Dividend once recommended by the Board of Directors cannot be changed ahead of the scheduled AGM.

Declaration of Dividend

It is the Company's practice to declare dividend on annual basis based on annual financial performance. However, the Board may also declare interim dividend based on periodic financial results. Historically the Company declared dividend in either cash or stock or in prudent combination of cash and stock.

Key Factors in Dividend Decisions

The circumstances for dividend pay-out decision depends on various external and internal factors while recommending/declaring dividend, the Board of Directors shall consider among others:

External Factors:

- Endeavoring to retain a certain portion of profits to build up the reserves for future requirements as per norms;
- Evaluating the market trends in terms of technological changes which may require the Company to conserve the resources;
- Considering the restrictions, if any, imposed by the Act and other applicable laws;
- Legal and regulatory compulsion and tax implication of retention and payout;
- Dividend distribution tax or any tax deduction at source as required by tax regulations;
- Any debt/loan covenants restricting dividend announcements; and
- Other factors beyond control of the Management like biographical (caused by pandemic/catastrophic, etc.) matters, natural calamities, etc. materially effecting operations of the Company may also impact the decision about dividend declaration.

Internal Factors

- Company's current net earnings i.e. Profitability of the Company;
- Liquidity of the Funds i.e. accumulated distributable reserves/surplus and availability of free cash flow;
- Capital expenditure requirements for the existing businesses;
- BMRE status (Expansion/Modernization) of the Company;
- Investments in subsidiaries/associate(s) of the Company;
- Cost of raising funds from the alternate sources;
- Cost of servicing outstanding debts;
- Funds for meeting contingent liabilities;
- Mergers and acquisitions;
- Consistency of the dividend over reasonable and foreseeable coming years and also shareholders' perceptions; and
- Any other factors reasonably considered proper by the Board of Directors.

Eligibility of Shareholders for Dividend

Dividend is declared on the face value of each Equity Share. Unless otherwise stated, all the holders of Equity Shares whose names appear on the register of the Company on the Record Date declared by the Company for entitlement of dividend are eligible to get the dividend.

Timing of Dividend Announcement and Payment

The Board of Directors of the Company in its meeting duly held within 120 days from the date of closing of the financial year takes the decision of Annual dividend to be distributed to the entitled Shareholders. Such decisions are based on the results of the audited financial statements. The dividend recommended by the Directors is notified to the Shareholders through stock exchanges, website and public media (printing and digital).

Dividend recommendations made by the Directors are to be placed in the Annual General Meeting of the Company for the Shareholders' approval. Dividend are transferred to the respective shareholders' account within 30 days from the date of its approval. Interim Dividend if any declared by the Company, are paid within 30 days from the Record Date fixed by the Company for the entitlement of such dividend.

Disclaimer

The above Policy Statement neither gives a guarantee of dividend to be declared by the Company nor does it constitute a commitment for any future dividend and thus be read as a general guidance on different dividend related issues. The policy upholds the Board's absolute/complete liberty to recommend any dividend in deviation of the policy.

Policy Approval and Effective Date

This Policy approved by the Board of Directors of the Company at its meeting held on September 21, 2021 is effective and applicable for dividend, if any, to be declared for the particular Financial Year.

Disclosure

This "Dividend Distribution Policy" and annual "Dividend Distribution Compliance Report" shall be disclosed in the Annual Report of the Company and on the Company's website: www.ibnsinapharma.com.

Review and Amendment

As necessitated by the legal and regulatory requirements and for any other obvious reasons deemed to be pertinent in this regard, the Board may amend, abrogate, modify or revise any or all provisions of this Policy. However, amendments already made and/or to be made in this behalf in the Act or in the Listing Regulations shall be binding even if not incorporated in this Policy.

UNCLAIMED DIVIDEND INFORMATION

| Cash Dividend | |
|------------------------|-----------------------|
| PARTICULARS | AMOUNT IN TAKA |
| Dividend for 1993-2018 | 29,281,978 |

NB: Unclaimed Dividend from 1992-93 to 2018 Tk. 29,281,977.74 transferred to the Capital Market Stabilization Fund (CMSF). May be seen also Company's website: www.ibnsinapharma.com

| Cash Dividend | |
|----------------------|-----------------------|
| PARTICULARS | AMOUNT IN TAKA |
| Dividend for 2019 | 4,423,318 |
| Dividend for 2020 | 7,996,366 |
| Dividend for 2021 | 10,218,498 |
| Total | 22,638,182 |

| Stock Dividend | |
|-----------------------|------------------------|
| PARTICULARS | NUMBER OF SHARE |
| Dividend for 2009 | 173,840 |
| Dividend for 2010 | 187,290 |
| Dividend for 2011 | 297,118 |
| Dividend for 2012 | 297,255 |
| Dividend for 2013 | 177,184 |
| Dividend for 2014 | 98,206 |
| Dividend for 2015 | 205,107 |
| Dividend for 2016 | 102,350 |
| Dividend for 2017 | 233,625 |
| Dividend for 2018 | 258,686 |
| Total | 2,030,661 |

NB: 2,030,661 Number of Bonus Shares as Unclaimed Stock Dividend from 2009 to 2018 transferred to the Capital Market Stabilization Fund (CMSF). May be seen also Company's website: www.ibnsinapharma.com

INTERNAL CONTROL, INTERNAL AUDIT AND COMPLIANCE AND RISK MANAGEMENT

Internal Control

Internal Control is the mechanism to provide reasonable assurance to the Company ongoing basis regarding the achievement of objectives in the effectiveness and efficiency of operations, the reliability of financial reporting and compliance with applicable laws, regulations and internal policies. The primary objective of Internal Control and Compliance is to help the Company perform better and add value with its resources. Through the internal control system, Company identifies its weaknesses associated with the process and adopts appropriate measures to overcome. The main objectives of internal control are as follows:

a) Operational Objectives:
Achievement of company's mission and vision;

b) Reporting Objectives:
Timely, accurate, and comprehensive reporting-financial and non-financial, internal and external;

c) Compliance Objectives:
Conducting activities and taking specific actions following applicable laws and regulations.

The IBN SINA Pharmaceutical Industry PLC (IPI) and its subsidiaries has established an effective internal control system whose primary aim is to ensure the overall management of risks and provide reasonable assurance that the objectives set by the Company will be met. It has been designed to develop a high-level risk culture among the personnel of the Company, establish an efficient and effective operating model of the Company, ensure the reliability of internal and external information including accounting and financial information, secure the Company's operations and assets and comply with the laws, regulatory requirements and internal policies.

Internal Audit and Compliance

Internal Auditing is an independent, objective assurance and consulting activity designed to add value and improve an organization's operations. Audit Department is committed to meet the standards of best professional practices. Risk-based internal audit methodology is being applied for

auditing functions. Risk-based internal audit includes, in addition to selective transaction testing, and evaluation of the risk management systems and control procedures prevailing in various areas of the company operations.

IPI has a strong internal audit team comprised of three units to carry out their audit activities, namely head office audit, factory audit and all depots audit.

Risk Management / Risk Mitigation

Principally, risks are defined as uncertainties that might result in adverse variations in profitability or losses, financial or otherwise. The core risk areas of the business operations comprise of Internal Control Risks, Regulatory Risk, Technology Related Risk, Exchange rate risks, Operational Risk, Customers Demand related Risk, Operational Risk, Credit Risk, Growth Uncertainties Risk, Product Development and Launching Risk, Cyber Security Risk, Data Privacy Risk, Environment Risk, Health & Safety ('EHS') Risk, Sustainability Distribution Risk and Liquidity Risk. Some of these Risks and their

mitigation measures/plans are discussed as follows:

Regulatory Risk

The Company operates under The Drugs Ordinance 1982, The Companies Act 1994, Directorate General of Drug Administration (DGDA) Regulations, The Income Tax Ordinance 1984, Income Tax Rules 1984, Customs Act 1969, Value Added Tax (VAT) Act 1991, Value Added Tax (VAT) Rules 1991, Bangladesh Securities and Exchange Rules, 1987 and other Rules and Regulations of the Country. Any abrupt changes to the policies made by the regulatory authorities may adversely affect the business of the Company.

Mitigation

The IBN SINA Pharmaceutical Industry PLC is the ranked Pharmaceutical Company of the country. It is doing business following all the rules and regulations of the land. Change in regulations brings changed strategies for doing the business by the management of the Company. Besides, many of the patented drugs/molecules will be off and it is an opportunity for the manufacturer to freely manufacture, promote and distribute without any restriction.

Technology Related Risk

The pharmaceutical company is highly technology based industry. Hence, the technology always plays a vital role here. Adaptation of better know-how can help to gain remarkable core competencies that certainly create competitive advantages like increased productivity; reduce costs, better perception of customers. Firms are exposed to technology risks when there are better technologies available in the market than the one used by the Company, which may cause operational inefficiency.

Mitigation

We have clear intent in adapting the latest technology in the Company and the management is aware of technological changes and always trying to adopt new technology according to its needs. Furthermore, routine and proper preventive maintenance of the equipment ensures longer service life of the existing equipment and facilities.

Currency Exchange rate risk

Exchange rate risk relates to the core business of IPI since it mostly imports materials from abroad in foreign currency. The Company imports raw materials against the payment of foreign currency and the price of raw material in the international market are relatively volatile. Unfavorable volatility or currency fluctuation may affect the profitability of the Company.

Mitigation

The volatility of Taka against Dollar and the recent trend of local currency devaluation may expose

foreign currency risk. However, IPI can significantly reduce the foreign currency risk and price escalation risk through forwarding bookings if it is justifiable in terms of cost-benefit analysis. The company also maintains Economic Order Quantity (EOQ) for its material imports, which provides a considerable cushion against an adverse movement of the exchange rate and price in the international market.

Operational Risk

IPI relies on suppliers for ingredients and various third parties for certain manufacturing-related services to produce material that meets appropriate content, quality, and stability standards of the company products and after approval, it is being released for commercial distribution. IPI may not be able to produce its drug substance or drug product to appropriate standards without the required support from its suppliers and vendors.

Mitigation

IPI has a good number of approved vendors for ingredients and services. It uses to conduct vendor audit and its concerned professionals are very conscious regarding the vendor issue. Further, none of the suppliers accounts for a significant amount of total purchases.

Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Credit risk helps users of Financial Statements to assess the credit quality of the entity's financial assets and level and sources of impairment loss. Management has a credit policy in place and exposure to credit risk is monitored on an ongoing basis.

Mitigation

To mitigate the credit risk the management of the Company follows robust credit control and collection policies. The Company has a dedicated credit collections team who is responsible for recovery of the dues and performs collecting the receivables as per Company's credit and collection policy.

Growth Uncertainties Risk

IPI faces growth uncertainties risk due to different geographical conditions, which is unique to each of the geography. While we enjoy market leading positions in certain therapeutics, incremental high growth similar to previous years may prove to be challenging on account of continued commoditization and hyper-competition. Any regulatory decision to add new products of the Directorate General of Drug Administration ('DGDA') or bring about change in the mechanism of calculating price ceiling may potentially impact our margins adversely. High level of competition in the generics space also impacts growth.

Mitigation

Prescription business: We launched 'Favipiravir' a comprehensive COVID-19 portfolio during the reporting period. Besides, IPI also ensured continued availability of certain products such as Azithromycin, Paracetamol, among others, which were complementary to the COVID-19 portfolio.

Expanding the products portfolio of consumer business to leverage the scale of operations is usually being done. As part of our strategy, we continue to synergize the distribution channel engaged for prescription, trade generics and consumer health segments and improve accessibility directly to consumers with therapy-shaping initiatives and ecosystem partnerships.

Supply Chain Disruptions Risk

Last year's supply chain ecosystem was characterized by rising prices of raw materials and transportation cost. We also witnessed minor disruptions due to COVID-19. This has posed some challenges around timely availability of raw materials at reasonable costs.

Mitigation

We maintain sufficient inventory coverage for key strategic molecules. We prioritized supply strategy defined for critical, life-saving medicines to prevent stock-outs of APIs and intermediates and efficiently managed the export logistics. We pursue for the development of alternate vendors to ensure smooth supply chain which ensures timely availability and cost optimization.

Internal Control Risks

Internal control risks are risks that affect the efficiency and effectiveness of internal controls and thus affect the achievement of business objectives. Lack of well-defined internal controls may have a potentially adverse impact on IPI's profitability, brand and business sustainability.

Mitigation

Internal controls defines in the IPI's environment comprises a mix of preventive and detective controls. Such controls may be manual or automated in nature principles followed while designing controls. We have segregated the duties and authorization of reconciliation, physical inventory, periodic review, information technology general controls, including security and change controls. We have a well-defined Code of Conduct acts as most vulnerable to shape regularity coupled with robust whistle-blowing mechanism. We have a comprehensive risk-based audit universe and audit plans strengthening the internal financial controls system.

Cyber Security Risk

Cyber security risk is the probability of exposure or loss of critical assets and sensitive information due

to cyber-attacks which can lead to productivity and reputational damage. During the year, pharmaceutical companies continued to be a high value target for ransomware, phishing and other forms of cyber-attacks. With a significant percentage of employees across the globe operating from home, certain network and data related risks have aggravated.

Mitigation

We align cyber and digital risk management framework with philosophy, principles and directives of Confidentiality, Integrity, Availability, Reliability and Safety.

Our cyber and digital risk management frameworks are aligned with the latest technology of global and industry perspective. We usually follow an effective risk management and governance considering the risk based approach, cyber risk quantification, cyber insurance and integrated reporting. The Company facilitates the hybrid (digital cum physical) work environment(s) and builds the risk awareness culture in the organization. We have adopted zero trust model/framework to address the cyber risk.

Environment, Health & Safety ('EHS') and Sustainability

Safety at all IPI workplaces is both a priority and a regulatory requirement. EHS incidents pose critical regulatory, reputational, and business continuity risks and impact long term sustainability. IPI recognizes the effect of global climate change on the environment and the communities that it operates in, together with the people involved in the supply chain. Severe storms, flooding, accelerated melting of glaciers, and frequent droughts have strong correlation with climate change. Overall, the various consequences of climate change pose a threat to business continuity, human safety and long term sustainability.

Mitigation

Our corporate EHS activity provides oversight on safety and operating exposures and issues standardized corporate EHS guidelines to our manufacturing sites. We ensure compliance with the local regulations and best-in-class industry safety standards across our locations. The Company is vigilant about EHS management system to address the potential risks in this respect.

Conclusion

The above mitigation measures/plans are to establish for a sound system of risk management supervision and internal control to identify, assess, monitor and manage material risks related to the conduct of The IBN SINA Pharmaceutical Industry PLC and its Subsidiaries activities. The aims are to constantly improve the management of risk; better understand the reward-to-risk balance and reduce the risks to an acceptable level.

POLICY ON COMMUNICATION WITH THE SHAREHOLDERS AND OTHER STAKEHOLDERS



Annual Report



Annual General Meeting



Announcements to DSE and CSE



Quarterly Financial Statement



Published to News Paper and Online News Portal



Corporate website



Investor Presentations



One-to-one Discussions



Feedback Surveys

Communication With Shareholders

The Company encourages communication with shareholders on an ongoing basis throughout the year and welcomes their participation in the Annual General Meeting (AGM). At the AGM, the Company's management receives shareholders' valuable opinions and makes every effort to implement these for the betterment of the Company. The Company discloses the quarterly and yearly financial performance and other reports in due course for meeting the best interests of shareholders.

Company's Website

The Company's website www.ibnsinapharma.com displays management portfolio, vision and mission, investor relations, products, promotions and events. All information regarding financial statements, pattern of shareholding, corporate governance, notices, price sensitive information, code of conduct for the board, dividend policy, Unclaimed dividend etc. are duly uploaded.

All disclosures required by the Bangladesh Securities and Exchange Commission, Listing Regulations-2015 of The Dhaka Stock Exchange Ltd. and The Chittagong Stock Exchange Ltd. in the form of Price Sensitive Information are made adequately and promptly. In addition to ensuring timely compliance, this also enables dissemination of information to all stakeholders and the public through print and online media.

Grievance Redressal

The IBN SINA Pharmaceutical Industry PLC strongly believes in maintaining smooth and cooperative

relationships with all stakeholders. We pursue a proactive and high quality shareholder's redressal policy to handle all grievances and complaints in an effective and fair manner. Any query received from investors is treated fairly and with the overall objective of dealing with it in a timely and transparent manner.


Investor Complaint Redressal

- Any investor may lodge their complaint relating to their investment in the Company through a formal letter sent to the official's email of Share and Public Relation Department or by phone call to the Share Department;
- The Share and Public Relation Department officials review the investors complaint on a weekly basis;
- A designated person of the Company addresses investor grievances on a daily basis;
- Managing requests for updating of e-Tin number in the BO account if cash dividend is declared;
- Handling requests for updating of bank account details in the BO account while sending dividend through the BEFTN system;
- Folioholders are being handled in due course to meet their requirements;
- Review the instances of non-receipt of Annual Report and the declared dividend; and
- Consider all matters related to shareholders of the Company efficiently and with due importance.



Organizational Chart

The IBN SINA Pharmaceutical Industry PLC



NB. This Organizational Chart was approved in 276th Board Meeting held on 18.08.2020

Report to the Shareholders of
The IBN SINA Pharmaceutical Industry PLC
on
Compliance of Corporate Governance Code

We have examined the compliance status to the Corporate Governance Code by **The IBN SINA Pharmaceutical Industry PLC** for the year ended 30 June 2022. This Code relates to the Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 03 June 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.


This is a scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

- (a) The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above mentioned Corporate Governance Code issued by the Commission.
- (b) The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code.
- (c) Proper books and records have been kept by the Company as required under the Companies Act, 1994, the securities laws and other relevant laws; and
- (d) The Governance of the Company is **satisfactory**.

For, Itrat Husain & Associates

Dhaka, 04 September, 2022


Itrat Husain FCMA, FCS
Chief Executive

ANNEXURE -C

Compliance Status on Corporate Governance Code of BSEC

[As Per Condition No. 1(5)(xxvii)]

Status of compliance with the conditions imposed by the Commission's Notification No. BSEC / CMRRCD / 2006-158 / 207 / Admin / 80 dated 03 June 2018 issued under section 2CC of Securities and Exchange Ordinance 1969

(Report under Condition No. 9)

| Condition No. | Title | Compliance Status | | Remarks (if any) |
|---------------|---|-------------------|--------------|-------------------------------|
| | | Complied | Not Complied | |
| 1.1 | Board Size (number of Directors -minimum 5 and maximum 20) | √ | | |
| 1.2 | Independent Directors: | | | |
| 1.2(a) | At least one fifth of Directors should be Independent Directors; | √ | | |
| 1.2(b)(i) | Independent Director does not hold any share or holds less than 1 % share of the total paid-up shares; | √ | | |
| 1.2(b)(ii) | Not a Sponsor of the Company or non-connectivity with the company's sponsor or director or shareholder who holds 1 % or more shares on the basis of family relationship.; | √ | | |
| 1.2(b)(iii) | Who has not been an executive of the company in immediately preceding 2 financial years | √ | | |
| 1.2(b)(iv) | Does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary/associated companies; | √ | | |
| 1.2(b)(v) | Not a Member or TREC, Director or Officer of any Stock Exchange | √ | | |
| 1.2(b)(vi) | Not a Shareholder/Director/Officer of any Member/TREC holder of Stock Exch. | √ | | |
| 1.2(b)(vii) | Not a partner or an executive or was not a partner or an executive during the preceding 3 (Three) years of the concerned Company's statutory audit firm. | √ | | |
| 1.2(b)(viii) | Shall not be an Independent Director in more than 5 listed companies; | √ | | |
| 1.2(b)(ix) | Not Convicted by a court of competent jurisdiction as a defaulter in payment of any loan/advance to a Bank or a Non-Bank Financial Institution. | √ | | |
| 1.2(b)(x) | Non convicted for a criminal offence involving moral turpitude; | √ | | |
| 1.2(c) | Appointment of Independent Director shall be by Board and subsequently approved by shareholders in the AGM; | √ | | There is a agenda in this AGM |
| 1.2(d) | The post of Independent Director(s) cannot remain vacant for more than 90 (ninety) days. | √ | | |
| 1.2(e) | Tenure of office of an Independent Director (for a period of 3 years, may be extended for 1 term only); | √ | | There is a agenda in this AGM |
| 1.3 | Qualification of Independent Director | | | |
| 1.3(a) | Shall be a knowledgeable individual with integrity who is able to ensure compliance with financial, regulatory and corporate laws and can make meaningful contribution to business; | √ | | |
| 1.3(b)(i) | Business Leader who is or was a promoter or director of an unlisted company. | √ | | |
| 1.3(b)(ii) | Corporate Leader who is or a top level executive of an unlisted company having 100 million paid up capital or of a listed company. | √ | | |
| 1.3(b)(iii) | Former official of government not below 5th grade of salary | | | Not Applicable |
| 1.3(b)(iv) | University Teacher who has educational background in Economics or Commerce or Business Studies or Law. | | | Not Applicable |
| 1.3(b)(v) | Professional like practicing Advocate, Chartered Accountant/Cost Accountant/ Chartered Secretary or equivalent qualification | √ | | |
| 1.3(c) | The Independent Director shall have at least 10 (ten) years of experiences. | √ | | |
| 1.3(iii)(d) | Relaxation of qualifications of Independent Directors subject to prior approval of the Commission. | | | Not Applicable |
| 1(4) | Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer | | | |
| 1(4)(a) | The posts of Chairperson of the Board and MD/CEO shall be filled by different individuals. | √ | | |
| 1(4)(b) | MD and/or CEO of a listed company shall not hold the same position in another listed company. | √ | | |
| 1(4)(c) | The Chairperson shall be elected from among the non-executive directors. | √ | | |
| 1(4)(d) | The Board shall clearly define respective roles and responsibilities of the Chairperson and the Managing Director and/or CEO. | √ | | |
| 1(4)(e) | In absence of Chairperson of the Board, for the particular Board Meeting, Chairperson may be elected from one of non-executive directors and to be duly recorded. | | | Not Applicable |

| Condition No. | Title | Compliance Status | | Remarks (if any) |
|-------------------|---|-------------------|--------------|-------------------------------|
| | | Complied | Not Complied | |
| 1(5) | The Directors' Report to Shareholders | | | |
| 1.5(i) | Industry outlook and possible future developments in the industry; | √ | | |
| 1.5(ii) | Segment-wise or product-wise performance; | √ | | |
| 1.5(iii) | Risks and concerns including internal and external risk factor; | √ | | |
| 1.5(vi) | Discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin; | √ | | |
| 1.5(v) | Discussion on continuity of any extra-ordinary activities and their implications; | √ | | |
| 1.5(vi) | Detail disclosure on related party transactions; | √ | | |
| 1.5(vii) | Utilization from public issues, rights issues and/or through any others instruments; | | | Not Applicable |
| 1.5(viii) | Explanation if the financial results deteriorate after going for IPO, RPO, Rights Offer, Direct Listing, etc.; | | | Not Applicable |
| 1.5(ix) | Significant variance between Quarterly Financial performance and Annual Financial Statements and explanation thereon; | √ | | |
| 1.5(x) | Remuneration to Directors including Independent Directors; | √ | | |
| 1.5(xi) | Statement about fairness of financial statements; | √ | | |
| 1.5(xii) | Maintenance of proper books of account; | √ | | |
| 1.5(xiii) | Application of appropriate accounting policies and estimates; | √ | | |
| 1.5(xiv) | Application of International Accounting Standards (IAS)/International Financial Reporting Standards (IFRS) as applicable in Bangladesh; | √ | | |
| 1.5(xv) | Efficiency of Internal control system; | √ | | |
| 1.5(xvi) | Statement about the interest of minority shareholders have been protected; | √ | | |
| 1.5(xvii) | Statement about the ability to continue as going concern; | √ | | |
| 1.5(xviii) | Significant deviations from the last year's operation results of the issuer company shall be highlighted and the reasons there of should be explained. | √ | | |
| 1.5(xix) | Key operating and financial data of at least preceding 5 (Five) years; | √ | | |
| 1.5(xx) | Reason for non declaration of dividend; | | | Not Applicable |
| 1.5(xxi) | Board's statement to the effect that no bonus shares or stock dividend paid as interim dividend. | | | -Do- |
| 1.5(xxii) | Number of Board Meetings (no. of Board Meetings held and attendance by each director); | √ | | Page no. 126 may be seen |
| 1.5(xxiii) | The pattern of shareholding; | | | |
| 1.5(xxiii)(a) | Parent/Subsidiary/Associated Companies and other related parties (name wise details); | √ | | Page no. 167, 194 may be seen |
| 1.5(xxiii)(b) | Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children (name wise details); | √ | | Page no. 78 may be seen |
| 1.5(xxiii)(c) | Executives; | | | |
| 1.5(xxiii)(d) | Shareholders holding ten percent (10%) or more voting interest in the company (name wise details). | √ | | |
| 1.5(xxiv) | Appointment or reappointment of a director, disclosure | | | |
| 1.5(xxiv)(a) | Brief resume of the Director; | √ | | Page no. 24-31 may be seen |
| 1.5(xxiv)(b) | Nature of his/her expertise in specific functional areas; | √ | | |
| 1.5(xxiv)(c) | Names of companies in which the person also holds the directorship and the membership of committees of the board. | √ | | |
| 1.5(xxv) | Management discussion and analysis signed by CEO or MD | | | |
| 1(5)(xxv)(a) | Accounting policies and estimation for preparation of financial statements. | √ | | Annexure-A |
| 1(5)(xxv)(b) | Changes in accounting policies and estimation as well as cash flows on absolute figure for such changes | √ | | -Do- |
| 1(5)(xxv)(c) | Comparative analysis and financial position as well as cash flow for current financial year with immediate preceding five years explaining reasons | √ | | -Do- |
| 1(5)(xxv)(d) | Compare financial performance or results and financial position as well as cash flows with the peer industry scenario. | √ | | -Do- |
| 1(5)(xxv)(e) | Briefly explain the financial and economic scenario of the country and the globe; | √ | | -Do- |
| 1(5)(xxv)(f) | Risks and concerns issues related to the financial statements; | √ | | -Do- |
| 1(5)(xxv)(g) | Future plan or projection or forecast for company's operation shall be explained to the shareholders in the next AGM; | √ | | -Do- |
| 1(5)(xxvi) | Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(30) shall be disclosed as per Annexure-A; | √ | | Page no. 137 may be seen |
| 1(5)(xxvii) | Report as well as certificate regarding compliance of conditions of this Code as required under condition no. 9 shall be disclosed; | √ | | Page no. 147 may be seen |

| Condition No. | Title | Compliance Status | | Remarks (if any) |
|---------------|---|-------------------|--------------|--------------------------|
| | | Complied | Not Complied | |
| 1(6) | Meeting of the Board of Directors and Compliance under Bangladesh Secretarial Standards (BSS) | √ | | In Practice |
| 1(7) | Code of Conduct for the Chairperson, other Board Members and Chief Executive Officer | | | |
| 1(7)(a) | The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC) | √ | | |
| 1(7)(b) | The code of conduct as determined by the NRC shall be posted on the website | √ | | |
| 2 | Governance of Board of Directors of Subsidiary Company | | | |
| 2(a) | Provisions relating to the composition of the Board of the holding company shall be made applicable to the composition of the Board of the subsidiary. | √ | | |
| 2(b) | At least 1 Independent Director of holding company also be a director of the subsidiary company. | √ | | |
| 2(c) | Minutes of subsidiary to be placed in the following meeting of holding company. | √ | | |
| 2(d) | Minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company. | √ | | |
| 2(e) | The Audit Committee of the holding company shall also review the financial statements in particular the investments made by the subsidiary company. | √ | | |
| 3 | Managing Director (MD) or Chief Executive Officer, Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS) | | | |
| 3.1 | Appointment | | | |
| 3(1)(a) | Board shall appoint MD or CEO, CS, CFO, and HIAC. | √ | | |
| 3(1)(b) | The positions of the MD,CEO,CS,CFO & HIAC shall be filled by different individuals. | √ | | |
| 3(1)(c) | MD or CEO, CS, CFO, and HIAC of a listed company shall not hold any executive position in any other company at the same time. | √ | | |
| 3(1)(d) | The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS. | √ | | |
| 3(1)(e) | MD or CEO, CS, CFO, and HIAC shall not be removed from their position without approval of the Board and be disseminated to the commission and exchange. | √ | | |
| 3.2 | Requirement to attend Board of Directors' Meetings | | | |
| 3.2 | MD or CEO,CS,CFO and HIAC shall attend the meetings of the Board and CS, CFO & HIAC shall not attend such part of which involves their personal matters. | √ | | |
| 3.3 | Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer (CFO) | | | |
| 3.3(a) | MD or CEO and CFO to certify that they have reviewed financial statements to the best of their knowledge. | √ | | Page no. 137 may be seen |
| 3(3)(a)(i) | The statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading. | √ | | |
| 3(3)(a)(ii) | The statements together present a true and fair view of the company's affairs and are in compliance | √ | | |
| 3(3)(b) | MD or CEO and CFO to certify on due diligence in the Report. | √ | | |
| 3(3)(c) | The certification of the MD/CEO and CFO shall be disclosed in the Annual Report. | √ | | Page no. 137 may be seen |
| 4 | Board of Directors' Committee - Board shall have at least: | | | |
| 4(i) | Audit Committee | √ | | |
| 4(ii) | Nomination and Remuneration Committee | √ | | |
| 5 | Audit Committee | | | |
| 5.1 | Responsibility to the Board of Directors | | | |
| 5(i)(a) | Company shall have an Audit Committee as a sub-committee of the Board. | √ | | |
| 5(i)(b) | Audit Committee shall assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the Company. | √ | | |
| 5(i)(c) | Audit Committee shall report on its activities to the Board of Directors. | √ | | |
| 5.2 | Constitution of the Audit committee | | | |
| 5(2)(a) | The Audit Committee shall be composed of at least 3 (three) members. | √ | | |
| 5(2)(b) | Board shall appoint members of the Audit Committee who shall be non-executive director. | √ | | |
| 5(2)(c) | All members of the Audit Committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial. | √ | | |
| 5(2)(d) | When the term of service of the Committee member expires, Board shall appoint new Committee member immediately or not later than 1 month of vacancy. | √ | | |
| 5(2)(e) | The Company Secretary shall act as the Secretary of the Audit Committee | √ | | |
| 5(2)(f) | Quorum shall not constitute without at least 1 independent director. | √ | | |

| Condition No. | Title | Compliance Status | | Remarks (if any) |
|----------------|---|-------------------|--------------|------------------|
| | | Complied | Not Complied | |
| 5.3 | Chairperson of the Audit Committee | | | |
| 5(3)(a) | The Board shall select Chairperson of the Audit Committee who will be ID. | √ | | |
| 5(3)(b) | Absence of chairperson, the remaining members may elect one of them and reason of absence to be recorded in the minutes. | √ | | |
| 5(3)(c) | Chairperson of the Audit Committee shall remain present in the AGM. | √ | | |
| 5.4 | Meeting of the Audit Committee | | | |
| 5(4)(a) | The Audit Committee shall conduct at least 4 meetings in a financial year. | √ | | |
| 5(4)(b) | Quorum: presence of 2 or 2/3 members whichever is higher and 1 independent director is must. | √ | | |
| 5.5 | Role of Audit Committee | | | |
| 5(5)(a) | Oversee the financial reporting process. | √ | | |
| 5(5)(b) | Monitor choice of accounting policies and principles. | √ | | |
| 5(5)(c) | Internal Audit and Compliance process to ensure that it is adequately resourced. | √ | | |
| 5(5)(d) | Oversee hiring and performance of external auditors. | √ | | |
| 5(5)(e) | Hold meeting with the auditors, review the annual financial statements before submission to the Board for approval or adoption. | √ | | |
| 5(5)(f) | Review with the management, the annual financial statements before submission to the Board for approval. | √ | | |
| 5(5)(g) | Review with the management, the quarterly and half yearly financial statements before submission to the Board for approval. | √ | | |
| 5(5)(h) | Review adequacy of internal audit function. | √ | | |
| 5(5)(i) | Review the management's discussion and analysis before disclosing in the Annual Report. | √ | | |
| 5(5)(j) | Review statement of all related party transactions submitted by the Management. | √ | | |
| 5(5)(k) | Review management letters or letter of Internal Control weakness issued by statutory auditors. | √ | | |
| 5(5)(l) | Oversee determination of audit fees and evaluate performance of external auditors. | √ | | |
| 5(5)(m) | Oversee whether IPO/RPO proceeds utilized as per the published Prospectus. | | | Not Applicable |
| 5.6 | Reporting of the Audit Committee | | | |
| 5.6(a) | Reporting to the Board of Directors | | | |
| 5(6)(a)(i) | The Audit Committee shall report on its activities to the Board. | √ | | |
| 5(6)(a)(ii) | Shall report immediately the Board on the followings: | | | |
| 5(6)(a)(ii)(a) | Report on conflicts of interests. | | | |
| 5(6)(a)(ii)(b) | Suspected or presumed fraud or irregularity or material defect identified in the internal audit and compliance process. | | | |
| 5(6)(a)(ii)(c) | Suspected infringement of laws, regulatory compliance including securities related laws, relies and regulation. | | | |
| 5(6)(a)(ii)(d) | Any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately. | √ | | |
| 5.6(b) | Reporting to the Authorities | | | Not Applicable |
| 5.7 | Reporting to the Shareholders and General Investors | √ | | |
| 6 | Nomination and Remuneration Committee (NRC) | | | |
| 6.1 | Responsibility to the Board of Directors: | | | |
| 6(i)(a) | The company shall have a NRC as a sub-committee of the Board. | √ | | |
| 6(i)(b) | NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications and policy for remuneration of directors, top level executives. | √ | | |
| 6(i)(c) | The Terms of Reference of the NRC shall be clearly set forth in writing. | √ | | |
| 6.2 | Constitution of the NRC | | | |
| 6(2)(a) | The Committee shall comprise of at least three members including an ID. | √ | | |
| 6(2)(b) | All members of the Committee shall be non-executive directors. | √ | | |
| 6(2)(c) | Members of the Committee shall be nominated and appointed by the Board. | √ | | |
| 6(2)(d) | Board have authority to remove and appoint any member of the committee. | √ | | |
| 6(2)(e) | Board shall fill the vacancy within 180 days of such vacancy in the Committee. | | | |
| 6(2)(f) | The Chairperson of the Committee may appoint/co-opt any external non-voting expert for valuable advice. | | | Not Applicable |
| 6(2)(g) | The company secretary shall act as the secretary of the committee. | √ | | |
| 6(2)(h) | Quorum shall not constitute without at least 1 independent director. | √ | | |
| 6(2)(i) | No member of the NRC shall receive any remuneration/advisory, other than Director's fees or honorarium from the Company. | √ | | |

| Condition No. | Title | Compliance Status | | Remarks (if any) |
|---------------|---|-------------------|--------------|--------------------------|
| | | Complied | Not Complied | |
| 6.3 | Chairperson of the NRC | | | |
| 6(3)(a) | Board shall select 1 member of the NRC to be Chairperson of the Committee who shall be an Independent Director. | √ | | |
| 6(3)(b) | Absence of chairperson, the remaining members may elect one of them and reason of absence to be recorded in the minutes. | √ | | |
| 6(3)(c) | Chairperson of the NRC shall attend the AGM. | √ | | |
| 6.4 | Meeting of the NRC | | | |
| 6(4)(a) | The NRC shall conduct at least one meeting in a financial year. | √ | | |
| 6(4)(b) | The Chairperson of the NRC, may convene any emergency meeting. | √ | | |
| 6(4)(c) | Quorum: presence of 2 or 2/3 members whichever is higher and 1 independent director is must. | √ | | |
| 6(4)(d) | Proceedings of NRC meeting shall be recorded in the minutes and such minutes shall be confirmed in the next meeting. | √ | | |
| 6.5 | Role of NRC | | | |
| 6(5)(a) | NRC shall be independent and responsible/accountable to the Board and to the shareholders. | √ | | |
| 6(5)(b) | NRC shall oversee, among others, the following matters and make report with recommendation to the Board: | √ | | |
| 6(5)(b)(i) | Formulating the criteria for qualification and remuneration of the directors and top level executives considering the following: | √ | | |
| 6(5)(b)(i)(a) | Level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully. | √ | | |
| 6(5)(b)(i)(b) | Relationship of remuneration to performance is clear and meets appropriate performance benchmarks. | √ | | |
| 6(5)(b)(i)(c) | Remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long term performance. | √ | | |
| 6(5)(b)(ii) | Devising a policy on Board's diversity taking into consideration age, experience etc. | √ | | |
| 6(5)(b)(iii) | Identifying persons who are qualified the criteria laid down and recommend their appointment and removal to the Board. | √ | | |
| 6(5)(b)(iv) | Formulating criteria for evaluation of performance of independent directors and the Board. | √ | | |
| 6(5)(b)(v) | Identifying company's needs for employees at different levels and determine their selection, transfer or replacement. | √ | | |
| 6(5)(b)(vi) | Developing recommending and reviewing annually the company's human resources and training policies. | √ | | |
| 6(5)(c) | The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC at a glance in its annual report. | √ | | Page no. 132 may be seen |
| 7 | External or Statutory Auditors | | | |
| 7(1) | Issuer company shall not engage its external auditors to perform the following services: | | | |
| 7(1)(i) | Appraisal or valuation services or fairness opinions. | √ | | |
| 7(1)(ii) | Financial information systems design and implementation. | √ | | |
| 7(1)(iii) | Book keeping or other service related to the account ion records. | √ | | |
| 7(1)(iv) | Broker-dealer services | √ | | |
| 7(1)(v) | Actuarial services | √ | | |
| 7(1)(vi) | Internal/special audit services. | √ | | |
| 7(1)(vii) | Any services that the Audit Committee may determine. | √ | | |
| 7(1)(viii) | Certification services on compliance of corporate governance. | √ | | |
| 7(1)(ix) | Any other service that may create conflict of interest. | √ | | |
| 7(2) | No partner or employees of the External/Statutory Auditors audit firms shall possess any share of the company they audit at least during the tenure. | √ | | |
| 7(3) | Representative of External Auditors shall remain present in the AGM. | √ | | |
| 8 | Maintaining a website by the company | | | |
| 8(1) | The company shall have an official website linked with that of the stock exchange. | √ | | |
| 8(2) | The company shall keep the website functional from the date of listing. | √ | | |
| 8(3) | The company shall make available the detailed disclosures on its website as required under the listing regulations of the concerned stock exchanges. | √ | | |
| 9 | Reporting and Compliance of Corporate Governance | | | |
| 9(1) | The company shall obtain a certificate from a practicing professional firm on yearly basis regarding compliance of conditions of Corporate Governance | √ | | Page no. 147 may be seen |
| 9(2) | The professional who will provide the certificate on compliance of Corporate Governance shall be appointed by the Shareholders in the AGM. | √ | | |
| 9(3) | The directors of the company shall state, in accordance with the Annexure-C attached, in the directors report whether the company has complied with these conditions. | √ | | Page no. 52 may be seen |



REPORTS AND FINANCIAL STATEMENTS



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস

৯-জি, মতিঝিল বানিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali
CHARTERED ACCOUNTANTS
9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.
Extension Office: Property Heights, 1st Floor
12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867
PABX: 9576118-9, 9576128
FAX: +88-02-9516236
E-mail: wali@satcombd.com
Web: www.msw-bd.com

INDEPENDENT AUDITOR'S REPORT

To the Shareholders of THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the Consolidated Financial Statements of The IBN SINA Pharmaceutical Industry PLC, which comprise the Consolidated Statement of Financial Position as at June 30, 2022, the Consolidated Statement of Profit or Loss and Other Comprehensive Income, Consolidated Statement of Changes in Equity and Consolidated Statement of Cash Flows for the year then ended, and notes to the Consolidated Financial Statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying Consolidated Financial Statements give true and fair view, in all material respects, of the Consolidated Financial Position of the Company as at June 30, 2022, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies act 1994, the Securities and Exchange Rules 1987 and other applicable law and regulations.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

| Risk | Our response |
|---|--|
| Revenue recognition | |
| At the year ended, the company's reported total revenue of Tk. 847.98 Crore. Time of revenue recognition is matter. Considering the other inherent risk of the existence and the accuracy on revenue recognition, the revenue has been selected as key audit matter. | We have tested the design and operating effectiveness of key controls focusing on the following: <ul style="list-style-type: none">● Policy of revenue recognition.● Issuance of VAT challan;● Segregation of duties in invoice creation and modification; and● Timing of revenue recognition. Our substantive procedures in relation to the revenue recognition comprises the following: <ul style="list-style-type: none">● Obtaining supporting documentation for sales transactions recorded either side of year end as well as credit notes issued after the year end date to determine whether revenue was recognized in the correct period;● Critically assessing manual journals posted to revenue to identify unusual or irregular items; and● Finally assessed the appropriateness and presentation of disclosures against relevant accounting Standards. |
| Please see the note no. 24 in these financial statements. | |

Associated firm of **Reddy Siddiqui & Kabani**, Park View, 183-189 The Vale, London, W3 7RW, UK
E-mail: mail@reddysiddiqui.com, Website: www.reddysiddiqui.com



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস

৯-জি, মতিবিল বানিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali

CHARTERED ACCOUNTANTS

9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.

Extension Office: Property Heights, 1st Floor

12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867

PABX: 9576118-9, 9576128

FAX: +88-02-9516236

E-mail: wali@satcombd.com

Web: www.msw-bd.com

| Risk | Our response |
|--|---|
| <p>Valuation of inventory</p> <p>The balance of inventory of the Company at the year-end was Tk. 100.76 Crore held in the company's store.</p> <p>Inventories are carried at the lower of cost and net realizable value. As a result, the Management has applied judgments in determining the appropriate values for slow-moving or obsolete items.</p> | <p>We challenged the appropriateness of management's assumptions applied in calculating the value of the inventory and related provisions by:</p> <ul style="list-style-type: none"> ● evaluating the design and implementation of key inventory controls operating across the Company in respect of inventory management; ● to attend the physical inventory counts and reconciling the count results to the inventory listings to test the completeness of data; ● to review the inventory costing procedures and methodology. ● comparing the net realizable value, obtained through a detailed review of sales subsequent to the year-end, to the cost price of a sample of inventories and comparison to the associated provision to assess whether inventory provisions are complete; ● reviewing the historical accuracy of inventory provisioning, and the level of inventory write-offs during the year; and ● challenging the completeness of inventory provisions through assessing actual and forecast sales of inventory lines to assess whether provisions for slow-moving/obsolete stock are valid and complete. |
| Please see the note no. 08.A in these financial statements. | |
| Measurement and recognition of deferred tax | |
| <p>The balance of reported deferred tax liability of the company was Tk.11.77 Crore as on June 30, 2022.</p> <p>The risk for the financial statements is that these provisions are not properly measured for all types of temporary difference as per IAS 12: Income Tax.</p> | <p>We obtained an understanding, evaluated the design and tested the operational effectiveness of the Company's key controls over the recognition and measurement of deferred tax.</p> <p>We have assessed the appropriateness of the carrying amounts of net asset value as per tax base and accounting base.</p> <p>We have also assessed the rate of deferred for each temporary difference.</p> <p>Also, we examined the accounting treatment of deferred tax.</p> |
| Please see the note no. 18 in these financial statements. | |

Associated firm of **Reddy Siddiqui & Kabani**, Park View, 183-189 The Vale, London, W3 7RW, UK
E-mail: mail@reddysiddiqui.com, Website: www.reddysiddiqui.com



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস
৯-জি, মতিঝিল বাণিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali
CHARTERED ACCOUNTANTS
9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.
Extension Office: Property Heights, 1st Floor
12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867
PABX: 9576118-9, 9576128
FAX: +88-02-9516236
E-mail: wali@satcombd.com
Web: www.msw-bd.com

| Risk | Our response |
|---|---|
| Consolidation of the financial statements | |
| <p>It is mentioned here that the Company has prepared and published consolidated financial statements of the group as whole by taking consideration of three subsidiary named The IBN SINA API Industry Ltd. with 99.99% of controlling stake, The IBN SINA Natural Medicine Ltd. with 99.99% of controlling stake and The IBN SINA Polymer Industry Ltd. With 65% of controlling stake and one associate (for the part of the year) named The IBN SINA Consumer Products Ltd. with 40% stake. And related disposal of entire investment in Associate Company.</p> <p>The key risk is that whether the consolidated financial statements of the company are prepared in compliance with IFRS 10: Consolidated Financial statements and IFRS 3: Business Combination and provide adequate disclosure in required standard.</p> | <p>We have obtained a good understanding of the structure of the group, the significance (ie materiality) of each component of the group, the mechanics of the consolidation process, and the risk of material misstatement presented by each of the company's financial statements. We have also established materiality level for the group in aggregate, and for the individually significant components. The types of audit procedures that was performed include:</p> <ul style="list-style-type: none">● checking that figures taken into the consolidation have been accurately extracted from the financial statements of the components.● evaluating the classifications of the components of the group - for example, whether the components have been correctly identified and treated as subsidiaries, associates.● reviewing the disclosures necessary in the group financial statements, such as related party transactions and minority interests.● gathering evidence appropriate to the specific consolidation adjustments made necessary by financial reporting standards, including, for example:<ul style="list-style-type: none">■ the calculation of goodwill and its impairment review■ cancellation of inter-company balances and transactions■ Provision for unrealised profits, if any, as a result of inter-company transactions fair value adjustments needed for assets and liabilities held by the component.■ The recognition of part of income & expenses and related gain or loss upon disposal of the subsidiary. |

Associated firm of **Reddy Siddiqui & Kabani**, Park View, 183-189 The Vale, London, W3 7RW, UK
E-mail: mail@reddysiddiqui.com, Website: www.reddysiddiqui.com



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস

৯-জি, মতিঝিল বানিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali
CHARTERED ACCOUNTANTS
9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.
Extension Office: Property Heights, 1st Floor
12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867
PABX: 9576118-9, 9576128
FAX: +88-02-9516236
E-mail: wali@satcombd.com
Web: www.msw-bd.com

Other Information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditor's report thereon. We have not been provided the Director's report and other information contained within the annual report except the financial statements to the date of our auditor's report. We expect to obtain the remaining reports of the Annual report after the date of our auditor's report. Management is responsible for the other information.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Our opinion on the financial statements does not cover other information and we do not express any form of assurance conclusion thereon.

Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs as explained, and for such internal control as management determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error. The Companies Act, 1994 require the Management to ensure effective internal audit, internal control and risk management functions of the Company.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস
৯-জি, মতিঝিল বানিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali
CHARTERED ACCOUNTANTS
9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.
Extension Office: Property Heights, 1st Floor
12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867
PABX: 9576118-9, 9576128
FAX: +88-02-9516236
E-mail: wali@satcombd.com
Web: www.msw-bd.com

● Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

● Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

● Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the company audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements


In accordance with the Companies Act 1994 and the Securities and Exchange Rules 1987, we also report the following:

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) In our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of these books;
- c) The Statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts and returns; and
- d) The expenditure incurred was for the purposes of the Company's business.

Dated, Dhaka
September 05, 2022

Malek Siddiqui Wali
Chartered Accountants

Data Verification Code (DVC) No.
2209120247AS584103


Md. Waliullah, FCA
Enrolment No: 0247

Associated firm of **Reddy Siddiqui & Kabani**, Park View, 183-189 The Vale, London, W3 7RW, UK
E-mail: mail@reddysiddiqui.com, Website: www.reddysiddiqui.com

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2022

| | | AMOUNT IN TAKA | |
|---|---------|----------------------|----------------------|
| | | 30 June 2022 | 30 June 2021 |
| ASSETS | | | |
| Non-Current Assets | | 2,627,085,917 | 2,387,579,274 |
| Property, Plant and Equipment | 04.A | 2,342,489,248 | 2,209,734,247 |
| Capital Work-In-Progress | 05.A | 144,253,344 | 111,409,695 |
| Right of Use Assets | 05.B | 109,228,940 | 9,566,112 |
| Investment in Marketable Securities (AFS) | 06 | 31,114,385 | 5,179,715 |
| Investment in Associates | 07 | - | 51,689,505 |
| Current Assets | | 1,683,200,873 | 1,457,828,253 |
| Inventories | 08.A | 1,007,567,964 | 782,163,655 |
| Trade and Other Receivables | 09 | 53,825,299 | 27,271,285 |
| Advances, Deposits & Prepayments | 10.A | 279,202,125 | 367,157,429 |
| Cash & Cash Equivalents | 11.A | 342,605,485 | 281,235,883 |
| TOTAL ASSETS | | 4,310,286,790 | 3,845,407,527 |
| SHAREHOLDERS' EQUITY AND LIABILITIES | | | |
| Equity | | 2,625,049,957 | 2,149,551,055 |
| Equity Attributable to the Owners of the Company | | 2,604,390,765 | 2,146,199,473 |
| Share Capital | 12 | 312,436,270 | 312,436,270 |
| Tax Holiday Reserve | 13 | 4,392,110 | 4,392,110 |
| Unrealised Gain on Marketable Securities (AFS) | 14 | (685,588) | 145,087 |
| Retained Earnings | 15.A | 2,288,247,972 | 1,829,226,006 |
| Non Controlling Interest | 15.B | 20,659,192 | 3,351,582 |
| LIABILITIES | | | |
| Non-Current Liabilities | | 561,216,121 | 540,577,920 |
| Long Term Finance | 16 | 368,006,389 | 419,621,065 |
| Retirement Benefit Obligations | 17.A | 734,704 | 94,029 |
| Lease Liability | 17.B | 74,750,975 | 1,993,508 |
| Deferred Tax Liability | 18 | 117,724,054 | 118,869,318 |
| Current Liabilities | | 1,124,020,711 | 1,155,278,552 |
| Short Term Finance | 20 | 534,291,102 | 377,502,715 |
| Current Portion of Long Term Finance | 21 | 92,237,234 | 67,532,217 |
| Trade And Other Payable | 22.A | 309,298,806 | 377,762,866 |
| Unclaimed Dividend | 22.A.1 | 22,638,182 | 53,184,517 |
| Provision for Corporate Tax | 23.A | 165,555,387 | 279,296,238 |
| TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES | | 4,310,286,790 | 3,845,407,527 |
| Net Assets Value (NAV) Per Share | | 83.36 | 68.69 |
| | 33.01.B | | |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 05, 2022 and were signed on its behalf by:







Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

Dated, Dhaka;
September 05, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 30 June 2022

| | | AMOUNT IN TAKA | |
|--|---------|---------------------------------|---------------------------------|
| | Notes | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| REVENUE | 24 | 8,479,819,569 | 7,376,042,094 |
| Cost of goods sold | 25 | (4,913,749,450) | (4,275,324,899) |
| GROSS PROFIT | | 3,566,070,119 | 3,100,717,195 |
| OPERATING EXPENSES | | (2,704,571,030) | (2,332,073,597) |
| Administrative expenses | 27.01 | (192,588,364) | (163,902,209) |
| Selling & Distribution expenses | 28 | (2,511,982,666) | (2,168,171,388) |
| OPERATING PROFIT | | 861,499,089 | 768,643,598 |
| Financial charges | 33.04 | (47,329,924) | (39,998,318) |
| Other income | 29.01 | 27,321,901 | 13,463,364 |
| Net profit from operation | | 841,491,066 | 742,108,643 |
| Workers' P.P. fund & welfare fund | 30 | (40,341,605) | (35,733,665) |
| Share of associate profit/loss | | (1,286,976) | (1,926,929) |
| PROFIT BEFORE TAX | | 799,862,485 | 704,448,050 |
| Income Tax Expenses | 31.02 | (194,187,861) | (215,476,279) |
| NET PROFIT AFTER TAX | | 605,674,624 | 488,971,771 |
| Profit/(Loss) Attributable to: | | | |
| Owner of the Company | | 605,867,013 | 489,123,389 |
| Non-controlling interest | | (192,390) | (151,618) |
| | | 605,674,624 | 488,971,771 |
| Other Comprehensive Income: | | | |
| Change in fair value of marketable securities | 32 | (922,972) | 397,210 |
| Deferred tax | | 92,297 | (39,721) |
| Total other comprehensive income for the year (net of tax) | | (830,675) | 357,489 |
| Total Comprehensive Income for the year | | 604,843,949 | 489,329,260 |
| Total Comprehensive income Attributable to: | | | |
| Owners of the Company | | 605,036,339 | 489,480,878 |
| Non-controlling interest | | (192,390) | (151,618) |
| | | 604,843,949 | 489,329,260 |
| Earnings Per Share (EPS) | 33.01.A | 19.39 | 15.66 |
| Number of Shares used to compute EPS | | 31,243,627 | 31,243,627 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 05, 2022 and were signed on its behalf by:


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Dated, Dhaka;
September 05, 2022


Malek Siddiqui Wali
Chartered Accountants

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the year ended 30 June 2022

AMOUNT IN TAKA

| Particulars | Paid up Capital | Tax Holiday Reserve | Gain on Marketable Securities (unrealized) | Retained Earnings | Non Controlling Interest | Total |
|--|--------------------|---------------------|--|----------------------|--------------------------|----------------------|
| Balance as at 30 June 2020 | 312,436,270 | 4,392,110 | (212,402) | 1,460,390,581 | 40 | 1,777,006,599 |
| Statement of profit or loss and other Comprehensive Income for the year ended 30 June 2021 | | | 357,489 | 489,123,389 | (151,618) | 489,329,260 |
| Dividend for the year 30 June 2020 (Cash-38.50%) | | | | (120,287,964) | | (120,287,964) |
| Issued during the year | | | | | 3,503,160 | 3,503,160 |
| Balance as at 30 June 2021 | 312,436,270 | 4,392,110 | 145,087 | 1,829,226,006 | 3,351,582 | 2,149,551,055 |
| Statement of profit or loss and other Comprehensive Income for the year ended 30 June 2022 | - | - | (830,675) | 605,867,013 | (192,390) | 604,843,949 |
| Dividend for the year 30 June 2021 (Cash-47%) | - | - | - | (146,845,047) | - | (146,845,047) |
| Issued during the year | - | - | - | - | 17,500,000 | 17,500,000 |
| Balance as at 30 June 2022 | 312,436,270 | 4,392,110 | (685,588) | 2,288,247,972 | 20,659,192 | 2,625,049,957 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 05, 2022 and were signed on its behalf by:

 **Chief Financial Officer**
 **Company Secretary**
 **Director**
 **Managing Director**
 **Chairman**

Dated, Dhaka;
September 05, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

CONSOLIDATED STATEMENT OF CASH FLOWS

For the year ended 30 June 2022

| | AMOUNT IN TAKA | |
|---|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| Cash Flows From Operating Activities: | | |
| Received from revenue and others | 8,468,889,193 | 7,381,147,135 |
| Payment for operation, expenses & others | (7,794,752,393) | (6,606,929,973) |
| Miscellaneous income | 2,137,661 | 3,349,419 |
| Cash generated from operations | 676,274,462 | 777,566,581 |
| Payment for income tax | (216,766,485) | (186,639,692) |
| Payment for financial charges | (40,943,264) | (38,760,107) |
| Net cash provided by operating activities | 418,564,713 | 552,166,782 |
| Cash Flows From Investing Activities: | | |
| Acquisition of property, plant and equipment | (365,164,426) | (242,527,129) |
| Proceeds from sales of motor vehicles | - | 1,434,018 |
| Investment in associates | 60,000,000 | - |
| Investment in API Services Ltd. | - | (3,000,000) |
| Dividend received/ IBBL-MPB | 1,152,477 | 430,542 |
| Received from bank deposits | 1,711,913 | 1,634,481 |
| Net cash used in investing activities | (302,300,036) | (242,028,088) |
| Cash Flows From Financing Activities: | | |
| Payment of dividend | (177,391,381) | (131,507,691) |
| Long term finance received/(paid) from bank (Net) | (51,614,676) | 171,699,256 |
| Transactions Non Controlling Interest | 17,500,000 | 3,503,160 |
| Short term finance received/(paid) from bank (Net) | 159,437,580 | (272,311,929) |
| Net Cash used in financing activities | (52,068,478) | (228,617,203) |
| Increase/(decrease) in cash and cash equivalents | 64,196,199 | 81,521,491 |
| Cash and cash equivalents at the opening | 281,235,883 | 199,913,735 |
| Foreign exchange fluctuation gain/(loss) on FCAD ERQ accounts | (2,826,598) | (199,343) |
| Cash and cash equivalents at the closing | 342,605,485 | 281,235,883 |
| NOCFPS (Note 33.02.01) | 13.40 | 17.67 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 05, 2022 and were signed on its behalf by:

 **Chief Financial Officer**
 **Company Secretary**
 **Director**
 **Managing Director**
 **Chairman**

Dated, Dhaka;
September 05, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

STATEMENT OF FINANCIAL POSITION

As at 30 June 2022

| | | AMOUNT IN TAKA | |
|---|--------|----------------------|----------------------|
| | | 30 June 2022 | 30 June 2021 |
| ASSETS | | | |
| Non-Current Assets | | 2,678,535,914 | 2,470,531,996 |
| Property, Plant and Equipment | 04 | 2,213,259,449 | 2,166,874,444 |
| Capital Work-In-Progress | 05 | 100,933,339 | 100,722,420 |
| Right of Use Assets | 05.B | 109,228,940 | 9,566,112 |
| Investment in Marketable Securities (AFS) | 06 | 31,114,385 | 5,179,715 |
| Investment in Associate | 07 | - | 51,689,505 |
| Investment in Subsidiary | 07.1 | 223,999,800 | 136,499,800 |
| Current Assets | | 1,629,268,293 | 1,384,872,310 |
| Inventories | 08 | 889,378,019 | 781,760,330 |
| Trade and Other Receivables | 09 | 40,192,601 | 27,271,285 |
| Advances, Deposits & Prepayments | 10 | 253,373,523 | 342,082,195 |
| Cash and Cash Equivalents | 11 | 238,154,480 | 233,758,499 |
| Assets held under disposal group | 46.5 | 208,169,670 | - |
| TOTAL ASSETS | | 4,307,804,207 | 3,855,404,306 |
| SHAREHOLDERS' EQUITY AND LIABILITIES | | | |
| Equity | | 2,623,828,948 | 2,159,859,988 |
| Share Capital | 12 | 312,436,270 | 312,436,270 |
| Tax Holiday Reserve | 13 | 4,392,110 | 4,392,110 |
| Unrealised Gain on Marketable Securities (AFS) | 14 | (685,588) | 145,087 |
| Retained Earnings | 15 | 2,307,686,156 | 1,842,886,521 |
| LIABILITIES | | | |
| Non-Current Liabilities | | 561,216,121 | 540,577,920 |
| Long Term Finance | 16 | 368,006,389 | 419,621,065 |
| Retirement Benefit Obligations | 17.A | 734,704 | 94,029 |
| Lease Liability | 17.B | 74,750,975 | 1,993,508 |
| Deferred Tax Liability | 18 | 117,724,054 | 118,869,318 |
| Current Liabilities | | 1,122,759,138 | 1,154,966,398 |
| Short Term Finance | 20 | 534,291,102 | 377,502,715 |
| Current Portion of Long Term Finance | 21 | 92,237,234 | 67,532,217 |
| Trade and Other Payable | 22 | 308,550,556 | 377,676,616 |
| Unclaimed Dividend | 22.A.1 | 22,638,182 | 53,184,517 |
| Provision For Corporate Tax | 23 | 165,042,065 | 279,070,334 |
| TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES | | 4,307,804,207 | 3,855,404,306 |
| Net Assets Value (NAV) Per Share | 33.01 | 83.98 | 69.13 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 05, 2022 and were signed on its behalf by:







Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

Dated, Dhaka;
September 05, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 30 June 2022

(Revised)

| | Notes | AMOUNT IN TAKA | |
|--|-------|---------------------------------|---------------------------------|
| | | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| CONTINUING OPERATION | | | |
| REVENUE | 24 | 7,438,877,348 | 6,458,307,149 |
| Cost of goods sold | 25 | (4,304,173,685) | (3,740,101,879) |
| Gross profit | | 3,134,703,663 | 2,718,205,270 |
| OPERATING EXPENSES | | | |
| Administrative expenses | 27 | (163,121,613) | (135,591,949) |
| Selling & Distribution expenses | 28 | (2,168,679,922) | (1,865,043,536) |
| OPERATING PROFIT | | 802,902,128 | 717,569,785 |
| Financial charges | 33.04 | (47,329,924) | (39,998,318) |
| Other income | 29 | 26,363,837 | 12,719,232 |
| Net profit from operation | | 781,936,042 | 690,290,699 |
| Workers' P.P. fund and welfare fund | 30 | (37,235,050) | (32,870,986) |
| Share of associate profit/(loss) | | (1,286,976) | (1,926,929) |
| PROFIT BEFORE TAX | | 743,414,016 | 655,492,784 |
| INCOME TAX EXPENSES | | | |
| | 31 | (181,474,220) | (203,802,324) |
| PROFIT FROM CONTINUING OPERATIONS | | 561,939,795 | 451,690,460 |
| DISCONTINUED OPERATION | | | |
| Profit from Discontinued Operation Net of Tax | 46.4 | 49,704,886 | 45,802,863 |
| NET PROFIT AFTER TAX | | 611,644,682 | 497,493,323 |
| Other Comprehensive Income | | | |
| Change in fair value of Marketable Securities | 32 | (922,972) | 397,210 |
| Deferred tax | | 92,297 | (39,721) |
| Total other comprehensive income for the year (net of tax) | | (830,675) | 357,489 |
| Total Comprehensive Income for the period | | 610,814,007 | 497,850,812 |
| Earnings Per Share (EPS) | 33 | 19.58 | 15.92 |
| Earnings Per Share (EPS)-Continuing operation | | 17.99 | 14.46 |
| Number of Shares Used to compute EPS | | 31,243,627 | 31,243,627 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 05, 2022 and were signed on its behalf by:

 Chief Financial Officer
  Company Secretary
  Director
  Managing Director
  Chairman

Dated, Dhaka;
September 05, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

STATEMENT OF CHANGES IN EQUITY

For the year ended 30 June 2022

AMOUNT IN TAKA

| Particulars | Paid up Capital | Tax Holiday Reserve | Gain on Marketable Securities (unrealized) | Retained Earnings | Total |
|--|-----------------|---------------------|--|-------------------|---------------|
| Balance as at 1 July 2020 | 312,436,270 | 4,392,110 | (212,402) | 1,465,681,162 | 1,782,297,140 |
| Statement of profit or loss and other Comprehensive Income for the year ended 30 June 2021 | - | - | 357,489 | 497,493,323 | 497,850,812 |
| Dividend for the year 30 June 2020 (Cash-38.50%) | - | - | - | (120,287,964) | (120,287,964) |
| Balance as at 30 June 2021 | 312,436,270 | 4,392,110 | 145,087 | 1,842,886,521 | 2,159,859,988 |
| Statement of profit or loss and other Comprehensive Income for the year ended 30 June 2022 | - | - | (830,675) | 611,644,682 | 610,814,007 |
| Dividend for the year 30 June 2021 (Cash-47.00%) | - | - | - | (146,845,047) | (146,845,047) |
| Balance as at 30 June 2022 | 312,436,270 | 4,392,110 | (685,588) | 2,307,686,155 | 2,623,828,948 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 05, 2022 and were signed on its behalf by:

 **Chief Financial Officer**
 **Company Secretary**
 **Director**
 **Managing Director**
 **Chairman**

Dated, Dhaka;
September 05, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

STATEMENT OF CASH FLOWS

For the year ended 30 June 2022

| | AMOUNT IN TAKA | |
|---|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| Cash Flows From Operating Activities: | | |
| Received from revenue and others | 8,468,889,193 | 7,381,147,135 |
| Payment for operation, expenses & others | (7,788,249,234) | (6,598,317,740) |
| Miscellaneous income | 2,137,661 | 3,349,419 |
| | 682,777,620 | 786,178,814 |
| Cash generated from operations | | |
| Payment for income tax | (216,670,678) | (186,565,279) |
| Payment for Financial charges | (40,943,264) | (38,760,107) |
| Net cash provided by operating activities | 425,163,679 | 560,853,428 |
| Cash Flows From Investing Activities: | | |
| Acquisition of property, plant and equipment | (322,778,947) | (229,801,515) |
| Proceeds from sales of motor vehicles | - | 1,434,018 |
| Investment in associates (disposal) | 60,000,000 | - |
| Investment in Subsidiary | (87,500,000) | (67,630,280) |
| Dividend received/ IBBL-MPB | 1,152,477 | 430,542 |
| Received from bank deposits | 753,849 | 890,349 |
| Net cash used in investing activities | (348,372,621) | (294,676,886) |
| Cash Flows From Financing Activities: | | |
| Payment of dividend | (177,391,381) | (131,507,691) |
| Long term finance received/(paid) from bank (Net) | (51,614,676) | 171,699,256 |
| Short term finance received/(paid) from bank (Net) | 159,437,580 | (272,311,929) |
| Net cash used in financing activities | (69,568,478) | (232,120,363) |
| Increase/(decrease) in cash and cash equivalents | 7,222,580 | 34,056,179 |
| Cash and cash equivalents at the opening | 233,758,499 | 199,901,663 |
| Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts | (2,826,598) | (199,343) |
| Cash and cash equivalents at the closing | 238,154,480 | 233,758,499 |
| NOCFPS (Note 33.02) | 13.61 | 17.95 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 05, 2022 and were signed on its behalf by:

 **Chief Financial Officer**
 **Company Secretary**
 **Director**
 **Managing Director**
 **Chairman**

Dated, Dhaka;
September 05, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended on 30 June 2022

1. Reporting entity

1.1 The company and the group

The IBN SINA Pharmaceutical Industry PLC (the Company/Group) was incorporated in Bangladesh on 22 December 1983 under the Companies Act, 1913 (replaced by the Companies Act 1994) and it was converted into a Public Limited Company in 1989.

The registered office of the company is at Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207. The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE).

As the 99.99% shareholder of The IBN SINA API Industry Ltd. The IBN SINA Pharmaceutical Industry PLC started its operation as a group company from 16 September 2019. Hereinafter it is referred as the group as and where applicable for the purpose of preparing consolidated financial statements.

1.2 Nature of business

The Company involves in production of pharmaceutical drugs and natural medicines and selling them in both local and international market.

1.3 Subsidiary companies

The IBN SINA API Industry Ltd.

The IBN SINA API Industry Ltd. was incorporated in Bangladesh on 16 September 2019 under the Company Act, 1994. The Company involves in manufacturing, trading and other related activities of Active Pharmaceutical Ingredients and other related products.

The IBN SINA Natural Medicine Ltd.

The IBN SINA Natural Medicine Ltd. was incorporated in Bangladesh on 02 December 2020 under the Company Act, 1994. The Company involves in importing, manufacturing, trading and other related activities of natural medicine and other related products.

The IBN SINA Polymer Industry Ltd.

The IBN SINA Polymer Industry Ltd. was incorporated in Bangladesh on 25 March 2021 under the Company Act, 1994. The Company involves in manufacturing, trading and other related activities of Polymer Plastic Bottles, Plastic Tubes, Laminated tubes and other related products.

2. Basis of preparation of financial statements

2.1 Statement on compliance

The financial statements have been prepared in accordance with International Accounting Standard (IAS) and International Financial Reporting Standards (IFRS) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and subsequently adopted by Financial Reporting Council, Bangladesh, the Companies Act, 1994, Securities and Exchange Rules, 1987 and other relevant laws as applicable.

2.2 Other regulatory compliances

The Group is also required to comply with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

- The Income Tax Ordinance 1984
- The Income Tax Rules 1984
- The Value Added Tax Act 2012
- The Value Added Tax Rules 2016
- The Drugs Act 1940 and the Drug Rules 1946
- The Drugs (Control) Ordinance 1982
- The Customs Act 1969
- The Stamp Act 1899
- The Bangladesh Securities and Exchange Commission Act 1993
- The Bangladesh Securities and Exchange Commission Rules 1987
- DSE/CSE Rules
- Listing Regulations, 2015
- Bangladesh Labor Act, 2006 (as amended to 2018)

2.3 Authorization for issue

The financial statements were authorized for issue by the Board of Directors in its meeting held on 05 September 2022 for publication.

2.4 Basis of measurement

The financial statements have been prepared on historical cost basis except for certain assets which are stated either at revalued amount or fair market value as explained in the accompanying notes.

2.5 Accrual basis of accounting

The IBN SINA Pharmaceutical Industry PLC prepares its financial statements, except for cash flow information, using the accrual basis of accounting. Since the accrual basis of accounting is used, the group recognizes items as assets, liabilities, equity, income and expenses (the elements of financial statements) when they satisfy the definitions and

recognition criteria for those elements in the IFRS conceptual Framework.

2.6 Presentations of financial statements

The presentation of these financial statements is in accordance with the guidelines provided by IAS 1: Presentation of Financial Statements. The financial statements comprise of:

- (a) Consolidated Statement of Financial Position as at 30 June 2022
- (b) Consolidated Statement of Profit or Loss and Other Comprehensive Income for the year ended 30 June 2022
- (c) Consolidated Statement of Changes in Equity for the year ended 30 June 2022
- (d) Consolidated Statement of Cash Flows for the year ended 30 June 2022
- (e) Consolidated Notes, comprising summary of significant accounting policies and other explanatory information.

2.7 Functional and presentation currency

Functional and presentation currency items included in these financial statements are measured using the currency of the primary economic environment in which the group operates ('the functional currency'). These financial statements are presented in Bangladesh Taka ("BDT") which is also the functional currency of the group. The amounts in these financial statements have been rounded off to the nearest BDT except otherwise indicated.

2.8 Use of estimates and judgments

The preparation of financial statements in conformity with International Financial Reporting Standards requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected as required by IAS 8: "Accounting Policies, Changes in Accounting Estimates and Errors".

2.9 Investment in Subsidiary and Investment in associates

2.9.A Investment in Subsidiary

An investor (parent) controls an investee (subsidiary) when the investor is exposed, or has rights, to variable returns from its involvement with the investee (subsidiary) and has the ability to affect those returns through its power over the investee

(subsidiary). A subsidiary company is a company that is owned or controlled by another company (parent) and whose decision is influenced by another company (parent). Investment in subsidiary has been recorded at cost in the financial statement of the company. The IBN SINA Pharmaceutical Industry PLC holds 99.99% of its subsidiary (The IBN SINA API Industry Ltd. and The IBN SINA Natural Medicine Ltd.) and 65% of its subsidiary (The IBN SINA Polymer Industry Ltd.) equity shares as at year end.

2.9.1 Consolidated Financial Statements

The group has prepared separate financial statements and consolidated financial statements for the group separately. In the Consolidated financial statements:

- items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries have been combined;
- the carrying amount of the parent's investment in the subsidiary and the parent's portion of equity of the subsidiary have been offset (eliminated)
- intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between entities of the group i.e. profits or losses
- resulting from intragroup transactions that are recognised in assets, such as inventory and fixed assets, have been eliminated in full.

2.10 Materiality, aggregation and off setting

Each material item as considered by management significant has been displayed separately in the financial statements. No amount has been set off unless the Group has legal right to set off the amounts and intends to settle on net basis. Income and expenses are presented on a net basis only when permitted by the relevant accounting standards. The values of assets or liabilities as shown in the statement of financial position are not off-set by way of deduction from another liability or asset unless there exist a legal right therefore. No such incident existed during the year.

2.11 Going concern assumption

The financial statements are prepared on the basis of going concern assumption. As per management assessment there is no material uncertainties related to events or conditions which may cast significant doubt upon the Group's ability to continue as a going concern.

2.12 Reporting period

The reporting period of the group covers 12 (twelve) months from 01st July 2021 to 30th June 2022.

2.13 Comparative information

Comparative information has been disclosed in respect of 2021-2022 in accordance with IAS-1

"Presentation of Financial Statements" for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current periods of financial statements. Prior year figure has been re arranged wherever considered necessary to ensure comparability with the current year.

3. Significant accounting policies

3.1 Property, plant and equipment

Recognition and measurement

An item shall be recognized as property, plant and equipment's if, and only it is probable that future economic benefits associated with the item will flow to the entry, and the cost of the item can be measured reliably.

Items of property, plant and equipment's are measured at cost less accumulated depreciation as per IAS 16: Property, Plant and Equipment.

The cost of an item of property, plant and equipment comprises its purchase price, import duties and non-refundable taxes, after deducting trade discount and rebates, and any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the intended manner. The cost also includes the cost of replacing part of the property, plant and equipment and borrowing costs for term debt availed for the construction/ Implementation of the PPE, if the recognition criteria are met.

The cost of self-constructed assets includes the cost of material and direct labor and other costs directly attributable to bringing the assets to a working condition inclusive of inward freight, duties and non-refundable taxes for their intended use.

Subsequent costs

The subsequent expenditure is only capitalized as part of assets when the useful life or economic benefit or both of that asset is increased provided that it is probable that the future economic benefits embodied within the part will flow to the group and its cost can be measured reliably. The costs of day to day servicing of property, plant and equipment are recognized in the Statement of Profit or loss and other comprehensive income as 'Repair and Maintenance' when it is incurred.

Depreciation on non-current assets

Depreciation is provided to amortize the cost of the assets after commissioning, over the period of their expected useful lives, in accordance with the provision of IAS 16 "Property, Plant and Equipment". Depreciation is charged on additions made during the year from the month in which those assets are put into ready for use. Depreciation is charged on all

the fixed assets except land and land development on reducing balance method at the following rates.

| Particular of Assets | Rate of Depreciation |
|------------------------|----------------------|
| Building | 2.5% |
| Plant & Machinery | 10% |
| Internal Road | 10% |
| Installations | 10% |
| Equipment | 10% |
| Computers | 30% |
| Furniture & Fixtures | 10% |
| Motor vehicles | 20% |
| Spare & Loose Tools | 30% |
| Library Books | 30% |
| Temporary Construction | 30% |

Depreciation methods, useful lives and residual values are reviewed after each reporting period. No estimate of Property, Plant and equipment was revised during the year.

Impairment

The carrying amounts of property, plant and equipment are reviewed at each reporting date to determine whether there is any indication of impairment loss. If any such indication exists, recoverable amount is estimated to determine the extent of the impairment loss, if any. Impairment loss is recorded on judgmental basis, for which provision may differ in the future years based on the actual experience.

Disposal of property, plant and equipment

An item of Property, Plant and Equipment is removed from the statement of financial position when it is disposed off or when no future economic benefits are expected from its use or disposal. The gain or loss on the disposal of an item of Property, Plant and Equipment is included in the statement of income of the period in which the de-recognition occurs.

Capital work in progress

Property, plant and equipment under construction / acquisition have been accounted for as capital work-in-progress until construction / acquisition is completed and measured at cost.

3.2 Intangible assets and research and development expenditures

Intangible assets are stated at cost less provisions for amortization and impairments, if any. License,

patents, know-how and marketing rights acquired are amortized over their estimated useful lives, using the straight line basis, from the time they are available for use. The cost of acquiring and developing computer software for internal use and internet sites for external use are capitalized as intangible assets where the software or site supports a significant business system and the expenditure leads to the creation of a durable asset.

In compliance with the requirements of IAS 38 "Intangible Assets", research, development and experimental costs are usually absorbed as revenue charges as and when incurred. However, the research and development expenditures that is definite to yield benefit to the Group and is material in the Group's and/ local context, are capitalized as per IAS-38.

3.3 Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds as per IAS 23: Borrowing Costs.

3.4 Revenue

The Group recognises as revenue the amount that reflects the consideration to which the Group expects to be entitled in exchange for goods or services when (or as) it transfers control to the customer. To achieve that core principle, this standard establishes a five-step model as follows:

- Identify the contract with a customer;
- Identify the performance obligations in the contract;
- Determine the transaction price;
- Allocate the transaction price to the performance obligations in the contract; and
- Recognise revenue when (or as) the entity satisfies a performance obligation.

Considering the five steps model, the Group recognises revenue when (or as) the Group satisfies a performance obligation by transferring promised goods to a customer. Goods are considered as transferred when (or as) the customer obtains control of those goods. Revenue from sale of goods is measured at the fair value of the consideration received or receivable net of returns and allowances, trade discounts, rebates and Value Added Tax (VAT).

Sale of goods

Revenue from the sale of goods is recognised when

control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods. The Group has generally concluded that it is the principal in its revenue arrangements because it typically controls the goods or services before transferring them to the customer.

Profit on bank deposits

Profit on bank deposits have been accounted on accrual basis.

Dividends

Revenue is recognised when the group's right to receive the payment is established, which is generally the date when shareholders approve the dividend.

3.5 Financial instruments

IFRS 9 sets out requirements for recognising and measuring financial assets, financial liabilities and some contracts to buy or sell non-financial items.

The details of new significant accounting policies and the nature and effect of the changes to previous accounting policies are set out below.

Classification and measurement of financial assets and financial liabilities

IFRS 9 largely retains the existing requirements in IAS 39 for the classification and measurement of financial liabilities. However, it eliminates the previous IAS 39 categories for financial assets of held to maturity, loans and receivables and available for sale.

The adoption of IFRS 9 has not had a significant effect on the group's accounting policies related to financial liabilities. The impact of IFRS 9 on the classification and measurement of financial assets is set out below.

Under IFRS 9, on initial recognition, a financial asset is classified as measured at: amortised cost; Fair Value through Other Comprehensive Income (FVOCI) - debt investment; Fair Value through Other Comprehensive Income (FVOCI) - equity investment; or Fair Value Through Profit or Loss (FVTPL). The classification of financial assets under IFRS 9 is generally based on the business model in which a financial asset is managed and its contractual cash flow characteristics. Derivatives embedded in contracts where the host is a financial asset in the scope of the standard are never separated. Instead, the hybrid financial instrument as a whole is assessed for classification.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

- a. it is held within a business model whose objective is to hold assets to collect contractual cash flows; and

b. its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

a. it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and

b. its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the group may irrevocably elect to present subsequent changes in the investment's fair value in OCI. This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL.

A financial asset (unless it is a trade receivable without a significant financing component that is initially measured at the transaction price) is initially measured at fair value plus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition.

The following accounting policies apply to the subsequent measurement of financial assets.

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

Financial assets at amortised cost

These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on de-recognition is recognized in profit or loss. Trade receivables are classified as financial assets measured at amortised cost.

Debt investments at FVOCI

These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognised in profit or loss. Other net gains and losses are recognised in OCI. On de-recognition, gains and losses accumulated in OCI are reclassified to profit or loss.

Equity investments at FVOCI

These assets are subsequently measured at fair value. Dividends are recognised as income in profit

or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are never reclassified to profit or loss.

Impairment of financial assets

IFRS 9 replaces the 'incurred loss' model in IAS 39 with an 'expected credit loss' (ECL) model. The new impairment model applies to financial assets measured at amortised cost, contract assets and debt investments at FVOCI, but not to investments in equity instruments.

The financial assets at amortised cost consist of trade receivables, cash and cash equivalents, and corporate debt securities. The group measures loss allowances at an amount equal to ECL from trade receivables.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the group considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on The group's historical experience and informed credit assessment and including forward-looking information.

The group considers a financial asset to be in default when the debtor is unlikely to pay its credit obligations to the group in full, without recourse by The group to actions such as realizing security (if any is held).

Measurement of Expected Credit Losses (ECL)

ECLs are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the entity in accordance with the contract and the cash flows that the group expects to receive). ECLs are discounted at the effective interest rate of the financial asset.

Presentation of impairment

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets. For debt securities at FVOCI, the loss allowance is recognised in OCI, instead of reducing the carrying amount of the asset.

Impairment losses related to trade receivables and others, including contract assets, are presented separately in the notes to the financial statement.

3.6 Impairment of Non-financial assets

The carrying amounts of the Group's non-financial assets (other than inventories) are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication

exists, then the asset's recoverable amount is estimated in order to determine the extent of impairment loss (if any). Where it is not possible to determine the recoverable amount of an individual asset, the Group estimates the recoverable amount of the Cash Generating Unit (CGU) to which the asset belongs. An impairment loss is recognised if the carrying amount of an asset or its CGU exceeds its recoverable amount.

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU.

Impairment losses are recognised in profit or loss. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation, if no impairment loss had been recognised.

3.7 Inventories

Inventories consisting of raw materials, work in progress, finished goods are valued at lower of cost and net realizable value. Cost of inventories include expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Cost of inventories is determined by using the weighted average cost formula. Where necessary, allowance is provided for damaged, obsolete and slow-moving items to adjust the carrying amount of inventories to the lower of cost and net realizable value. Net realizable value is based on estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

3.8 Cash and cash equivalents

Cash and cash equivalents consists of cash on hand and with banks on current accounts, deposit accounts and short term investments which are held and available for use by the group without any restriction. There is insignificant risk of change in value of the same.

3.9 Earnings Per Share (EPS)

Earnings Per Share (EPS) are calculated in accordance with the International Accounting Standard IAS- 33 "Earnings Per Share".

Basic earnings per share

Basic earnings per share is calculated by dividing the profit or loss attributable to ordinary equity holders

of the entity by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share

For the purpose of calculating diluted earnings per shares, an entity adjusts profit or loss attributable to each ordinary equity holders of the entity, and weighted average number of shares outstanding, for the effects of all dilutive potential ordinary shares. Diluted EPS is only calculated where the group has commitment to issue ordinary share in future at reporting date. No such commitment is hold by group at reporting date.

3.10 Foreign currency transactions

Foreign currency transactions are recorded, on initial recognition in the functional currency at the spot exchange rate ruling at the transaction date.

At the end of each reporting period in compliance with the provision of IAS 21: The Effects of Changes in Foreign Exchange Rates.

a) Foreign currency monetary items are translated using the closing rate.

b) Non-monetary items that are measured in terms of historical costs in a foreign currency are translated using the exchange rate at the date of the transaction.

c) Non-monetary items that are measured at fair value in a foreign currency is translated using the exchange rate at the date when the fair value is determined.

Exchange differences arising on the settlement of monetary items or on translating monetary items at rate different from those at which they were translated on initial recognition during the period or in previous financial statements is recognized in profit or loss in the period in which they arise.

Amount in FCAD ERQ Account and any other foreign currency balance have been translated into taka at the reporting date at the exchange rate prevailing on that date and gain/(loss) have been accounted for as other income/(loss) in statement of profit or loss and comprehensive income.

3.11 Employee benefits

The group maintains both defined contribution plan and defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective trust deeds and rules. Both of the plans are funded and are recognised/approved under Income Tax Ordinance 1984 from National Board of Revenue (NBR).

(a) Defined contribution plan (provident fund)

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contribution to defined contribution plans are recognised as an employee benefit expense in profit or loss in the period during which related services are rendered by employees. Advance contributions are recognised as an asset to the extent that a cash refund or a reduction in future payment is available.

The IBN SINA Pharmaceutical Industry PLC has a separate recognised provident fund scheme. All permanent employees of The IBN SINA Pharmaceutical Industry PLC contribute 10% of their basic salary to the provident fund and the group makes matching contributions.

The group recognises contribution to defined contribution plan as an expense when an employee has rendered related services in exchange for such contribution. The legal and constructive obligation is limited to the amount The IBN SINA Pharmaceutical Industry PLC agrees to contribute to the fund.

(b) Defined benefit plan (gratuity)

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The employee gratuity plan is considered as defined benefit plan as it meets the recognition criteria. The group's obligation is to provide the agreed benefits to current and former employees. The net defined benefit liability/(asset) in respect of a defined benefit plan is recognised in the statement of financial position.

Current service cost, past service cost and gain/loss on settlement and net interest on the net defined benefit liability/(asset) are recognized in profit or loss. Service cost and gain/loss on settlement are classified as personnel expense.

The gratuity is calculated for all the employees prescribed by the rates as per Labor Act 2006 (as amended to 2018) for their service with the group. The gratuity fund is administered by the Board of Trustees.

Superannuation Fund:

The group has established a Superannuation Fund in the year 2013 to extend financial help to the employees and their family members as per rules in case of severe diseases, physical disability, death and retirement. Every year the Company contributed to the Fund and will continue its support in the coming days.

Workers' Profit Participation Fund (WPPF)

The Company provides 5% of its profit before Tax after charging contribution to WPPF in accordance with Bangladesh Labor Act, 2006 (as amended to 2018)

(c) Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.

3.12 Accruals, provisions and contingencies

(a) Accruals

Accruals are liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees. Accruals are reported as part of trade and other payables.

(b) Provisions

A provision is recognised in the statement of financial position when the company has a legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provision is ordinarily measured at the best estimate of the expenditure required to settle the present obligation at the reporting date. Where the group expects some or all of a provision to be reimbursed, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the income statement net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. During the reporting year the group has made sufficient provisions where applicable.

(c) Contingencies

A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the group; or a present obligation that arises from past events but is not recognised because it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation; or the amount of the obligation cannot be measured with sufficient reliability.

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence

of one or more uncertain future events not wholly within the control of the group. At the reporting date the group does not have any contingent asset.

Contingent liabilities and assets are not recognised in the statement of financial position of the group.

3.13 Operating Segments

No geographical segment reporting is applicable for the Group as required by IFRS 08: Operating Segments, as the Group operates in a single geographical area and has a single business line of product i.e. manufacturing and selling of medicine.

3.14 Statement of cash flows

The Statement of Cash Flows has been prepared in accordance with the requirements of IAS 7: Statement of Cash Flows. The cash generating from operating activities has been reported using the Direct Method as prescribed by the Securities and Exchange Rules, 1987 and as the benchmark treatment of IAS 7 whereby major classes of gross cash receipts and gross cash payments from operating activities are disclosed.

3.15 Related party disclosures

As per International Accounting Standards IAS-24: 'Related Party Disclosures', parties are considered to be related if one of the parties has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions. The Group carried out transactions in the ordinary course of business on an arm's length basis at commercial rates with its related parties. Related party disclosures have been given in Note 36.

3.16 Income tax

Income tax expense comprises current and deferred taxes. Income tax expense is recognised in profit or loss except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity in accordance with IAS 12: Income Tax.

3.17 (a) Current tax

Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous periods. The tax rate used for the reporting period was 22.5% as a publicly traded company.

3.17 (b) Deferred tax

Deferred tax is recognized as income or an expense amount within the tax charge, and included in the net profit or loss for the period. Deferred tax relating to items dealt with other comprehensive income is recognized as tax relating to other comprehensive

income within the statement of profit or loss and other comprehensive income.

Taxable Temporary difference

A deferred tax liability is recognised for all taxable differences, except to the extent that the deferred tax liability arises from the initial recognition of goodwill; or the initial recognition of an asset or liability in a transaction which is not a business combination; and at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

Revaluations to fair value - Investment in marketable securities

The revaluation does not affect taxable profits in the period of revaluation and consequently, the tax base of the asset is not adjusted. Hence a temporary difference arises. This is provided for in full based on the difference between carrying amount and tax base. An upward revaluation is therefore given rise to a deferred tax liability.

Deductible temporary difference

A deferred tax asset is recognised for all deductible temporary differences to the extent that it is probable that taxable profit will be available against which the deductible temporary difference can be utilized, unless the deferred tax asset arises from the initial recognition of an asset or liability in a transaction that is not a business combination; and at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

3.18 Events after the reporting period

Events after the reporting period that provide additional information about the group's position at the statement of financial position date are reflected in the financial statements as per International Accounting Standards IAS-10: 'Events after the Reporting Period'.

All material events occurring after the balance sheet date have been considered and where necessary, adjusted for or disclosed.

3.19 Compliance with financial reporting standards as applicable in Bangladesh

The Group as per Para-12 of Securities & Exchange Rule-1987, with the following International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS) as adopted by The Institute of Chartered Accountants of Bangladesh (ICAB) and subsequently adopted by the Financial Reporting Council, Bangladesh in preparing the financial statements.

| Sl. No. | IAS No. | IAS Title | Compliance Status |
|---------|---------|--|-------------------|
| 1 | 1 | Presentation of Financial Statements | Complied |
| 2 | 2 | Inventories | Complied |
| 3 | 7 | Statement of Cash Flows | Complied |
| 4 | 8 | Accounting Policies, Changes in Accounting Estimates and Errors | Complied |
| 5 | 10 | Events after the Reporting Period | Complied |
| 6 | 12 | Income Taxes | Complied |
| 7 | 16 | Property, Plant & Equipment | Complied |
| 8 | 19 | Employee Benefits | Complied |
| 9 | 20 | Accounting for Government Grants and Disclosure of Government Assistance | Not Applicable |
| 10 | 21 | The Effects of Changes in Foreign Exchange Rates | Complied |
| 11 | 23 | Borrowing Cost | Complied |
| 12 | 24 | Related Party Disclosures | Complied |
| 13 | 26 | Accounting and Reporting by Retirement Benefit Plans | Not Applicable |
| 14 | 27 | Separate Financial Statements | Complied |
| 15 | 28 | Investments in Associates and joint ventures | Complied |
| 16 | 29 | Financial Reporting in Hyperinflationary Economics | Not Applicable |
| 17 | 31 | Interest in Joint Ventures | Not Applicable |
| 18 | 32 | Financial Instruments: Presentation | Complied |
| 19 | 33 | Earnings per Share | Complied |
| 20 | 34 | Interim Financial Reporting | Complied |
| 21 | 36 | Impairment of Assets | Complied |
| 22 | 37 | Provisions, Contingent Liabilities and Contingent Assets | Complied |
| 23 | 38 | Intangible Assets | Complied |
| 24 | 40 | Investment Property | Not Applicable |
| 25 | 41 | Agriculture | Not Applicable |

| Sl. No. | IFRS No. | IFRS Title | Compliance Status |
|---------|----------|--|-------------------|
| 1 | 1 | First-time adoption of International Financial Reporting Standards | Not Applicable |
| 2 | 2 | Share-based Payment | Not Applicable |
| 3 | 3 | Business Combinations | Not Applicable |
| 4 | 4 | Insurance Contracts | Not Applicable |
| 5 | 5 | Non-current Assets Held for Sale and Discontinued Operations | Complied |
| 6 | 6 | Exploration for and Evaluation of Mineral Resources | Not Applicable |
| 7 | 7 | Financial Instruments: Disclosures | Complied |
| 8 | 8 | Operating Segments | Complied |
| 9 | 9 | Financial Instrument | Complied |
| 10 | 10 | Consolidated Financial Statements | Complied |
| 11 | 11 | Joint Arrangements | Not Applicable |
| 12 | 12 | Disclosure of Interests in other Entities | Complied |
| 13 | 13 | Fair Value Measurement | Complied |
| 14 | 14 | Regulatory Deferral Accounts | Not Applicable |
| 15 | 15 | Revenue from Contracts with Customers | Complied |
| 16 | 16 | Lease | Complied |

3.20 Leases

IFRS 16 introduces a single, on-balance sheet lease accounting model for lessees. A lessee recognises a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. There are recognition exemptions for short-term leases and leases of low-value items. The rental payment of short term (temporary) and low value lease is charged as expenses when they incurred.

Upon initial recognition of lease liability, subsequently it has been accounted for using amortised cost. Meaning that initial liability plus financial cost at group's incremental borrowing cost less rental payment.

Lease Liabilities

Previously, the Group recognised operating lease expense on a straight-line basis over the term of the lease, and recognised liabilities only to the extent that there was a timing difference between actual lease payments and the expense recognised.

The Group has no finance lease.

Lease Assets (Right of Use Of Assets)

The lease assets are depreciated over its useful life on monthly basis using straight-line method.

3.21 Changes in accounting policies

The Group has consistently applied the accounting policies to all periods presented in these consolidated financial statements.

| | | AMOUNT IN TAKA | |
|--|------------|----------------------|----------------------|
| 04. PROPERTY, PLANT AND EQUIPMENT | | 30 June 2022 | 30 June 2021 |
| Cost | | | |
| Opening balance | | 3,221,268,535 | 2,872,974,134 |
| Addition during the year | | 322,568,027 | 352,617,686 |
| Disposal/Adjustment during the year | | - | (4,323,285) |
| Closing balance | | 3,543,836,562 | 3,221,268,535 |
| Accumulated Depreciation | | | |
| Opening balance | | 1,054,394,091 | 869,527,947 |
| Charged during the year | | 199,301,082 | 188,972,041 |
| Disposal/Adjustment during the year | | - | (4,105,898) |
| Closing balance | | 1,253,695,173 | 1,054,394,090 |
| Closing balance of written down value (WDV) | | 2,290,141,389 | 2,166,874,444 |
| Assets held under disposal group | Note-46.05 | (76,881,940) | - |
| | | 2,213,259,449 | 2,166,874,444 |

The factory land and land development (803 decimal) and building are pledged as security for long term and short term bank finance of the company. Please see the annexure -A.

04 A. CONSOLIDATED PROPERTY, PLANT AND EQUIPMENT

| | | |
|--|----------------------|----------------------|
| The IBN SINA Pharmaceutical Industry PLC | 2,290,141,389 | 2,166,874,444 |
| The IBN SINA API Industry Ltd. | 52,347,859 | 42,859,803 |
| | 2,342,489,248 | 2,209,734,247 |

05. CAPITAL WORK-IN-PROGRESS

A) Construction work-in-progress (Building)

| | | |
|--|-------------------|-------------------|
| Opening balance | 72,549,664 | 42,997,913 |
| Addition during the year | 67,054,426 | 29,551,751 |
| Transferred to property, plant and equipment | (72,549,664) | - |
| Closing balance | 67,054,425 | 72,549,664 |

B) Machinery in transit and installation

| | | |
|--|--------------------|--------------------|
| Opening balance | 28,172,756 | 180,540,678 |
| Addition during the year | 156,577,136 | 220,944,592 |
| Transferred to property, plant and equipment | (150,870,977) | (373,312,514) |
| Closing balance | 33,878,914 | 28,172,756 |
| | 100,933,339 | 100,722,420 |

i) A new building is being constructed in the factory premises located at Shafipur, Gazipur to increase the overall production capacity of The IBN SINA Pharmaceutical Industry PLC. The amount of machinery in transit represents the amount for opening the LC for the procurement of machineries for newly constructed factory building and increasing production capacity of existing factory which have not received yet.

05.A CONSOLIDATED CAPITAL WORK-IN-PROGRESS

A) Construction work-in-progress (Building)

| | | |
|--|--------------------|-------------------|
| Opening balance | 83,236,939 | 48,757,241 |
| Addition during the year | 92,364,129 | 34,479,698 |
| Transferred to property, plant and equipment | (72,549,664) | - |
| Closing balance | 103,051,403 | 83,236,939 |

B) Machinery in transit and installation

| | | |
|--|--------------------|--------------------|
| Opening balance | 28,172,756 | 180,540,678 |
| Addition during the year | 163,900,163 | 220,944,592 |
| Transferred to property, plant and equipment | (150,870,977) | (373,312,514) |
| Closing balance | 41,201,941 | 28,172,756 |
| | 144,253,344 | 111,409,695 |

05.B RIGHT OF USE ASSETS (ROU)**Cost:**

| | | |
|-------------------------------------|--------------|------------|
| Opening balance | 62,623,935 | 62,623,935 |
| Addition during the year | 124,022,667 | - |
| Disposal/Adjustment during the year | (56,394,000) | - |

Closing balance**Accumulated Depreciation:**

| | | |
|-------------------------------------|--------------|--------------|
| Opening balance | 53,057,823 | (26,436,339) |
| Addition during the year | 24,359,839 | (26,621,484) |
| Disposal/Adjustment during the year | (56,394,000) | - |

Closing balance**Closing balance of Written Down Value (WDV)****06. INVESTMENT IN MARKETABLE SECURITIES (FAIR VALUE)**

| | | |
|---|------------|-----------|
| Exim Bank Limited | 3,597,000 | 523,160 |
| First Security Islami Bank Ltd. | 15,900,000 | - |
| Shahjalal Islami Bank Ltd. | 1,990,000 | - |
| Al-Arafa Islami Bank Ltd. | 2,560,000 | - |
| Social Islami Bank Ltd | 2,126,250 | - |
| Islami Bank Bangladesh Ltd. (IBBL) in MPB | 4,941,135 | 4,656,555 |

The above investment in marketable securities are designated as Fair Value through other comprehensive income by the management. These are measured at fair value and presented as non-current asset. Unrealized gain/(loss) from the above investment were recognized in other comprehensive income. Please see the annexure B.

07. INVESTMENT IN ASSOCIATES**Investment in shares**

| | | |
|-----------------|------------|------------|
| Opening balance | 60,000,000 | 60,000,000 |
| Less: Disposal | 60,000,000 | - |

Post acquisition cumulative profit/(loss)

| | | |
|---|-------------|-------------|
| Opening retained earnings balance of loss | (8,310,495) | (6,383,565) |
| Add: Current year loss | (1,286,976) | (1,926,929) |
| Add: Gain on disposal | 9,597,471 | - |

Proportion of ownership

Investment in associate have been valued at cost.
No loan or advance has been given to associate company.

07.1 INVESTMENT IN SUBSIDIARY

| | | |
|------------------------------------|-------------|------------|
| The IBN SINA API Industry Ltd. | 154,999,800 | 99,999,800 |
| The IBN SINA Natural Medicine Ltd. | 30,000,000 | 30,000,000 |
| The IBN SINA Polymer Industry Ltd. | 39,000,000 | 6,500,000 |

- The IBN SINA API Industry Ltd. is a 99.99% owned subsidiary company. Tk.5.50 crore have been paid during the year as a part of share capital.
- The IBN SINA Natural Medicine Ltd. is a 99.99% owned subsidiary company.
- The IBN SINA Polymer Industry Ltd. is a 65% owned subsidiary company. Tk.3.25 crore have been paid during the year as a part of share capital.

| | AMOUNT IN TAKA | |
|--|--------------------|---------------------|
| | 30 June 2022 | 30 June 2021 |
| 05.B RIGHT OF USE ASSETS (ROU) | | |
| Cost: | | |
| Opening balance | 62,623,935 | 62,623,935 |
| Addition during the year | 124,022,667 | - |
| Disposal/Adjustment during the year | (56,394,000) | - |
| Closing balance | 130,252,602 | 62,623,935 |
| Accumulated Depreciation: | | |
| Opening balance | 53,057,823 | (26,436,339) |
| Addition during the year | 24,359,839 | (26,621,484) |
| Disposal/Adjustment during the year | (56,394,000) | - |
| Closing balance | 21,023,662 | (53,057,823) |
| Closing balance of Written Down Value (WDV) | 109,228,940 | 9,566,112 |
| 06. INVESTMENT IN MARKETABLE SECURITIES (FAIR VALUE) | | |
| Exim Bank Limited | 3,597,000 | 523,160 |
| First Security Islami Bank Ltd. | 15,900,000 | - |
| Shahjalal Islami Bank Ltd. | 1,990,000 | - |
| Al-Arafa Islami Bank Ltd. | 2,560,000 | - |
| Social Islami Bank Ltd | 2,126,250 | - |
| Islami Bank Bangladesh Ltd. (IBBL) in MPB | 4,941,135 | 4,656,555 |
| | 31,114,385 | 5,179,715 |
| 07. INVESTMENT IN ASSOCIATES | | |
| Investment in shares | | |
| Opening balance | 60,000,000 | 60,000,000 |
| Less: Disposal | 60,000,000 | - |
| | - | 60,000,000 |
| Post acquisition cumulative profit/(loss) | | |
| Opening retained earnings balance of loss | (8,310,495) | (6,383,565) |
| Add: Current year loss | (1,286,976) | (1,926,929) |
| Add: Gain on disposal | 9,597,471 | - |
| | - | (8,310,495) |
| | | 51,689,505 |
| Proportion of ownership | 0% | 40% |
| Investment in associate have been valued at cost. No loan or advance has been given to associate company. | | |
| 07.1 INVESTMENT IN SUBSIDIARY | | |
| The IBN SINA API Industry Ltd. | 154,999,800 | 99,999,800 |
| The IBN SINA Natural Medicine Ltd. | 30,000,000 | 30,000,000 |
| The IBN SINA Polymer Industry Ltd. | 39,000,000 | 6,500,000 |
| | 223,999,800 | 136,499,800 |

AMOUNT IN TAKA

30 June 2022

30 June 2021

08. INVENTORIES

| | | |
|---------------------------|-----------------------------|--------------------|
| Raw materials | 301,656,999 | 203,135,206 |
| Packing materials | 135,762,831 | 112,592,756 |
| Work-in-process | 93,570,389 | 87,572,144 |
| Finished goods | 302,212,680 | 222,215,206 |
| Physicians' samples | 4,145,856 | 3,638,179 |
| Pad & literature | 3,686,249 | 2,907,461 |
| Spares & stores | 218,832 | 183,882 |
| Indirect materials | 316,022 | 273,393 |
| Printing & stationery | 343,295 | 274,563 |
| Laboratory chemicals | 194,369 | 189,537 |
| Material in transit | 164,925,529 | 148,778,003 |
| | 1,007,033,051 | 781,760,330 |
| Inventories held for sale | Note-46.05 (117,655,032) | - |
| | 889,378,019 | 781,760,330 |

i) The inventory quantity can not be disclosed as some of material contain in liter, some are in pieces , some are in box and some are in kg, gram, milligram and ton as such quantity can not be inserted.

ii) There is no damage goods or slow moving item in the inventory list.

iii) As part of loan condition all of the company's inventory are pledged as security for loan finance of the company.

iv) Inventory for Raw materials , Packing materials, Work In Process, Finished goods and pad & literature increased during the period for ensuring smooth supply of products.

08.A CONSOLIDATED INVENTORIES

| | | |
|-----------------------|----------------------|--------------------|
| Raw materials | 302,191,912 | 203,538,531 |
| Packing materials | 135,762,831 | 112,592,756 |
| Work-in-process | 93,570,389 | 87,572,144 |
| Finished goods | 302,212,680 | 222,215,206 |
| Physicians' samples | 4,145,856 | 3,638,179 |
| Pad & literature | 3,686,249 | 2,907,461 |
| Spares & stores | 218,832 | 183,882 |
| Indirect materials | 316,022 | 273,393 |
| Printing & stationery | 343,295 | 274,563 |
| Laboratory chemicals | 194,369 | 189,537 |
| Material in transit | 164,925,529 | 148,778,003 |
| | 1,007,567,964 | 782,163,655 |

09. TRADE AND OTHER RECEIVABLES

| | | |
|-------------------------------------|----------------------------|-------------------|
| Trade receivable | 43,609,681 | 23,609,681 |
| Receivable from provident fund (PF) | 1,073,348 | 613,125 |
| Dividend receivable | 1,547,169 | 394,692 |
| Other receivable-toll charge | 7,595,101 | 2,653,787 |
| | 53,825,299 | 27,271,285 |
| Trade receivable held for sale | Note-46.05 (13,632,698) | - |
| | 40,192,601 | 27,271,285 |

i) Amount are receivables from customers mainly different hospitals, medical colleges, clinics, diagnostic centers. No amount was due from the directors (including the Managing Director), managers and other officers of the company or any of them either severally or jointly with any other person.

ii) Other receivable increased during the year as few month toll charge bill remain receivable.

10. ADVANCES, DEPOSITS & PREPAYMENTS

a. Advances against

| | | |
|---------------------------|-------------------|-------------------|
| Salary | 3,913,210 | 3,663,147 |
| Expenses/works/others | 9,986,634 | 7,106,346 |
| Depot rent | 8,641,447 | 11,150,455 |
| Motor cycles-to employees | 9,602,277 | 7,606,797 |
| Others | 679,814 | 712,908 |
| | 32,823,382 | 30,239,653 |

b. Income tax

| | | |
|--------------------------|--------------------|--------------------|
| Opening balance | 290,522,128 | 133,670,451 |
| Addition | 216,670,678 | 186,565,279 |
| Adjusted during the year | (308,981,678) | (29,713,602) |
| | 198,211,128 | 290,522,128 |

c. Deposits

| | | |
|----------------|-------------------|-------------------|
| Security money | 22,331,836 | 21,320,410 |
|----------------|-------------------|-------------------|

d. Pre payments

| | | |
|-----------------|--------------------|--------------------|
| Value Added Tax | 7,177 | 4 |
| | 253,373,523 | 342,082,195 |

10.1 MATURITY ANALYSIS

| | | |
|---|--------------------|--------------------|
| Realisable/adjustable with in one year. | 231,712,523 | 320,421,195 |
| Realisable/adjustable after one year. | 21,661,000 | 21,661,000 |
| | 253,373,523 | 342,082,195 |

10.A CONSOLIDATED ADVANCES, DEPOSITS & PREPAYMENTS

a. Advances against

| | | |
|--|-------------------|-------------------|
| Salary | 3,913,210 | 3,663,147 |
| Expenses/works/others | 10,644,197 | 7,106,346 |
| Depot rent | 8,641,447 | 11,150,455 |
| Motor cycles-to employees | 9,602,277 | 7,606,797 |
| The IBN SINA API Industrial Park Services Ltd. | 25,000,000 | 25,000,000 |
| Others | 679,814 | 712,908 |
| | 58,480,945 | 55,239,653 |

b. Income tax

| | | |
|--------------------------|--------------------|--------------------|
| Opening balance | 290,597,362 | 133,671,271 |
| Addition | 216,766,483 | 186,639,692 |
| Adjusted during the year | (308,981,678) | (29,713,602) |
| | 198,382,167 | 290,597,362 |

c. Deposits

| | | |
|----------------|-------------------|-------------------|
| Security money | 22,331,836 | 21,320,410 |
|----------------|-------------------|-------------------|

d. Pre payments

| | | |
|-----------------|--------------------|--------------------|
| Value Added Tax | 7,177 | 4 |
| | 279,202,125 | 367,157,429 |

i) The company did not give any advance, deposit and prepayment to the director's of the company, subsidiary, associates and other connected party and employees advances are realised in normal course of business.

ii) Advance against works decrease during this year to meet up business needs.

iii) Advance income tax increase during this year to meet up regulatory requirement.

iv) Security money increase during this year as security money given by various parties.

11. CASH & CASH EQUIVALENTS

- a. Cash in hand
- b. Cash at banks
- c. Imprest cash

| AMOUNT IN TAKA | | |
|--|--------------------|------------|
| 30 June 2022 | 30 June 2021 | |
| 2,916,699 | 5,673,476 | |
| 231,587,781 | 219,815,023 | |
| 3,650,000 | 8,270,000 | |
| 238,154,480 | 233,758,499 | |
| CASH AT BANKS | | |
| a. With Islami Bank Bangladesh Ltd. In SND Accounts | 108,667,642 | 60,946,521 |
| In MSA Accounts | 767,441 | 750,812 |
| In FCAD ERQ Accounts | 31,373,076 | 5,899,575 |
| Cash with IBBL Securities Ltd. | 3,145,642 | - |
| b. With Al-Arafah Islami Bank Ltd. in SND/AWCA Accounts | 25,877,525 | 84,811,332 |
| c. With Prime Bank Ltd. in Current Account (Islamic banking branch) | 29,741 | 29,741 |
| d. With Shimanto Bank Ltd. in SND Account | 16,435 | 16,435 |
| e. With First Security Islami Bank Ltd. in SND Accounts | 28,944,415 | 40,462,040 |
| f. With Sonali Bank Ltd. in ERQ Account | 528,528 | 520,520 |
| g. With Sonali Bank Ltd. in STD Account | 32,237,338 | 26,378,048 |
| 231,587,781 | 219,815,023 | |

- i) The bank reconciliation was performed at the year end and found in order.
- ii) Physical cash counting were taken place at the year end and no surplus or deficit was found.

11.A CONSOLIDATED CASH & CASH EQUIVALENTS

- a. Cash in hand
- b. Cash at banks
- c. Imprest cash

| | | |
|---|--------------------|--------------------|
| 2,916,699 | 5,673,476 | |
| 336,038,786 | 267,292,407 | |
| 3,650,000 | 8,270,000 | |
| 342,605,485 | 281,235,883 | |
| Authorized | | |
| 50,000,000 Ordinary Shares of Tk. 10 each | 500,000,000 | 500,000,000 |
| Issued, Subscribed & Paid-Up : | | |
| 31,243,627 Ordinary Shares of Tk. 10 each fully paid up in cash | 312,436,270 | 312,436,270 |

12. SHARE CAPITAL

Authorized

50,000,000 Ordinary Shares of Tk. 10 each

Issued, Subscribed & Paid-Up :

31,243,627 Ordinary Shares of Tk. 10 each fully paid up in cash

The Shareholdings consist of :

Holder

Sponsor
Institutions
General Public

| No. of Holders | Total Holdings | Percentage |
|----------------|-------------------|----------------|
| 1 | 13,843,312 | 44.31% |
| 209 | 7,520,106 | 24.07% |
| 11,875 | 9,880,209 | 31.62% |
| 12,085 | 31,243,627 | 100.00% |

AMOUNT IN TAKA

30 June 2022

30 June 2021

The distribution schedule showing the number of share holders and their share holdings as on 30.06.2022 are as follows:

| Range of holdings | No. of Holders | Total Holdings | Percentage |
|-------------------------|----------------|-------------------|----------------|
| Less than 500 shares | 9,676 | 1,855,062 | 5.94% |
| 500 to 5,000 shares | 2,030 | 2,961,079 | 9.48% |
| 5,001 to 10,000 shares | 187 | 1,332,927 | 4.27% |
| 10,001 to 20,000 shares | 92 | 1,229,696 | 3.94% |
| 20,001 to 30,000 shares | 34 | 785,754 | 2.51% |
| 30,001 to 40,000 shares | 13 | 449,353 | 1.44% |
| 40,001 to 50,000 shares | 16 | 722,012 | 2.31% |
| Above 50,000 shares | 37 | 21,907,744 | 70.12% |
| | 12,085 | 31,243,627 | 100.00% |

The shares are listed with the Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The shares were quoted at Tk. 296.70 in the Dhaka Stock Exchange Limited as at 30.06.2022 and at Tk. 289.50 in the Chittagong Stock Exchange Limited as at 30.06.2022 respectively.

13. TAX HOLIDAY RESERVE

4,392,110

4,392,110

This represents provision made out of profit of Tax Holiday period in accordance with section 45 (2B) and section 46A (2) of Income Tax Ordinance 1984.

14. UNREALISED GAIN ON MARKETABLE SECURITIES

Closing market value of marketable securities

31,114,385

5,179,715

Less: Cost of marketable securities

31,876,149

5,018,507

Unrealised gain before adjustment of deferred tax

(761,764)

161,208

Less: Deferred tax on unrealised gain (loss)

76,176

16,121

Net unrealised gain/(loss) on marketable securities

(685,588)

145,087

15. RETAINED EARNINGS

Opening Balance

1,842,886,521

1,465,681,162

Dividend paid

(146,845,047)

(120,287,964)

Add: Net profit during the year

611,644,682

497,493,323

2,307,686,156

1,842,886,521

15.A CONSOLIDATED RETAINED EARNINGS

Opening Balance

1,829,226,006

1,460,390,581

Dividend paid

(146,845,047)

(120,287,964)

Add: Net profit during the year

605,867,013

489,123,389

2,288,247,972

1,829,226,006

15.B NON CONTROLLING INTEREST

The IBN SINA API Industry Ltd.

200

200

The IBN SINA Natural Medicine Ltd.

3,000

3,000

The IBN SINA Polymer Industry Ltd. (Paid by The IBN SINA Trust)

21,000,000

3,500,000

Add: Share of Profit/(Loss)

(344,008)

(151,618)

20,659,192

3,351,582

| | | AMOUNT IN TAKA | |
|---|---------|--------------------|--------------------|
| | | 30 June 2022 | 30 June 2021 |
| 16. LONG TERM FINANCE | | | |
| i) From Al-Arafah Islami Bank Ltd. Secured (Under Hire Purchase Shirkatul Melk-HPSM) | | 438,187,799 | 484,783,270 |
| Current maturity transferred to current liability | | | |
| i) From Al-Arafah Islami Bank Ltd. Secured (Under Hire Purchase Shirkatul Melk) | Note-21 | (70,181,410) | (65,162,205) |
| LONG TERM FINANCE - net off current maturity | | 368,006,389 | 419,621,065 |

- i) Loan amount represent the amounts which would be due for repayment after 12 (twelve) months from the date of Statement of Financial position @ 9% of profit.
- ii) The loan was taken from Al-Arafah Islami Bank Ltd. against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import capital machinery and motor vehicle under Hire Purchase Shirkatul Melk.
- iii) HPSM is repayable in 84 monthly equal installment.
- iv) Currently all of the company's HPSM and other loans are classified as standard by the Bank.
- v) Information regarding loan fall due after five years.

| | | |
|------------------------------------|--------------------|--------------------|
| Loan fall due from 2 to 5 years | 292,125,199 | 323,188,847 |
| Loan fall due from 6 to more years | 75,881,189 | 96,432,218 |
| | 368,006,389 | 419,621,065 |

17.A RETIREMENT BENEFIT OBLIGATIONS

| | | |
|----------------------------|----------------|---------------|
| Opening balance | 94,029 | 78,797 |
| Provision during the year | 97,965,798 | 86,531,199 |
| Less: Paid during the year | (97,325,123) | (86,515,967) |
| | 734,704 | 94,029 |

17.B LEASE LIABILITY

| | | |
|--|-------------------|------------------|
| Opening Balance | 4,363,520 | 25,369,109 |
| Addition during the year | 107,361,667 | - |
| Finance charge | 6,386,660 | 1,238,211 |
| Paid during the year | (21,305,048) | (22,243,800) |
| Closing balance | 96,806,799 | 4,363,520 |
| Less : Transferred to current maturity | (22,055,824) | (2,370,012) |
| | 74,750,975 | 1,993,508 |

- i) The company has lease against its Head Office and its Depot at Mohammadpur and Mirpur, Dhaka respectively.
- ii) Lease period is upto 31.10.2026.
- iii) Monthly rental payment is Tk.2,324,351.
- iv) Balance of rent advance as of June 30, 2022 of Tk. 15,994,333.
- v) Monthly adjustment Tk. 83,333.

18. DEFERRED TAX LIABILITY/(ASSETS)

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS 12 Income Taxes. Related deferred tax (expense)/income have been disclosed in note 19. The components of deferred tax assets and liabilities are given below:

| Particulars | Carrying amount | Tax base value | Taxable (deductible) temporary difference | Applicable tax rate | Deferred tax liability/(assets) |
|--|----------------------|----------------------|---|---------------------|---------------------------------|
| Property, plant and equipment | 2,290,141,389 | 1,696,833,341 | 593,308,048 | 20.00% | 118,661,610 |
| Gratuity | 98,059,828 | 97,325,123 | (734,705) | 20.00% | (146,941) |
| Lease | 12,422,141 | 15,994,333 | (3,572,192) | 20.00% | (714,438) |
| Unrealised gain on marketable securities | (761,764) | - | (761,764) | 10.00% | (76,176) |
| For the year 2021-2022 | 2,399,861,593 | 1,810,152,798 | 588,239,387 | | 117,724,054 |

| Particulars | Carrying amount | Tax base value | Taxable (deductible) temporary difference | Applicable tax rate | Deferred tax liability/(assets) |
|--|----------------------|----------------------|---|---------------------|---------------------------------|
| Property, plant and equipment | 2,166,874,444 | 1,637,826,077 | 529,048,367 | 22.50% | 119,035,883 |
| Gratuity | 86,609,997 | 86,515,967 | (94,030) | 22.50% | (21,157) |
| Lease | 5,202,592 | 5,920,500 | (717,908) | 22.50% | (161,529) |
| Unrealised gain on marketable securities | 161,208 | - | 161,208 | 10.00% | 16,121 |
| For the year 2020-2021 | 2,258,848,241 | 1,730,262,544 | 528,397,637 | | 118,869,318 |

| | AMOUNT IN TAKA | |
|--|--------------------|--------------------|
| | 30 June 2022 | 30 June 2021 |
| 19. DEFERRED TAX (EXPENSES)/INCOME | | |
| Closing balance of deferred tax liability | 117,724,054 | 118,869,317 |
| Opening balance of deferred tax liabilities | 118,869,317 | 108,988,015 |
| Total deferred tax expenses | (1,145,264) | 9,881,303 |
| Less/Add: Deferred tax expenses related to other comprehensive income | 92,297 | (39,721) |
| | (1,052,966) | 9,841,582 |
| 20. SHORT TERM FINANCE | | |
| A. From Al-Arafah Islami Bank Ltd. - Secured (Under Composite facilities LC-(MPI/TR)) | 534,291,102 | 377,502,715 |
| | 534,291,102 | 377,502,715 |

- i) Loan amount represent the amounts which would be due for repayment within 12 (twelve) months from the date of statement of financial position @ 9% of profit and 0.25% commission per quarter to be paid.
- ii) The loan was taken from Al-Arafah Islami Bank Ltd. against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import Pharmaceuticals raw materials, imported goods and to purchase business items from local market under Composite investment facilities LC/MPI/MIB/ TR/UPAS/ Baimuajjal agreement.
- iii) Short term loan is repayable with in twelve months.
- iv) Currently all of the company's MPI/UPAS and other loans are classified as standard by the Bank.

21. CURRENT PORTION OF LONG TERM FINANCE

| | | |
|--|-------------------|-------------------|
| i) From Al-Arafah Islami Bank Ltd.-Secured (Note-16) (Under Hire Purchase Shirkatul Melk) | 70,181,410 | 65,162,205 |
| ii) Current portion of lease | 22,055,824 | 2,370,012 |
| | 92,237,234 | 67,532,217 |

The amounts represent current maturity of long term finance obtained from Al-Arafah Islami Bank Ltd. and lease liability which are repayable within next 12 (Twelve) months from the date of Statement of Financial Position.

22. TRADE AND OTHER PAYABLE

| | | |
|---|--------------------|--------------------|
| Payable to suppliers | 165,514,675 | 231,649,393 |
| Accrued expenses | 94,826,462 | 101,855,213 |
| Security money received from employees and others | 7,867,814 | 8,438,345 |
| Workers' profit participation fund & welfare fund | 40,341,605 | 35,733,665 |
| | 308,550,556 | 377,676,616 |

- i) Payable to suppliers decreased during this period as higher amount was paid to suppliers.

| | AMOUNT IN TAKA | |
|---|--------------------|--------------------|
| | 30 June 2022 | 30 June 2021 |
| 22.A CONSOLIDATED TRADE AND OTHER PAYABLE | | |
| Payable to suppliers | 166,176,675 | 231,649,393 |
| Accrued expenses | 94,912,712 | 101,941,463 |
| Security money received from employees and others | 7,867,814 | 8,438,345 |
| Workers' profit participation fund & welfare fund | 40,341,605 | 35,733,665 |
| | 309,298,806 | 377,762,866 |
| 22.A.1 UNCLAIMED DIVIDEND : | | |
| Opening | 53,184,517 | 64,404,243 |
| Addition | 146,845,047 | 120,287,964 |
| Paid to share holders | (148,109,403) | (131,507,691) |
| Paid to Capital Market Stabilisation Fund | (29,281,978) | - |
| | 22,638,182 | 53,184,517 |
| 22.A.2 UNCLAIMED DIVIDEND : | | |
| Year-wise break-up of the above is as follows : | | |
| Previous years | - | 30,599,507 |
| 2017-18 | - | 5,594,304 |
| 2018-19 | 4,423,318 | 7,105,354 |
| 2019-20 | 7,996,366 | 9,885,352 |
| 2020-21 | 10,218,498 | - |
| | 22,638,182 | 53,184,517 |
| 23. INCOME TAX LIABILITY | | |
| Opening balance | 279,070,334 | 103,372,479 |
| Prior year tax assessment adjustment | 29,911,344 | 48,311,580 |
| Current tax provision | 165,042,064 | 157,099,877 |
| | 474,023,743 | 308,783,936 |
| Adjusted during the year | (308,981,678) | (29,713,602) |
| | 165,042,065 | 279,070,334 |
| 23.A CONSOLIDATED INCOME TAX LIABILITY | | |
| Opening balance | 279,296,238 | 103,375,142 |
| Prior year tax assessment adjustment | 29,911,344 | 48,311,580 |
| Current tax provision | 165,329,483 | 157,323,117 |
| | 474,537,065 | 309,009,840 |
| Adjusted during the year | (308,981,678) | (29,713,602) |
| | 165,555,387 | 279,296,238 |

i) Income tax liability decrease during this year as last year income tax assessment was completed.

ii) Tax rate is applicable as Finance Act 2022.

24. REVENUE

This is made up as follows:

Local revenue
Export revenue

Revenue from discontinued operations Note-46.4

| AMOUNT IN TAKA | |
|---------------------------------|---------------------------------|
| 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| 8,386,522,094 | 7,284,944,034 |
| 93,297,475 | 91,098,060 |
| 8,479,819,569 | 7,376,042,094 |
| (1,040,942,221) | (917,734,945) |
| 7,438,877,348 | 6,458,307,149 |

24. A. The above revenue represent the following

| Product Group | Unit | 2021-2022 | | 2020-2021 | |
|--------------------|--------|---------------|----------------------|---------------|----------------------|
| | | Quantity | Amount | Quantity | Amount |
| Tablet | Pcs | 1,346,046,065 | 3,213,453,208 | 1,149,069,488 | 2,636,147,892 |
| Capsule | Pcs | 328,765,219 | 1,741,621,910 | 283,102,393 | 1,507,190,653 |
| Dry Syrup / ORS | Bottle | 24,420,342 | 364,752,048 | 24,610,609 | 327,386,273 |
| Liquid Bottles | Bottle | 30,142,788 | 2,037,106,892 | 26,761,576 | 1,903,916,034 |
| Drops | Pcs | 6,154,193 | 393,396,027 | 6,474,745 | 352,897,243 |
| Ointment | Pcs | 4,913,622 | 165,843,582 | 4,240,247 | 129,000,097 |
| Injection | Pcs | 5,187,863 | 563,645,902 | 4,686,750 | 519,503,901 |
| Total Value | | | 8,479,819,569 | | 7,376,042,094 |

24.B. Timing of revenue recognition

Products transferred at a point in time

Products and services transferred over time

| | |
|----------------------|----------------------|
| 8,479,819,569 | 7,376,042,094 |
| - | - |
| 8,479,819,569 | 7,376,042,094 |

25. COST OF GOODS SOLD

This is arrived at as follows:

Raw materials consumed Note-25.1
Packing materials consumed Note-25.2

Opening work-in-process

Closing work-in-process

Total Consumption

Manufacturing expenses Note-26

Cost of Production

Opening finished goods

Closing finished goods

Cost of physicians' samples

Cost of goods sold for discontinued operations Note-46.4

| | |
|----------------------|----------------------|
| 2,476,203,036 | 2,202,808,334 |
| 1,504,817,261 | 1,286,163,244 |
| 3,981,020,298 | 3,488,971,579 |
| 87,572,144 | 70,297,526 |
| (93,570,389) | (87,572,144) |
| 3,975,022,053 | 3,471,696,961 |
| 1,054,309,691 | 891,070,063 |
| 5,029,331,744 | 4,362,767,023 |
| 222,215,206 | 165,834,854 |
| (302,212,680) | (222,215,206) |
| 4,949,334,270 | 4,306,386,671 |
| (35,584,820) | (31,061,773) |
| 4,913,749,450 | 4,275,324,899 |
| (609,575,765) | (535,223,020) |
| 4,304,173,685 | 3,740,101,879 |

25.1 RAW MATERIALS CONSUMED

This is arrived at as follows :

Opening stock

Purchases

Closing stock

| | |
|----------------------|----------------------|
| 203,135,206 | 162,965,057 |
| 2,574,724,829 | 2,242,978,483 |
| (301,656,999) | (203,135,206) |
| 2,476,203,036 | 2,202,808,334 |

25.2 PACKING MATERIALS CONSUMED

This is arrived at as follows :-

Opening stock

Purchases

Closing stock

| | |
|----------------------|----------------------|
| 112,592,756 | 100,936,884 |
| 1,527,987,336 | 1,297,819,116 |
| (135,762,831) | (112,592,756) |
| 1,504,817,261 | 1,286,163,244 |

| | AMOUNT IN TAKA | |
|--|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| 26. MANUFACTURING EXPENSES | | |
| Salary, wages & allowances | 543,733,041 | 461,972,226 |
| Travelling & Conveyance | 1,043,050 | 754,018 |
| Printing & stationery | 4,735,747 | 4,709,455 |
| Repairs & Maintenance-Building | 25,934,824 | 6,191,234 |
| Repairs & Maintenance- Machinery & Equipment | 67,487,978 | 55,548,597 |
| Vehicle fuel & maintenance | 12,041,275 | 11,642,479 |
| Medical expenses | 697,339 | 874,860 |
| Power & Fuel | 137,097,216 | 127,666,184 |
| Training expenses | 10,876 | 8,605 |
| Insurance Premium | 8,318,024 | 8,575,250 |
| Entertainment | 3,904,700 | 2,182,090 |
| Staff Welfare | 43,979,430 | 31,465,183 |
| Telephone, Fax, etc. | 1,757,206 | 1,407,762 |
| Fees & charges | 6,253,381 | 4,637,091 |
| Donation & subscription | - | 23,000 |
| Advertisement | - | 29,250 |
| News paper & periodicals | 26,650 | 79,745 |
| Staff Uniform | 2,395,017 | 3,438,459 |
| Laboratory chemicals & stores | 27,304,814 | 11,056,668 |
| Indirect materials | 9,065,643 | 7,143,720 |
| Depreciation | 158,276,497 | 151,663,828 |
| Damaged & lost goods | 244,876 | - |
| Sundry expenses | 2,108 | 360 |
| | 1,054,309,691 | 891,070,063 |

(a) The number of employees employed in the factory throughout the year who received aggregate remuneration less than Tk.36,000 was nil.

(b) The number of employees employed in the factory for part of the year who received aggregate remuneration less than Tk.3,000 per month was nil.

(c) Salary, wages & allowances include P.F. contribution of Tk. 13,450,524 and Gratuity of Tk.22,417,540.

(d) Cost of materials, expenses incurred for factory overhead and depreciation expense during the reporting period increased due to increase in revenue, increase in production and addition of fixed assets respectively.

| | AMOUNT IN TAKA | |
|---|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| 27. ADMINISTRATIVE EXPENSES | | |
| Salary, wages & allowances | 100,461,514 | 82,004,096 |
| Directors' remuneration | 13,500,000 | 11,750,000 |
| Directors' meeting fee | 1,521,300 | 1,491,600 |
| Travelling & conveyance | 2,775,542 | 2,837,611 |
| Repairs & maintenance-building & equipment | 7,790,056 | 4,441,448 |
| Vehicle fuel & maintenance | 3,755,175 | 3,023,104 |
| Audit fees | 373,750 | 633,500 |
| Medical expenses | 61,632 | 258,733 |
| Postage & stamp | 64,247 | 110,302 |
| Training expenses | 691,416 | 492,385 |
| Insurance premium | 591,300 | 385,377 |
| Entertainment | 3,600,318 | 1,700,357 |
| Staff uniform | 158,259 | 111,510 |
| Staff welfare | 2,524,949 | 2,689,821 |
| Telephone, fax, etc. | 1,297,898 | 1,344,330 |
| Fees & charges | 2,641,543 | 2,055,643 |
| Bank Charge | 531,090 | 433,778 |
| Donation & subscription | 334,767 | 20,000 |
| Advertisement | 5,340,878 | 5,808,323 |
| News paper & periodicals | 171,531 | 185,331 |
| Printing & stationery | 1,280,874 | 1,659,924 |
| Water, electricity & gas | 3,066,543 | 2,353,248 |
| Annual general meeting expenses | 1,886,615 | 1,238,252 |
| Expenses relating to dividend | 454,530 | 513,940 |
| Depreciation | 27,055,525 | 26,202,628 |
| Sundry expenses | 9,150 | 5,800 |
| Expenses relating to CSR | 4,007,260 | 1,108,724 |
| | 185,947,662 | 154,859,764 |
| Expenses related with discontinued operations Note-46.4 | (22,826,048) | (19,267,815) |
| | 163,121,613 | 135,591,949 |

(a) The number of employees employed in the administration department throughout the year who received aggregate remuneration less than Tk.36,000 was nil.

(b) Salary, wages & allowances include P.F. contribution of Tk. 3,512,820 and Gratuity of Tk.4,391,025.

(c) The number of employees employed in the administration department for part of the year who received aggregate remuneration less than Tk 3,000 per month was nil.

| | AMOUNT IN TAKA | |
|---|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| 27.01 CONSOLIDATED ADMINISTRATIVE EXPENSES | | |
| Salary, wages & allowances | 103,723,371 | 84,397,978 |
| Directors' remuneration | 13,500,000 | 11,750,000 |
| Directors' meeting fee | 1,521,300 | 1,491,600 |
| Travelling & conveyance | 2,775,542 | 2,837,611 |
| Repairs & maintenance-building & equipment | 7,790,056 | 4,441,448 |
| Vehicle fuel & maintenance | 3,755,175 | 3,023,104 |
| Audit fees | 460,000 | 719,750 |
| Medical expenses | 61,632 | 258,733 |
| Postage & stamp | 64,247 | 110,302 |
| Training expenses | 691,416 | 492,385 |
| Insurance premium | 591,300 | 385,377 |
| Entertainment | 3,600,318 | 1,700,357 |
| Staff uniform | 158,259 | 111,510 |
| Staff welfare | 2,524,949 | 2,689,821 |
| Telephone, fax, etc. | 1,297,898 | 1,344,330 |
| Research & development | 2,089,223 | 5,438,956 |
| Preliminary expenses | - | 780,416 |
| Fees & charges | 3,494,473 | 2,092,971 |
| Bank charge | 616,839 | 474,698 |
| Donation & subscription | 334,767 | 20,000 |
| Advertisement | 5,340,878 | 5,808,323 |
| News paper & periodicals | 171,531 | 185,331 |
| Printing & stationery | 1,280,874 | 1,659,924 |
| Water, electricity & gas | 3,066,543 | 2,353,248 |
| Annual general meeting expenses | 1,886,615 | 1,238,252 |
| Expenses relating to dividend | 454,530 | 513,940 |
| Depreciation | 27,320,218 | 26,467,321 |
| Sundry expenses | 9,150 | 5,800 |
| Expenses relating to CSR | 4,007,260 | 1,108,724 |
| | 192,588,364 | 163,902,209 |

28. SELLING & DISTRIBUTION EXPENSES

| | AMOUNT IN TAKA | |
|---|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| Salary, wages & allowances | 1,563,770,707 | 1,349,707,655 |
| Travelling & conveyance | 4,825,248 | 2,101,050 |
| Head office & sales centers rent | 21,620,190 | 24,036,790 |
| Printing & stationery | 7,865,206 | 10,070,423 |
| Repairs & maintenance-building & equipment | 6,493,801 | 5,938,224 |
| Vehicle fuel & maintenance | 21,106,975 | 17,117,107 |
| Medical expenses | 742,385 | 1,017,437 |
| Water, electricity & gas | 1,044,198 | 1,296,222 |
| Postage & stamp | 594,245 | 390,680 |
| Field forces conference expenses | 38,189,720 | 10,188,250 |
| Insurance premium | 2,750,277 | 2,006,166 |
| Entertainment | 1,888,417 | 1,157,517 |
| Training expenses | 3,279,826 | 926,525 |
| Staff welfare | 3,492,688 | 2,131,303 |
| Telephone, fax, etc. | 7,108,576 | 10,126,258 |
| Fees & charges | 424,621 | 536,179 |
| Advertisement | 479,294 | 30,000 |
| Incentive | 66,583,792 | 71,188,995 |
| Detailing bag & brief case | 1,272,065 | 854,076 |
| Field personnel expenses | 366,172,352 | 315,809,990 |
| Product development expenses | 1,817,771 | 672,395 |
| Product pad & literature | 30,816,253 | 27,863,875 |
| Promotional expenses | 41,895,568 | 36,497,216 |
| Physicians' samples | 43,396,122 | 37,880,210 |
| Market survey & research | 4,634,273 | 6,215,325 |
| Export expenses | 20,570,158 | 5,106,668 |
| Delivery expenses | 210,569,123 | 185,009,741 |
| Depreciation | 38,328,900 | 37,727,069 |
| Sundry expenses | 40,351 | - |
| Loss on sale of vehicle | - | 4,251,527 |
| Staff uniform | 209,565 | 316,516 |
| | 2,511,982,666 | 2,168,171,388 |
| Expenses related with discontinued operations Note-46.4 | (343,302,744) | (303,127,852) |
| | 2,168,679,922 | 1,865,043,536 |

(a) The number of employees employed in the selling & distribution department throughout the year who received aggregate remuneration less than Tk.36,000 was nil.

(b) Salary, wages & allowances include P.F. contribution of Tk.53,809,860 and Gratuity of Tk.71,157,233.

(c) The number of employees employed in the selling & distribution department for part of the year who received aggregate remuneration less than Tk.3,000 per month was nil.

(d) Field personnel expense increase due to increase of field personnel movement in order to increase sales.

(e) Delivery expense increase due to increase of sales representative movement in order to increase sales and covid-19.

29. OTHER INCOME

| | AMOUNT IN TAKA | |
|---|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| Dividend income/ IBBL-MPB | 1,617,169 | 825,234 |
| Profit on bank deposits | 753,849 | 890,349 |
| Gain on sale of motor vehicles | - | 1,216,631 |
| Foreign exchange fluctuation gain/(Loss) on FCAD ERQ accounts | (2,826,598) | (199,343) |
| Toll charge-Income | 14,010,938 | 6,023,817 |
| Gain on disposal-The IBN SINA Consumer Product Ltd. | 9,597,471 | - |
| Export Cash Incentive | 1,908,000 | 692,064 |
| Received from PF* | 1,073,348 | 2,251,834 |
| Miscellaneous income | 229,661 | 1,018,646 |
| | 26,363,837 | 12,719,232 |

*The amount of provident fund forfeiture has been returned during this period from The IBN SINA Pharmaceutical Industry PLC. Employees provident fund and also recognized as other income as per circular of Financial Reporting Council, Bangladesh no:179/FRC/FRM/Circular/2020/2 dated July 07, 2020.

29.1 CONSOLIDATED OTHER INCOME

| | | |
|---|-------------------|-------------------|
| Dividend income/ IBBL-MPB | 1,617,169 | 825,234 |
| Profit on bank deposits | 1,711,913 | 1,634,481 |
| Gain on sale of Motor Vehicles | - | 1,216,631 |
| Foreign exchange fluctuation gain/(Loss) on FCAD ERQ accounts | (2,826,598) | (199,343) |
| Toll charge-Income | 14,010,938 | 6,023,817 |
| Export Cash Incentive | 1,908,000 | 692,064 |
| Gain on disposal-The IBN SINA Consumer Product Ltd. | 9,597,471 | - |
| Received from PF | 1,073,348 | 2,251,834 |
| Miscellaneous income | 229,661 | 1,018,646 |
| | 27,321,901 | 13,463,364 |

30. WORKERS' P.P FUND & WELFARE FUND

| | | |
|------------------------|-------------------|-------------------|
| Continued operation | 37,235,050 | 32,870,986 |
| Discontinued operation | 3,106,555 | 2,862,679 |
| | 40,341,605 | 35,733,665 |

This represents 5% of net profit before tax after charging the contribution as per provision of the Bangladesh Labour Act, 2006 and is payable to workers as defined in the said Act.

31. INCOME TAX EXPENSES

| | | |
|---|--------------------|--------------------|
| Current Tax | 165,042,064 | 157,099,878 |
| Deferred Tax income/(expense) (Note-19) | (1,052,966) | 9,841,582 |
| Prior year tax assessment adjustment | 29,911,344 | 48,311,580 |
| | 193,900,442 | 215,253,039 |
| Tax expenses in relation to Continuing operation | 181,474,220 | 203,802,324 |
| Tax expenses in relation to discontinuing operation Note-46.4 | 12,426,222 | 11,450,716 |
| | 193,900,442 | 215,253,039 |

31.1 Reconciliation of Effective Tax Rate

| Types of income | Income | 2021-2022 | | 2020-2021 | |
|---|--------------------|--------------------|--------------------|--------------------|---------------|
| | | Effective Tax Rate | Tax expenses | Tax expenses | Rate |
| Capital gain | - | 15.00% | - | - | 15.00% |
| Dividend income | 1,617,169 | 20.00% | 323,434 | 165,047 | 20.00% |
| Income from associates | (1,286,976) | 0.00% | - | - | 0.00% |
| Business Income | 805,214,931 | 20.00% | 161,042,986 | 160,615,813 | 22.50% |
| | 805,545,124 | 20.03% | 161,366,420 | 160,780,860 | 22.56% |
| Non deductible expenses | | 1.96% | 15,828,588 | 17,061,760 | 2.39% |
| The effect of changes of effective tax rate on opening temporary difference | | -1.64% | (13,205,910) | (10,901,161) | - |
| Under estimation in prior year | | 3.71% | 29,911,344 | 48,311,580 | 6.78% |
| | | 24.07% | 193,900,442 | 215,253,039 | 24.95% |

| | AMOUNT IN TAKA | |
|--|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| 31.02 CONSOLIDATED INCOME TAX EXPENSES | | |
| Current Tax | 165,329,483 | 157,323,117 |
| Deferred Tax income/(expense) | (1,052,966) | 9,841,582 |
| Prior year tax assessment adjustment | 29,911,344 | 48,311,580 |
| | 194,187,861 | 215,476,279 |
| 32. CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES | | |
| Closing value of marketable securities | (761,764) | 161,208 |
| Opening value of marketable securities | 161,208 | (236,002) |
| | (922,972) | 397,210 |

33. EARNINGS PER SHARE (EPS)

Basic earnings per share has been calculated as follows :
Earnings attributable to the Ordinary Shareholders (Net profit after tax)
Divided by number of Ordinary Shares
EARNINGS PER SHARE (EPS)

| | 2021-22 | | 2020-21 |
|--|-------------------------|---------------------------|--------------|
| | Continuing Operation | Discontinued Operation | Total |
| | 561,939,795 | 49,704,886 | 611,644,682 |
| | 31,243,627 | 31,243,627 | 31,243,627 |
| | 17.99 | 1.59 | 19.58 |
| | | | 15.92 |

Earning Per Share (EPS) increased during the year 2021-2022 due to increase in sales and maintaining stable expenses growth.

33.01.A CONSOLIDATED EARNINGS PER SHARE (EPS)

Basic earnings per share has been calculated as follows :
Earnings attributable to the Owners of the company
Divided by number of Ordinary Shares
EARNINGS PER SHARE (EPS)

| | | |
|--|--------------|--------------|
| | 605,867,013 | 489,123,389 |
| | 31,243,627 | 31,243,627 |
| | 19.39 | 15.66 |

33.01 NET ASSETS VALUE PER SHARE (NAV)

Net Assets Value
Divided by number of Ordinary Shares
Net Assets Value Per Share

| | | |
|--|---------------|---------------|
| | 2,623,828,948 | 2,159,859,988 |
| | 31,243,627 | 31,243,627 |
| | 83.98 | 69.13 |

Net Assets Value Per Share (NAV) increased during the year 2021-2022 due to increase in sales, maintaining stable expenses growth and increase in retained earnings.

33.01.B CONSOLIDATED NET ASSETS VALUE PER SHARE (NAV)

Net Assets Value
Less: Non-Controlling Interest
Equity Attributable to the Owners of the Company
Divided by number of Ordinary Shares
Net Assets Value Per Share

| | | |
|--|---------------|---------------|
| | 2,625,049,957 | 2,149,551,055 |
| | (20,659,192) | (3,351,582) |
| | 2,604,390,765 | 2,146,199,473 |
| | 31,243,627 | 31,243,627 |
| | 83.36 | 68.69 |

33.02 NET OPERATING CASH FLOWS PER SHARE (NOCFPS)

Net cash provided by operating activities
Divided by number of Ordinary Shares

| | | |
|--|--------------|--------------|
| | 425,163,679 | 560,853,428 |
| | 31,243,627 | 31,243,627 |
| | 13.61 | 17.95 |

Decrease in NOCFPS arise due to increase of supplier payment and others and changes in current assets and liabilities.

33.02.01 CONSOLIDATED NET OPERATING CASH FLOWS PER SHARE (NOCFPS)

Net cash provided by operating activities
Divided by number of Ordinary Shares

| | | |
|--|--------------|--------------|
| | 418,564,713 | 552,166,782 |
| | 31,243,627 | 31,243,627 |
| | 13.40 | 17.67 |

AMOUNT IN TAKA

**01 July 2021 to
30 June 2022**

**01 July 2020 to
30 June 2021**

33.03 RECONCILIATION OF NET PROFIT WITH CASH FLOWS FROM OPERATING ACTIVITIES

| | | |
|--|--------------------|--------------------|
| Profit before tax (PBT) | 805,545,124 | 712,746,362 |
| Adjustment | | |
| Depreciation | 223,660,922 | 215,593,525 |
| Deferred Tax | (1,145,264) | 9,881,303 |
| Unrealized foreign exchange loss | 2,826,598 | 199,343 |
| Share of associate profit/loss | 1,286,976 | 1,926,929 |
| Gain on sale of Motor Vehicles | - | 1,216,631 |
| Dividend received | 1,617,169 | 825,234 |
| Interest Income | (753,849) | (890,349) |
| Change In operating assets | | |
| Increase in inventory | (225,272,721) | (138,890,223) |
| Increase in accounts receivables | (26,554,014) | (1,926,593) |
| Decrease in advances, deposits and prepayments | (3,595,155) | (2,161,699) |
| Increase/(decrease) in trade and other payable | (95,478,841) | (12,356,880) |
| Increase/(decrease) in retirement benefit obligation | 640,675 | 15,232 |
| Tax paid during the year | (216,670,678) | (186,565,279) |
| Interest Expense | (40,943,264) | (38,760,107) |
| | 425,163,679 | 560,853,428 |

33.03A CONSOLIDATED RECONCILIATION OF NET PROFIT WITH CASH FLOWS FROM OPERATING ACTIVITIES

| | | |
|--|--------------------|--------------------|
| Profit before tax (PBT) | 799,862,485 | 704,448,050 |
| Adjustment | | |
| Depreciation | 223,925,615 | 215,858,218 |
| Deferred Tax | (1,145,264) | 9,881,303 |
| Unrealized foreign exchange loss | 2,826,598 | 199,343 |
| Share of associate profit/loss | 1,286,976 | 1,926,929 |
| Gain on sale of Motor Vehicles | - | 1,216,631 |
| Dividend received | 1,617,169 | 825,234 |
| Interest Income | (753,849) | (890,349) |
| Change In operating assets | | |
| Increase in inventory | (225,404,309) | (138,782,204) |
| Increase in accounts receivables | (26,554,014) | (1,926,593) |
| Decrease in advances, deposits and prepayments | (4,259,891) | (5,154,398) |
| Increase/(decrease) in trade and other payable | (95,767,732) | (10,050,813) |
| Increase/(decrease) in retirement benefit obligation | 640,675 | 15,232 |
| Tax paid during the year | (216,766,483) | (186,639,692) |
| Interest Expense | (40,943,264) | (38,760,107) |
| | 418,564,713 | 552,166,782 |

33.04 FINANCE CHARGE

| | | |
|---------------------------------------|-------------------|-------------------|
| Finance charge for long term finance. | 40,943,264 | 38,760,107 |
| Finance charge for lease | 6,386,660 | 1,238,211 |
| | 47,329,924 | 39,998,318 |

34. VALUE OF IMPORTS ON CIF BASIS

Materials (raw & packing)
Components & spare parts
Capital goods

| AMOUNT IN THOUSAND TAKA | |
|---------------------------------|---------------------------------|
| 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| 1,711,502 | 1,426,252 |
| 20,884 | 17,404 |
| 299,349 | 249,458 |
| 2,031,737 | 1,693,114 |

34.01 VALUE OF IMPORT AND LOCAL PURCHASE

Value of import and local purchase Raw materials consist of 946 items which 84.24% are imported.

Value of import and local purchase Packing materials consist of 3,005 items which 15.76% are imported.

35. INSTALLED CAPACITY, ACTUAL PRODUCTION ON SINGLE SHIFT BASIS AND REASONS FOR SHORT-FALL DURING THE YEAR ENDED 30th June, 2022 :

| Product Group | Unit | Quantity in Thousand | | | |
|-----------------|--------|----------------------|-------------------|-----------|-------------------|
| | | 2021-2022 | | 2020-2021 | |
| | | Installed | Actual production | Installed | Actual production |
| Tablet | Pcs | 1,082,526 | 1,491,748 | 1,082,526 | 1,310,815 |
| Capsule | Pcs | 373,602 | 415,447 | 277,602 | 314,728 |
| Dry Syrup / ORS | Bottle | 57,773 | 26,366 | 38,573 | 27,082 |
| Liquid | Bottle | 33,171 | 33,876 | 33,171 | 29,939 |
| Drops | Pcs | 6,124 | 7,044 | 6,124 | 6,551 |
| Ointment | Pcs | 16,555 | 5,718 | 12,235 | 4,203 |
| Injection | Pcs | 18,798 | 6,053 | 18,798 | 4,847 |

Production was made keeping in view market demand.

36. RELATED PARTY TRANSACTIONS

During the year, the company carried out transactions with related parties in the normal course of business and on an arm's length basis. The name of related parties, relationship, types of transaction and their total value have been set out in accordance with the provisions of IAS 24 "Related Party Disclosures". Transaction with related parties are executed on the same terms as those of other customers of similar credentials and do not involve more than a normal risk.

| Name of Party | Relationship | Nature of transaction | Transaction | | 2022 | 2021 |
|--|---------------------|---|-------------|------------|----------------------|------------|
| | | | Dr. | Cr. | Receivable/(Payable) | |
| 1.The IBN SINA Trust | Sponsor Shareholder | Dividend Payment | 64,828,566 | - | - | - |
| | | Received for Share capital (The IBN SINA Polymer Industry Ltd.) | | 17,500,000 | - | - |
| | | Disposal of The IBN SINA Consumer Products Ltd. | 60,000,000 | | - | - |
| 2. The IBN SINA Consumer Products Ltd. | Associate | Disposal of share Capital | 60,000,000 | | - | - |
| 3. The IBN SINA API Industry Ltd. | Subsidiary (99.99%) | Acquisition of share Capital Loan | - | 55,000,000 | 154,999,800 | 99,999,800 |
| 4. The IBN SINA Natural Medicine Ltd. | Subsidiary (99.99%) | Acquisition of share Capital | - | - | 30,000,000 | 30,000,000 |
| 5. The IBN SINA Polymer Industry Ltd. | Subsidiary (65%) | Acquisition of share Capital | 32,500,000 | - | 39,000,000 | 6,500,000 |

36.1 TRANSACTIONS WITH KEY MANAGEMENT PERSONNEL

| Particulars | 2021-2022 | 2020-2021 |
|------------------------------|------------|------------|
| Short term employee benefits | 13,500,000 | 11,275,000 |
| Post-employment benefits | - | - |
| Other long term benefits | - | - |

Key management personnel compensation includes benefits for employees of the rank of director and above. No remuneration is given to the board of director's apart from attendance fees in connection with Board and sub committee meeting during the year 2021-2022 attendance fees in connection with Board and Sub Board committee meeting are Tk.1,521,300 (2020-2021 Tk.1,491,600).

DEBTS DUE FROM AND DUE TO KEY MANAGEMENT PERSONNEL.

There is no debts due from and due to key management personnel of the company.

37. Commitment and contingency. There was no contract for Capital Expenditure remaining to be executed and not provided for at 30 June 2022.

38. There was no general nature of credit facilities available to the company under any contract other than trade credit available in the ordinary course of business and not availed of as on 30.06.2022.

39. No brokerage or discount other than usual trade discount against sales was paid during the year.

40. As there was no sales agent, commission therefore was not paid.

41. During the year under review USD 26,425 equivalent to Tk.2,271,291 have been paid for registration and consultancy fees.

41.1 There is no regular employees who received remuneration less than 36,000 in aggregate throughout the financial year.

41.2 At the end of this year closing balance of FCAD ERQ account was USD \$371,470 out of which USD \$365,310 in IBBL and USD \$ 6,160 in Sonali Bank Ltd.

42. As there was no non-resident shareholder, no dividend was remitted abroad.

43. During the year the company (a) earned foreign exchange of US\$ 1,030,448 equivalent to Tk.93,297,475 on account of export sale, (b) but did not earn or receive any income in respect of royalty, technical know-how, professional & advisory fees, interest & dividend.

44. There were aggregating claims of Tk. 11,047,567 in respect of assessment years 2012-2013, 2013-2014 and 2014-2015 respectively against the Company for Income Tax in different years but no asset or liability was recognized for the claims. The Company filed Income Tax Reference case with High Court Division of the Supreme Court & Appeals remained pending for adjustment for these cases.

45. There was no contingent liability other than letters of credit outstanding for importation of raw & packing materials, capital goods as on 30.06.2022.

46. FINANCIAL RISK MANAGEMENT

The company management has overall responsibility for the establishment and oversight of the company's risk management framework. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities. The company has exposure to the following risks from its use of financial instruments.

- (a) Credit Risk
- (b) Liquidity Risk
- (c) Market Risk

46.1 Credit Risk

Credit risk is the risk of a financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the company's receivables. Management has a credit policy in place and the exposure to credit risk is monitored on an ongoing basis. As at 30 June 2022, substantial part of the receivables are as follows and subject to insignificant credit risk. Risk exposures from other financial assets, i.e. Cash at bank and other external receivables are also nominal.

(i) Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting data was:

| | AMOUNT IN TAKA | |
|----------------------------|--------------------|--------------------|
| | 30 June 2022 | 30 June 2021 |
| Accounts receivable | | |
| Advance to employees | 3,913,210 | 3,663,147 |
| Advance to supplies | 9,986,634 | 7,106,346 |
| Trade receivable | 43,609,681 | 23,609,681 |
| Other receivables | 26,518,639 | 22,123,947 |
| Security deposit | 22,331,836 | 21,320,410 |
| Imprest cash | 3,650,000 | 8,270,000 |
| Cash at bank | 231,587,781 | 219,815,023 |
| | 341,597,782 | 305,908,555 |

The aging of trade receivables at the reporting date is as follows:

Trade receivables

| | | |
|---------------------|-------------------|-------------------|
| Below 30 days | 26,165,809 | 14,165,809 |
| With in 31-90 days | 15,263,388 | 5,902,420 |
| With in 91-120 days | 2,180,484 | 3,541,452 |
| Above 120 days | - | - |
| | 43,609,681 | 23,609,681 |

i) To mitigate the credit risk against trade receivables, the company has a system of specific credit line period to the customers. This outstanding period and amount are regularly monitored. The company endeavors to cover the credit risks on all other receivables, where possible, by restricting credit facility and stringent monitoring.

ii) All of the company's advance, trade receivable are considered good. All of the receivable are considered collectable and hence no doubtful or bad receivable included under trade receivable.

iii) The company did not make any advance, deposit, prepayment to the director, subsidiary, associates or other connected party and advance employees are realized in normal course of business.

iv) Security deposit includes advance Tk. 11,661,000 given for head office rent which is adjustable at end of rent agreement.

Consolidated Accounts receivable:

| | | |
|----------------------|--------------------|--------------------|
| Advance to employees | 3,913,210 | 3,663,147 |
| Advance to supplies | 10,644,197 | 7,106,346 |
| Trade receivable | 43,609,681 | 23,609,681 |
| Other receivables | 26,518,639 | 22,123,947 |
| Security deposit | 22,331,836 | 21,320,410 |
| Imprest cash | 3,650,000 | 8,270,000 |
| Cash at bank | 336,038,786 | 267,292,407 |
| | 446,706,350 | 353,385,939 |

The aging of trade receivables at the reporting date is as follows:

Trade receivables

| | | |
|---------------------|-------------------|-------------------|
| Below 30 days | 26,165,809 | 14,165,809 |
| With in 31-90 days | 15,263,388 | 5,902,420 |
| With in 91-120 days | 2,180,484 | 3,541,452 |
| Above 120 days | - | - |
| | 43,609,681 | 23,609,681 |

AMOUNT IN TAKA

30 June 2022

30 June 2021

46.2 Liquidity Risk

Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity (cash and cash equivalents) is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the company's reputation. Typically, the company ensures that it has sufficient cash and cash equivalents to meet expected operational expenses, including financial obligations through preparation of the cash flow forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date. The carrying amount of financial liabilities represent the maximum exposure to liquidity risk. The maximum exposure to liquidity risk as at 30th June was:

| | | |
|--|--------------------|--------------------|
| Trade and other payables | 165,514,675 | 231,649,393 |
| Security money received from employees | 7,867,814 | 8,438,345 |
| Other current liabilities | 40,341,605 | 35,733,665 |
| | 213,724,094 | 275,821,403 |

46.3 Market Risk

Market risk is the risk that any change in market prices, such as foreign exchange rates and interest rates will affect the company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters.

(i) Interest Rate Risk

Interest rate risk is the risk that fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rate. Exposure to fair value movement relates to fixed rate instrument subject to fair value accounting and exposure to cash flow fluctuation relates to variable rate instruments. The Company is primarily exposed to cash flow fluctuation arising from variable rate borrowings. The objective of interest rate management for The IBN SINA Pharmaceutical Industry PLC is to reduce financial cost and ensure predictability.

(ii) Currency Risk

The company is exposed to currency risk on certain revenues and purchases such as revenue from foreign customers and import of raw material, machineries and equipment. Majority of the company's foreign currency transactions are denominated in USD and relate to procurement of raw materials, machineries and equipment from abroad.

46.4 Discontinued operation

The Board of Directors of The IBN SINA Pharmaceutical Industry PLC in its 298th Meeting held on Saturday, May 28, 2022 ended at 4:00 PM at the Board Room of the Company has decided to demerge the Natural Medicine Division of the Company by transferring its "Assets and Liabilities to be audited" as at June 30, 2022 to its 99.99% owned Subsidiary Company named: The IBN SINA Natural Medicine Ltd. in exchange of consideration other than cash as against acquiring of Shares (99.99% Shares) held by the holding Company, The IBN SINA Pharmaceutical Industry PLC, for better management and ease of operation of its natural medicine production and businesses subject to approval by the Shareholders in the next Annual General Meeting of the Company and compliance with the necessary regulatory requirements in this regard and also BSEC's approval, if any.

Considering this fact, the operating result (revenue, cost of sales, other expenses and tax expenses) of discontinued operation is presented separately from continuing operation (face of Profit or Loss statement) as note in the financial statements in reference to the Paragraph 33 of IFRS 5: Non-current assets held for sale and discontinued operations. The net result (Profit After Tax) of Natural Medicine Division (disposal group) is shown in the face of profit or loss statement.

However, the separation of Natural Medicine Division is merely transferring from Parent company to Subsidiary company, so, this shall not be considered as disposal/separation in group perspective. As such, the operating result (revenue, cost of sales, other expenses and tax expenses) of Natural Medicine Division is considered as continued operation in group (consolidation) reporting purposes.

| | AMOUNT IN TAKA | |
|--|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| REVENUE | 1,040,942,221 | 917,734,945 |
| Cost of goods sold | (609,575,765) | (535,223,020) |
| GROSS PROFIT | 431,366,456 | 382,511,925 |
| | (366,128,793) | (322,395,668) |
| OPERATING EXPENSES | | |
| Administrative expenses | (22,826,048) | (19,267,815) |
| Selling & Distribution expenses | (343,302,744) | (303,127,852) |
| | 65,237,664 | 60,116,257 |
| OPERATING PROFIT | - | - |
| Financial charges | - | - |
| Other income | 65,237,664 | 60,116,257 |
| Net profit from operation | (3,106,555) | (2,862,679) |
| Workers' P.P. fund & welfare fund | - | - |
| Share of associate profit/loss | 62,131,108 | 57,253,578 |
| PROFIT BEFORE TAX | | |
| Income Tax Expenses: | | |
| Current tax | (12,426,222) | (11,450,716) |
| NET PROFIT AFTER TAX | 49,704,886 | 45,802,863 |
| | | |
| 46.5 Assets held under disposal group | | |
| Property, Plant and Equipment | 76,881,940 | |
| Inventories | 117,655,032 | |
| Trade and Other Receivables | 13,632,698 | |
| | 208,169,670 | |

The board has decided to transfer the above assets to subsidiary company at carrying value which also represents fair value.

47. EVENTS AFTER THE REPORTING PERIOD :

47.A The Board of Directors of the Company approved the Financial Statements as on 05/09/2022 and recommended 60% cash dividend for the financial year ended June 30, 2022.

47.B The Board of Directors of the company has decided to sale/transfer 40% share holding of The IBN SINA Consumer Ltd. at face value i.e. 6,000,000 share Tk. 10 per share and Tk. 60,000,000 to Panacea Company Ltd.

Except the facts and figures stated above, there is no other entry or note that has to be disclosed in the Financial Statements.

**PROPERTY, PLANT AND EQUIPMENT (PPE)
AS AT 30 JUNE, 2022**

**Annexure-A
Amount in Taka**

| Particulars | Cost/Revaluation | | | Rate | Depreciation | | | Written down value on 30.06.2022 |
|---------------------------|----------------------|--------------------------|-----------------------|--------|---------------------|--------------------|-----------------------|----------------------------------|
| | On 01.07.2021 | Addition during the year | Disposal / Adjustment | | Total on 30.06.2022 | For the Year | Disposal / Adjustment | |
| Land & Land Development | 342,667,512 | 79,586,577 | - | - | - | - | - | 422,254,089 |
| Building | 177,079,375 | 72,549,664 | - | 2.50% | 4,784,440 | - | 50,944,273 | 198,684,766 |
| Plant & Machinery | 1,715,265,527 | 28,009,218 | - | 10.00% | 109,627,773 | - | 737,045,144 | 1,006,229,601 |
| Internal Road | 4,842,880 | - | - | 10.00% | 168,270 | - | 3,328,446 | 1,514,434 |
| Installations | 48,084,272 | 45,840,000 | - | 10.00% | 4,644,691 | - | 27,202,051 | 66,722,221 |
| Equipment | 549,421,925 | 58,681,419 | - | 10.00% | 42,991,103 | - | 188,050,670 | 420,052,674 |
| Computers | 49,698,176 | 4,310,448 | - | 30.00% | 5,198,185 | - | 39,780,482 | 14,228,142 |
| Furniture & Fixtures | 80,846,174 | 6,379,392 | - | 10.00% | 4,541,300 | - | 43,203,019 | 44,022,548 |
| Motor Vehicles | 215,996,872 | 27,211,309 | - | 20.00% | 24,678,717 | - | 132,997,337 | 110,210,844 |
| Spares & Loose Tools | 28,009,108 | - | - | 30.00% | 2,273,103 | - | 22,705,202 | 5,303,906 |
| Library Books | 867,659 | - | - | 30.00% | 23,431 | - | 812,987 | 54,672 |
| Temporary Construction | 8,489,054 | - | - | 30.00% | 370,068 | - | 7,625,562 | 863,492 |
| TOTAL-30 June 2022 | 3,221,268,535 | 322,568,027 | - | | 199,301,082 | - | 1,253,695,173 | 2,290,141,389 |
| TOTAL-30 June 2021 | 2,872,974,134 | 352,617,686 | (4,323,285) | | 188,972,041 | (4,105,898) | 1,054,394,091 | 2,166,874,444 |

ALLOCATION OF DEPRECIATION

| Allocation to | Note no. | Allocated Depreciation 2021-2022 | | Allocated Depreciation 2020-2021 | |
|---------------------------------|----------|----------------------------------|--------------------|----------------------------------|--------------------|
| | | PPE | ROU | PPE | ROU |
| Manufacturing Expenses | Note-26 | 158,276,497 | - | 151,663,828 | - |
| Administrative Expenses | Note-27 | 16,975,628 | 10,079,896 | 15,291,379 | 10,911,249 |
| Selling & Distribution Expenses | Note-28 | 24,048,957 | 14,279,943 | 22,016,834 | 15,710,235 |
| Total | | 199,301,082 | 24,359,839 | 188,972,041 | 26,621,484 |
| | | | 223,660,922 | | 215,593,525 |

Investment of Marketable Securities (Fair Value): 2021-2022

Annexure-B
Amount in Taka

| Sl. No. | Name of Company Mutual Fund/Bond | No. of Shares Held | Face Value per Share | Cost Holding | Average Cost | Quoted Rate per Share as on 30-06-2022 | Total Market Value of Shares as on 30-06.2022 | Unrealised Gain/(Loss) |
|---------|---|--------------------|----------------------|-------------------|--------------|--|---|------------------------|
| 1 | Exim Bank | 330,000 | 10.00 | 3,935,320 | 11.93 | 10.90 | 3,597,000 | (338,320) |
| 2 | First Security Islami Bank Ltd. | 1,500,000 | 10.00 | 16,462,240 | 10.97 | 10.60 | 15,900,000 | (562,240) |
| 3 | Shahjalal Islami Bank Ltd. | 1000,00 | 10.00 | 2,096,388 | 20.96 | 19.90 | 1,990,000 | (106,388) |
| 4 | Al-Arafa Islami Bank Ltd. | 1000,00 | 10.00 | 2,633,035 | 26.33 | 25.60 | 2,560,000 | (73,035) |
| 5 | Social Islami Bank Ltd | 157,500 | 10.00 | 2,159,166 | 13.71 | 13.50 | 2,126,250 | (32,916) |
| 6 | Islami Bank Bangladesh Ltd. (IBBL)-in Mddaraba Perpetual Bond (MPB) | 4,590 | 1,000.00 | 4,590,000 | 1,000.00 | 1,076.50 | 4,941,135 | 351,135 |
| | | 2,192,090 | | 31,876,149 | | | 31,114,385 | (761,764) |

The above Investment in Marketable Securities that are designated as available for sale by the management. These are measured at fair value and presented as non-current asset and unrealized gain/(loss) from the above investment are recognized as other comprehensive income.

Gain/(Loss) On Marketable Securities (Unrealised):

Unrealised Gain/(Loss) Position (Closing)
Unrealised Gain/(Loss) Position (Opening)
Gain on Marketable Securities during the year

| AMOUNT IN TAKA | |
|------------------------------|------------------------------|
| 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| (761,764) | 161,208 |
| 161,208 | (236,002) |
| (922,972) | 397,210 |

THE IBN SINA NATURAL MEDICINE LTD.



DIRECTORS' REPORT

to the Shareholders for the year ended June 30, 2022

Dear Shareholders,

The Board of The IBN SINA Natural Medicine Ltd. hereby presents the Directors' Report along with its audited financial statements of the Company. The report contains the Statement of Financial Position as at June 30, 2022, Statement of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flows for the year ended June 30, 2022 and the Auditors' Report thereon in terms of the provisions of Section 184 of the Companies Act 1994, IAS and IFRS, Codes and the guidelines issued by the Bangladesh Securities and Exchange Commission (BSEC).

The Company has been conducting the business as manufacturer, exporter, supplier, distributor, dealer, agent, whole seller, retailer of all kinds of natural medicine- Unani, Ayurvedic and Herbal, nutritional, nutraceutical products and dietary supplements, health food products, food supplement, therapeutic food, medical nutrition, medicated consumer products, medicated cosmetics and toiletries. It is expected to commence its business as a distinct entity in a separate dedicated building new production facility by the end of the year 2022.

Demerging of Natural Medicine Division from The IBN SINA Pharmaceutical Industry PLC (IPI), holding Company of The IBN SINA Natural Medicine Ltd. and taking over of its Net Assets as at 30 June 2022 to effect allotment of shares of The IBN SINA Natural Medicine Ltd. to IPI in exchange of consideration other than cash as against the said Net Assets.

For better management and to make ease of operation of natural medicine production and

businesses, the Board of Directors of the holding Company, IPI has decided to demerge the Natural Medicine Division by transferring its "Assets and Liabilities duly audited" as at year ended June 30, 2022 in the form of "Net Assets" at Tk. 20,81,69,670 (Taka Twenty Crore Eighty One Lac Sixty Nine Thousand Six Hundred and Seventy) as at June 30, 2022 to its 99.99% owned Subsidiary Company- The IBN SINA Natural Medicine Ltd. in exchange of consideration other than cash as against acquiring of the shares held by the holding Company, The IBN SINA Pharmaceutical Industry PLC subject to approval in the AGM of the Company as "Special Resolution" and compliance with the necessary regulatory requirements in this regard.

In this regard, a 'Vendors Agreement' was executed between The IBN SINA Pharmaceutical Industry PLC (Vendor) and The IBN SINA Natural Medicine Ltd. (Vendee) to effect allotment of 2,08,16,967 nos. of shares of Vendee to IPI in exchange of consideration other than cash as against the said Net Assets.

Operational Results

The brief summary of operational performance during the year 2021-22 is as follows:-

| Particulars | July 01, 2021 to June 30, 2022 (Amount in Taka) | July 01, 2020 to June 30, 2021 (Amount in Taka) |
|------------------------------|--|--|
| Revenue | NIL | NIL |
| Gross Profit | NIL | NIL |
| NET PROFIT AFTER TAX | (198,468) | (433,885) |
| Gross Profit Ratio (%) | NIL | NIL |
| Net Profit Ratio (%) | NIL | NIL |
| Net Asset Value (NAV) | 29,370,648 | 29,569,115 |

The above result reveals that factory building of the Company has not started its commercial operation yet. The above amount expended mainly for Company registration and other legal and regulatory purposes. The loss incurred is expected to be recovered from upcoming commercial operations of the Company.

Shareholding

The present shareholding pattern of the Company is as follows:-

| Name of the Shareholders | Shareholding (Shares) | % of Shareholding |
|--|-----------------------|-------------------|
| The IBN SINA Pharmaceutical Industry PLC | 1,19,99,700 | 99.9970 |
| Prof. Dr. AKM Sadrul Islam | 100 | 0.0010 |
| Kazi Harun or Rashid | 100 | 0.0010 |
| Prof. Dr. Choudhury Mahmood Hasan | 100 | 0.0010 |
| Total | 120,00,000 | 100 |

On the basis of above shareholdings, The IBN SINA Natural Medicine Ltd. has the status of Subsidiary to The IBN SINA Pharmaceutical Industry PLC.

Board of Directors

The following persons are the Members of the Board of Directors of the Company:

| Name | Designation |
|--|----------------------|
| Prof. Dr. AKM Sadrul Islam | Chairman |
| Kazi Harun or Rashid | Managing Director |
| Prof. Dr. Choudhury Mahmood Hasan | Director |
| Prof. ANMA Zaher (Nominated by The IBN SINA Pharmaceutical Industry PLC) | Director |
| Abdus Sadeque Bhuiyan | Independent Director |

The number of Board meetings of The IBN SINA Natural Medicine Ltd. held during the year under review was 4 (Four).

Financial Position

The Statement of Financial Position as on June 30, 2022, Statement of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flows ended at June 30, 2022 are placed herewith.

Dividend Declaration

The development works of The IBN SINA Natural Medicine Ltd. project is in progress. We are hopeful within the reasonable time; commencement of business of Natural Medicine will be kicked-off soon unveiling as a commercial venture, In-Sha-Allah.

As per audited accounts of the Company as at 30 June 2022, the net profit/loss after tax stood Tk. (198,468/-) as loss for the same period.

Hence, the Board of Directors of The IBN SINA Natural Medicine Ltd. in its 11th meeting held on 03.09.2022 has recommended not to declare any dividend for the year under review.

Independent Director

As per Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC), the

learned and veteran professional Md. Rafiqul Islam Khan, FCA had performed the duties as Independent Directors of the Company with dedication and sincerity.

Being the tenure of office of Independent Directorship of Md. Rafiqul Islam Khan, FCA ended on 31st December 2021, as per BSEC's Notification, Dated- 03 June 2018 on Corporate Governance Code, Abdus Sadeque Bhuiyan BSS (Hon's) MSS, DU Ex-Deputy Managing Director of Islami Bank Bangladesh Ltd. (IBBL) has been nominated to be appointed as Independent Director of the Company for the first term from 18.01.2022 to 17.01.2025.

Compliance of BSEC's Code of Governance of Board of Directors of The IBN SINA Natural Medicine Ltd., Subsidiary Company of The IBN SINA Pharmaceutical Industry PLC.

As per Condition No. 2 of Corporate Governance Code of BSEC's notification No. BSEC/CMRRCD/2006-158/207/Admin/80 Date: 3 June 2018 relating to Governance of Board of Directors of Subsidiary Company, the Board duly

complied with the required conditions of the Code mentioned below -

(a) Provisions relating to the composition of the Board of the holding company, The IBN SINA Pharmaceutical Industry PLC was made applicable to the composition of the Board of the subsidiary company, The IBN SINA Natural Medicine Ltd.;

(b) Abdus Sadeque Bhuiyan Independent Director of the holding company is the Independent Director on the Board of The IBN SINA Natural Medicine Ltd.;

(c) The minutes of the Board meeting of The IBN SINA Natural Medicine Ltd. were placed for review at the following Board meeting of the holding company, The IBN SINA Pharmaceutical Industry PLC;

(d) The minutes of the respective Board meeting of the holding company, The IBN SINA Pharmaceutical Industry PLC duly stated that they have reviewed the affairs of The IBN SINA Natural Medicine Ltd. also;

(e) The Audit Committee of the holding Company, IPI PLC also reviewed the financial statements, in particular the investments made by the Subsidiary Company, The IBN SINA Natural Medicine Ltd.

Appointment of Auditors

Malek Siddiqui Wali, Chartered Accountants, Statutory Auditors of the Company, audited the Accounts for the year 2021-22. Malek Siddiqui Wali, Chartered Accountants retired end of 2021-22.

The Company has received Expression of Interest

(EOI) to be appointed as Statutory Auditors from two (2) recognized Chartered Accountants firms. The profile of these two audit firms was reviewed by the Audit Committee its 104th meeting held on 03.09.2022 and recommended to appoint S F Ahmed & Co. Chartered Accountants as Statutory Auditors of the Company for the financial year, 2022-23.

After review and discussion over the profile and particulars of the said Firms and being eligible as per Law, the Board of Directors of The IBN SINA Natural Medicine Ltd. in its 11th meeting held on 03.09.2022 has concurred with the recommendation of Audit Committee to appoint S F Ahmed & Co., Chartered Accountants as Statutory Auditors of the Company for the year 2022-23 with a remuneration of Tk. 50,000/- (Fifty Thousand) subject to approval in the AGM of the Company.

Acknowledgement

The Board of Directors thankfully acknowledge the devotion and dedication of all the employees without which the Company's development works-in-progress could not have attained satisfactory as reported above.

The Board also record with appreciation the support, services and co-operation rendered by all concerned.

Allah Hafiz.

Signed on behalf of the Board of Directors.



Kazi Harun or Rashid
Managing Director



Prof. Dr. AKM Sadrul Islam
Chairman



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস

৯-জি, মতিঝিল বাণিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali

CHARTERED ACCOUNTANTS

9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.

Extension Office: Property Heights, 1st Floor

12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867

PABX: 9576118-9, 9576128

FAX: +88-02-9516236

E-mail: wali@satcombd.com

Web: www.msw-bd.com

INDEPENDENT AUDITOR'S REPORT

To the shareholders of THE IBN SINA NATURAL MEDICINE LTD.

Report on the Audit of the Financial Statements

Opinion:

We have audited the financial statements of The IBN SINA Natural Medicine Ltd., which comprise the Statement of Financial Position as at June 30, 2022, the Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and Notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements give true and fair view, in all material respects, of the financial position of the Company as at June 30, 2022, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies act 1994 and other applicable law and regulations.

Basis for Opinion:

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information:

The other information comprises all of the information in the Annual Report other than the financial statements and our auditor's report thereon. We have not been provided the Director's report and other information contained within the annual report except the financial statements to the date of our auditor's report. We expect to obtain the remaining reports of the Annual report after the date of our auditor's report. Management is responsible for the other information.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Our opinion on the financial statements does not cover other information and we do not express any form of assurance conclusion thereon.

Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls:

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs as explained, and for such internal control as management determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error. The Companies Act, 1994 requires the Management to ensure effective internal audit, internal control and risk management functions of the Company.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস
৯-জি, মতিঝিল বাণিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali
CHARTERED ACCOUNTANTS
9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.
Extension Office: Property Heights, 1st Floor
12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867
PABX: 9576118-9, 9576128
FAX: +88-02-9516236
E-mail: wali@satcombd.com
Web: www.msw-bd.com

Auditor's Responsibilities for the Audit of the Financial Statements:

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

" Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

" Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.

" Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

" Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

" Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

" Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the company audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Associated firm of **Reddy Siddiqui & Kabani**, Park View, 183-189 The Vale, London, W3 7RW, UK
E-mail: mail@reddysiddiqui.com, Website: www.reddysiddiqui.com



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস
৯-জি, মতিঝিল বাণিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali

CHARTERED ACCOUNTANTS

9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.

Extension Office: Property Heights, 1st Floor
12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867

PABX: 9576118-9, 9576128

FAX: +88-02-9516236

E-mail: wali@satcombd.com

Web: www.msw-bd.com

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, we also report the following:

- a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) in our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of these books;
- c) the Statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts and returns; and
- d) the expenditure incurred was for the purposes of the Company's business.

Dated, Dhaka

September 03, 2022

Data Verification Code (DVC) No.

2209121099AS915264

Malek Siddiqui Wali

Chartered Accountants

Anjan Mallik, FCA

Enrolment No: 1099

THE IBN SINA NATURAL MEDICINE LTD.

STATEMENT OF FINANCIAL POSITION

As at 30 June 2022

| | AMOUNT IN TAKA | |
|---|-------------------|-------------------|
| | 30 June 2022 | 30 June 2021 |
| ASSETS | | |
| Non-Current Assets | | |
| Property, Plant and Equipment | - | - |
| Capital Work-In-Progress | - | - |
| Total Non- Current Assets | - | - |
| Current Assets | | |
| Inventories | - | - |
| Advance | - | - |
| Cash and Cash Equivalents | 29,399,398 | 29,597,865 |
| Total Current Assets | 29,399,398 | 29,597,865 |
| TOTAL ASSETS | 29,399,398 | 29,597,865 |
| SHAREHOLDERS' EQUITY AND LIABILITIES | | |
| Shareholders' Equity | | |
| Share Capital | 30,003,000 | 30,003,000 |
| Retained Earnings/(Accumulated losses) | (632,353) | (433,885) |
| | 29,370,648 | 29,569,115 |
| LIABILITIES | | |
| Current Liabilities | | |
| Loan from IBN SINA Pharma | - | - |
| Trade and Other Payable | 28,750 | 28,750 |
| Total Current Liabilities | 28,750 | 28,750 |
| TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES | 29,399,398 | 29,597,865 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 03, 2022 and were signed on its behalf by:


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Dated, Dhaka;
September 03, 2022


Malek Siddiqui Wali
Chartered Accountants

THE IBN SINA NATURAL MEDICINE LTD.

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 30 June 2022

| | AMOUNT IN TAKA | |
|----------------------------------|---------------------------------|-------------------------------------|
| | 01 July 2021 to 30 June 2022 | 17 December 2020 to 30 June 2021 |
| REVENUE | | |
| Cost of goods sold | - | - |
| GROSS PROFIT | - | - |
| OPERATING EXPENSES | | |
| Administrative expenses | (198,468) | (433,885) |
| Selling & Distribution expenses | (198,468) | (433,885) |
| | - | - |
| OPERATING PROFIT | (198,468) | (433,885) |
| Financial charges | - | - |
| Other income (Bank Profit) | - | - |
| NET PROFIT FROM OPERATION | (198,468) | (433,885) |
| PROFIT BEFORE TAX | (198,468) | (433,885) |
| Income tax expenses | - | - |
| NET PROFIT AFTER TAX | (198,468) | (433,885) |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 03, 2022 and were signed on its behalf by:


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Dated, Dhaka;
September 03, 2022


Malek Siddiqui Wali
Chartered Accountants

THE IBN SINA NATURAL MEDICINE LTD.
STATEMENT OF CHANGES IN EQUITY

For the year ended 30 June 2022

AMOUNT IN TAKA

| Particulars | Share Capital | Share Premium | Retained Earnings/ (Accumulated Losses) | Total |
|-----------------------------------|-------------------|---------------|--|-------------------|
| Balance as at 01 July 2020 | - | - | - | - |
| Issue during the year | 30,003,000 | - | - | 30,003,000 |
| Net profit/(Loss) for the year | - | - | (433,885) | (433,885) |
| Balance as at 01 July 2021 | 30,003,000 | - | (433,885) | 29,569,115 |
| Issue during the year | - | - | - | - |
| Net profit/(Loss) for the year | - | - | (198,468) | (198,468) |
| Balance as at 30 June 2022 | 30,003,000 | - | (632,353) | 29,370,648 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 03, 2022 and were signed on its behalf by:

 **Chief Financial Officer**
 **Company Secretary**
 **Director**
 **Managing Director**
 **Chairman**

Dated, Dhaka;
September 03, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA NATURAL MEDICINE LTD

STATEMENT OF CASH FLOWS

For the year ended 30 June 2022

| | AMOUNT IN TAKA | |
|--|---------------------------------|-------------------------------------|
| | 01 July 2021 to 30 June 2022 | 17 December 2020 to 30 June 2021 |
| A. Cash flows from operating activities | | |
| Payment for operation, expenses & others | (177,602) | (405,135) |
| Payment for Tax | - | - |
| Bank Charge | (20,866) | - |
| Net cash used by operating activities | (198,468) | (405,135) |
| B. Cash flows from investing activities | | |
| Acquisition of property, plant and equipment | - | - |
| Bank Profit | - | - |
| Net cash used in investing activities | - | - |
| C. Cash flows from financing activities | | |
| Share Capital | - | 30,003,000 |
| Loans and borrowings | - | - |
| Net cash from financing activities | - | 30,003,000 |
| D. Net increase/(decrease) in cash and cash equivalents (A+B+C) | (198,468) | 29,597,865 |
| E. Opening cash and cash equivalents | 29,597,865 | - |
| F. Closing cash and cash equivalents | 29,399,398 | 29,597,865 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 03, 2022 and were signed on its behalf by:

| | | | | |
|---|---|---|---|---|
|  |  |  |  |  |
| Chief Financial Officer | Company Secretary | Director | Managing Director | Chairman |

Dated, Dhaka;
September 03, 2022


Malek Siddiqui Wali
Chartered Accountants

THE IBN SINA API INDUSTRY LTD.



DIRECTORS' REPORT

to the Shareholders for the year ended June 30, 2022

Dear Shareholders,

With pleasure the Board of The IBN SINA API Industry Ltd. presents the Directors' Report along with the audited financial statements of the Company containing the Statement of Financial Position as of June 30, 2022, Statement of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flows for the year ended June 30, 2022 and the Auditors' Report thereon in terms of the provisions of Section 184 of the Companies Act 1994, IAS and IFRS Codes and the guidelines issued by the Bangladesh Securities and Exchange Commission (BSEC).

The IBN SINA API Project is located at API Industrial Park, a project under BSCIC, Government of Bangladesh, Gazaria, Munshigonj. The project works was started in 2019 with an aim to commence production in 2021 but due to Covid situation, the trial production time has been rescheduled to December 2022. If we can short trial production in December-2022, hopefully the commercial production can be started in July-2023.

The Company's principal objective is to conduct business of Active Pharmaceutical Ingredients (API), Raw Materials of Medicine, producing in self-contained state-of-art production facility and marketing of the same in the local and abroad. Synthesis API molecules in Bangladesh will certainly lead us to self-reliance in pharma raw materials production for our own use and local market use. At the same time creating new opportunities to export API molecules to different countries as well, which in turn will create an opportunity to earn foreign currency.

Operational Results

The brief summary of operational performance during the year 2021-22 is as follows: -

| Particulars | July 01, 2021 to June 30, 2022 (Amount in Taka) | July 01, 2020 to June 30, 2021 (Amount in Taka) |
|------------------------------|--|--|
| Revenue | NIL | NIL |
| Gross Profit | NIL | NIL |
| NET PROFIT AFTER TAX | (5,221,905) | (7,654,473) |
| Gross Profit Ratio (%) | NIL | NIL |
| Net Profit Ratio (%) | NIL | NIL |
| Net Asset Value (NAV) | 136,833,041 | 87,054,946 |

The above result reveals that the company is under construction (project) stage. The above amount expended mainly for construction, salary and research & development purposes. The loss incurred is expected to be recovered from upcoming commercial operations of the Company.

Shareholding

The present shareholding pattern of the Company is as follows:-

| Name of the Shareholders | Shareholding (Shares) | % of Shareholding |
|--|-----------------------|-------------------|
| The IBN SINA Pharmaceutical Industry PLC | 99,99,980 | 99.9998 |
| Prof. Dr. AKM Sadrul Islam | 10 | 0.0001 |
| Prof. Dr. Choudhury Mahmood Hasan | 10 | 0.0001 |
| Total | 100,00,000 | 100 |

On the basis of above shareholdings, The IBN SINA API Industry Ltd. has the status of Subsidiary to The IBN SINA Pharmaceutical Industry PLC.

Board of Directors

The following persons are the Members of the Board of Directors of the Company:

| Name | Designation |
|---|----------------------|
| Prof. Dr. AKM Sadrul Islam | Chairman |
| Prof. Dr. Choudhury Mahmood Hasan | Managing Director |
| Kazi Harun or Rashid (Nominated by The IBN SINA Pharmaceutical Industry PLC) | Director |
| Prof. Col. Dr. Zehad Khan (Retd.) (Nominated by The IBN SINA Pharmaceutical Industry PLC) | Director |
| Abdus Sadeque Bhuiyan (Nominated by The IBN SINBA Pharmaceutical Industry PLC) | Independent Director |

The number of Board meetings of The IBN SINA API Industry Ltd. held during the year under review was 4 (Four).

Capital Expenditure

Several contracts of capital expenditure like development of API molecules, civil construction of API project building and R&D building etc. are being executed by the Contractors and running bills are accounted for but the unfinished contracts have not been reflected in this Financial Statements.

Financial Position

The Statement of Financial Position as on June 30, 2022, Statement of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flows ended at June 30, 2022 are placed herewith.

Dividend Declaration

The development works of The IBN SINA API Industry Ltd. project is in progress. We are hopeful, as soon as commencement of production of API will be kicked-off, The IBN SINA API Industry Ltd. will emerge as a commercial venture.

As per audited accounts of the Company as at 30 June 2022, the net profit/loss after tax stood Tk. (5,221,905/=) as loss for the same period.

Hence, the Board of Directors of The IBN SINA API Industry Ltd. in its 15th meeting held on 03.09.2022 has recommended not to declare any dividend for the year under review, the matter was approved in the 3rd AGM of the Company.

Independent Director Appointment

The tenure of office of Independent Directorship of Md. Rafiqul Islam Khan, FCA ended on 31 December 2021, as per BSEC's Notification, Dated- 03 June 2018 on Corporate Governance Code and being nominated by the Board of holding Company, The IBN SINA Pharmaceutical Industry PLC in its 293rd meeting held on 16.01.2022, Abdus Sadeque Bhuiyan BSS (Hon's) MSS, DU Ex-Deputy Managing Director of Islami Bank Bangladesh Ltd. (IBBL) has

been recommended to be appointed as Independent Director of the Company for the first term from 18.01.2022 to 17.01.2025.

Amendment of the Company Name

The registered name of the Company was changed substituting "The IBN SINA API Industry Ltd." in place of Company's existing name "IBN SINA API Limited" and amendment in the relevant Clauses/Articles of the Memorandum and Articles of Association of the Company was made and authenticated from the relevant authorities by adopting the special resolution in the 1st EGM of the Company held on February 15, 2022.

Compliance of BSEC's Code of Governance of Board of Directors of Subsidiary Company, The IBN SINA API Industry Ltd.

As per Condition No. 2 of Corporate Governance Code of BSEC's notification No. BSEC/CMRRCD/2006-158/207/Admin/80 Date: 3 June 2018 relating to Governance of Board of Directors of Subsidiary Company, the Board duly complied with the required conditions of the Code mentioned below -

(a) Provisions relating to the composition of the Board of the holding company, The IBN SINA Pharmaceutical Industry PLC was made applicable to the composition of the Board of the Subsidiary Company, The IBN SINA API Industry Ltd.;

(b) Abdus Sadeque Bhuiyan BSS (Hon's) MSS, DU Independent Director of the holding Company is the Independent Director on the Board of The IBN SINA API Industry Ltd.;

(c) The minutes of the Board meeting of The IBN SINA API Industry Ltd. were placed for review at the following Board meeting of the holding Company, The IBN SINA Pharmaceutical Industry PLC;

(d) The minutes of the respective Board meeting of the holding Company, The IBN SINA Pharmaceutical Industry PLC duly stated that they reviewed the affairs of The IBN SINA API Industry Ltd. also;

(e) The Audit Committee of the holding Company also reviewed the financial statements, in particular the investments made by the Subsidiary Company, The IBN SINA API Industry Ltd.

Appointment of Auditors

Malek Siddiqui Wali, Chartered Accountants performed as Statutory Auditors of the Company for the financial year as at June 30, 2022. Malek Siddiqui Wali, Chartered Accountants has not given their expression of interest to be re-appointed as Auditors for the next financial year.

The Company has received Expression of Interest (EOI) to be appointed as Statutory Auditors from two (2) recognized Chartered Accountants firms for the year 2022-23. The profile of these two audit firms was reviewed by the Audit Committee and recommended to appoint S F Ahmed & Co.

Chartered Accountants as Statutory Auditors of the Company for the financial year, 2022-23.

The Board of Directors of The IBN SINA API Industry Ltd. in its 15th meeting held on 03.09.2022 has concurred with the opinion of Audit Committee and hence recommended in favour of S F Ahmed & Co., Chartered Accountants to be appointed as Statutory Auditors of the Company for the year 2022-23 with a remuneration of Tk. 25,000/- (Twenty Five Thousand Taka) excluding VAT.

Acknowledgement

The Board of Directors thankfully acknowledge the devotion and dedication of all the employees without which the Company's development works-in-progress could not have attained satisfactory as reported above.

The Board also record with appreciation the support, services and co-operation rendered by all concerned.

Allah Hafiz.

Signed on behalf of the Board of Directors.



Prof. Dr. Choudhury Mahmood Hasan
Managing Director



Prof. Dr. AKM Sadrul Islam
Chairman



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস
৯-জি, মতিঝিল বানিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali
CHARTERED ACCOUNTANTS
9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.
Extension Office: Property Heights, 1st Floor
12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867
PABX: 9576118-9, 9576128
FAX: +88-02-9516236
E-mail: wali@satcombd.com
Web: www.msw-bd.com

INDEPENDENT AUDITOR'S REPORT

To the Shareholders of THE IBN SINA API INDUSTRY LTD.

Report on the Audit of the Financial Statements

Opinion:

We have audited the financial statements of The IBN SINA API Industry Ltd., which comprise the Statement of Financial Position as at June 30, 2022, the Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and Notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements give true and fair view, in all material respects, of the financial position of the Company as at June 30, 2022, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies act 1994 and other applicable law and regulations.

Basis for Opinion:

We conducted our audit in accordance with International Standards on Auditing (ISA). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information:

The other information comprises all of the information in the Annual Report other than the financial statements and our auditor's report thereon. We have not been provided the Director's report and other information contained within the annual report except the financial statements to the date of our auditor's report. We expect to obtain the remaining reports of the Annual report after the date of our auditor's report. Management is responsible for the other information.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Our opinion on the financial statements does not cover other information and we do not express any form of assurance conclusion thereon.

Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls:

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs as explained, and for such internal control as management determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error. The Companies Act, 1994 requires the Management to ensure effective internal audit, internal control and risk management functions of the Company.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Associated firm of **Reddy Siddiqui & Kabani**, Park View, 183-189 The Vale, London, W3 7RW, UK
E-mail: mail@reddysiddiqui.com, Website: www.reddysiddiqui.com



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস
৯-জি, মতিঝিল বানিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali
CHARTERED ACCOUNTANTS
9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.
Extension Office: Property Heights, 1st Floor
12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867
PABX: 9576118-9, 9576128
FAX: +88-02-9516236
E-mail: wali@satcombd.com
Web: www.msw-bd.com

Auditor's Responsibilities for the Audit of the Financial Statements:

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

" Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

" Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.

" Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

" Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

" Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

" Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the company audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস
৯-জি, মতিঝিল বাণিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali
CHARTERED ACCOUNTANTS
9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.
Extension Office: Property Heights, 1st Floor
12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867
PABX: 9576118-9, 9576128
FAX: +88-02-9516236
E-mail: wali@satcombd.com
Web: www.msw-bd.com

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, we also report the following:

- a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) in our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of these books;
- c) the Statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts and returns; and
- d) the expenditure incurred was for the purposes of the Company's business.

Dated, Dhaka
September 03, 2022

Data Verification Code (DVC) No.
2209121099AS157563

Malek Siddiqui Wali
Chartered Accountants

Anjan Mallik, FCA
Enrolment No: 1099

THE IBN SINA API INDUSTRY LTD.
STATEMENT OF FINANCIAL POSITION

As at 30 June 2022

| | AMOUNT IN TAKA | |
|---|--------------------|-------------------|
| | 30 June 2022 | 30 June 2021 |
| ASSETS | | |
| Non-Current Assets | | |
| Property, Plant and Equipment | 52,347,859 | 42,859,803 |
| Capital Work-In-Progress | 43,320,005 | 10,687,274 |
| Total Non- Current Assets | 95,667,863 | 53,547,077 |
| Current Assets | | |
| Inventories | 534,913 | 403,325 |
| Advance | 25,828,603 | 25,075,234 |
| Cash and Cash Equivalents | 15,955,736 | 8,283,964 |
| Total Current Assets | 42,319,252 | 33,762,523 |
| TOTAL ASSETS | 137,987,115 | 87,309,600 |
| SHAREHOLDERS' EQUITY AND LIABILITIES | | |
| Shareholders' Equity | | |
| Share Capital | 155,000,000 | 100,000,000 |
| Retained Earnings | (18,166,959) | (12,945,054) |
| | 136,833,041 | 87,054,946 |
| LIABILITIES | | |
| Current Liabilities | | |
| Trade and Other Payable | 1,154,073 | 254,654 |
| Total Current Liabilities | 1,154,073 | 254,654 |
| TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES | 137,987,115 | 87,309,600 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 03, 2022 and were signed on its behalf by:


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Dated, Dhaka;
 September 03, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA API INDUSTRY LTD.

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME


For the year ended 30 June 2022

| | AMOUNT IN TAKA | |
|-----------------------------------|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| REVENUE | - | - |
| Cost of goods sold | - | - |
| GROSS PROFIT | - | - |
| OPERATING EXPENSES | (5,892,549) | (8,175,365) |
| Administrative expenses | (5,892,549) | (8,175,365) |
| Selling & Distribution expenses | - | - |
| OPERATING PROFIT | (5,892,549) | (8,175,365) |
| Financial charges | - | - |
| Other income (Bank Profit) | 958,064 | 744,132 |
| NET PROFIT FROM OPERATION | (4,934,485) | (7,431,233) |
| Workers' P.P. Fund & Welfare Fund | - | - |
| PROFIT BEFORE TAX | (4,934,485) | (7,431,233) |
| Income tax expenses | (287,419) | (223,240) |
| NET PROFIT AFTER TAX | (5,221,905) | (7,654,473) |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 03, 2022 and were signed on its behalf by:


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Dated, Dhaka;
September 03, 2022


Malek Siddiqui Wali
Chartered Accountants

THE IBN SINA API INDUSTRY LTD.
STATEMENT OF CHANGES IN EQUITY

For the year ended 30 June 2022

AMOUNT IN TAKA

| Particulars | Share Capital | Share Premium | Retained Earnings/ (Accumulated Losses) | Total |
|-----------------------------------|--------------------|---------------|--|--------------------|
| Balance as at 01 July 2020 | 50,000,040 | - | (5,290,581) | 44,709,459 |
| Addition during the year | 49,999,960 | - | - | 49,999,960 |
| Net profit/(Loss) for the year | - | - | (7,654,473) | (7,654,473) |
| Balance as at 30 June 2021 | 100,000,000 | - | (12,945,054) | 87,054,946 |
| Issue during the year | 55,000,000 | - | - | 55,000,000 |
| Net profit/(Loss) for the year | - | - | (5,221,905) | (5,221,905) |
| Balance as at 30 June 2022 | 155,000,000 | - | (18,166,959) | 136,833,041 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 03, 2022 and were signed on its behalf by:


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Dated, Dhaka;
 September 03, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA API INDUSTRY LTD.
STATEMENT OF CASH FLOWS

For the year ended 30 June 2022

| | AMOUNT IN TAKA | |
|--|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| A. Cash flows from operating activities | | |
| Payment for operation, expenses & others | (5,805,007) | (7,802,653) |
| Payment for Tax | (95,806) | (74,413) |
| Net cash used by operating activities | (5,900,812) | (7,877,066) |
| B. Cash flows from investing activities | | |
| Acquisition of property, plant and equipment | (42,385,479) | (12,725,614) |
| Investment in API Services Ltd. | - | (3,000,000) |
| Bank Profit | 958,064 | 744,132 |
| Net cash used in investing activities | (41,427,415) | (14,981,482) |
| C. Cash flows from financing activities | | |
| Share Capital | 55,000,000 | 49,999,960 |
| Loans and borrowings | - | (18,869,520) |
| Net cash from financing activities | 55,000,000 | 31,130,440 |
| D. Net increase/(decrease) in cash and cash equivalents (A+B+C) | 7,671,773 | 8,271,892 |
| E. Opening cash and cash equivalents | 8,283,964 | 12,072 |
| F. Closing cash and cash equivalents | 15,955,737 | 8,283,964 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 03, 2022 and were signed on its behalf by:


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Dated, Dhaka;
 September 03, 2022


Malek Siddiqui Wali
 Chartered Accountants



THE IBN SINA
POLYMER INDUSTRY LTD.

DIRECTORS' REPORT

to the Shareholders for the year ended June 30, 2022

Dear Shareholders,

The Board of The IBN SINA Polymer Industry Ltd. is hereby presenting the Directors' Report along with the audited financial statements of the Company containing the Statement of Financial Position as of June 30, 2022, Statement of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flows for the year ended June 30, 2022 and the Auditors' Report thereon as per Section 184 of the Companies Act 1994, IAS and IFRS Codes and the guidelines issued by the Bangladesh Securities and Exchange Commission (BSEC).

The Company's principal objective is to carry on manufacturing and selling of Polymer products including PET bottles, compression molding, plastic caps, eye drops plastic vials, plastic drops, douche plastic bottles, polybags, etc. in first phase. In second phase, the Company intends to manufacture printed aluminum blister foils, laminated strips foils, PVC films, poly laminated alu foils, etc.

The IBN SINA Pharmaceutical Industry PLC and its sister concerns are major user of this products. After

fulfilling the captive need, the excess capacity of the company will be utilized by selling its products to the fellow pharma and related concerns locally and abroad in future.

The IBN SINA Polymer Project is located at Chalkpara, Mawna, Gazipur, Bangladesh. The basic land development works of the project has been started, Building construction works is underway. Hopefully the works will be completed within the projected time.

Operational Results

The brief summary of operational performance during the year 2021-22 is as follows:

| Particulars | July 01, 2021 to June 30, 2022 (Amount in Taka) | July 01, 2020 to June 30, 2021 (Amount in Taka) |
|------------------------------|--|--|
| Revenue | NIL | NIL |
| Gross Profit | NIL | NIL |
| NET PROFIT AFTER TAX | (549,685) | (433,195) |
| Gross Profit Ratio (%) | NIL | NIL |
| Net Profit Ratio (%) | NIL | NIL |
| Net Asset Value (NAV) | 59,017,121 | 9,566,805 |

The above result reveals that the project is not yet set into operation. The above expenditure amount mainly incurred for preliminary and other regulatory expense purpose.

Shareholding

The present shareholding pattern of the Company is as follows:

| Name of the Shareholders | Shareholding (Shares) | % of Shareholding |
|---|-----------------------|-------------------|
| The IBN SINA Trust Represented by Prof. Dr. Choudhury Mahmood Hasan | 35,00,000 | 35 |
| The IBN SINA Pharmaceutical Industry PLC Represented by Prof. Dr. AKM Sadrul Islam and Kazi Harun or Rashid | 65,00,000 | 65 |
| Total | 100,00,000 | 100 |

On the basis of above shareholdings, The IBN SINA Polymer Industry Ltd. has the status of Subsidiary to The IBN SINA Pharmaceutical Industry PLC.

Board of Directors

The following persons are the Members of the Board of Directors of the Company:

| Name | Designation |
|--|----------------------|
| Prof. Dr. Choudhury Mahmood Hasan (Nominated by The IBN SINA Trust) | Chairman |
| Kazi Harun or Rashid (Nominated by The IBN SINA Pharmaceutical Industry PLC) | Managing Director |
| Prof. Dr. AKM Sadrul Islam (Nominated by The IBN SINA Pharmaceutical Industry PLC) | Director |
| Dr. Mohammad Ayub Mia (Nominated by The IBN SINA Pharmaceutical Industry PLC) | Director |
| Md. Abdus Salam FCA, FCS | Independent Director |

The number of Board meetings of The IBN SINA Polymer Industry Ltd. held during the year under review was 4 (Four).

Financial Position

The Statement of Financial Position as on June 30, 2022, Statement of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flows ended at June 30, 2022 are placed herewith.

Dividend Declaration

The IBN SINA Polymer Industry Ltd. is now project stage. As per audited accounts of the Company as at 30 June 2022, the net profit/loss after tax stood Tk. (549,685/=) as loss for the same period.

Hence, the Board of Directors of The IBN SINA Polymer Industry Ltd. in its 9th meeting held on 03.09.2022 has recommended not to declare any dividend for the year under review.

Amendment of the Company Name

The registered name of the Company was changed substituting "The IBN SINA Polymer Industry Ltd." in place of Company's existing name "IBN SINA Polymer Industry Ltd." and amendment in the relevant Clauses/Articles of the Memorandum and Articles of Association of the Company was made and authenticated from the relevant authorities by adopting the special resolution in the 1st EGM of the Company held on February 15, 2022.

Compliance of BSEC's Code of Governance of Board of Directors of The IBN SINA Polymer Industry Ltd., Subsidiary Company of The IBN SINA Pharmaceutical Industry PLC.

As per Condition No. 2 of Corporate Governance Code of BSEC's notification No. BSEC/CMRRCD/2006-158/207/Admin/80 Date: 3 June 2018 relating to Governance of Board of Directors of Subsidiary Company, the Board duly complied with the required conditions of the Code mentioned below -

(a) Provisions relating to the composition of the Board of the holding Company, The IBN SINA Pharmaceutical Industry PLC was made applicable to the composition of the Board of the Subsidiary company, The IBN SINA Polymer Industry Ltd.;

(b) Md. Abdus Salam FCA, FCS Independent Director of the holding Company is the Independent Director on the Board of The IBN SINA Polymer Industry Ltd.;

(c) The minutes of the Board meeting of The IBN SINA Polymer Industry Ltd. were placed for review at the following Board meeting of the holding Company, The IBN SINA Pharmaceutical Industry PLC;

(d) The minutes of the respective Board meeting of the holding company, The IBN SINA Pharmaceutical Industry PLC duly stated that reviewed the affairs of The IBN SINA Polymer Industry Ltd. also;

(e) The Audit Committee of the holding Company also reviewed the financial statements, in particular the investments made by the Subsidiary Company, The IBN SINA Polymer Industry Ltd.

Appointment of Auditors

Malek Siddiqui Wali, Chartered Accountants performed as Statutory Auditors of the Company for the financial year as at June 30, 2022. Malek Siddiqui Wali, Chartered Accountants has not given their expression of interest to be re-appointed as Auditors for the next financial year.

The Company has received Expression of Interest (EOI) to be appointed as Statutory Auditors from two (2) recognized Chartered Accountants firms for the year 2022-23. The profile of these two audit firms was reviewed by the Audit Committee and recommended to appoint S F Ahmed & Co. Chartered Accountants as Statutory Auditors of the Company for the financial year, 2022-23.

The Board of Directors of The IBN SINA Polymer Industry Ltd. in its 9th meeting held on 03.09.2022 has concurred with the opinion of Audit Committee

and hence recommended in favour of S F Ahmed & Co., Chartered Accountants to be appointed as Statutory Auditors of the Company for the year 2022-23 with a remuneration of Tk. 25,000/- (Twenty Five Thousand) excluding VAT.

Acknowledgement

The Board of Directors thankfully acknowledge the devotion and dedication of all the employees without which the Company's development works-in-progress could not have attained satisfactory as reported above.


The Board also record with appreciation the support, services and co-operation rendered by all concerned.

Allah Hafiz.

Signed on behalf of the Board of Directors.



Kazi Harun or Rashid
Managing Director



Prof. Dr. Choudhury Mahmood Hasan
Chairman



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস
৯-জি, মতিবিল বানিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali
CHARTERED ACCOUNTANTS
9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.
Extension Office: Property Heights, 1st Floor
12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867
PABX: 9576118-9, 9576128
FAX: +88-02-9516236
E-mail: wali@satcombd.com
Web: www.msw-bd.com

INDEPENDENT AUDITOR'S REPORT

To the Shareholders of THE IBN SINA POLYMER INDUSTRY LTD.

Report on the Audit of the Financial Statements

Opinion:

We have audited the Financial Statements of The IBN SINA Polymer Industry Ltd., which comprise the Statement of Financial Position as at June 30, 2022, the Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and Notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements give true and fair view, in all material respects, of the financial position of the Company as at June 30, 2022, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies act 1994 and other applicable law and regulations.

Basis for Opinion:

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information:

The other information comprises all of the information in the Annual Report other than the financial statements and our auditor's report thereon. We have not been provided the Director's report and other information contained within the annual report except the financial statements to the date of our auditor's report. We expect to obtain the remaining reports of the Annual report after the date of our auditor's report. Management is responsible for the other information.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Our opinion on the financial statements does not cover other information and we do not express any form of assurance conclusion thereon.

Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls:

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs as explained, and for such internal control as management determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error. The Companies Act, 1994 requires the Management to ensure effective internal audit, internal control and risk management functions of the Company.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস

৯-জি, মতিঝিল বানিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali
CHARTERED ACCOUNTANTS
9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.
Extension Office: Property Heights, 1st Floor
12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867
PABX: 9576118-9, 9576128
FAX: +88-02-9516236
E-mail: wali@satcombd.com
Web: www.msw-bd.com

Auditor's Responsibilities for the Audit of the Financial Statements:

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

" Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

" Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.

" Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

" Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

" Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

" Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the company audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Associated firm of **Reddy Siddiqui & Kabani**, Park View, 183-189 The Vale, London, W3 7RW, UK
E-mail: mail@reddysiddiqui.com, Website: www.reddysiddiqui.com



মালেক সিদ্দিকী ওয়ালী, চার্টার্ড একাউন্টেন্টস
৯-জি, মতিঝিল বানিজ্যিক এলাকা, ঢাকা-১০০০

Malek Siddiqui Wali
CHARTERED ACCOUNTANTS
9-G, Motijheel C/A, 2nd Floor, Dhaka-1000, Bangladesh.
Extension Office: Property Heights, 1st Floor
12, R.K. Mission Road, Dhaka-1000.

PHONE: 9513471, 9569867
PABX: 9576118-9, 9576128
FAX: +88-02-9516236
E-mail: wali@satcombd.com
Web: www.msw-bd.com

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, we also report the following:

- a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) in our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of these books;
- c) the Statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts and returns; and
- d) the expenditure incurred was for the purposes of the Company's business.

Dated, Dhaka
September 03, 2022

Data Verification Code (DVC) No.
2209121099AS184364

Malek Siddiqui Wali
Chartered Accountants

Anjan Mallik, FCA
Enrolment No: 1099

THE IBN SINA POLYMER INDUSTRY LTD.

STATEMENT OF FINANCIAL POSITION

As at 30 June 2022

| | AMOUNT IN TAKA | |
|---|-------------------|------------------|
| | 30 June 2022 | 30 June 2021 |
| ASSETS | | |
| Non-Current Assets | | |
| Property, Plant and Equipment | - | - |
| Capital Work-In-Progress | - | - |
| Total Non- Current Assets | - | - |
| Current Assets | | |
| Inventories | - | - |
| Advance | - | - |
| Cash and Cash Equivalents | 59,095,871 | 9,595,555 |
| Total Current Assets | 59,095,871 | 9,595,555 |
| TOTAL ASSETS | 59,095,871 | 9,595,555 |
| SHAREHOLDERS' EQUITY AND LIABILITIES | | |
| Shareholders' Equity | | |
| Share Capital | 60,000,000 | 10,000,000 |
| Retained Earnings/(Accumulated losses) | (982,880) | (433,195) |
| | 59,017,121 | 9,566,805 |
| LIABILITIES | | |
| Current Liabilities | | |
| Loan from IBN SINA Pharma | - | - |
| Trade and Other Payable | 78,750 | 28,750 |
| Total Current Liabilities | 78,750 | 28,750 |
| TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES | 59,095,871 | 9,595,555 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 03, 2022 and were signed on its behalf by:







Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

Dated, Dhaka;
September 03, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA POLYMER INDUSTRY LTD.
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 30 June 2022

| | AMOUNT IN TAKA | |
|-----------------------------------|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| REVENUE | - | - |
| Cost of goods sold | - | - |
| GROSS PROFIT | - | - |
| OPERATING EXPENSES | (549,685) | (433,195) |
| Administrative expenses | (549,685) | (433,195) |
| Selling & Distribution expenses | - | - |
| OPERATING PROFIT | (549,685) | (433,195) |
| Financial charges | - | - |
| Other income (Bank Profit) | - | - |
| NET PROFIT FROM OPERATION | (549,685) | (433,195) |
| Workers' P.P. Fund & Welfare Fund | - | - |
| Share of associate profit/Loss | - | - |
| PROFIT BEFORE TAX | (549,685) | (433,195) |
| Income tax expenses | - | - |
| NET PROFIT AFTER TAX | (549,685) | (433,195) |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 03, 2022 and were signed on its behalf by:

 **Chief Financial Officer**
  **Company Secretary**
  **Director**
  **Managing Director**
  **Chairman**

Dated, Dhaka;
September 03, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA POLYMER INDUSTRY LTD.
STATEMENT OF CHANGES IN EQUITY

For the year ended 30 June 2022

AMOUNT IN TAKA

| Particulars | Share Capital | Share Premium | Retained Earnings/ (Accumulated Losses) | Total |
|-----------------------------------|-------------------|---------------|--|-------------------|
| Balance as at 01 July 2020 | 10,000,000 | - | (433,195) | 9,566,805 |
| Addition during the year | - | - | - | - |
| Net profit/(Loss) for the year | - | - | - | - |
| Balance as at 30 June 2021 | 10,000,000 | - | (433,195) | 9,566,805 |
| Addition during the year | 50,000,000 | - | - | 50,000,000 |
| Net profit/(Loss) for the year | - | - | (549,685) | (549,685) |
| Balance as at 30 June 2022 | 60,000,000 | - | (982,880) | 59,017,121 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 03, 2022 and were signed on its behalf by:

 **Chief Financial Officer**
 **Company Secretary**
 **Director**
 **Managing Director**
 **Chairman**

Dated, Dhaka;
September 03, 2022


Malek Siddiqui Wali
 Chartered Accountants

THE IBN SINA POLYMER INDUSTRY LTD.

STATEMENT OF CASH FLOWS

For the year ended 30 June 2022

| | AMOUNT IN TAKA | |
|--|---------------------------------|---------------------------------|
| | 01 July 2021 to 30 June 2022 | 01 July 2020 to 30 June 2021 |
| A. Cash flows from operating activities | | |
| Payment for operation, expenses & others | (482,555) | (404,445) |
| Payment for Tax | - | - |
| Bank Charge | (17,130) | - |
| Net cash used by operating activities | (499,685) | (404,445) |
| B. Cash flows from investing activities | | |
| Acquisition of property, plant and equipment | - | - |
| Bank Profit | - | - |
| Net cash used in investing activities | - | - |
| C. Cash flows from financing activities | | |
| Share Capital | 50,000,000 | 10,000,000 |
| Loans and borrowings | - | - |
| Net cash from financing activities | 50,000,000 | 10,000,000 |
| D. Net increase/(decrease) in cash and cash equivalents (A+B+C) | 49,500,316 | 9,595,555 |
| E. Opening cash and cash equivalents | 9,595,555 | - |
| F. Closing cash and cash equivalents | 59,095,871 | 9,595,555 |

These financial statements should be read in conjunction with annexed notes.

The Financial Statements were approved by the board of Directors on September 03, 2022 and were signed on its behalf by:

 **Chief Financial Officer**
 **Company Secretary**
 **Director**
 **Managing Director**
 **Chairman**

Dated, Dhaka;
September 03, 2022


Malek Siddiqui Wali
 Chartered Accountants

EXCERPTS FROM 37TH ANNUAL GENERAL MEETING

The 37th Annual General Meeting of the The IBN SINA Pharmaceutical Industry PLC was held on 18 November, 2021 at Digital (Virtual) Platform. A good number of Shareholders attended the AGM by Digital Platform. Kazi Harun or Rashid, Chairman of the Company presided over the meeting. After recitation from the Holy Quran, the Annual General Meeting was started by the welcome address to the Shareholders by the Chairman.


The Annual General Meeting is a forum through which the shareholders are informed of Company's activities and progress. The Chairman of the meeting invited comments on Directors' Report and Audited Financial Statements for the year ended 30 June, 2021. In the question and answer session, shareholders were encouraged to ask questions before approving the particular agenda. The shareholders expressed their views on the important activities of the company, its success and progress in the competitive local and overseas markets.

The due process of election and detailed information of "voting results" of each agenda and its resolution was authenticated by Independent Scrutinizer appointed for the purpose as per BSEC's instruction and reported the same to the BSEC within the stipulated time of conclusion of AGM.

The Managing Director Prof. Dr. A.K.M. Sadrul Islam thanked the shareholders for their constructive suggestions for the sustainable improvement of the Company. Strategies and future strategy of the company had also been discussed. Shareholders put up their valuable recommendations which were discussed and reviewed in the subsequent Board Meeting and proper actions in this respect had duly been taken. The meeting approved 47% Cash dividend as against per share of Tk. 10 for the year 2020-21.



Annual Report Review Checklist



Corporate Objectives, Values & Structure

- Vision and Mission ----- 10, 11
- Overall strategic objectives ----- 13
- Core values and code of conduct/ethical principles ----- 14
- Profile of the Company ----- 20-22
- Directors' profiles and their representation on Board of other companies & Organization Chart ----- 23-31



Management Report and analysis including Directors' Report/ Chairman's Review/ Managing Director's Review etc.

- A general review of the performance of the company ----- 48
- Description of the performance of the various activities / products / segments of the company and its group companies during the period under review. ----- 48-58
- A brief summary of the Business and other Risks facing the organization and steps taken to effectively manage such risks ----- 54, 62
- A general review of the future prospects/outlook. ----- 62
- Information on how the company contributed to its responsibilities towards the staff (including health & safety) ----- 54, 56
- Information on company's contribution to the national exchequer & to the economy ----- 54



Sustainability Reporting

- Social Responsibility Initiatives (CSR) ----- 110
- Environment related Initiatives ----- 95, 96, 115, 121
- Environmental & Social Obligation ----- 95, 96, 121
- Integrated Reporting ----- 80


| | | |
|--|--|----------|
| Appropriateness of Disclosure of Accounting Policies and General Disclosures | Disclosure of adequate and properly worded accounting policies relevant to Assets, Liabilities, Income and Expenditure in line with best reporting standards ----- | 167-176 |
| | Any specific accounting policies ----- | 167 |
| | Impairment of Assets ----- | 169, 171 |
| | Changes in accounting policies/Changes in accounting estimates ----- | 173 |


| | | |
|---------------------|--|-----|
| Segment Information | Segment related information bifurcating Segment revenue, segment results ----- | 174 |
| | Availability of information regarding different segments and units of the entity as well as non-segmental entities/units ----- | 174 |

| | | |
|------------------|------------------------|-----|
| Segment analysis | Segment Revenue ----- | 198 |
| | Segment Results ----- | 198 |
| | Revenue ----- | 198 |
| | Operating profit ----- | 198 |

| | | |
|--|--|----------|
| Financial Statements (Including Formats) | Disclosures of all contingencies and commitments ----- | 195 |
| | Comprehensive related party disclosures ----- | 194 |
| | Disclosures of Remuneration & Facilities provided to Directors and Managing Director ----- | 189, 195 |
| | Statement of Financial Position / Balance Sheet and relevant schedules ----- | 159 |
| | Income Statement / Profit or Loss Account and relevant schedules ----- | 160 |
| | Statement of Changes in Equity / Reserves & Surplus Schedule ----- | 161 |
| | Disclosure of Types of Share Capital ----- | 181 |
| | Statement of Cash Flow ----- | 162 |
| | Extent of compliance with the core IAS/IFRS or equivalent National Standards ----- | 175, 176 |
| | Disclosures / Contents of Notes to the Accounts ----- | 167-176 |

| | | | |
|---|---|---|---------------|
|  | → | Board of Directors, Chairman and Managing Director----- | 124-126 |
| | → | Audit Committee (Composition, role, meetings, attendance, etc.) Internal Control & Risk Management ----- | 127, 129, 142 |
| | → | Ethics and Compliance ----- | 15 |
| | → | Remuneration and other Committees of the Board ----- | 127 |
| | → | Human Capital ----- | 88 |
| | → | Communication to Shareholders & Stakeholders - Information available on website ----- - Other information ----- | 145 145 |
| | → | Environmental and Social Obligations ----- | 115-116, 121 |
| | → | Management Review and Responsibility ----- | 125, 126 |
| | → | Disclosures by Board of Directors and Audit ----- | 122-128 |

| | | | |
|--|---|--|--------------|
|  | → | Description of the Risk Management Framework ----- | 142 |
| | → | Risk Mitigation Methodology ----- | 142-144 |
| | → | Disclosure of Risk Reporting ----- | 142-144, 195 |

| | | | |
|---|---|---|-----|
|  | → | Distribution of shareholding (Number of shares as well as category wise, e.g. Promoter group, FII etc.) ----- | 76 |
| | → | Shares held by Directors/Executives and relatives of Directors/Executives ----- | 78 |
| | → | Redressal of investors' complain ----- | 145 |

| | | | |
|---|---|------------------------------------|----|
|  | → | Earnings per Share ----- | 69 |
| | → | Net Assets ----- | 74 |
| | → | Stock Performance ----- | 73 |
| | → | Shareholders' Funds ----- | 73 |
| | → | Return on Shareholders' Fund ----- | 73 |

| | | | |
|---|---|--|----|
| Horizontal/Vertical Analysis including following. | → | Operating Performance (Income Statement) ----- | 64 |
| | → | Total Revenue ----- | 64 |
| | → | Operating profit ----- | 64 |
| | → | EPS ----- | 64 |

| | | | |
|---|---|---|----------|
| Statement of Financial Position (Balance Sheet) | ● | Any specific accounting policies ----- | 167-176 |
| | ● | Shareholders' Fund ----- | 181-182 |
| | ● | Property Plant & Equipment ----- | 177, 199 |
| | ● | Net Current Assets ----- | 159 |
| | ● | Long Term Liabilities/Current Liabilities ----- | 159 |

| | | | |
|--|---|---|----|
| Profitability/ Dividends/ Performance and Liquidity Ratios | → | Gross Profit Ratio ----- | 63 |
| | → | Earning before Interest, Depreciation and Tax ----- | 63 |
| | → | Price Earning Ratio ----- | 63 |
| | → | Current Ratio ----- | 63 |
| | → | Return on Capital Employed ----- | 63 |
| | → | Debt Equity Ratio ----- | 63 |

| | | | |
|---|---|---|----|
| Statement of Value Added and Its Distribution | → | Government as Taxes ----- | 65 |
| | → | Shareholders as dividend ----- | 65 |
| | → | Employees as bonus/remuneration ----- | 65 |
| | → | Retained by the entity ----- | 65 |
| | → | Market Share information of the Company's Product/service ----- | 66 |
| | → | Economic value added ----- | 67 |

| | | | |
|------------------------|---|--------------------------------------|--------|
| Additional Disclosures | → | Our Six Capital: ----- | 85-119 |
| | → | Our Approach to Sustainability ----- | 79 |
| | → | Human Resource Accounting ----- | 120 |
| | → | Business Model ----- | 84 |
| | → | Statekeholders information ----- | 76-78 |

Corporate Governance Disclosure Checklist

| SI. No. | Particulars | Page No. |
|----------|---|----------|
| 1 | BOARD OF DIRECTORS, CHAIRMAN AND CEO | |
| 1.1 | Company's policy on appointment of directors disclosed | 124 |
| 1.2 | Adequate representation of non-executive directors i.e. one third of the board subject to a minimum of two | 125 |
| 1.3 | At least one independent director on the board and disclosure/affirmation of the board on such director's independence | 56, 125 |
| 1.4 | Chairman to be independent of CEO | 125 |
| 1.5 | Responsibilities of the Chairman of the board appropriately defined and disclosed. Disclosure of independence of Non-Executive Directors | 125 |
| 1.6 | Existence of a scheme for annual appraisal of the board's performance and disclosure of the same | 125 |
| 1.7 | Disclosure of policy on annual evaluation of the CEO by the Board | 125 |
| 1.8 | Disclosure of policy on training (including details of the counting training program) of directors and type and nature of training courses organized for directors during the year existence of a scheme for annual appraisal of the boards performance | 126 |
| 1.9 | At least one director having through knowledge and expertise finance and accounting to provide guidance in the matters applicable to accounting and auditing standards to ensure reliable financial reporting | 126 |
| 1.10 | Disclosure of number of meetings of the board and participation of each directors (at least 4 meetings are required to be held) | 126 |
| 1.11 | Directors issue a report on compliance with best practices on corporate governance that is reviewed by external auditors | 52, 147 |
| 2 | VISION/MISSION AND STRATEGY | |
| 2.1 | Company's vision/mission statements are approved by the board and disclosed in the annual report | 10-11 |
| 2.2 | Identification of business objectives and areas of business focus disclosed | 12 |
| 2.3 | General description of strategies to achieve the company's business objectives | 13 |
| 3 | AUDIT COMMITTEES | |
| 3.1 | Appointment and Composition | 127, 129 |
| 3.1.1 | Whether the audit committee chairman is an independent Non-Executive Director and Professionally Qualified | 129 |
| 3.1.2 | Whether it has specific terms of reference and whether it is empowered to investigate/question employees and retain external counsel | 129-130 |
| 3.1.3 | More than two thirds of the members are to be Non-Executive Directors | 129 |
| 3.1.4 | All members of the audit committee to be suitably qualified and at least one member to have expert knowledge of finance and accounting | 129 |
| 3.1.5 | Head of internal audit to have direct access to audit committee | 128, 130 |
| 3.1.6 | The committee to meet at least 4 times a year and the number of meetings and attendance by individuals members disclosed in the annual report | 129 |

| Sl. No. | Particulars | Page No. |
|------------|--|------------------|
| 3.2 | OBJECTIVE AND ACTIVITIES | |
| 3.2.1 | Statement of Audit Committees review to ensure that internal controls are well conceived properly administrative and satisfactorily monitored | 129-131 |
| 3.2.2 | Statement to indicate audit committees role in ensuring compliance with laws, regulations and timely settlements of statutory dues | 129-131 |
| 3.3.3 | Statement of Audit Committee involvement in the review of external audit function -Ensure effective coordination of external audit function -Ensure independence of external auditors -To review the external auditors findings in order to be satisfied that appropriate action is being taken -Review and approve any non audit work assigned to the external auditor and ensure that such work does not compromise the independence of external auditors -Recommend external auditor for appointment/reappointment | 129-131 |
| 3.2.4 | Statement on Audit committee involvement in selection of appropriate accounting policies that are in line with applicable accounting standards and annual review | 130 |
| 3.2.5 | Statement on Audit committee involvement in the review and recommend to the board of directors, annual and interim financial release | 130-131 |
| 3.2.6 | Reliability of the management information used for such computation | 129-131 |
| 4 | INTERNAL CONTROL & RISK MANAGEMENT | |
| 4.1 | Statement of director's responsibility to establish appropriate system of internal control | 55, 142 |
| 4.2 | Narrative description of key features of the internal control system and the manner in which the system is monitored by the board, audit committee or senior management | 142-144 |
| 4.3 | Statement that the directors have reviewed the adequacy of the system of internal controls | 55 |
| 4.4 | Disclosure of the identification of risk the company is exposed to both internally and externally | 142-144 |
| 4.5 | Disclosure of the strategies adopted to manage and mitigate the risks | 142-144 |
| 5 | ETHICS AND COMPLIANCE | |
| 5.1 | Disclosure of statement of ethics and values, covering basic principles such as integrity, conflict of interest, compliance with the laws and regulations, etc | 15, 54 |
| 5.2 | Dissemination/communication of the statement of ethics & business practices to all directors and employees and their acknowledgement of the same | 15 |
| 5.3 | Board's statement on its commitment to establishing high level of ethics and compliance within the organization | 54 |
| 5.4 | Establishing effective anti-fraud programs and controls, including effective protection of whistle blowers, establishing a hot line reporting of irregularities etc | 55 |
| 6 | REMUNERATION COMMITTEE | |
| 6.1 | Disclosure of the charter (role and responsibilities) of the committee | 127, 132 |
| 6.2 | Disclosure of the composition of the committee (majority of the committee should be nonexecutive directors, but should also include some executive directors) | 132 |
| 6.3 | Disclosure of key policies with regard to remuneration of directors, senior management and employees | 127, 132 |
| 6.4 | Disclosure of number of meetings and works performed | 127, 132 |
| 7 | HUMAN CAPITAL | |
| 7.1 | Disclosure of general description of the policies and practices codified and adopted by the company with respect of Human Resource Development and Management, including succession planning, merit based recruitment, performance appraisal system, promotion and reward and motivation, training and development, grievance management and counseling | 88 |
| 7.2 | Organizational Chart | 146 |
| 8 | COMMUNICATION TO SHAREHOLDERS AND STAKEHOLDERS | |
| 8.1 | Disclosure of the company's policy/strategy to facilitate effective communication with the shareholders and other stakeholders | 58, 145 |
| 8.2 | Disclosure of company's policy on ensuring participation of shareholders in the Annual General Meeting and providing reasonable opportunity for the shareholder participation in the AGM | 58, 145 |
| 9 | ENVIRONMENTAL AND SOCIAL OBLIGATIONS | |
| 9.1 | Disclosure of general description of the company's policies and practices relating to social and environmental responsibility of the entity | 95, 96, 121 |
| 9.2 | Disclosure of specific activities undertaken by the entity in pursuance of these policies and practices | 95, 96, 115, 116 |

Virtual Annual General Meeting (AGM) Logistics

Pursuant to the Bangladesh Securities and Exchange Commission's Directive No. BSEC/CMRRCD/2009-193/08 dated March 10, 2021, a listed Company can arrange virtual Annual General Meeting via live webcast by using digital platform. Accordingly the 38th AGM (Virtual Meeting) of The IBN SINA Pharmaceutical Industry PLC has been scheduled to be held on Sunday, 30 October 2022 at 9:30 AM by using digital platform and online Shareholders' tools enabling the Shareholders to participate fully, and equally, from any location around the world.



Sunday
30 October 2022



TIME
9:30 AM



LIVE WEBCAST
<https://agmbd.live/ibnsinapharma2022>



The **IBN SINA** Pharmaceutical Industry PLC

Corporate Office: Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur Dhaka-1207, Bangladesh, Tel: +880-2-41022148, 41022150-58, 41022174
Website: www.ibnsinapharma.com, E-mail: shareipi@ibnsinapharma.com
Factory: Shafipur, Kaliakoir, Gazipur, Bangladesh